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This dissertation is focused on the genetic epidemiological investigations of coronary 
artery disease (CAD) and its related risk factor traits. 
 
With the rapid development of genome-wide association study (GWAS), many single 
nucleotide polymorphisms (SNPs) have been reported to be associated with CAD and 
its related traits.  Rs6903956 on androgen-dependent tissue factor pathway inhibitor 
(TFPI) regulating protein (ADTRP) gene was identified to associate with CAD in a 
GWAS conducted in a Han Chinese population.  The association has been replicated 
in the Singaporean Chinese and we investigated whether the genetic variant in the 
ADTRP gene was associated with plasma coagulation factors, Factor VII (FVII) and 
fibrinogen in the Singaporean Chinese. 
 
The identification of many other SNPs associated with CAD and its related traits by 
GWAS also provides a chance to evaluate whether the inclusion of genetic variants 
into phenotypic based risk prediction models, such as the Adult Treatment Panel III 
(ATPIII) model from the Framingham Heart Study (FHS) could improve risk 
prediction accuracy and performances.  We utilized SNPs from GWAS catalog to 
construct various forms of Genetic Risk Score (GRS) for augmenting the ATPIII 
model.  C-statistics and net reclassification improvement (NRI) index were used to 




As with all complex traits, it is known that gene-gene and gene-environment 
interactions also play a role in determining the outcome of CAD and its related risk 
factors.  The last component of the dissertation included gene-diet interaction study 
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Chapter 1: Introduction 
1.1 Coronary artery disease 
Coronary heart disease (CHD), also widely known as ischemic heart disease (IHD) [1] 
or coronary artery disease (CAD) is the most common type of cardiovascular disease 
(CVD) [2].  The essential mechanism of CAD involves atherosclerosis of the heart 
arteries [3].  Atherosclerosis is a phenomenon that the artery walls become thick due 
to the accumulation of white blood cells (foam cells) and fatty acids inside the blood 
vessel walls.  Fibrofatty plaques will form at the accumulation areas.  The 
development of plaques will reduce the elasticity of the artery walls, gradually affect 
blood flow and eventually lead to increased pulse pressure.  The progression of 
CAD will last for decades [4].  Patients will usually be asymptomatic and not aware 
of their disease status until a sudden heart attack finally arises. 
 
Myocardial infarction (MI), commonly known as heart attack, is the most severe 
complication for CAD.  CAD and MI are leading causes of mortality and morbidity 
worldwide [5].  It accounted for 8.14 million global deaths (16.8%) in 2013, the 
number of which had rose rapidly since 1990 (5.74 million deaths) [2].  CAD may 
influence individuals at any age groups but will be more common in older age groups 
[6] and in males [7].  According to world health statistics in 2012 [8], the largest 
proportion of non-communicable disease (NCD) deaths is attributed to CVD (48.0%), 
and it is estimated that the annual death caused by CVD will increase to 25 million in 
2030.  Although the mortality and morbidity rate of CAD has decreased from 1980 
2 
 
to 2010 in developed countries due to improved prevention and treatment [9, 10], it 
increased rapidly in developing countries.  In Asia, there is an increasing CAD 
burden due to rising prevalence of sedentary lifestyle and changes in food 
consumption [11, 12].  Although South Asian only accounts for 20% of the world's 
population, 60% of the world's CVD burden is estimated to occur in Asia.  In 
Singapore, CAD is the No.3 killer only after cancer and pneumonia 
(https://www.moh.gov.sg/content/moh_web/home/statistics/Health_Facts_Singapore/
Principal_Causes_of_Death.html).  Therefore, it is essential to investigate the 
epidemiology of CAD to reduce the disease burden both on the health systems and 
individuals in Asia. 
 
CAD is a complex disease.  Both genetic and lifestyle factors, as well as their 
interactions contribute to the etiology of CAD.  Many environmental and lifestyle 
factors promote the progression of CAD.  These risk factors include behavioural risk 
factors (unhealthy diet, lack of physical activity, excessive alcohol intake and tobacco 
use), metabolic risk factors (high blood pressure, diabetes, elevated blood cholesterol, 
overweight and obesity) and some other risk factors such as depression [3].  
Cigarette smoking is the strongest environmental risk factor of CAD, which accounts 
for about 36% of cases [13].  Obesity is associated with 20% [13] of CAD cases and 
physical inactivity was shown to associate with 7-12% of cases [14].  Interventional 
studies showed that some risk factors could be modified to reduce the mortality and 
morbidity of CAD, especially behavioural risk factors [15-17].  Thus further studies 
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to investigate the casual relationship between risk factors and CAD and possible 
mechanisms involved are needed. 
 
Besides lifestyle factors, genetic variations are likely to have a prominent role in the 
etiology of CAD as the heritability of CAD is estimated to be up to 60% [18-20].  
Previously, many genes involved in metabolic pathways related to CAD have been 
identified through candidate gene approach, such as ATP-binding cassette, subfamily 
a, member 1 (ABCA1) in lipid metabolic pathway and angiotensin converting enzyme 
(ACE) in the blood pressure regulation [21, 22].  In recent years, the advances of 
large scale genome-wide association studies (GWAS) have made it possible to assess 
many single nucleotide polymorphisms (SNPs) across the genome and uncovered 
SNPs that are associated with CAD and its related risk factor traits.  The rapid 
development and the reduction in the cost made GWAS a powerful tool to provide a 
valuable first insight into candidate loci or genetic architecture of CAD for 
subsequent validation and biological analysis [23]. 
 
1.2 Coronary artery disease related traits 
1.2.1 Obesity and body mass index 
The body mass index (BMI) or Quetelet index is a simple index to quantify the 
amount of tissue mass in an individual.  It is calculated as weight in kilograms (kg) 
divided by height in meter square (m2) thus is universally expressed in the unit of 
kg/m2.  Based on the value of BMI, the World Health Organization (WHO) defines 
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overweight as the value of BMI greater than or equal to 25 kg/m2 and obesity as the 
value of BMI greater than or equal to 30 kg/m2 [24].  Some Asian countries 
including Singapore use lower BMI values as cut-off for overweight (BMI ≥ 23 
kg/m2) and obesity (BMI ≥ 27.5 kg/m2) [25] since there are several studies shown that 
compared with Caucasians at the same BMI level, Asians have higher proportion of 
body fat and higher risk for several diseases [26-28].  Overweight and obesity, 
which are defined as the abnormal or excessive accumulation of fat, are major health 
problems worldwide.  A total of 2.8 million people die each year due to being 
overweight or obese worldwide [29] according to world health statistics in 2012 [8].  
The mortality rate was higher in individuals who were overweight and obese than 
those were underweight [24].  The worldwide prevalence of obesity has been more 
than two times higher since 1980.  In 2014, more than 1.9 billion adults (18 years 
and above) were overweight (39%) and over 600 million of these individuals were 
obese (13%).  Women were more likely to be overweight (40% Vs 38%) and obese 
(15% Vs 11%) than men [24].  In Singapore, obesity places the 4th heaviest disease 
burden on the whole society after hypertension, diabetes and high total cholesterol.  
Between 1998 and 2004, the prevalence of obesity among Singaporean adults aged 18 
to 69 years old increased slowly from 6.0% to 6.9% while the prevalence increased 
rapidly and jumped to 10.8% only after 6 years in 2010 
(https://www.moh.gov.sg/content/moh_web/home/statistics/Health_Facts_Singapore/
Disease_Burden.html).  Being overweight or obese will lead to deleterious 
metabolic effects on lipid levels and blood pressure.  In addition, individuals who 
5 
 
are overweight or obese will have higher risk for various diseases, such as type 2 
diabetes, CHD, ischaemic stroke, obstructive sleep apnea, musculoskeletal disorders 
and certain types of cancers [8, 30]. 
 
Obesity is a complex disease, which is associated with both environmental factors, 
such as dietary intake and physical inactivity, and genetic components as well as their 
interactions [31-33].  Overweight and obesity are mainly attributed to an energy 
imbalance between calories intake (diet) and expenditure (physical activity).  There 
has been a global increase of energy-dense western style food intake and decrease in 
amount of physical activity due to sedentary lifestyle [34].  Overweight and obesity 
are mostly preventable if making the right choice of food and engaging in regular 
exercise.  Besides lifestyle factors, genetic factors also play an essential part in the 
progression of obesity.  Among all the genes reported, fat mass and 
obesity-associated protein (FTO) is the most valid and with the largest effect size on 
obesity risk [35].  In addition to environmental and genetic factors acting 
independently, it is suggested that the association between genes and 
overweight/obesity could be modified by dietary intake [36-39].  Thus investigating 
the gene-diet interaction for obesity might uncover the mechanisms involved and 
provide additional guidance to reduce the prevalence of overweight and obesity. 
 
1.2.2 High density lipoprotein 
High-density lipoprotein (HDL) is the smallest and densest lipoprotein particles with 
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the protein to lipids proportion being highest among the five major lipoprotein groups.  
Lipoproteins are complex particles which are responsible for lipids transportation 
around the body within the bloodstream.  Usually larger lipoprotein will transport fat 
molecules such as cholesterol, phospholipids and triglycerides (TG) to cells while 
HDL is just the opposite that it removes fat from cells.  The fat removed is mostly 
delivered by HDL through both direct and indirect pathways to the liver and 
steroidogenic organs and is excreted into the bile and transformed into bile acids.  
HDL is sometimes regarded as "good cholesterol" since it can remove fat molecules 
out of artery walls.  The removal of fat could help to reduce macrophage 
accumulation and thus prevent or even regress atherosclerosis.  The most classical 
pathway indicating the protective function of HDL toward atherosclerosis is the 
reverse cholesterol transport (RCT).  HDL plays a central role in RCT, a multi-step 
process that transports cholesterol from the peripheral tissues, for instance foam cells 
and macrophages, to the liver for excretion into the bile via plasma.  Low 
concentration of HDL level (men < 40 mg/dL and women < 50 mg/dL) is strongly 
associated with accumulation of plaques within the arteries walls and will eventually 
lead to increased risk of stroke, sudden plaque ruptures, cardiovascular disease and 
vascular disease [40, 41].  Every 1 mg/dl decrease in HDL level will lead to a 6% 
increase in cardiovascular risk [42]. 
 
Cholesterol ratio is the ratio between HDL and total cholesterol level in the plasma.  
In the last decade, some researchers believe that lipoprotein ratios would be much 
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more important than the absolute lipoprotein levels in some aspects, such as risk 
prediction for heart disease [43].  Thus cholesterol ratio has become another 
important area of interest in addition to absolute levels of HDL, TG, total cholesterol 
(TC) and low-density lipoprotein (LDL). 
 
High concentration of HDL level (> 60 mg/dL) has a protective effect against 
vascular disease.  The level of HDL tends to be higher in women than in men, both 
in size and the cholesterol content.  In addition, many lifestyle factors could affect 
HDL levels.  Moderate alcohol intake could increase HDL levels and lower risk and 
all-cause mortality rate of cardiovascular disease [44].  Changes in the exercise and 
dietary habits, such as increase the amount of soluble fiber intake and decrease 
carbohydrate intake, also have a positive effect of elevating HDL level.  In addition, 
increasing the strength of aerobic exercise and keep normal weight could also help 
with raising the HDL levels.  Identifying more elements that could affect HDL levels 
and investigating the possible mechanisms involved is important in the diagnosis, 
treatment and prevention of heart disease [45]. 
 
1.3 Objectives and aims 
1.3.1 Study I - The genetic variation rs6903956 in the novel ADTRP gene 
is not associated with levels of plasma coagulation factors in the 
Singaporean Chinese (Chapter 4) 
GWAS has reported that rs6903956 within the first intron of androgen-dependent 
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tissue factor pathway inhibitor (TFPI) regulating protein (ADTRP) gene was 
associated with CAD risk in the Han Chinese population [46].  The association has 
been replicated in several independent Chinese cohorts, including our Singaporean 
Chinese [47] and Japanese but with different risk allele in the Japanese [48].  
However, the mechanism involved is largely unknown.  Previously it was reported 
that the association was not explained by lipid levels [47].  Factor VII (FVII) and 
fibrinogen are the key factors in coagulation cascade and independent risk predictors 
for CAD [49-52].  The aim of this study was to investigate whether there is any 
association between the genetic variant on ADTRP and plasma coagulation factors, 
FVII and fibrinogen levels, in the Singapore Chinese population. 
 
1.3.2 Study II - Utility of genetic and non-genetic risk factors in predicting 
Coronary Heart Disease in Singaporean Chinese (Chapter 5) 
In recent years, numerous phenotype based equations for predicting risk of ‘hard’ 
coronary heart disease (‘hard’ CHD), which includes myocardial infarction and 
coronary death, are available.  The most frequently used model among them is the 
Framingham Risk Equation, which includes major CHD risk factors, such as age, 
HDL, TC, systolic blood pressure (SBP), current smoking status and use of 
anti-hypertensive medication.  Although the original phenotype-based risk 
prediction model performed well in multiple cohorts with or without model 
recalibration, there are still a large number of individuals with few risk factors and 
predicted to be at low risk of developing disease were actually CHD patients.  Some 
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studies tried to include other phenotypic risk predictors, such as biomarker 
high-sensitive C-reactive protein (hsCRP) and creatinine, into the risk prediction 
model, but the improvement was limited [53-55].  Besides lifestyle factors, genetic 
information are likely to have a prominent role in the etiology of CHD.  However, 
limited data exists regarding the utility of genetic information for risk prediction in 
Chinese populations.  The aim of the study was to evaluate whether genetic factors 
could improve prediction accuracy of incident ‘hard’ CHD in a Chinese population, 
beyond the use of traditional risk factors and biomarkers. 
 
1.3.3 Study III - Interactions between genes and dietary intake and their 
effect on body mass index in the Singaporean Chinese population 
(Chapter 6) 
Recent GWAS have identified 97 BMI associated SNPs.  These obesity risk SNPs 
are generally transferable between ethnic groups, for which similar associations have 
been reported.  Differences however, exist in dietary patterns between ethnic groups 
and whether dietary intake of various nutrients can modify obesity associations at 
these recently identified risk loci, especially in the Asian population, is not well 
understood.  The aims of this study were to investigate: 
(1) The association between dietary components and BMI; 
(2) The association between BMI associated risk loci / weighted Genetic Risk Score 
(wGRS) and BMI in Singapore Chinese cohorts; 




(4) Interaction between known index variants at obesity risk loci and intake of various 
dietary components for BMI in the Singaporean Chinese population. 
 
1.3.4 Study IV - Interactions between high-density lipoprotein associated 
risk loci and SNPs across the genome on high-density lipoprotein levels 
and cholesterol ratio in Singaporean Chinese (Chapter 7) 
Plasma HDL level is strongly associated with accumulation of atherosclerosis within 
the arteries walls and risk of vascular disease.  Large scale GWAS have identified 
many SNPs associated with blood HDL levels.  However, the SNPs uncovered thus 
far only explained a very small fraction of HDL variation.  One possible explanation 
for the ‘missing heritability’ is the gene-gene interaction.  The aim of this study was 
to investigate the interactions between HDL associated risk loci from GWAS catalog 
and independent SNPs across the genome for HDL levels and cholesterol ratio in 
Singaporean Chinese cohorts thus to extend the understanding of the genetic basis of 




Chapter 2: Literature Review 
This chapter summarizes the literature pertinent to the epidemiological investigation 
of CAD and its related risk factor traits.  We first reviewed the pathology of CAD, 
followed by GWAS, the most powerful tool to date for studying genetic basis of the 
complex diseases.  The development of the well-known cardiovascular cohort study, 
Framingham Heart Study (FHS) and the CHD risk perdition models derived from 
FHS will be reviewed thereafter.  Lastly, gene-gene and gene-environment 
interaction studies for CAD and its related traits will also be surveyed. 
 
2.1 Pathology of coronary artery disease 
Atherosclerosis, also known as arteriosclerotic vascular disease (ASVD), is a 
progressive disease characterized by thickening of artery walls due to invasion and 
accumulation of foam cells (white blood cells), lipids and fibrous elements.  The 
accumulations of white blood cells (WBCs) are named ‘fatty streaks’ because of the 
similar appearance with marbled steak and they contain both living and dead cells as 
well as lipids.  In humans, the ‘fatty streaks’ begin in the first decade of life in the 
aorta, then during the second decade in the coronary arteries, followed by the cerebral 
arteries during the third or fourth decades [56].  Different regions of arteries have 
different probability for lesion formation.  The branch and curvature parts of the 
arteries are preferred sites for formation of lesions.  The ‘fatty streaks’ will reduce 
the flexibility of the artery walls but they are only the precursors of more advanced 
lesions (fibrous lesions).  They are not clinically significant and will not affect the 
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flow of blood for decades.  The advanced lesions are a result of accumulation of 
necrotic debris which are rich in lipids and smooth muscle cells (SMCs) and are 
usually with a ‘fibrous cap’ made up by SMCs and extracellular matrix.  The 
calcification and ulceration at the luminal surface will make the lesions more 
complex.  Rupture or erosion of the lesion will cause the formation of thrombus or 
blood clot, leading to stroke (in the cerebral arteries) or myocardial infarction (in the 
coronary arteries). 
 
Atherosclerosis is a chronic disease, which influences blood vessels as a result of 
long term inflammatory response of WBCs.  The process can be promoted by high 
level of LDL which carry cholesterol and triglycerides and low level of functional 
HDL, which removes fats and cholesterol from the macrophages. 
 
A normal artery contains three morphologically distinct layers, intima, media and 
adventitia.  The intima is the innermost layer bounded by endothelial cells (ECs) and 
elastic fibers.  The middle layer media is made up by SMCs and the outermost 
adventitia is full of connective tissues as well as small amount of fibroblasts and 
SMCs.  The development of atherosclerotic plaques can be divided into several 
stages, lesion initiation, inflammation, foam cell formation, fibrous plaques and 
advanced lesions and thrombosis [56] (Figure 1). 
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2.1.1 Lesion initiation 
As mentioned above, the intima and media layer are separated by a monolayer of ECs.  
It is a selectively permeable barrier between blood and tissues and generates 
molecules to regulate various biological processes, such as preventing the irregular 
migration and proliferation of SMCs and thrombosis [57]. 
 
When the level of circulating LDL increases in the blood, the accumulation will be 
promoted in the subendothelial matrix, which initializes atherosclerosis.  The 
invasion and retention of LDL in the artery walls are influenced by the interaction 
between apolipoprotein B (apoB) and matrix proteoglycans [58].  Besides LDL, 
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other lipoproteins containing apoB could also accumulate in the artery and lead to 
atherosclerosis [59].  Previous studies showed that only the trapped LDL undergoing 
modification, such as oxidation, the most significant for lesion formation at early 
stage, other than native LDL will be taken up by macrophages and promote 
inflammation as well as foam-cell formation [60].  Functional HDL can remove 
excess cholesterol from peripheral tissues and inhibit oxidation of lipoprotein.  Thus 
HDL has a protective effect on atherosclerosis. 
 
2.1.2 Inflammation 
The accumulation of modified LDL motivates the ECs to produce large amount of 
proinflammatory elements including growth factors and adhesion molecules. These 
elements will trigger the recruitment of monocytes and lymphocytes in the artery 
walls and promote atherosclerosis.  The fabrication of anti-atherogenic mediator, 
nitric oxide (NO) could also be reduced by LDL [61].  Besides modified LDL, 
haemodynamic forces, level of homocysteine, sex hormones, diabetes and infection 
could also modulate and promote inflammation [62]. 
 
The binding of monocytes to the ECs is crucial for atherosclerosis and mediated by 
both adhesion molecules and chemotactic factors.  The adhesion molecule, selectins 
promotes the early adhesion of leukocytes with the endothelial surface [63].  The 
integrin alpha 4 beta 1 (Very Late Antigen-4, VLA-4) interacts with both vascular cell 
adhesion molecule 1 (VCAM-1) and the chorionic somatomammotropin hormone 
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1 (CS-1) to contribute to the firm adhesion of monocytes and T cells to endothelium 
[64].  It is also found that monocyte chemotactic protein (MCP-1) and its receptor 
C-C motif chemokine receptor 2 (CCR2) could significantly induce atherosclerotic 
lesions formation and development by promoting recruitment of monocytes [65]. 
 
2.1.3 Foam cell formation 
Only the highly oxidized (extensively modified) LDL particles can be absorbed 
rapidly and sufficiently by macrophages to form foam cells.  A number of enzymes 
are involved in the modification of LDL to form atherosclerotic lesions 
(phospholipase, sphingomyelinase and myeloperoxidase).  Phospholipase can induce 
oxidation of LDL [66].  Sphingomyelinase can promote aggregation, retention and 
enhanced uptake by macrophages of lipoprotein [67].  Finally, myeloperoxidase 
generates hypochlorous acid and tyrosyl radical and promotes modified LDL binding 
to macrophage scavenger receptors [68].  Two scavenger receptors, CD36 and SR-A 
could mediate the uptake of extensively modified LDL by macrophages to form foam 
cells [69, 70].  Cytokines and peroxisome proliferator-activated receptor-γ (PPAR-γ) 
regulate scavenger receptors expression [71].  Apolipoprotein E (apoE) secreted by 
macrophages could reduce the transformation of macrophages to foam cells by 
promoting cholesterol efflux to HDL thus it has a protective effect on atherosclerosis. 
 
2.1.4 Fibrous plaques 
Fibrous plaques contain a rising accumulation of extracellular lipid as well as SMCs 
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and extracellular matrix derived from SMCs.  The migration and proliferation of 
SMCs and production of extracellular matrix are influenced by growth factors and 
cytokines secreted by T cells and macrophages.  It is also found that the interaction 
between CD40 and its ligand CD40L (CD154) plays an important role in the 
development of advanced lesions [72].  The interaction leads to the production of 
several inflammatory cytokines.  Many risk factors promote the development of 
fibrous lesions, such as hormones, high blood pressure and elevated homocysteine 
levels.  Oestrogen could influence plasma lipoprotein levels and stimulate 
production of prostacyclin and NO thus it is anti-atherogenic [73].  Infection by 
cytomegalovirus will induce arterial restenosis and atherosclerosis [74]. 
 
2.1.5 Advanced lesions and thrombosis 
It is suggested that an acute occlusion due to rupture or erosion of the lesion other 
than the growth and development of advanced lesions leads to acute coronary events.  
Rupture usually occurs at the edge of vulnerable lesions, which contain increased 
numbers of foam cells.  Many factors contribute to the stability of atherosclerotic 
lesions such as calcification and neovascularization as well as the expression of some 
molecules which can mediate thrombosis. 
 
2.2 Genome-wide association study 
GWAS is an examination of many SNPs in different individuals to see if any SNP is 
associated with a diseases trait from the DNA of participants.  Genotypes of 
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different individuals that were either with (cases) or without (controls) a disease or 
with different degree of phenotypes for a particular trait such as HDL levels were 
compared.  This approach investigates the whole genome thus it is non-hypothesis 
driven compared to a candidate gene approach.  It is under the assumption that 
common genetic variation plays a central part in explaining the heritability of 
common diseases [75].  In addition, GWAS shows superiority for investigating 
complex and common diseases compared to linkage studies [76].  However, 
researchers should still take note that GWAS has some limitations such as requiring 
generally a large sample size to attain adequate statistical power after correcting for 
multiple testing.  The first GWAS was published successfully in 2005 with 
age-related macular degeneration as outcome [77].  To date, hundreds of human 
diseases and traits have been investigated by GWAS and thousands of SNPs have 
been identified.  Raw GWAS data should undergo important quality control steps to 
eliminate as much spurious findings as possible.  In the following sections, GWAS 
of CAD and its related traits will first be reviewed, followed by some key 
components for GWAS, including genotype calling, quality control, linkage 
disequilibrium, imputation, meta-analysis and multiple testing. 
 
2.2.1 GWAS of CAD 
To date, GWAS have identified 144 SNPs from 97 different risk loci that are 
associated with CAD / CHD / MI / MI early onset [78].  Most of the association 
have been replicated in independent cohorts, indicating the robustness of the results.  
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Detailed information of the association results are presented in Table 1 [78]. 
 
Among the 144 SNPs reported in CAD GWAS, 95 of them (65.97%) are within or 
near protein-coding genes and 14 of them are known to be functional.  The most 
well-replicated and strongest associations were found between SNPs from 9p21.3 and 
CAD.  The associations between this locus with both CAD and MI were first 
reported in Caucasians in 2007 [79-81].  In addition, they have been replicated in 
Asian population, including Koreans [82], Japanese [83] and Han Chinese [84] but 
not in African-Americans [85].  The associations are independent of any known 
CAD risk factors and the genetic variants from 9p21.3 were associated with an 
increased 18%-47% risk of CAD.  However, the mechanism involved is largely 
unknown since this region is a gene desert and is not known to have any genes coding 
for proteins.  However, the region was found to be overlapped with an annotated 
non-coding RNA (ncRNA), named ANRIL [86].  The length of ANRIL is 126.3 kb 
and its 5’UTR overlapped with cyclin-dependent kinase 2B (CDKN2B).  CDKN2B 
and cyclin-dependent kinase 2A (CDKN2A) are the nearest genes to this region.  
Some studies showed that the genetic variation in 9p21.3 has an effect on the 
expression of CDKN2A/B in vascular SMCs and can affect the proliferation of 
vascular SMCs, which plays a key role in the pathogenesis of atherosclerosis [87].  
Another functional study showed that 9p21.3 may promote atherosclerosis by 
regulating ANRIL expression in primary aortic SMCs.  The association can thus alter 
gene expression that controls cellular proliferation pathway [88].  It is also reported 
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Table 1: Main GWAS findings for CAD / CHD / MI / MI early onset 
  SNPs Region Disease/Trait Sample Size Mapped gene Risk Allele Context p OR or beta Reference 
1 rs12740374 1p13.3 CHD 8,090 / 8,849 CELSR2 T UTR-3 9.00E-29 0.18 [85] 
2 rs599839 1p13.3 CHD 




4.00E-09 1.29 [81] 
86,995 / 56,682 A 3.00E-10 1.11 [89] 
3 rs602633 1p13.3 CAD 109,124 CELSR2 - PSRC1 T   1.00E-08 1.11 [90] 
4 rs646776 1p13.3 




8.00E-12 1.19 [91] 
CHD 30,482 / 40,593 T 6.00E-10 1.14 [92] 
5 rs17114036 1p32.2 




4.00E-19 1.17 [89] 
CAD 109,124 G 1.00E-08 1.15 [90] 
6 rs17114046 1p32.2 




2.00E-07 NR [92] 
CHD 30,482 / 40,593 ? 3.00E-07 
 
NR [93] 
7 rs11206510 1p32.3 
MI (early onset) 6,042 / 19,492 
BSND - PCSK9 
T 
  
1.00E-08 1.15 [91] 
CHD 86,995 / 56,682 T 9.00E-08 1.08 [89] 
8 rs12239436 1p32.3 CHD 8,090 / 8,849 MIR4422 - GOT2P1 A   5.00E-06 0.09 [85] 
9 rs2229238 1q21.3 CHD 13,949 / 11,032 IL6R ? UTR-3 7.00E-07 1.45 [94] 
10 rs1028771 1q25.3 CHD 8,090 / 8,849 LAMC2 A intron 4.00E-06 0.22 [85] 
11 rs12734338 1q32.1 CHD 94 from 32 families PPP1R12B G intron 3.00E-07 29 [95] 
12 rs7526425 1q32.3 CHD 8,090 / 8,849 RD3 - SLC30A1 ?   1.00E-06 1.16 [85] 
13 rs17465637 1q41 




1.00E-06 1.20 [81] 
MI (early onset) 6,042 / 19,492 C 1.00E-09 1.14 [91] 
CHD 86,995 / 56,682 C 1.00E-08 1.14 [89] 
14 rs744487 1q42.3 CHD 8,090 / 8,849 TARBP1 - IRF2BP2 A   5.00E-06 0.07 [85] 
15 rs17672135 1q43 CHD 4,864 / 2,519 FMN2 T intron 2.00E-06 1.43 [80] 
16 rs2346177 2p21 CHD 8,090 / 8,849 EPAS1 - TMEM247 A   2.00E-06 0.07 [85] 
17 rs11684202 2p23.3 CHD 8,090 / 8,849 DTNB A intron 6.00E-06 0.09 [85] 
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Table 1 (continued): Main GWAS findings for CAD / CHD / MI / MI early onset 
  SNPs Region Disease/Trait Sample Size Mapped gene Risk Allele Context p OR or beta Reference 
18 rs13015955 2p24.1 CHD 8,090 / 8,849 RNA5SP87 - KLHL29 A   4.00E-07 0.18 [85] 
19 rs2123536 2p24.1 CHD 6,534 / 26,932 OSR1 - CISD1P1 T   7.00E-11 1.12 [84] 
20 rs4665630 2p24.1 CHD 8,090 / 8,849 KLHL29 ? intron 1.00E-07 1.21 [85] 
21 rs7569328 2p24.1 CHD 8,090 / 8,849 C2orf43 - APOB T   1.00E-07 0.10 [85] 
22 rs13424957 2q24.3 CHD 8,090 / 8,849 LOC101929633 ? intron 3.00E-06 1.24 [85] 
23 rs2080401 2q31.1 CHD 8,090 / 8,849 HMGB1P4 - LINC01124 A   7.00E-06 0.72 [85] 
24 rs7586970 2q32.1 CHD 30,482 / 40,593 TFPI ? missense (Asn ⇒ Ser) 9.00E-06 NR [92] 
25 rs840616 2q32.1 CHD 30,482 / 40,593 IMPDH1P7 - CALCRL ?   7.00E-07 NR [92] 
26 rs6725887 2q33.2 




1.00E-08 1.17 [91] 
CHD 86,995 / 56,682 C 1.00E-09 1.14 [89] 
CAD 109,124 C 2.00E-08 1.14 [90] 
27 rs17458018 2q35 CHD 13,949 / 11,032 FN1 ? intron 7.00E-06 1.22 [94] 
28 rs2943634 2q36.3 CHD 4,864 / 2,519 NYAP2 - MIR5702 C   2.00E-07 1.21 [81] 
29 rs10933436 2q37.1 CHD 86,995 / 56,682 INPP5D A intron 7.00E-06 1.06 [89] 
30 rs4618210 3p24.3 MI 4,864 / 39,809 PLCL2 G intron 3.00E-09 1.10 [96] 
31 rs7651039 3p25.1 CHD 86,995 / 56,682 BTD C intron 2.00E-06 1.06 [89] 
32 rs2306374 3q22.3 CHD 86,995 / 56,682 MRAS C intron 3.00E-08 1.12 [89] 
33 rs9818870 3q22.3 




7.00E-13 1.15 [97] 
CAD 109,124 T 1.00E-07 1.11 [90] 
34 rs11920719 3q26.2 CHD 8,090 / 8,849 TNIK A intron 4.00E-06 0.10 [85] 
35 rs17589290 4q25 CHD 8,090 / 8,849 RPL36AP23 - CCDC34P1 ?   6.00E-06 1.43 [85] 
36 rs3853444 4q25 CHD 94 from 32 families PITX2 - MIR297 G   5.00E-06 7.69 [95] 
37 rs10026364 4q28.3 CHD 8,090 / 8,849 PES1P1 - RPS2P27 T   4.00E-06 1.28 [85] 
38 rs1395821 4q31.22 CHD 30,482 / 40,593 TTC29 - MIR548G ?   7.00E-07 NR [92] 
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Table 1 (continued): Main GWAS findings for CAD / CHD / MI / MI early onset 
  SNPs Region Disease/Trait Sample Size Mapped gene Risk Allele Context p OR or beta Reference 
39 rs1878406 4q31.22 CAD 109,124 PRMT5P1 - EDNRA T   1.00E-06 1.1 [90] 
40 rs1842896 4q32.1 CHD 6,534 / 26,932 MTND1P22 - GUCY1A3 T   1.00E-11 1.14 [84] 
41 rs11748327 5p15.33 MI 1,733 / 11,397 IRX1 - LINC01020 ?   5.00E-13 1.25 [98] 
42 rs17577085 5q31.3 CHD 8,090 / 8,849 SPRY4 - RPS12P10 ?   4.00E-06 2.63 [85] 
43 rs13161895 5q35.3 CHD 8,090 / 8,849 RNF130 T intron 6.00E-07 0.15 [85] 
44 rs6905288 6p21.1 CHD 13,949 / 11,032 TRNAI25 T   7.00E-08 1.23 [94] 
45 rs12205331 6p21.31 CAD 109,124 ANKS1A T intron 6.00E-06 1.08 [90] 
46 rs17609940 6p21.31 CHD 86,995 / 56,682 ANKS1A G intron 1.00E-08 1.07 [89] 
47 rs11752643 6p21.32 CHD 2,143 / 9,928 TRNAI25 T   5.00E-07 1.26 [83] 
48 rs9268402 6p21.32 CHD 6,534 / 26,932 C6orf10 G nearGene-5 3.00E-15 1.16 [84] 
49 rs3869109 6p21.33 CHD 13,949 / 11,032 TRNAI25 G   1.00E-09 1.14 [94] 
50 rs12526453 6p24.1 




1.00E-09 1.12 [91] 
CHD 86,995 / 56,682 C 1.00E-09 1.10 [89] 
51 rs1332844 6p24.1 CHD 30,482 / 40,593 PHACTR1 T intron 6.00E-08 1.11 [92] 
52 rs9349379 6p24.1 




9.00E-26 NR [92] 
CHD 30,482 / 40,593 ? 9.00E-26 NR [93] 
CHD 1,949 / 2,547 G 8.00E-10 1.34 [99] 
CHD 6,534 / 26,932 G 2.00E-09 1.15 [84] 
53 rs9369640 6p24.1 CAD 109,124 PHACTR1 C intron 3.00E-11 1.10 [90] 
54 rs16893526 6q14.1 CHD 5,031 / 54,758 FAM46A - IBTK G   5.00E-06 1.13 [100] 
55 rs12200560 6q16.1 CHD 13,949 / 11,032 FHL5 - RPS7P8 ?   6.00E-07 1.11 [94] 
56 rs12190287 6q23.2 




1.00E-12 1.08 [89] 
CAD 109,124 G 2.00E-09 1.11 [90] 
57 rs12524865 6q23.2 CHD 6,534 / 26,932 LOC100507308 C intron 2.00E-07 1.11 [84] 
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Table 1 (continued): Main GWAS findings for CAD / CHD / MI / MI early onset 
  SNPs Region Disease/Trait Sample Size Mapped gene Risk Allele Context p OR or beta Reference 
58 rs6922269 6q25.1 CHD 4,864 / 2,519 MTHFD1L A intron 3.00E-08 1.23 [81] 
59 rs675026 6q25.2 CHD 8,090 / 8,849 OPRM1 ? cds-synon 5.00E-06 1.20 [85] 
60 rs2048327 6q25.3 CAD 109,124 SLC22A3 C intron 1.00E-06 1.07 [90] 
61 rs365302 6q25.3 CHD 5,031 / 54,758 FNDC1 C intron 8.00E-07 1.11 [100] 
62 rs3798220 6q25.3 CHD 86,995 / 56,682 LPA C missense (Ile ⇒ Met) 3.00E-11 1.51 [89] 
63 rs7801190 7q22.1 CHD 8,090 / 8,849 SLC12A9 C intron 3.00E-08 1.31 [85] 
64 rs10953541 7q22.3 CHD 30,482 / 40,593 BCAP29 C intron 3.00E-08 1.08 [92] 
65 rs7808424 7q31.2 CHD 86,995 / 56,682 ASZ1 G nearGene-5 1.00E-06 1.10 [89] 
66 rs11556924 7q32.2 
CHD 86,995 / 56,682 
ZC3HC1 
C 
missense (Arg ⇒ His) 
9.00E-18 1.09 [89] 
CAD 109,124 T 3.00E-10 1.10 [90] 
67 rs13232179 7q36.1 CHD 8,090 / 8,849 WDR86-AS1 - CRYGN A   1.00E-06 1.67 [85] 
68 rs264 8p21.3 CAD 109,124 LPL A intron 3.00E-07 1.11 [90] 
69 rs6601299 8p23.1 CHD 8,090 / 8,849 LOC157273 T intron 1.00E-08 0.14 [85] 
70 rs4875320 8p23.2 CHD 8,090 / 8,849 CSMD1 A intron 6.00E-06 0.10 [85] 
71 rs10757274 9p21.3 CHD 6,534 / 26,932 CDKN2B-AS1 G intron 8.00E-45 1.37 [84] 
72 rs10757278 9p21.3 MI 8,335 / 9,289 UBA52P6 - DMRTA1 G   1.00E-20 1.28 [79] 
73 rs1333049 9p21.3 
CHD 4,864 / 2,519 
UBA52P6 - DMRTA1 
C 
  
1.00E-13 1.47 [80] 
CHD 4,864 / 2,519 C 3.00E-19 1.36 [81] 
CHD 5,031 / 54,758 C 7.00E-58 1.27 [100] 
CAD 109,124 C 3.00E-56 1.24 [90] 
74 rs4977574 9p21.3 




3.00E-44 1.29 [91] 
CHD 86,995 / 56,682 G 1.00E-22 1.29 [89] 
CHD 30,482 / 40,593 G 2.00E-25 1.20 [92] 
MI 4,864 / 39,809 C 8.00E-06 1.22 [96] 
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Table 1 (continued): Main GWAS findings for CAD / CHD / MI / MI early onset 
  SNPs Region Disease/Trait Sample Size Mapped gene Risk Allele Context p OR or beta Reference 
75 rs1333042 9p21.3 CHD 5,714 / 8,028 CDKN2B-AS1 ? intron 1.00E-09 1.30 [82] 
76 rs7865618 9p21.3 CHD 5,031 / 54,758 CDKN2B-AS1 A intron 2.00E-27 1.18 [100] 
77 rs944797 9p21.3 CHD 2,143 / 9,928 CDKN2B-AS1 C intron 6.00E-16 1.25 [83] 
78 rs4743150 9q22.33 CHD 30,482 / 40,593 HEMGN - ANP32B ?   5.00E-06 NR [92] 
79 rs2515629 9q31.1 CHD 8,090 / 8,849 ABCA1 A intron 5.00E-07 0.12 [85] 
80 rs514659 9q34.2 CHD 10,034 / 19,169 ABO C intron 8.00E-09 1.21 [101] 
81 rs579459 9q34.2 
CHD 86,995 / 56,682 
ABO - SURF6 
C 
  
4.00E-14 1.10 [89] 
CAD 109,124 C 2.00E-07 1.10 [90] 
82 rs2505083 10p11.23 CHD 30,482 / 40,593 KIAA1462 C intron 4.00E-08 1.07 [92] 
83 rs3739998 10p11.23 CHD 2,905 / 16,131 KIAA1462 C missense (Ser ⇒ Thr) 1.00E-11 1.15 [102] 
84 rs1746048 10q11.21 
MI (early onset) 6,042 / 19,492 
LINC00841 - CXCL12 
C 
  
7.00E-09 1.17 [91] 
CHD 86,995 / 56,682 C 3.00E-10 1.09 [89] 
85 rs501120 10q11.21 
CHD 4,864 / 2,519 
LINC00841 - CXCL12 
T 
  
9.00E-08 1.33 [81] 
CAD 109,124 C 2.00E-06 1.09 [90] 
86 rs1412444 10q23.31 




3.00E-13 1.09 [92] 
CHD 5,031 / 54,758 T 4.00E-08 1.10 [100] 
87 rs12413409 10q24.32 




1.00E-09 1.12 [89] 
CHD 30,482 / 40,593 ? 4.00E-06 NR [92] 
CAD 109,124 A 1.00E-06 1.12 [90] 
88 rs7901695 10q25.2 CHD 8,090 / 8,849 TCF7L2 ? intron 1.00E-06 1.19 [85] 
89 rs10895547 11q22.3 CHD 8,090 / 8,849 PDGFD T intron 3.00E-06 0.07 [85] 
90 rs974819 11q22.3 CHD 30,482 / 40,593 MTND1P36 - MIR4693 T   2.00E-09 1.07 [92] 
91 rs12269901 11q23.3 CHD 8,090 / 8,849 RPS27P19 - PAFAH1B2 C   2.00E-06 0.07 [85] 
92 rs1263173 11q23.3 CHD 8,090 / 8,849 APOA5 - APOA4 A   2.00E-07 0.09 [85] 
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Table 1 (continued): Main GWAS findings for CAD / CHD / MI / MI early onset 
  SNPs Region Disease/Trait Sample Size Mapped gene Risk Allele Context p OR or beta Reference 
93 rs9326246 11q23.3 CAD 109,124 RPL15P15 - BUD13 C   3.00E-07 1.15 [90] 
94 rs964184 11q23.3 CHD 86,995 / 56,682 ZPR1 G intron 1.00E-17 1.13 [89] 
95 rs4937126 11q24.2 CHD 86,995 / 56,682 ST3GAL4 G intron 5.00E-06 1.06 [89] 
96 rs7136259 12q21.33 CHD 6,534 / 26,932 ATP2B1 T intron 6.00E-10 1.11 [84] 
97 rs3782889 12q24.11 CHD 5,714 / 8,028 MYL2 C intron 4.00E-14 1.26 [82] 
98 rs886126 12q24.11 CHD 5,714 / 8,028 CUX2 T intron 1.00E-06 1.14 [82] 
99 rs11066015 12q24.12 CHD 5,714 / 8,028 ACAD10 A intron 5.00E-11 1.41 [82] 
100 rs3184504 12q24.12 
CHD 86,995 / 56,682 
SH2B3 
T 
missense (Trp ⇒ Arg) 
6.00E-06 1.07 [89] 
CAD 109,124 T 9.00E-07 1.07 [90] 
101 rs3782886 12q24.12 MI 4,864 / 39,809 - A   1.00E-14 1.46 [96] 
102 rs671 12q24.12 CHD 2,143 / 9,928 ALDH2 A missense (Glu ⇒ Lys) 2.00E-34 1.43 [83] 
103 rs11066280 12q24.13 CHD 6,534 / 26,932 HECTD4 A intron 2.00E-11 1.19 [84] 
104 rs2259816 12q24.31 CHD 2,520 / 38,253 HNF1A T intron 5.00E-07 1.08 [97] 
105 rs9508025 13q12.3 CHD 5,714 / 8,028 FLT1 C intron 6.00E-07 1.14 [82] 
106 rs9546711 13q31.1 CHD 8,090 / 8,849 LINC00333 A   2.00E-06 1.66 [85] 
107 rs7323893 13q31.2 CHD 8,090 / 8,849 TET1P1 - RPL29P29 T   1.00E-07 0.14 [85] 
108 rs4773144 13q34 




4.00E-09 1.07 [89] 
CAD 109,124 G 2.00E-06 1.08 [90] 
109 rs2895811 14q32.2 CHD 86,995 / 56,682 HHIPL1 C intron 1.00E-10 1.07 [89] 
110 rs937254 15q21.3 CHD 8,090 / 8,849 GCOM1;MYZAP A intron; intron 1.00E-06 0.08 [85] 
111 rs12595292 15q22.31 CHD 8,090 / 8,849 PLEKHO2 A cds-synon 9.00E-06 0.11 [85] 
112 rs17228212 15q22.33 CHD 4,864 / 2,519 SMAD3 C intron 2.00E-07 1.21 [81] 
113 rs1445021 15q23 CHD 8,090 / 8,849 ITGA11 - CORO2B A   9.00E-06 0.14 [85] 
114 rs2472299 15q24.1 CHD 30,482 / 40,593 CYP1A1 - CYP1A2 ?   3.00E-06 NR [92] 
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Table 1 (continued): Main GWAS findings for CAD / CHD / MI / MI early onset 
  SNPs Region Disease/Trait Sample Size Mapped gene Risk Allele Context p OR or beta Reference 
115 rs1994016 15q25.1 CHD 10,034 / 19,169 ADAMTS7 C intron 5.00E-13 1.19 [101] 
116 rs3825807 15q25.1 CHD 86,995 / 56,682 ADAMTS7 A missense (Ser ⇒ Pro) 1.00E-12 1.08 [89] 
117 rs4380028 15q25.1 CHD 30,482 / 40,593 ADAMTS7 - TRNAK6 C   4.00E-09 1.07 [92] 
118 rs7173743 15q25.1 CAD 109,124 ADAMTS7 - TRNAK6 C   7.00E-08 1.08 [90] 
119 rs3883013 15q25.2 CHD 94 from 32 families UBE2Q2P1 G intron 3.00E-07 29 [95] 
120 rs7203193 16p13.13 CHD 8,090 / 8,849 LITAF A nearGene-3 3.00E-06 0.08 [85] 
121 rs16965039 16q13 CHD 8,090 / 8,849 NLRC5 T intron 6.00E-07 0.14 [85] 
122 rs3729639 16q22.1 CHD 8,090 / 8,849 E2F4;EXOC3L1 T nearGene-5; 
 
2.00E-11 0.09 [85] 
123 rs8060686 16q22.1 CHD 8,090 / 8,849 EDC4 T cds-synon 8.00E-06 0.07 [85] 
124 rs16971384 16q22.3 CHD 8,090 / 8,849 ZFHX3 A intron 5.00E-06 0.07 [85] 
125 rs8055236 16q23.3 CHD 4,864 / 2,519 CDH13 G intron 6.00E-06 1.91 [80] 
126 rs12936587 17p11.2 
CHD 86,995 / 56,682 
EEF1A1P43 - RAI1 
G 
  
4.00E-10 1.07 [89] 
CAD 109,124 A 2.00E-07 1.08 [90] 
127 rs1231206 17p13.3 CHD 86,995 / 56,682 SMG6 A intron 9.00E-10 1.07 [89] 
128 rs216172 17p13.3 CHD 86,995 / 56,682 SMG6 C intron 1.00E-09 1.07 [89] 
129 rs2281727 17p13.3 CAD 109,124 SMG6 G intron 1.00E-07 1.07 [90] 
130 rs11650066 17q12 CHD 30,482 / 40,593 ASIC2 ? intron 6.00E-06 NR [92] 
131 rs46522 17q21.32 CHD 86,995 / 56,682 UBE2Z T intron 2.00E-08 1.06 [89] 
132 rs6504218 17q23.3 CHD 30,482 / 40,593 PECAM1 ? intron 1.00E-06 NR [92] 
133 rs1122608 19p13.2 




2.00E-09 1.15 [91] 
CHD 86,995 / 56,682 G 1.00E-09 1.14 [89] 
CAD 109,124 T 3.00E-11 1.14 [90] 
134 rs11669133 19p13.2 CHD 8,090 / 8,849 SMARCA4 A intron 1.00E-08 0.17 [85] 
135 rs11671653 19p13.2 CHD 8,090 / 8,849 DNM2 A intron 9.00E-07 0.11 [85] 
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Table 1 (continued): Main GWAS findings for CAD / CHD / MI / MI early onset 
  SNPs Region Disease/Trait Sample Size Mapped gene Risk Allele Context p OR or beta Reference 
136 rs4804155 19p13.2 CHD 8,090 / 8,849 DOCK6 C intron 5.00E-06 0.08 [85] 
137 rs3803915 19p13.3 MI 4,864 / 39,809 AP3D1 - DOT1L C   4.00E-09 1.12 [96] 
138 rs1475591 21q22.11 CHD 8,090 / 8,849 UBE3AP2 - TIAM1 T   6.00E-06 1.18 [85] 
139 rs9982601 21q22.11 
MI (early onset) 6,042 / 19,492 
LINC00310 - KCNE2 
T 
  
6.00E-11 1.20 [91] 
CHD 86,995 / 56,682 T 4.00E-10 1.18 [89] 
CAD 109,124 T 3.00E-10 1.18 [90] 
140 rs1735151 21q22.2 CHD 8,090 / 8,849 IGSF5 T intron 9.00E-06 1.16 [85] 
141 rs688034 22q12.1 CHD 4,864 / 2,519 SEZ6L T intron 4.00E-06 1.11 [80] 
142 rs5943057 Xq23 CHD 30,482 / 40,593 CHRDL1 ? intron 9.00E-07 NR [92] 
143 rs1190739 Xq26.3 CHD 8,090 / 8,849 SNORD61 - SRRM1P3 T   5.00E-06 0.07 [85] 
144 rs5904726 Xq27.3 CHD 8,090 / 8,849 MIR508 - MIR514B A   9.00E-06 0.06 [85] 
CAD: coronary artery disease; CHD: coronary heart disease; MI: myocardial infarction; OR: odds ratio; UTR: untranslated region 
Sample size was displayed as Initial Sample Size / Replication Sample Size
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that the enhancer interval in 9p21.3 can physically interact with methylthioadenosine 
phosphorylase (MTAP), CDKN2A/B and downstream of INFA21 in human vascular 
endothelium cells (HUVEC) [103].  The structure of the chromatin and the 
transcriptional regulation of the 9p21 region could be strongly influenced by 
activation of interferon gamma (IFNγ) thus a link between 9p21.3 and response to 
inflammatory signaling in vascular cells was established [103]. 
 
As mentioned above, 95 of the CAD associated SNPs are within or near 
protein-coding genes.  Some of these genes are related to CAD risk factors, such as 
cholesteryl ester transfer protein (CETP) [104], a gene involved in the transportation 
of cholesteryl ester from HDL to other lipoproteins and apolipoprotein A5 (APOA5), 
a gene regulating the plasma level of a major CAD risk factor, triglyceride [105].  
However, many genetic variants revealed by GWAS lack of biological relevance and 
the mechanisms involved are largely unknown, such as dynamin 2 (DNM2), the 
protein encoded by which is one of the subfamilies of GTP-binding proteins.  This is 
one of the drawbacks of GWAS.  It can easily discovered SNPs associated with a 
disease but on its own, is unable to specify the casual relationship involved [106]. 
 
Ethnicity also plays an essential role in identification of CAD related genetic 
variations.  Some SNPs are generally transferable between ethnic groups, such as 
the genetic variants from the 9p21.3 region and SNPs from 6p24.1 region [84, 99] 
while some other SNPs have been identified specifically in certain ethnicities thus far.  
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One of the examples is rs6903956 in the C6orf105 region.  The association was first 
identified in a GWAS conducted in Han Chinese population with a discovery cohort 
of 230 cases and 230 controls followed by a validation cohort of 572 cases and 436 
cohorts.  The association was then replicated in a larger cohort of 2,668 cases and 
3,917 controls.  The minor allele A of rs6903956 was found to reduce mRNA 
expression of C6orf105 and increase risk of CAD [46].  The SNP was also reported 
to be associated with angiographical characteristics of coronary atherosclerosis in a 
Chinese population [107].  C6orf105 was later found to code for a transmembrane 
protein which could regulate TFPI both in native condition and treated with androgen 
in the aspect of mRNA expression, cellular distribution and cell associated 
anticoagulant activity [108].  Although the association failed to be replicated in a 
meta-analysis study conducted in two Chinese cohorts with larger sample size of 
1,515 cases and 5,019 controls in total, it has been replicated in other independent 
Chinese cohorts [107], including the Singaporean Chinese [47].  The mechanism 
underlying this association is still unknown. 
 
2.2.2 GWAS of CAD related risk factor traits 
CAD related risk factor traits including HDL cholesterol, LDL cholesterol, TG, 
diabetes, fasting glucose related traits, blood pressure (BP, systolic/diastolic blood 
pressure), obesity, BMI and C-reactive protein (CRP).  To date, 853 SNPs from 325 
loci were reported to be associated with these CAD related risk factor traits.  Among 
these SNPs, 518 SNPs (60.73%) are within or near protein-coding genes and 75 of 
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them are known to be functional. 
 
There are 110 SNPs from 71 loci that were found to be associated with BP, including 
SBP and DBP.  The first GWAS on BP was conducted in Framingham Heart Study 
in 2007 and weak association was found between SNPs in the 
renin-angiotensin-aldosterone pathway and BP [109].  A total of 211 SNPs from 107 
loci had an association with BMI or obesity.  The first BMI GWAS was conducted 
in 2007 and identified a genetic variant from FTO gene, which has shown the 
strongest association with BMI and obesity [110, 111] thus far.  In total, 48 SNPs 
from 23 risk loci had an effect on CRP level.  The first GWAS of CRP was 
conducted in a European population with a discovery cohort of 909 individuals 
followed by a replication with 5,106 subjects.  The study found that genetic variants 
from hepatocyte nuclear factor-1α (HNF1A) gene could affect CRP level [112].  A 
total of 209 SNPs from 123 loci were reported to be associated with type 2 diabetes, 
including fasting glucose-related traits.  The first GWAS for diabetes was carried out 
in Caucasians in 2007 with a discovery population of 661 cases and 614 controls 
followed by a replication cohort with 2,617 cases and 2,894 controls.  The study 
identified four loci associated with risk for diabetes, including one known association 
with transcription factor 7 like 2 (TCF7L2) gene and three novel associations [113].  
In total, 292 SNPs from 134 risk loci were reported to be associated with plasma lipid 
levels, including HDL, LDL and TG.  The first HDL GWAS was carried out in a 
cohort with a discovery population of 8,656 European ancestry individuals followed 
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by a replication population of 11,437 European ancestry individuals.  The study 
identified ten SNPs that were associated with plasma HDL levels [114], some of them 
was proven to implicate in lipid metabolism while some were newly identified.  The 
first LDL GWAS was conducted in 2008 and confirmed the association between 
SNPs close to proline and serine rich coiled-coil 1 (PSRC1) gene and LDL level in 
1,955 European ancestry hypertensive individuals and replicated the association in 
2,033 European ancestry individuals from 519 families as well as 1,461 European 
ancestry twins [115].  In 2007, the first TG GWAS was carried out in 5,217 
Caucasians.  The study identified and confirmed a novel association between genetic 
variant from glucokinase regulatory protein (GCKR) gene and serum TG level [116]. 
 
2.2.3 Genotype calling 
As mentioned previously, GWAS is usually an investigation of many SNPs in a group 
of cases and controls to determine if any SNP is associated with a diseases trait.  It is 
based on genotyping of a subset of SNPs that can provide as much as the coverage of 
the entire genome by linkage disequilibrium (LD) using genotype arrays.  Bi-allelic 
SNPs will have three genotypes, major allele homozygote (AA), heterozygote (Aa) 
and minor allele homozygote (aa).  The process of genotype determination for an 
individual at a specific SNP site by estimating the probability using genotype calling 
algorithms for the three genotypes is termed genotype calling.  Cutoff will be 
applied to determine the genotypes. Only those with values above the cutoff will be 
accepted while the rest will be set as missing.  Early studies used Phredtype quality 
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score of Q20 (QPhred = 20) as fixed cutoff and determined genotypes by counting the 
number of times each allele is observed.  Recent studies incorporate uncertainty in a 
probabilistic framework to deal with the issues caused by fixed cutoff, such as 
under-calling of heterozygous genotypes [117].  Development of genotype calling 
algorithms and choosing of cutoff are crucial for data quality.  It should be also 
noted that the minor allele frequency (MAF) can also affect genotype calling.  The 
accuracy is mostly gained for SNPs moderate or high allele frequencies [117]. 
 
2.2.4 Quality control 
Quality control (QC) is an essential process in GWAS to minimize bias and 
false-positive or false-negative findings.  It comprises SNP QC and sample QC. 
 
2.2.4.1 SNP QC 
SNP QC, also called per-marker QC, removes SNPs that had at least one of the 
following features (1) SNPs with excessive missing genotype (> 5.0%), (2) SNPs 
with significant departure from Hardy-Weinberg Equilibrium (HWE, P < 10-6-10-4) in 
controls, (3) SNPs with significantly different missingness in cases and controls, and 
(4) monomorphic SNPs or SNPs with very low minor allele frequency (MAF, < 1.0%) 
[118]. 
 
Excessive missing of genotypes or significantly different missingness in cases and 
controls indicate the poor quality of the genotype calling for the specific SNP.  HWE 
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is a statement that in the absence of evolutionary influences, such as mate choice and 
mutation, the allele and genotype frequencies in a population will stay constant from 
generation to generation.  It is normally examined by Pearson’s χ2 test.  Significant 
departure from HWE indicates genotype calling errors and selection bias [119].  
With the use of current genotype calling algorithms, it is difficult to determine the 
genotypes of rare variants.  Even though the genotype calling is correct, association 
signals observed at the site of these rare variants are less robust as they are driven by 
the genotypes of only a few individuals.  Thus those SNPs with MAF less than 0.01 
should be removed from further analysis. 
 
2.2.4.2 Sample QC 
Sample QC, also called per-individual QC, removes individuals that had at least one 
of the following features: (1) individuals with discordant information on gender, (2) 
individuals with excessive heterozygosity or missingness of genotypes, (3) duplicates 
(monozygotic twins) or related individuals (first-degree relatives), (4) individuals 
with divergent ancestry or discordant ethnic information [118]. 
 
Excessive missingness of genotypes indicates the poor quality of DNA samples.  
Heterozygosity is calculated as (N − O)/N, where N is the total number of 
non-missing genotypes and O is the observed number of homozygous genotypes for 
an individual.  Excessive of heterozygosity indicates contamination or inbreeding of 
DNA samples.  The presence of duplicates (monozygotic twins) or related 
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individuals (first-degree relatives) will introduce bias into studies since genotype 
within families will be over represented.  The familial relationship can be checked 
by identity by descent (IBD).  It calculates the shared allele proportion for each pair 
of samples for independent SNPs.  IBD of one means the samples are duplicates or 
monozygotic twins and IBD of 0.5 shows first degree familial relationship.  If 
individuals with divergent ancestry or discordant ethnic information are included in 
the study, the associations identified might be due to different population origins and 
thus spurious. 
 
2.2.5 Linkage disequilibrium 
LD is the non-random and dependent association between alleles at different loci.  If 
the frequency of association of different alleles at different loci were different from 
what is expected when the loci were independent and associated randomly, they were 
in LD with each other [120].  Many factors can affect LD between different loci, 
such as recombination rate, selection, population structure and mutation rate.  The 
LD between SNPs was calculated by the pairwise correlations (Pearson correlation) 
[121] using STATA 12.0 (Stata Corp, College station, TX).   
 
2.2.6 Imputation 
Genotype imputation is performed as a key step in most GWAS that can predict 
genotypes for SNPs not present on the genotyping chip [122].  This is achieved by 
using known haplotypes in a population based on high LD.  It could largely increase 
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the number of SNPs assessed for association and enables meta-analysis of GWAS 
across diverse cohorts or genotyped using different array chips.  Imputation is 
carried out by combining GWAS data based on tagging SNPs and a reference panel 
that have been genotyped for a larger number of genetic variants, such as those from 
the Hapmap [123] and 1000 Genome Project [124].  The most frequently used 
software for imputation currently as well as in our study is IMPUTE [125]. 
 
2.2.7 Meta-analysis 
Meta-analysis uses approaches from statistics to combines the data and results from 
multiple studies.  It is under the theory that a common truth behind all conceptually 
similar scientific studies might have certain measurement errors within individual 
studies but it can be revealed in a pooled estimate closest to the unknown common 
truth.  Meta-analysis can increase statistical power in the pooled study, improve 
estimates of effect size and resolve uncertainty between individual studies.  
Meta-analysis makes use of a common statistical measure among individual studies 
termed effect size with a standard error (SE).  A weighted average is calculated for 
effect size, which usually considers the sample sizes and study quality of different 
studies.  Several methods could be used to do the meta-analysis, such as the P value 
meta-analysis, fixed effects meta-analysis, random effect meta-analysis, Bayesian 
approach meta-analysis, multivariate approaches meta-analysis [126].  In this thesis, 
inverse variance-weighted, fixed-effects meta-analysis was used to meta-analyze the 
results from individual cohorts since fixed effects meta-analysis is the most popular 
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and powerful approach for prioritizing and discovering phenotype-associated SNPs 
[127].  It maximizes discovery power compared to random effects models [128].  
However, bias might exist if there is excessive heterogeneity [126].  Since the 
cohorts involved in the current studies are all Singaporean Chinese, we assumed that 
effect of each risk allele is the same in individual cohorts and Cochran’s Q test was 
used to measure between-study heterogeneity. 
 
2.2.8 Multiple testing 
As mentioned above, GWAS have several issues and limitations.  The issue of 
multiple testing is one of the limitations and it has been known that "the GWA 
approach can be problematic because the massive number of statistical tests 
performed presents an unprecedented potential for false-positive results" [129]. 
 
Multiple testing usually occurs when a study takes several statistical inferences into 
consideration simultaneously [130].  When a great number of statistical tests are 
performed, it will be more likely to introduce errors in inference or incorrectly reject 
the null hypothesis.  Several statistical methods have been developed to avoid 
multiple testing problems, such as false discovery rate (FDR) and Bonferroni 
correction.  FDR conceptualizes rate of type I error in null hypothesis testing when 
multiple testing are conducted.  It controls the expected proportion of rejecting null 
hypotheses incorrectly [131].  FDR is calculated as V / (V+S), where V is the total 
number of false positives (type I error) and S is the total number of true positives.  
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FDR is less stringent compared to Bonferroni correction.  Bonferroni correction also 
controls for type I error.  It maintains the familywise error rate (FWER) by using a 
more stringent statistical significance level, calculated as α / N, where α is the 
significance level and N is the total number of independent statistical tests. 
 
2.3 Framingham Heart Study and development of risk prediction 
models 
2.3.1 Framingham Heart Study 
In 1948, it was noted that 44% of total deaths were attributed to CVD, which was 20% 
higher than the proportion in 1940 [132].  However, almost nothing was known for 
the epidemiology of arteriosclerotic or hypertensive CVD at that time and it was 
believed that clogging and narrowing of arteries were normal phenomena due to 
aging.  The urgent need to elucidate the causes of CVD led to the inauguration of the 
FHS.  This is a long-term, longitudinal study conducted on the residents of the town 
Framingham, Massachusetts, USA.  It is the most seminal and well-designed 
prospective study in CVD epidemiology.  The investigation was inaugurated in 1948 
and recruited 5,209 healthy individuals aged 30 to 62 as its study subjects. It is still 
on-going currently and has two collateral investigations, the Offspring study initiated 
in 1971 and the Third generation study started in 2002 [133].  Some studies for CHD 
used FHS as a model for study design [134, 135].  Much of the current 
understanding of CVD, such as the contribution of lifestyle environmental factors and 
genetic factors to cardiac health, is obtained from the FHS.  In addition, the term 
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‘risk factor’ was first introduced by this study.  The FHS identifies a great many of 
risk factors related to CVD.  In 1956, it was revealed that risk of CVD was 
significantly associated with age and gender, with male having higher risk than 
female [136].  In 1960, FHS found cigarette smoking was a significant risk factor in 
the development of heart disease and that the association was dose related.  The 
finding was confirmed later along with other studies and further revealed that 
cigarette smoking can lead to angina pectoris, MI and even coronary death [137, 138].  
Later in 1961, high blood pressure, elevated serum cholesterol and electrocardiogram 
abnormalities were found to increase the risk of heart disease in FHS [139].  In 1967, 
it was identified that obesity [140] can increases risk while physical activities can 
decrease risk [141].  In 1970, an association was found between high blood pressure 
and increased risk of stroke [142] and atrial fibrillation can increase stroke risk by 
5-fold [143].  In 1976, it was shown that postmenopausal women have higher 
chance of getting heart disease than women who are premenopausal [144].  In 1978, 
psychosocial factors were found to have an effect on heart disease risk [145].  In 
1988, it was found that in contrast to LDL and total cholesterol level, high levels 
of HDL cholesterol could reduce risk of death [146].  In 1994, an association was 
found between enlarged left ventricle and increased stroke risk [147].  In 1998, an 
association was identified between atrial fibrillation and risk of all-cause mortality 
[148].  In 2001, it was found that in addition to hypertension (SBP no less than 
140 mm Hg and/or diastolic blood pressure (DBP) no less than 90 mm Hg), high 
normal blood pressure, also called pre-hypertension (SBP of 120-139 mm Hg and/or 
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DBP of 80-89 mm Hg) could also increase risk of CVD [149].  In 2002, obesity was 
confirmed to be a risk factor for heart failure [150].  In 2010, sleep apnea was found 
to be associated with increased risk of stroke [151]. 
 
2.3.2 Risk prediction models 
CHD is a chronic disease and the atherosclerotic process begins long before disease 
onset.  Many contributing risk factors modulate the probability of developing CHD.  
Being able to identify individuals who are apparently healthy but are at high risk of 
developing CHD would be important for implementing early intervention and 
treatment. 
 
As mentioned, many CHD risk factors have been identified in FHS, which makes it 
possible to use phenotypic risk factors to predict the probability of healthy individuals 
getting CHD after a couple of years.  In 1991, Anderson et al [152] developed the 
first prediction equation based on the Framingham data using a non-proportional 
hazards Weibull accelerated failure time regression model.  Prior to this study, most 
prediction equations used fixed follow-up period [153, 154].  The inclusion of the 
time period improved the accuracy of the prediction model.  However, in this study, 
the authors only derived the prediction equation using CHD, which includes MI, 
angina pectoris, coronary insufficiency, and sudden death, as the outcome.  For the 
risk predictors, they only made use of age, SBP, cholesterol, metropolitan relative 
weight and cigarette smoking.  The definition for the outcome was ambiguous and 
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only a few risk factors were taken into consideration.  Aware of the limitations of the 
study, Anderson et al revised the model in the same year [155].  In this updated study, 
more phenotypic risk factors were taken into account, including age, sex, SBP / DBP, 
cholesterol, HDL, smoking, diabetes and electrocardiography (ECG-LVH).  
Moreover, a point score algorithm was developed in the same study, which enabled 
the estimation of CHD risk for middle-aged patients by assigning a point score to 
each risk factor and then added up together.  The point score algorithm would be 
more applicable in clinical use than the equations.  The issue is that the updated 
study still mixed several CVD endpoints together, such as stroke, transient ischemia 
and CHD.  Although they are all under the category of CVD, they still have 
differences in origins.  To address this issue, the same group of authors developed 
separate prediction equations for several CVD endpoints, including MI, CHD, death 
from CHD, stroke, CVD, and death from CVD [156].  It was found that most 
estimation of predicted probabilities was quite accurate and a separate equation was 
desirable for stroke.  In 1998, Wilson et al [157] developed a simplified coronary 
prediction model, building on age, blood pressure, cigarette smoking, diabetes, HDL 
and cholesterol / LDL-C for males and females separately.  Blood pressure was 
categorized into the following: optimal (SBP less than 120 mm Hg and DBP less than 
80 mm Hg), normal BP (SBP: 120-129 mm Hg or DBP: 80-84 mm Hg), high normal 
BP (SBP: 130-139 mm Hg or DBP: 85-89 mm Hg), hypertension stage I (SBP: 
140-159 mm Hg or DBP 90-99 mm Hg) and hypertension stage II-IV (SBP no less 
than 160 or DBP no less than 100 mm Hg) according to Fifth Joint National 
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Committee on Hypertension (JNC-V) definitions [158].  Total cholesterol (less than 
200, 200-239, 240-279 and no less than 280 mg/dL), LDL (less than 130, 130-159 
and no less than 160 mg/dL) and HDL (less than 35, 35-59 and no less than 60 mg/dL) 
were all grouped into categorical variables according to National Cholesterol 
Education Program, Adult Treatment Panel II (NCEP ATP II) guidelines [159].  The 
model developed in this study was much simpler than previous ones and included risk 
factors commonly known in recent years.  In addition, the score sheet developed in 
this study was much more systematic and applicable.  As a result, the model has 
been widely used since then.  It allowed physicians to predict multivariate CHD risk 
in patients without overt symptom.  After the risk prediction equations were 
developed and validated in the FHS, researchers began to be interested in the 
performance of the models in various non-US cohorts [160-163].  Some studies 
found the performance of the FHS equations were acceptably accurate [160] while 
other studies found that the FHS equations would over-estimate individual risk in 
their cohorts [161-163].  Since the performance of the FHS equation was not 
satisfying in most of the non-US cohorts, recalibration of the model is necessary to 
improve the prediction accuracy.  In 2001, D'Agostino Sr et al first validated the 
FHS equation in 6 prospectively studied and ethnically diverse cohorts [164].  It was 
found that the FHS equation performed reasonably well for white men and women 
and for black men and women for prediction of CHD events within 5 years of 
follow-up while the equation over-estimated the risk of 5-year CHD events for 
Japanese American, Hispanic men and Native American women.  In the recalibrated 
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models, the regression coefficients were from the FHS while the mean values of the 
risk factors and average incidence rate were replaced by those estimated from the 
local cohorts.  After recalibration by taking into consideration the different 
prevalence of risk factors and underlying rates of developing CHD, the recalibrated 
FHS equation performed well in all the cohorts.  In 2004, the same recalibration 
method was applied to a large Chinese population [165].  It was also found that after 
recalibration, the model no longer over-estimated CHD risk in Chinese, which 
indicated the effectiveness of the recalibration method. 
 
Since CHD is a complex disease that both genetic, lifestyle factors and their 
interactions contribute to the etiology of the disease.  Therefore, besides lifestyle 
factors, genetic variations are likely to have a prominent role in the etiology of CHD.  
The advances of GWAS have made it possible to assess many SNPs across the 
genome and uncovered SNPs that are associated with CHD and its related risk factor 
traits.  The identification of these SNPs provides a chance to evaluate whether the 
inclusion of genetic variants could improve risk prediction model performances in 
addition to phenotypic risk factors.  Some studies have tried to integrate genetic 
factors into the model in European ancestry individuals, including the FHS [166-168].  
It was found that adding genetic factors will improve model performance in some of 
the investigation [166, 168] while others found that the results remained the same 
[167].  However, similar and systematic studies are lacking in non-European 
populations, including in Singaporean Chinese. 
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2.4 Gene-gene and gene-environment interaction studies 
As mentioned earlier, CAD as well as its metabolic risk factor traits, specifically 
referring to as BMI / obesity and HDL in this dissertation, are complex diseases that 
both genetic, lifestyle factors and their interactions contribute to the etiology of the 
disease.  In the last section of this chapter, research related to gene-gene and 
gene-environment interaction studies will be reviewed. 
  
2.4.1 Gene-gene interaction study 
Gene-gene interaction, also known as epistasis, is the phenomenon that the function 
of one gene is modified by other gene(s) thus the combined effect of multiple genes is 
different from their individual effect.  Statistically speaking, interaction indicates the 
departure from a linear model, which describes the relationship between some 
predictor variable(s) (independent variable) and the outcome variable (dependent 
variable) [169].  Epistasis can be classified into additivity, magnitude epistasis and 
sign epistasis.  Additivity indicates that there is no interaction exists between genes 
and the effect of the double mutation is calculated by summing up individual 
mutation effect together.  Magnitude epistasis includes positive epistasis, negative 
epistasis, synergistic epistasis and antagonistic epistasis.  Positive epistasis is that 
the phenotype of double mutation is fitter than expected from single mutation effects 
[170, 171].  If both of the mutations are beneficial, when the two mutations present 
together, the improvement will be larger.  If both of the mutations are deleterious, 
the combination of them will have a protective effect [172].  Negative epistasis is 
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just the opposite [173, 174].  Synergistic epistasis refers to as the fitness effect of 
two mutations is more drastic than expected from single effect while antagonistic 
epistasis is just the opposite [175].  Synergistic epistasis is negative and antagonistic 
epistasis is positive for deleterious mutations while situation is just the opposite for 
advantageous mutations.  Sign epistasis is the effect of one mutation becoming 
opposite in the presence of another mutation [176].  The most extreme form of sign 
epistasis is called reciprocal sign epistasis, which occurs when the effect of two 
deleterious genes becomes beneficial [177]. 
 
The interactions between genes have an essential role both in the function and 
structure of genetic pathways, as well as the evolutionary dynamics of complex 
diseases [170].  The motivation of gene-gene interaction investigation for human 
complex disease is the previous failures to replicate genetic findings in different 
cohorts and ethnicities.  It is believed that the differences between individual genetic 
effects in different cohorts might be due to fundamental complexity caused by 
epistasis [178, 179].  Several diseases have been shown to exhibit epistasis, such as 
type 2 diabetes [180], bipolar effective disorder [181] and CAD [182].  The major 
limitation of gene-gene interaction studies is the total number of tests conducted, 
which roughly equals to the square of the number of genes.  Stringent significance 
threshold will be set in order to control false positive findings thus the sample size of 




2.4.2 Gene-environment interaction study 
Gene–environment interaction (G×E) is the phenomenon that different genotypes 
respond to environmental variation differently.  It can lead to different disease 
phenotypes since the response to the same environmental factors are different in 
individuals with different genotypes.  Gene–environment interaction has two 
different conceptions, biometric / statistical interaction and developmental / 
commonsense interaction [184, 185].  The biometric (statistical) conception tries to 
measure the relative proportions of contributions to phenotypic variation within 
populations due to genetic and environmental factors while developmental 
(commonsense) conception commonly used in the area of developmental genetics and 
developmental psychobiology.  Gene-environment interaction studies can also be 
classified into different types, including synergy, modification and redundancy [186].  
The study of gene–environment interactions is important for several reasons.  First 
of all, a better estimation for the proportion of the disease explained by the 
environment, genes and their combined effect can be gained by conducting such 
studies (population-attributable risk).  Secondly, the association between 
environmental factors and diseases can be strengthened in genetically susceptible 
individuals, increasing the probability of identifying true associations.  Thirdly, it 
makes use of information on susceptibility genes to reveal the disease mechanisms 
and focus on the biological pathways and the environmental factors related to the 
pathways.  Fourthly, it identifies the key compounds leading to the disease from a 
mixture of compounds that human exposed to.  Fifthly, researchers can design new 
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preventive and therapeutic strategies based on biological pathways information.  
Lastly, individuals with different genotypes can respond to environmental stimuli 
differently according to the results from gene-environment interaction studies thus 




Chapter 3: Study populations and methods 
This thesis is focused on the genetic epidemiology of CAD and its risk factors in 
Singaporean Chinese who are mainly the second or third generation migrants from 
the southeastern coastal provinces of China (Fujian, Guangdong and Hainan).  It is 
the largest ethnic group in Singapore, constituting 76.2% of Singaporean citizens in 
2014 (http://www.nptd.gov.sg/portals/0/news/population-in-brief-2014.pdf).  In this 
chapter, detailed information regarding the Chinese cohorts, anthropometric and 
laboratory measurements, genotyping and quality control of SNPs and samples in 
these study populations that were involved in our multiple studies will be described. 
 
3.1 Study populations 
3.1.1 Singapore Chinese Health Study (Study II, III and IV) 
The Singapore Chinese Health Study (SCHS) is a population-based long term 
prospective study focused on the effect of dietary intake, genetic factors and 
environmental components on cancer and other chronic diseases in Singapore [188].  
A total of 63,257 Chinese individuals aged between 45-74 years (mean age 56.5), 
were recruited into SCHS from April 1993 to December 1998.  Participants of the 
study were restricted to Chinese individuals from two major dialect groups in 
Singapore, the Cantonese, who were originally from Guangdong Province and the 
Hokkiens, who originated from southern Fujian Province.  The study subjects were 
residing in government-built estates which housed 86% of the Singapore population 
during the enrolment period.  At recruitment, all the study subjects were interviewed 
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in-person at home by a trained interviewer with a structured questionnaire.  In April 
1994, a 3% random sample of study subjects was re-contacted for donation of blood 
specimens and the effort was later extended to include all consenting cohort enrollees, 
which led to the collection of blood in 28,439 participants by 2001.  The study was 
approved by the Institutional Review Boards (IRB) of the National University of 
Singapore (NUS) and the University of Minnesota (UMN), and all study subjects 
gave written informed consent. 
 
The first round of followed-up interviews was conducted from 1999 to 2004 and the 
second round was from 2006 to 2010.  During the second round follow-up, MI cases 
(definite MI, probable MI and suspect MI) and CHD death (definite fatal MI, definite 
fatal CHD and possible fatal CHD) were identified and verified in SCHS from the 
following three databases: (a) The Singapore Myocardial Infarction Registry (SMIR); 
(b) A government national hospital discharge database based on inpatient admission 
and discharge information followed by medical record review by a cardiologist using 
MI diagnostic criteria from the Multi-Ethnic Study of Atherosclerosis (ICD-9: 410); 
(c) The Singapore Registry of Births and Deaths (ICD-9: 410–414).  For each case, 
two controls that were alive and free of the disease at the time of the diagnosis or 
death of the index case were matched to the case on year of recruitment, date of birth, 
gender, father’s dialect group and the date of blood collection.  In total, there were 
761 incident cases, including 292 CHD death and 1,400 controls (N = 2,161).  This 
subset forms a CAD case-control study nested within the prospective SCHS.  In the 
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subsequent paragraphs, this subset of the cohort is referred to as SCHS. 
 
3.1.2 Singapore Prospective Study Program (Study III and IV) 
The Singapore Prospective Study Program (SP2) is a population-based 
cross-sectional study of adult Singaporean Chinese, Malay and Asian-Indian samples, 
aged between 24 to 95 years that comprises four previous studies, Thyroid and Heart 
Study (1982–1984) [189], National Health Survey (1992) [190], National University 
of Singapore Heart Study (1993–1995) [191], and the National Health Survey (1998) 
[192] (N = 11,053).  Individuals in these studies were sampled randomly from the 
Singapore population and a disproportionate sampling scheme was utilized to 
increase the sample sizes of Malays and Asian Indians.  After excluding individuals 
who were either deceased as shown by data linkage to the Registry of Births and 
Deaths (N = 517), emigrated (N = 6) and had errors in their identity card number (N = 
85), there were 10,445 individuals eligible for study.  Among these 10,445 subjects, 
2,673 were not contactable and 30 (0.3%) refused to participate.  Thus 7,742 
individuals (response rate: 74.1%) completed the questionnaire and 5,157 of them 
(66.6% of individuals with completed questionnaire) attended the subsequent clinical 
examination.  The flow chart for inclusion of subjects in SP2 has been described 
previously in other studies [193] (Figure 2).  The study was approved by the IRB of 
NUS and the Singapore General Hospital.  All participants gave informed written 




Figure 2: Flow chart of study subjects exclusion in the Singapore Prospective Study 
Program (Nang, Khoo et al. 2009) 
 
 
3.1.3 Singapore Chinese Eye Study (Study IV) 
The Singapore Chinese Eye Study (SCES) is an ongoing population-based 
cross-sectional study of adult Singaporean Chinese aged 40 years old and above. The 
study was conducted from February 2009 and the study subjects were residing in the 
southwestern part of Singapore.  SCES shared the same study protocol with the 
Singapore Malay Eye Study (SiMES) [194] and the Singapore Indian Eye Study 
(Sindi) [195].  The ethnicity of study subjects were established from a census list 
and verified using national identification cards and questionnaire [196].  Participants 
were selected on the basis of an age-stratified random sampling strategy with a list 
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provided by the Ministry of Home Affairs.  In total, 4,605 individuals were eligible 
to participate, and subsequently 3,353 participants were recruited (response rate: 
72.8%).  The study was approved by the IRB of the Singapore Eye Research 
Institute.  All participants gave written informed consent. 
 
3.2 Anthropometric and laboratory measurements 
3.2.1 Singapore Chinese Health Study 
At recruitment, all the study subjects were interviewed in-person by a trained 
interviewer at home with a structured questionnaire.  Cigarette smoking, history of 
diabetes and use of antihypertensive medication were self-reported during the 
interview.  SBP was measured by trained doctors and nurses after the participants 
were seated at rest for at least 5 minutes (mins) using Omron Automatic Digital 
Blood Pressure Monitors (HEM 705CP) three times with a 3-min interval between 
each measurement according to validated standard procedures [197].  The average 
value of the three readings was calculated. 
 
The blood samples from 28,439 participants were kept on ice during transport 
immediately after collection.  They were then separated into various components 
(plasma, serum, red blood cells and buffy coat) and moved into -80°C freezer for 
long-term storage [198]. 
 
Non-fasting total cholesterol concentration was measured based on an enzymatic 
51 
 
method, utilizing cholesterol esterase and cholesterol oxidase conversion [199] by 
using the Siemens Advia 2400 instrument.  HDL concentration was measured 
according to the method of Izawa et al [200].  Concentration of hsCRP was 
measured by particle enhanced immunoturbidimetric assay using Roche Cobas 
Intergra 400 plus (Roche Diagnostics, Rotkreuz, Switzerland).  Creatinine was 
measured by creatininase (Siemens Advia 2400) and hemoglobin A1c (HbA1c) was 
measured by cation-exchange high-performance liquid chromatography (HPLC, 
Biorad Variant II) [201, 202].  The within-batch coefficient of variations (CVs) were 
as follow: total cholesterol (0.5-1.5%), HDL (0.6-0.7%), hsCRP (0.5-2.3%), 
creatinine (0.6-1.1%) and HbA1c (0.9-1.0%).  The between-batch CVs were as 
follow: total cholesterol (1.0-1.3%), HDL (1.2-3.5%), hsCRP (0.9-3.5%), creatinine 
(0.3-1.8%) and HbA1c (0.0-1.0%) [203]. 
 
3.2.2 Singapore Prospective Study Program 
Detailed information on demography and use of anti-hypertensive medication was 
collected by using interviewer-administered questionnaires. 
 
As mentioned above, among 7,742 individuals who completed the questionnaire, 
5,157 of them attended the subsequent clinical examination.  Venous blood was 
drawn and collected after the participants were fasted overnight for 10 hours.  All 
biochemical analyses were performed at the National University Hospital Referral 
Laboratory.  Plasma concentration of total cholesterol and HDL were measured by 
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an automated autoanalyzer (ADVIA 2400; Bayer Diagnostics, Tarrytown, New York).  
The intraday CVs for total cholesterol and HDL were 0.80%-1.57% and 
0.56%-0.65%, respectively.  The interday CVs for total cholesterol and HDL were 
0.93%-1.15% and 1.18%-2.00% respectively [204]. 
 
3.2.3 Singapore Chinese Eye Study 
All study subjects were examined at the Singapore Eye Research Institute.  Data on 
demography and use of anti-hypertensive medication was collected by using 
interviewer-administered questionnaires [205]. 
 
Non-fasting venous blood sample (40ml) was collected for biochemistry tests.  
Plasma concentration of total cholesterol and HDL were measured by using 
turbidimetric inhibition immuno assays with Roche-Cobas® CE analyser (Roche 
Diagnostics, Germany) [206]. 
 
3.3 Genotyping and quality control 
GWAS is an investigation of common genetic variants (mainly SNPs) in a group of 
cases and controls to find out whether there is any variant associated with a disease.  
Genotyping is the process of determining the genetic makeup of an individual.  
Quality control (QC), which includes SNP QC and sample QC, is an essential 
procedure to minimize bias and false-positive or false-negative findings in GWAS.  
SNP QC would remove SNPs that at least had one of the following features: (1) SNPs 
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with excessive missing genotype (> 5.0%), (2) SNPs with significant departure from 
Hardy-Weinberg Equilibrium (HWE, P < 10-6-10-4), (3) SNPs with significantly 
different missingness in cases and controls, and (4) monomorphic SNPs or SNPs with 
very low minor allele frequency (MAF, < 1.0%).  Sample QC would remove 
individuals that had at least one of the following features: (1) individuals with 
discordant information on gender, (2) individuals with excessive heterozygosity or 
missing of genotypes, (3) duplicates (monozygotic twins) or related individuals 
(first-degree relatives), (4) individuals with divergent ancestry or discordant ethnic 
information [118]. 
 
3.3.1 Singapore Chinese Health Study 
A total of 2,161 individuals from SCHS were genotyped on Illumina ZHONGHUA 
Bead 8 Array version 1 (900,015SNPs) (San Diego, California, the United States).  
According to sample QC described above, 158 individuals were excluded due to low 
sample call rate (< 98.0%, N = 35), excessive heterozygosity (beyond the range of 
mean ± 3 standard deviation (SD), N = 20), related samples (monozygotic duplicates: 
N = 42; first-degree relatives: N = 25), discordant ethnicity (N = 2), and outliers 
identified by principle components analysis (N = 34).  After exclusion, there were 
2003 individuals (719 incident cases and 1,284 controls) left for the following 
analysis.  Among the 900,015 SNPs on the chip, 895,493 of them passed genotype 
calling algorithms.  We further excluded 24,461 non-autosomal SNPs, 467 low call 
rate SNPs (< 95.0%), 435 SNPs that significantly departed from HWE (PHWE < 10-6), 
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67,585 SNPs with low MAF (< 1.0%) and 1 SNP without strand information.  In 
total, 802,634 SNPs passed SNP QC procedure.  Detailed information on SNP and 
sample QC in SCHS is presented in Table 2. 
 
Table 2: Quality check of Single Nucleotide Polymorphisms and samples in the 
Singapore Chinese Health Study 
SNP QC 
 Number of exclusion (N) 
Non-autosomal SNPs 24,461 
Low call rate (< 95.0%) 467 
Departure from Hardy-Weinberg Equilibrium in controls (PHWE < 10-6) 406 
Low minor allele frequency (< 1.0%) 67,524 
SNP without strand information 1 
Number of SNPs remained 802,634 
Sample QC 
Low call rate (< 98.0%) 35 
Excessive heterozygosity (beyond the range of mean ± 3 standard deviation) 20 
Monozygotic duplicate 42 
First-degree relative 25 
Discordant ethnicity 2 
Second-degree relatives 17 
Population outlier 17 
Number of individuals remained 2003 
 
3.3.2 Singapore Prospective Study Program 
Among 5,157 individuals who were both completed the questionnaire and attended 
the subsequent clinical examination, 3,236 of them were Chinese ancestry.  A total 
of 3,066 Chinese were genotyped on three different Illumina arrays (San Diego, 
California, the United States): Illumina 1Mduov3 (SP21m, N = 1,016), HumanHap 
610Quad (SP2610, N = 1,467) and HumanHap550 (SP2550, N = 583).  Since 
SP2550 was relatively small, only SP2610 and SP21m were included in the 
subsequent studies.  Based on sample QC procedure, 272 individuals were excluded 
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due to low call rate and excessive heterozygosity (N = 22), relatedness (N = 226), 
discordant ethnic membership (N = 17) or discrepancy of information on gender 
between the genetically inferred and clinically recorded (N = 7) [207].  The number 
of SNPs covered by HumanHap 610Quad and 1Mduov3 was 620,881 and 1,185,068 
respectively [208].  In SP2610, we excluded 20,431 non-autosomal SNPs, 48,765 
SNPs with low call rate (< 95.0%), 53 SNPs that had significant departure from HWE 
(PHWE < 10-4) and 49,596 SNPs with low MAF (< 1.0%).  In SP21m, the number of 
SNPs excluded due to the same criteria with SP2610 was 48,765, 192,334, 122 and 
101,791, respectively.  Another 62 SNPs were further removed due to allelic 
discrepancies between chips.  Detailed information on SNP and sample QC in SP2 is 
presented in Table 3. 
 
3.3.3 Singapore Chinese Eye Study 
In total, 1,952 individuals from SCES were genotyped on the HumanHap 610Quad 
array.  According to sample QC, 63 individuals were excluded due to low call rate 
and excessive heterozygosity (N = 14), relatedness (N = 41), discordant ethnic 
membership (N = 6) or discrepancy in genders (N = 2) [207].  After exclusion, 1,889 
individuals were available for analysis.  A total of 87,891 autosomal SNPs were 
excluded due to low call rate (N = 26,437), monomorphism or low MAF (N = 59,633) 
or significantly deviating from HWE (PHWE < 10-6, N = 1,821).  Detailed information 




Table 3: Quality check of Single Nucleotide Polymorphisms and samples in the 
Singapore Prospective Study Program 
SNP QC 
 Number of exclusion (N) 
 610 1M 
Non-autosomal SNPs 20,431 48,765 
Low call rate (< 95.0%) 48,765 192,334 
Departure from Hardy-Weinberg Equilibrium in controls (PHWE < 10-4) 53 122 
Low minor allele frequency (< 1.0%) 49,596 101,791 
SNP with allelic discrepancies between chips 62 
Number of SNPs remained 492,579 841,994 
Sample QC 
Low call rate (< 98.0%) and excessive heterozygosity (beyond the range 
of mean ± 3 standard deviation) 
10 12 
Cryptic relationship 193 33 
Population outlier 10 7 
Gender mismatch 3 4 
Number of individuals remained  1146 953 
 
Table 4: Quality check of Single Nucleotide Polymorphisms and samples in the 
Singapore Chinese Eye Study 
SNP QC 
 Number of exclusion (N) 
Low call rate (< 95.0%) 26,437 
Departure from Hardy-Weinberg Equilibrium in controls (PHWE < 10-6) 1,821 
Monomorphism or low minor allele frequency (< 1.0%) 59,633 
Number of SNPs remained 492,108 
Sample QC 
Low call rate (< 98.0%) and excessive heterozygosity (beyond the range of 
mean ± 3 standard deviation) 
14 
Cryptic relationship 41 
Population outlier 6 
Gender mismatch 2 
Number of individuals remained 1889 
 
3.4 Imputation 
Genotype imputation is a mathematical approach that can predict unobserved 
genotypes by using known haplotypes in a population based on high LD.  It could 
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largely increase the number of SNPs studied and power of the analysis. 
 
3.4.1 Singapore Chinese Health Study 
In SCHS, additional autosomal SNPs were imputed with IMPUTE v2 [125].  
Genotype calls were based on HapMap East-Asian samples that were derived from 
Han Chinese from Beijing (CHB) and the Japanese in Tokyo (JPT).  A posterior 
probability of no less than 0.90, a call rate of no less than 95.0 % and info score more 
than 0.50 were applied to all imputed SNPs.  SNP QC was conducted separately in 
CAD cases and controls.  In cases, SNPs were excluded due to low MAF (N = 
207,426), significantly departed from HWE (PHWE < 10-5, N = 278), low call rate (N = 
433,049), low info score (N = 9) and 1,169,467 imputed SNPs were left for analysis.  
In controls, SNPs were excluded due to low MAF (N = 206,201), significantly 
departed from HWE (PHWE < 10-5, N = 794), low call rate (N = 426,042), low info 
score (N = 5) and 1,177,187 imputed SNPs passed QC [209].  The information 
regarding SCHS SNP QC is displayed in Table 5. 
 
3.4.2 Singapore Prospective Study Program 
In SP2, imputation was conducted by using IMPUTE v0.5.0 [125] for all study 
subjects to maximize the information available.  Genotype calls were based on the 
phased haplotypes in Phase 2 release 22 of the International HapMap Project 
(HapMap2 r22) East-Asian samples (CHB + JPT) [207, 208].  Actual genotyped 
calls were replaced back and a call rate of no less than 95.0 % and a posterior 
probability of no less than 0.90 were applied to all imputed SNPs.  In SP2610, SNPs 
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were excluded due to low MAF (N = 189,571), significantly departed from HWE 
(PHWE < 10-4, N = 392,044), low call rate (N = 1,668), low info score (N = 6) and 
1,342,046 imputed SNPs were left for analysis.  In SP21m, SNPs were excluded due 
to low MAF (N = 153,908), significantly departed from HWE (PHWE < 10-4, N = 
225,135), low call rate (N = 761), low info score (N = 4) and 1,229,818 imputed 
SNPs passed QC [208].  The information regarding SP2 SNP QC is displayed in 
Table 6. 
 
Table 5: Quality check of imputed Single Nucleotide Polymorphisms in the 
Singapore Chinese Health Study 
 MI cases MI controls 
Low minor allele frequency (< 1.0%) 207,426 206,201 
Departure from Hardy-Weinberg Equilibrium (PHWE 
< 10-5) 
278 794 
Low call rate (< 95.0%) 433,049 426,042 
Low info score (< 0.50) 9 5 
Number of SNPs remained 1,169,467 1,177,187 
 
Table 6: Quality check of imputed Single Nucleotide Polymorphisms in the 
Singapore Prospective Study Program 
 610 1M 
Low minor allele frequency (< 1.0%) 189,571 153,908 
Departure from Hardy-Weinberg Equilibrium (PHWE 
< 10-4) 
392,044 225,135 
Low call rate (< 95.0%) 1,668 761 
Low info score (< 0.50) 6 4 




Chapter 4: The genetic variation rs6903956 in the novel ADTRP 
gene is not associated with levels of plasma coagulation factors 
in the Singaporean Chinese 
4.1 Introduction 
CAD is one of the most important causes of mortality and morbidity in both 
developed and developing countries [5], with men having higher disease risk than 
women of a given age [7, 210].  In 2013, it resulted in 8.14 million deaths (16.8%) 
compared to 5.74 million deaths (12%) in 1990 [2].  CAD occurs when 
atherosclerosis develops and plaques form to narrow and block the coronary arteries.  
Patients may not be aware of it for decades until a sudden heart attack finally arises, 
which brings a heavy disease burden to the public health system and the individuals.  
CAD is a complex disease and its susceptibility is contributed by genetic and lifestyle 
components (smoking, diet and physical inactivity) as well as their interactions. 
 
With the recent rapid development of genotyping technologies, GWAS have 
increasingly been used to identify susceptibility loci for complex diseases.  Several 
novel susceptibility loci have also been reported for CAD thus far, including 
rs6903956 in the C6orf105 region of chromosome 6p24.1, which was specifically 
identified in the Chinese population.  The minor risk allele A of rs6903956 was 
found to be associated with reduced mRNA expression of C6orf105 and increased 
risk of CAD [46].  This region was later found to code for a novel transmembrane 
protein which could regulate mRNA expression, cellular distribution and 
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anticoagulant activity of tissue factor pathway inhibitor (TFPI), both in native 
conditions and in response to androgen.  Thus the novel protein has been named 
androgen-dependent TFPI regulating protein (ADTRP).  It was further reported that 
a decreased expression of ADTRP resulted in the reduction of mRNA expression of 
TFPI.  Therefore, ADTRP is postulated to have an anti-coagulating effect [108]. 
 
TFPI is a known inhibitor of coagulation, as it reversibly inhibits Factor Xa (FXa) 
and also tissue factor-factor VIIa (TF-FVIIa) complex in the presence of FXa.  
TF-FVIIa complex is the main initiator of the extrinsic coagulation cascade in 
cardiovascular disease [211].  Tissue factor (TF) is normally found on the outside of 
blood vessels and not exposed to the blood.  Once injury occurs, TF is exposed to 
the bloodstream and binds to circulating FVII [212, 213].  FVII will be then rapidly 
converted to the activated form (FVIIa), which binds factor X (FX) and results in its 
conversion to activated FX (FXa), leading eventually to thrombin activation.  
Thrombin converts soluble fibrinogen to insoluble fibrin strands and form blood clots 
[213-215].  Previous studies have shown that coagulation factors have an essential 
role in advancing atherosclerosis and CAD [49-51].  High levels of FVII coagulant 
activity (FVIIc) and fibrinogen have been found to be significantly associated with 
increased risk of coronary events [52]. 
 
Previously, the association between rs6903956 within the first intron of ADTRP and 
risk for CAD was replicated in our Singaporean Chinese population [47].  The study 
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also found that the association was not mediated through plasma lipid levels.  As 
ADTRP has been found to up-regulate TFPI, we hypothesized that it is likely to have 
an impact on key coagulation factors, such as FVIIc and fibrinogen, which are known 
to have an association with CAD risk.  The effect of the genetic variant in ADTRP 
on CAD might thus be due to its impact on plasma FVII and fibrinogen levels.  This 
study was conducted to investigate the effect of the rs6903956 variant on FVIIc and 
fibrinogen levels in both Singaporean Chinese adults and neonates. 
 
4.2 Method 
4.2.1 Study population 
To determine the impact of the ADTRP genetic variant on plasma FVIIc and 
fibrinogen, we conducted the analysis in a group of healthy subjects who were free 
from CAD at the time of recruitment.  In total, 421 adult subjects were included in 
the analysis. The participants were volunteers who underwent regular medical 
examination at a health screening center in the community.  The participants were 
excluded from the study if they suffered from (1) hypertension, (2) CAD, (3) diabetes, 
(4) had abnormal ECG.  All the study subjects were required to fill in a 
questionnaire which included the following information: age, height, weight, race, 
cigarette smoking history, oral contraceptives usage, medical history and family 
history.  Body mass index (BMI) was calculated as weight in kilograms (kg) divided 




The neonatal subjects involved in our study were recruited from consecutive healthy 
Chinese newborn babies who were delivered at the National University Hospital in 
Singapore.  The following groups of subjects were excluded from the analysis: (1) 
babies of mixed heritage; (2) parents with vague information on family or medical 
history; (3) premature babies with less than 37 weeks of gestational age or less than 
2500 grams of birth weight; (4) babies who needed medical treatment or observation 
in the neonatal ward for had perinatal problems, and those with major congenital 
deformities, or known or suspected chromosomal syndromes; (5) mothers with 
recognized medical problems before pregnancy, or gestational conditions such as 
diabetes or pregnancy-induced hypertension [216].  A total of 1,267 neonates were 
recruited from the three major ethnic groups in Singapore and of these, 447 of 
Chinese ethnicity with available FVIIc, fibrinogen and rs6903956 genotype 
information were included in our analysis.   
 
This study was carried out in accordance with the Declaration of Helsinki for 
experiments involving humans and was approved by the Hospital’s Domain Specific 
Review Board.  All adult subjects gave consent for their participation and for 
neonates, informed consent was sought from either of their parents. 
 
4.2.2 Blood collection 
Details of the blood collection procedures were reported previously for the adult [217] 
and neonatal populations [218].  Briefly, blood samples for the adult study were 
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collected after subjects had fasted overnight for at least 10 hours while the neonatal 
samples were obtained from umbilical cords.  Plasma was separated within 3 hours 
from blood collection tubes that were anti-coagulated with sodium citrate.  The 
plasma was aliquoted into three cryotubes, immediately snap-frozen in liquid nitrogen 
and stored at -70°C until use.  The analyses were performed within 4 weeks of 
storage.  Packed cells were stored at -20°C for the purpose of extraction of genomic 
DNA. 
 
4.2.3 Measurement of coagulation factors 
FVIIc was estimated by a one-stage semiautomatic bioassay in an H Amelung 
coagulometer at 37°C [219].  FVIIc can activate FX in the presence of tissue 
thromboplastin and calcium.  FVII deficient plasma will have a greatly prolonged 
prothrombin time (PT).  When FVII deficient plasma were mixed with the test 
plasma, the degree of correction of the PT is proportional to the level of plasma FVII 
of the participants. 
 
Fibrinogen was measured using the von Clauss assay [220] in the H Amelung 
coagulometer.  Soluble fibrinogen, in the presence of excess bovine thrombin, can 
be converted into insoluble fibrin and thus clot is formed.  The clotting time 





4.2.4 Genotype determination 
Genotype was determined by the polymerase chain reaction restriction fragment 
length polymorphism method (PCR–RFLP).  A 409 base pairs (bp) amplicon of the 
ADTRP gene was amplified from genomic DNA (forward primer: 
5′CTTCAACACTTGGGGGACCAACCTTAAGTATTAA3′ and reverse primer: 
5′AATAGTTAAGTGTATTTCTGACTCCACGTTGCTG3′).  The DNA sequence of 
the ADTRP was obtained from National Center for Biotechnology Information (NCBI) 
dbSNP database (build 37).  The amplification reactions were performed using 
T-Gradient Thermocyclers (Biometra) in a 20-μL mixture (1 × QIAGEN buffer, 10 
pmol of forward primer, 10 pmol of reverse primer, 200 μM of dNTP each, 0.5U of 
QIAGEN Taq DNA polymerase and 1 μL of the DNA template).  The PCR 
conditions were initial denaturation at 95°C for 4 minutes (Step 1), denaturation at 
94°C for 30 seconds (Step 2), annealing at 64°C for 45 seconds (Step 3), extension at 
72°C for 1 minute (Step 4) and a final extension of 72°C for 5 minutes (Step 5).  
Step 2-4 were repeated for 29 cycles before step 5 was executed.  The resultant PCR 
products were digested with ASeI in the thermal cycler at 37°C for 16 hours and at 
65°C for 20 minutes to heat inactivate the restriction enzyme.  The digested products 
were run on 3% agarose gel [47].  The presence of 2 DNA fragments with the length 
of 378 and 31 bp respectively indicated the presence of the minor risk A allele while a 
single band of 409 bp indicated the presence of the major G allele.  A total of 6 
random selected samples including two samples each for the three different genotypes 
were confirmed by Sanger sequencing.  Another 20 random samples were also 
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sequenced and all 26 samples had 100% concordance for genotypes obtained from 
both methods. 
 
4.2.5 Statistical analysis 
Among all the study subjects recruited, 309 adults and 447 neonates had complete 
information for both genotypes and coagulation factor measurements, thus data from 
these participants were included in the analysis. 
 
Quantitative variables were presented as mean ± SD (standard deviation) while 
categorical variables were presented as number of individuals (percentage %).  
Analysis was carried out in adults and neonates separately.  FVIIc and fibrinogen 
levels were not normally distributed in both adults and neonates.  Hence, they were 
both Z-score transformed for subsequent analysis.  Pearson’s χ2 test was also used to 
check whether genotype frequencies significantly departed from Hardy–Weinberg 
expectations (HWE).  Linear regression was used to investigate the association 
between rs6903956 and Z-score transformed coagulation factors.  In adults, age, 
BMI, gender and cigarette smoking status were included into the model as covariates 
while in neonates, gender, gestational age and birth weight were included as 
covariates.  All statistical analyses were carried out using STATA 12.0 (Stata Corp, 
College station, TX) and a 5% type I error was set to indicate statistical significance 





The main demographic and clinical characteristics of adult and neonatal study 
subjects are summarized in Table 7 and Table 8, respectively. 
 
Table 7: Descriptive characteristics of adult study subjects 
 N = 309 
Age (years) 34.95 ± 12.34 
BMI (kg/m2) 22.16 ± 3.55 
Gender (Male %) 154(49.84%) 
FVIIc (%) 114.28±36.53 
Fibrinogen (mg/dl) 276.45 ±64.78 







Data was presented as Mean ± Standard Deviation (SD) or N (%). 
 
Table 8: Demographics of the Chinese neonatal subjects 
 N = 447 
Gestational age (weeks) 39.15 ± 1.21 
Birth weight (g) 3253.05 ± 355.33 
Gender (Male %) 215 (48.10%) 
FVIIc (%) 59.73 ± 18.31 
Fibrinogen (mg/dl) 128.73 ± 53.40 
rs6903956  
GG 390 (87.25%) 
GA 57 (12.75%) 
Data was presented as Mean ± Standard Deviation (SD) or N (%). 
 
The observed genotype frequencies of rs6903956 did not depart significantly from 
HWE in both adults (p = 0.353) and neonates (p = 0.150).  The homozygous 
genotype for the minor allele A was absent in both cohorts.  The MAF of rs6903956 
was 5.0% and 6.4% respectively for adults and neonates, which is similar to the MAF 




Table 9 shows the association between coagulation factors and rs6903956 on ADTRP 
in adult and neonate population.  In adults, levels of FVIIc and fibrinogen were not 
found to be significantly impacted by rs6903956 after adjusting for the confounding 
effects of age, gender, BMI and cigarette smoking status (P for FVIIc = 0.464; P for 
fibrinogen = 0.349).  The association was also not significant in the neonates after 
adjusting for gestational age, gender and birth weight (P for FVIIc = 0.579; P for 
fibrinogen = 0.359). 
 
Table 9: Genotypic coagulation factors levels of rs6903956 in the Chinese adult and 
neonatal population 
 Adults Neonates 
 GG (N = 278) GA (N = 31) P* GG (N = 390) GA (N = 57) P* 
FVIIc 108.60 (36.00, 226.00) 108.00 (46.00, 160.00) 0.464 55.65 (25.99, 184.70) 54.24 (31.40, 150.70) 0.579 
Fibrinogen 266.35 (4.00, 584.26) 274.00 (62.44, 434.92) 0.349 132.53 (43.49, 260.30) 147.80 (46.11, 271.70) 0.359 
Data was presented as Median (Min, Max). 
*The association between genotype and z-score transformed coagulation factors were tested 
by linear regression adjusting for possible confounders. 
 
4.4 Discussion 
The formation of arterial thrombi induced by ruptured atherosclerotic plaques plays a 
central role in the development of CAD [221].  The exposure of a thrombogenic 
surface in the ruptured plaque triggers platelet activation and coagulation, which 
further promotes thrombosis in the coronary arteries.  The coagulation system 
consists of a series of procoagulant and anticoagulant proteins which are present in 
circulation [222].  In vivo, the exposure of TF to the circulating blood initiates 
activation of the extrinsic coagulation cascade.  It binds to FVII on the cell surface 
and the TF-FVII complex activates Factor IX (FIX) and FX.  FXa converts 
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prothrombin to thrombin and then thrombin activates platelets and converts 
fibrinogen to fibrin.  FVII plays a central role in initiating the process of coagulation 
in conjunction with TF while fibrinogen is essential for forming the final fibrin clot 
[223, 224].  Both FVII and fibrinogen were reported to be independent risk 
predictors for CAD [223, 225-227].  Several anticoagulant systems operate at the 
same time of coagulation to regulate procoagulant activity [222].  One of the 
important anticoagulants is TFPI, which inactivates both FVIIa and FXa, thus 
inhibiting the extrinsic coagulation pathway [228]. 
 
In 2011, Wang et al. [46] first showed that rs6903956, which is located in intron 1 of 
the C6orf105 region, on chromosome 6p24.1 was associated with CAD risk in Han 
Chinese population.  The mRNA expression of ADTRP gene was significantly lower 
in individuals with AA and AG genotypes compared to those with GG genotypes.  
Subsequently, this region has been reported by another group that encodes a gene for 
a androgen-dependent protein that could regulate the mRNA expression, cellular 
distribution and anticoagulant activity of TFPI [108].  It is suggested that a 
decreased expression of ADTRP may lead to a reduction in TFPI expression and thus 
result in an increased risk for atherosclerosis and CAD.  The association between 
rs6903956 and CAD risk has been replicated in independent Chinese cohorts [47, 
107].  This SNP was also reported to be associated with CAD in the Japanese, 
although the risk allele in their population was G and hence different from the 
Chinese [48].  This SNP has not been found to be associated with CAD in the 
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European populations [89]. 
 
Previously, our group replicated the association between rs6903956 and CAD risk in 
the Singaporean Chinese and found that plasma lipids such as HDL cholesterol, LDL 
cholesterol and triglycerides failed to explain the association [47].  Under the 
influence of androgen, ADTRP has been found to up-regulate TFPI [108]. This has 
downstream effects on FVII and fibrinogen, both of which are known to be associated 
with increased CAD risk [52].  In this study, we investigated whether there is any 
association between rs6903956 and two coagulation factors, FVII and fibrinogen.  
No significant association between the SNP and the two coagulation factors was 
observed in the adults and neonates.  We tested for the association in the neonatal 
cohort as we assumed that the effect of any genetic factors could be observable at 
birth.  Our group had previously shown that variation of FVIIc levels at birth could 
be significantly determined by genetic factors such as polymorphisms in the FVII 
gene [216].  Hence, determination of the potential impact of the ADTRP variant was 
extended to the neonatal population.  One advantage of studying genetic effects in 
the neonates is that the confounding effects of environmental factors could be 
minimized as these can be challenging to tease apart in adult studies. 
 
As there is no prior report on the effect of the ADTRP genetic variants on coagulation 
factor levels, we are unable to estimate the sample size require for such a study to be 
adequately powered.  The post analysis power estimates from this study is 15.12% 
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for FVIIc and 28.16% for fibrinogen.  Given the very small effect sizes observed in 
this study, a sufficiently large sample size to detect a statistically significant impact of 
rs6903956 on FVIIc and fibrinogen is estimated to be 7,000.  With such a large 
sample size required, it is unlikely that there is any notable impact of this SNP on 
these two coagulation factors. 
 
In conclusion, we found that despite the ADTRP gene being involved in the 
regulation of TFPI, its genetic variant rs6903956 is not associated with plasma FVIIc 




Chapter 5: Utility of genetic and non-genetic risk factors in 
predicting Coronary Heart Disease in Singaporean Chinese 
5.1 Introduction 
CHD and its complication, MI are leading causes of mortality and morbidity 
worldwide [5].  In Asia, there is an increasing CHD burden due to rising prevalence 
of sedentary lifestyle and changes in food consumption [11, 12].  CHD is a chronic 
disease and the atherosclerotic process begins long before disease onset.  Many 
contributing risk factors modulate the probability of developing CHD.  Being able to 
identify individuals who are apparently healthy but are at high risk of developing 
CHD would be important for implementing early intervention and treatment. 
 
A number of risk prediction methods have been developed to identify an individual’s 
risk of CHD by means of known risk factors, such as the Framingham Risk Equation, 
SCORE and QRISK [152, 155, 157, 229, 230].  The most frequently used model is 
the Framingham Risk Equation, of which the most updated version is based on The 
Adult Treatment Panel III (Third Report of the National Cholesterol Education 
Program Expert Panel on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults) [231].  It includes major CHD risk factors, such as age, HDL 
cholesterol, total cholesterol, SBP, current smoking status and use of 
anti-hypertensive medication [232].  Although the risk prediction model performed 
well in multiple cohorts with or without model recalibration [160, 164, 165, 233], it is 
suggested that 50% of individuals with few risk factors and predicted to be at low risk 
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of developing disease were actually CHD patients [234, 235].  This calls for the 
need to improve its risk prediction accuracy.  Some studies have focused on 
evaluating whether including other phenotypic risk factors, such as CRP could 
improve prediction performance, but the results thus far have been controversial 
[53-55, 203]. 
 
Besides lifestyle factors, genetic variations are likely to have a prominent role in the 
etiology of CHD as the heritability of CHD is estimated to be up to 60% [18-20].  
The advances of GWAS have made it possible to assess many SNPs across the 
genome and uncovered SNPs that are associated with CHD and its related risk factor 
traits.  The identification of these SNPs provides a chance to evaluate whether the 
inclusion of genetic variants could improve risk prediction model performances in 
addition to phenotypic risk factors.  Since the reported effect sizes of individual 
SNPs have been modest, a combined Genetic Risk Score (GRS) containing multiple 
SNPs should be considered instead to evaluate the role of all identified common 
variants in aggregate. 
 
In this study, we evaluated whether the inclusion of GRS could improve the 
prediction accuracy of incident ‘hard’ CHD (myocardial infarction and coronary 
death) beyond the use of phenotypic risk factors, which include conventional risk 
factors from ATPIII model as well as other biomarkers, such as hsCRP and creatinine.  
We sought to do this by comparing the discrimination and risk reclassification of the 
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models with and without GRS in a Singaporean Chinese population. 
 
5.2 Method 
5.2.1 Study population 
We used data from a case-control study (N = 2161; 761 cases and 1400 controls) 
nested within the SCHS, which is a long term prospective study focused on dietary, 
genetic and environmental determinants of cancer and other chronic diseases in 
Singapore [188].  Detailed information regarding SCHS was described in chapter 3. 
 
5.2.2 Outcome of the study  
The outcome of the study was ‘hard’ CHD, which includes myocardial infarction and 
coronary heart disease death.  Cases and controls were selected from participants 
who donated blood and were free of coronary heart disease or stroke at the time of 
blood collection.  Study subjects were followed up until 31 December 2010.  The 
incident cases of CHD were identified from the following three databases: (a) The 
SMIR; (b) A governmental national hospital discharge database based on inpatient 
admission and discharge information followed by medical record review by a 
cardiologist using MI diagnostic criteria from the Multi-Ethnic Study of 
Atherosclerosis; (c) The Singapore Registry of Births and Deaths.  For each case, 
two controls who were alive and free of coronary heart disease at the time of the 
diagnosis or death of the index case were matched to the case on year of recruitment, 
date of birth, gender, father’s dialect group and the date of blood collection.  
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Detailed information on the selection of participants is described previously in 
Chapter 3. 
 
5.2.3 Examination and laboratory measures 
Baseline information on age, current smoking status, diabetes, SBP and use of 
anti-hypertensive medication were obtained at recruitment.  Current smoking status, 
history of diabetes and use of anti-hypertensive medication were self-reported and 
obtained by participant interview.  SBP was measured three times with a 3-min 
interval between each measurement after the participants were seated at rest for at 
least 5 min, according to validated standard procedures [197].  The average value of 
the three readings was used for analysis.  Details of the procedures of blood 
collection, processing and storage for SCHS, as well as the analysis for the plasma 
biomarkers (total cholesterol, HDL cholesterol, hsCRP, creatinine and HbA1c) have 
been described previously in Chapter 3. 
 
5.2.4 Subset for statistical analysis 
Since the original ATPIII model is intended for individuals free of CHD and its risk 
equivalent, we excluded from our analysis subjects who were diabetic (either reported 
prior history of diabetes or level of hbA1c > 6.5%), with high level of hsCRP (> 10 
mg/L) or high level of serum creatinine (> 600 umol/L).  After exclusion, there were 




5.2.5 SNP selection and construction of GRS 
All SNPs included in the GRS were reported previously in the Catalog of Published 
GWAS [78] (https://www.ebi.ac.uk/gwas/) and were associated with CHD, MI or 
CHD risk factors, including HDL cholesterol, LDL cholesterol, triglycerides, diabetes, 
fasting glucose related traits, blood pressure, obesity, BMI and CRP.  Each SNP was 
coded as 0, 1 or 2 for common allele homozygous, heterozygous and risk allele 
homozygous, respectively. 
 
The construction of GRS can be carried out by a simple summation of risk allele that 
each individual carries or in a more sophisticated manner by weighting each risk 
allele with its effect size from the GWAS publication (∑ weight × SNP).  In order to 
compare whether there was a significant difference between unweighted and 
weighted GRS regarding their contribution to the improvement of model performance, 
a small set of SNPs (10 SNPs) was used to construct both the unweighted and 
weighted GRS.  The 10 SNPs included in these two GRS met the following criteria: 
(1) associated with CHD or MI; (2) genotyped in SCHS; (3) the risk alleles were 
consistent in GWAS publications and in SCHS.  The range of the unweighted and 
weighted GRS is 10.00 (4.00, 17.00) and 10.39 (3.36, 17.62) for men and 10.00 (4.00, 
16.00) and 10.55 (3.36, 16.68) for women, respectively.  Detailed information about 
the SNPs included in the unweighted and weighted GRS is presented in Table 10. 
 
After the comparison between weighted and unweighted GRS, four GRS were simply 
generated as a count of risk alleles.  Two GRS included only SNPs that were 
76 
 
Table 10: SNPs included in the unweighted and weighted Genetic Risk Score (GRS) 
 






1 rs974819 11q22.3 PDGFD 
MTND1P36 - 
MIR4693 
T 2.00E-09 0.07 





C 4.00E-09 0.07 
3 rs3729639 16q22.1 LCAT E2F4; EXOC3L1 T 2.00E-11 0.09 
4 rs17465637 1q41 MIA3 MIA3 C 1.00E-08 0.13 
5 rs2259816 12q24.31 HNF1A,C12orf43 HNF1A T 5.00E-07 0.08 
6 rs9268402 6p21.32 C6orf10, BTNL2 C6orf10 G 3.00E-15 0.15 
7 rs9349379 6p24.1 PHACTR1 PHACTR1 G 2.00E-09 0.14 
8 rs11556924 7q32.2 ZC3HC1 ZC3HC1 C 9.00E-18 0.09 
9 rs4977574 9p21.3 
CDKN2A, 
CDKN2B 
CDKN2B-AS1 G 1.00E-22 0.25 
10 rs579459 9q34.2 ABO ABO - SURF6 C 4.00E-14 0.10 
 
reported to be associated with CHD or MI (18-SNPs and 13-SNPs) while the other 
two contained SNPs associated with CHD and its risk factors (156-SNPs and 
51-SNPs).  Two different selection criteria were used.  The first only included 
SNPs that have been reported to be robustly associated with the outcome (P < 5×10-8) 
in at least two independent cohorts (18-SNPs and 156-SNPs).  The risk alleles of 
these SNPs were consistent in GWAS and in SCHS.  The second selection method 
used the Cox proportional hazards models with adjustments for age and gender to 
evaluate all the SNPs retrieved from the GWAS catalog.  Those associated with p 
values less than 0.10 in our dataset were used to build the GRS (13-SNPs and 
51-SNPs).  In men, the GRS are 18 (range: 10-26) for 18-SNPs; 12 (range: 6-19) for 
13-SNPs; 126 (range: 100-148) for 156-SNPs and 48 (range: 35-60) for 51-SNPs.  
In women, the GRS are 18 (range: 9-24) for 18-SNPs; 12 (range: 5-20) for 13-SNPs; 
126.5 (range: 104-144) for 156-SNPs and 48 (range: 35-63) for 51-SNPs. 
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Genome-wide genotyping and HapMap imputation data for 836 male (267 cases and 
569 controls) and 470 female (128 cases and 342 controls) SCHS samples were 
available for analysis and these methods have been described previously in Chapter 3.  
All SNPs used to construct the GRS had high call-rate (>95%), had genotype 
proportions that did not depart significantly from Hardy-Weinberg expectations and 
were uncorrelated (r2 < 0.2) with each other.  Detailed information about the SNPs 
included in the GRS is presented in Table 11. 
 
5.2.6 Risk prediction models 
To assess the effect of the GRS on risk prediction for ‘hard’ CHD, we considered 
adding the GRS to three different base models.  The first one (M1) is the recalibrated 
ATPIII model.  In this model, we used the regression coefficients from the FHS 
(https://www.framinghamheartstudy.org/risk-functions/coronary-heart-disease/hard-1
0-year-risk.php) and replaced the Framingham mean values of the risk factors and 
average incidence rate with those estimated from the SCHS study.  The second base 
model (M2) included all predictors and interaction terms from the ATPIII model but 
with the regression coefficients estimated using SCHS data.  The third base model 
(M3) included hsCRP and creatinine as risk factors in the model in addition to all 
predictors from the ATPIII model.  Creatinine and hsCRP were log transformed for 
men and used as quadratic term for women [203] in M3.  The comparison between 
different risk prediction models is presented in Table 12. 
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Table 11: SNPs included in the Genetic Risk Score (GRS) 





1 rs10923931 156-SNPs/51-SNPs 1p12 Type 2 diabetes NOTCH2, ADAM30 NOTCH2 Imputation T 4.00E-08 
2 rs12740374 18-SNPs/156-SNPs 1p13.3 CHD CELSR2, PSRC1, SORT1 CELSR2 Imputation T 2.00E-42 
3 rs7542900 51-SNPs 1p21.3 Type 2 diabetes SLC44A3, F3 F3 - KATNBL1P2 Genotype C 6.00E-06 
4 rs1514177 156-SNPs 1p31.1 Obesity TNNI3K TNNI3K;FPGT-TNNI3K Imputation C 5.00E-09 
5 rs2815752 156-SNPs 1p31.1 BMI NEGR1 RPL31P12 - KRT8P21 Genotype A 2.00E-22 
6 rs1748195 156-SNPs 1p31.3 Triglycerides ANGPTL3 DOCK7 Genotype C 2.00E-10 
7 rs4420065 156-SNPs 1p31.3 CRP LEPR LEPR - PDE4B Genotype C 4.00E-62 
8 rs17367504 156-SNPs 1p36.22 SBP 
MTHFR, NPPA, CLCN6, 
NPPB, AGTRAP 
MTHFR Genotype G 2.00E-16 
9 rs267733 156-SNPs 1q21.3 LDL ANXA9, CERS2 ANXA9 Genotype G 5.00E-09 
10 rs4537545 156-SNPs 1q21.3 CRP IL6R IL6R Genotype T 2.00E-14 
11 rs7553007 156-SNPs 1q23.2 CRP CRP CRP - RPL27P2 Genotype A 8.00E-44 
12 rs543874 156-SNPs 1q25.2 BMI SEC16B BRINP2 - SEC16B Genotype G 4.00E-23 
13 rs1689800 156-SNPs 1q25.3 HDL ZNF648 LOC100130996 Imputation G 5.00E-20 
14 rs17465637 18-SNPs/156-SNPs 1q41 CHD MIA3 MIA3 Genotype C 1.00E-08 
15 rs10489615 156-SNPs 1q42.13 HDL GALNT2 GALNT2 Genotype G 4.00E-09 
16 rs12239046 51-SNPs 1q44 CRP NLRP3 NLRP3 Imputation C 1.00E-15 
17 rs6029526 156-SNPs 20q12 LDL TOP1 TOP1 Imputation A 5.00E-18 
18 rs6102059 156-SNPs 20q12 LDL MAFB LOC102724968 Imputation T 4.00E-09 
19 rs1800961 156-SNPs 20q13.12 HDL HNF4A HNF4A Genotype T 2.00E-34 
20 rs4812829 156-SNPs 20q13.12 Type 2 diabetes HNF4A HNF4A Imputation A 5.00E-08 
21 rs7679 156-SNPs/51-SNPs 20q13.12 HDL PLTP PCIF1 Genotype C 4.00E-09 
22 rs13041126 156-SNPs 20q13.2 Obesity MRPS33P4 ERP29P1 - MRPS33P4 Imputation T 2.00E-08 
23 rs2836878 51-SNPs 21q22.2 CRP PSMG1 RPSAP64 - RPL23AP12 Genotype G 2.00E-07 
24 rs243021 156-SNPs/51-SNPs 2p16.1 Type 2 diabetes BCL11A RNA5SP94 - MIR4432 Genotype A 3.00E-15 
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25 rs1561288 156-SNPs 2p23.3 BMI POMC EFR3B Imputation T 5.00E-08 
26 rs780092 156-SNPs 2p23.3 Triglycerides GCKR GCKR Genotype G 5.00E-27 
27 rs12713956 156-SNPs 2p24.1 LDL APOB APOB Genotype G 4.00E-08 
28 rs1367117 156-SNPs 2p24.1 LDL APOB APOB Genotype A 1.00E-182 
29 rs2867125 156-SNPs 2p25.3 BMI TMEM18 FAM150B - TMEM18 Genotype C 3.00E-49 
30 rs4854307 51-SNPs 2p25.3 BMI Intergenic FAM150B - TMEM18 Genotype C 2.00E-06 
31 rs6734238 156-SNPs 2q13 CRP IL1F10 IL1F10 - IL1RN Imputation G 2.00E-17 
32 rs7560163 156-SNPs 2q23.3 Type 2 diabetes RBM43, RND3 RND3 - FABP5P10 Imputation C 7.00E-09 
33 rs13002573 156-SNPs 2q24.3 BP FIGN FIGN - PRPS1P1 Imputation G 2.00E-08 
34 rs11891401 51-SNPs 2q24.3 BP FIGN, GRB14 PRPS1P1 - GRB14 Imputation T 2.00E-06 
35 rs6725887 18-SNPs/13-SNPs/156-SNPs/51-SNPs 2q33.2 CHD WDR12 WDR12 Imputation C 1.00E-09 
36 rs824931 51-SNPs 2q36.1 BMI NR RPL23P5 - HSPA9P1 Imputation G 3.00E-06 
37 rs2972146 156-SNPs 2q36.3 HDL IRS1 NYAP2 - MIR5702 Imputation G 2.00E-17 
38 rs4607103 156-SNPs 3p14.1 Type 2 diabetes ADAMTS9 ADAMTS9-AS2 Genotype C 1.00E-08 
39 rs2535633 156-SNPs 3p21.1 BMI ITIH4 ITIH4 Imputation G 2.00E-10 
40 rs2013208 156-SNPs 3p21.31 HDL RBM5 RBM5 Genotype T 9.00E-12 
41 rs1717027 156-SNPs 3p22.1 BP ULK4 ULK4 Imputation T 5.00E-13 
42 rs7640978 156-SNPs 3p22.3 LDL CMTM6 CMTM6 Genotype T 1.00E-08 
43 rs7612463 156-SNPs 3p24.3 Type 2 diabetes UBE2E2 UBE2E2 Genotype C 7.00E-09 
44 rs7651039 13-SNPs/51-SNPs 3p25.1 CHD Intergenic BTD Genotype C 2.00E-06 
45 rs1801282 156-SNPs 3p25.2 Type 2 diabetes PPARG PPARG Genotype C 6.00E-10 
46 rs6805251 156-SNPs 3q13.33 HDL GSK3B GSK3B Imputation T 1.00E-08 
47 rs419076 156-SNPs/51-SNPs 3q26.2 BP MECOM MECOM Imputation T 2.00E-13 
48 rs7630877 51-SNPs 3q26.33 Type 2 diabetes PEX5L PEX5L Genotype A 7.00E-06 
49 rs4402960 156-SNPs 3q27.2 Type 2 diabetes IGF2BP2 IGF2BP2 Genotype T 9.00E-16 
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50 rs13130484 156-SNPs 4p12 BMI GNPDA2 PRDX4P1 - PRKRIRP9 Genotype T 6.00E-09 
51 rs4458523 156-SNPs 4p16.1 Type 2 diabetes WFS1 WFS1 Genotype G 2.00E-09 
52 rs6815464 156-SNPs 4p16.3 Type 2 diabetes MAEA MAEA Imputation C 2.00E-20 
53 rs6831256 156-SNPs 4p16.3 Triglycerides LRPAP1 DOK7 Genotype G 2.00E-12 
54 rs1458038 156-SNPs 4q21.21 BP FGF5 PRDM8 - FGF5 Genotype T 2.00E-23 
55 rs3822072 156-SNPs 4q22.1 HDL FAM13A FAM13A Imputation A 4.00E-12 
56 rs2602836 156-SNPs 4q23 HDL ADH5 LOC100507053 Imputation A 5.00E-08 
57 rs13139571 156-SNPs/51-SNPs 4q32.1 DBP GUCY1A3, GUCY1B3 GUCY1A3 Imputation C 2.00E-10 
58 rs1842896 18-SNPs/156-SNPs 4q32.1 CHD GUCY1A3 MTND1P22 - UCY1A3 Imputation T 1.00E-11 
59 rs1173766 156-SNPs 5p13.3 BP NPR3 NPR3 - RPS8P8 Imputation C 2.00E-08 
60 rs1421811 51-SNPs 5p13.3 BP NPR3 NPR3 Imputation G 2.00E-07 
61 rs6450176 156-SNPs 5q11.2 HDL ARL15 ARL15 Genotype A 7.00E-10 
62 rs702634 156-SNPs/51-SNPs 5q11.2 Type 2 diabetes ARL15 ARL15 Genotype A 7.00E-09 
63 rs12916 156-SNPs 5q13.3 LDL HMGCR HMGCR Genotype C 8.00E-78 
64 rs4457053 156-SNPs/51-SNPs 5q13.3 Type 2 diabetes ZBED3 ZBED3-AS1 Genotype G 3.00E-12 
65 rs261967 156-SNPs/51-SNPs 5q15 BMI PCSK1 PCSK1 - CAST Imputation C 8.00E-13 
66 rs4530754 156-SNPs 5q23.2 LDL CSNK1G3 CSNK1G3 Imputation G 4.00E-12 
67 rs4705952 156-SNPs 5q31.1 CRP IRF1 IRF1 - IL5 Genotype G 1.00E-08 
68 rs987237 156-SNPs 6p12.3 BMI TFAP2B TFAP2B Genotype G 3.00E-20 
69 rs6905288 13-SNPs/51-SNPs 6p21.1 CHD VEGFA TRNAI25 Imputation T 7.00E-08 
70 rs9470794 156-SNPs 6p21.2 Type 2 diabetes ZFAND3 ZFAND3 Imputation C 2.00E-10 
71 rs2254287 156-SNPs 6p21.32 LDL B3GALT4 COL11A2 Genotype G 5.00E-08 
72 rs9268402 18-SNPs/156-SNPs 6p21.32 CHD C6orf10, BTNL2 C6orf10 Genotype G 3.00E-15 
73 rs805303 156-SNPs 6p21.33 DBP BAT2, BAT5 BAG6 Genotype G 3.00E-11 
74 rs1799945 156-SNPs 6p22.2 DBP HFE HFE Genotype G 2.00E-15 
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75 rs3757354 156-SNPs 6p22.3 LDL MYLIP MYLIP Genotype T 2.00E-17 
76 rs7756992 156-SNPs 6p22.3 Type 2 diabetes CDKAL1 CDKAL1 Genotype G 8.00E-09 
77 rs9349379 18-SNPs/13-SNPs/156-SNPs/51-SNPs 6p24.1 CHD PHACTR1 PHACTR1 Genotype G 2.00E-09 
78 rs6901250 156-SNPs 6q22.1 CRP GPRC6A GPRC6A Genotype A 5.00E-08 
79 rs605066 156-SNPs 6q24.1 HDL CITED2 CITED2 - ATP5F1P6 Imputation C 3.00E-08 
80 rs6922269 18-SNPs/156-SNPs 6q25.1 CHD MTHFD1L MTHFD1L Imputation A 3.00E-08 
81 rs4607517 51-SNPs 7p13 
Fasting 
glucose-related traits 
GCK GCK - YKT6 Genotype A 2.00E-16 
82 rs17428471 156-SNPs 7p15.2 BP EVX1, HOXA RPL35P4 - EIF4HP1 Imputation T 2.00E-12 
83 rs4722551 156-SNPs 7p15.2 LDL MIR148A MIR148A - NFE2L3 Genotype C 4.00E-14 
84 rs1178979 156-SNPs 7q11.23 Triglycerides 
BAZ1B, BCL7B, TBL2, 
MLXIPL 
BAZ1B Genotype A 2.00E-12 
85 rs10953541 18-SNPs/156-SNPs 7q22.3 CHD Intergenic BCAP29 Imputation C 3.00E-08 
86 rs17477177 51-SNPs 7q22.3 BP PIK3CG CCDC71L -RNA5SP236 Genotype T 2.00E-13 
87 rs38855 156-SNPs 7q31.2 Triglycerides MET MET Genotype G 2.00E-08 
88 rs6467136 156-SNPs 7q32.1 Type 2 diabetes GCC1, PAX4 ZNF800 - GCC1 Imputation G 5.00E-11 
89 rs11556924 18-SNPs/156-SNPs 7q32.2 CHD ZC3HC1 ZC3HC1 Genotype C 9.00E-18 
90 rs972283 156-SNPs 7q32.3 Type 2 diabetes KLF14 KLF14 - MIR29A Genotype G 2.00E-10 
91 rs10105606 156-SNPs 8p21.3 Triglycerides LPL LPL - RPL30P9 Genotype C 4.00E-26 
92 rs10503669 51-SNPs 8p21.3 HDL LPL LPL - RPL30P9 Imputation A 4.00E-19 
93 rs7819412 156-SNPs 8p23.1 Triglycerides XKR6, AMAC1L2 XKR6 Genotype G 3.00E-08 
94 rs10102164 156-SNPs 8q11.23 LDL SOX17 TRMT112P7 - SEC11B Imputation A 4.00E-11 
95 rs2293889 156-SNPs 8q23.3 HDL TRPS1 TRPS1 Imputation T 4.00E-17 
96 rs2071518 156-SNPs 8q24.12 BP NOV NOV Genotype T 4.00E-09 
97 rs2001945 156-SNPs 8q24.13 Triglycerides Intergenic TRIB1 - LINC00861 Imputation C 1.00E-20 
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98 rs6987702 51-SNPs 8q24.13 LDL TRIB1 TRIB1 - LINC00861 Imputation G 3.00E-06 
99 rs10968576 156-SNPs 9p21.1 BMI LRRN6C LINGO2 Genotype G 3.00E-13 
100 rs4977574 18-SNPs/13-SNPs/156-SNPs/51-SNPs 9p21.3 CHD CDKN2A, CDKN2B CDKN2B-AS1 Genotype G 1.00E-22 
101 rs581080 156-SNPs 9p22.3 HDL TTC39B TTC39B Imputation G 1.00E-19 
102 rs17584499 156-SNPs 9p24.1 Type 2 diabetes PTPRD PTPRD Genotype T 9.00E-10 
103 rs7034200 51-SNPs 9p24.2 
Fasting 
glucose-related traits 
GLIS3 GLIS3 Genotype A 1.00E-13 
104 rs13292136 51-SNPs 9q21.31 Type 2 diabetes CHCHD9 KRT18P24 -CHCHD2P9 Imputation C 3.00E-08 
105 rs4149268 156-SNPs 9q31.1 HDL ABCA1 ABCA1 Genotype C 1.00E-10 
106 rs817858 51-SNPs 9q31.2 BMI RAD23B RAD23B - HMGN2P32 Imputation G 7.00E-06 
107 rs579459 18-SNPs/13-SNPs/156-SNPs/51-SNPs 9q34.2 CHD ABO ABO - SURF6 Genotype C 4.00E-14 
108 rs11014166 156-SNPs 10p12.31 DBP CACNB2 CACNB2 Imputation A 1.00E-08 
109 rs11257655 156-SNPs 10p13 Type 2 diabetes CDC123 CDC123 - CAMK1D Genotype T 3.00E-09 
110 rs1746048 18-SNPs/156-SNPs 10q11.21 CHD CXCL12 LINC00841 - CXCL12 Imputation C 3.00E-10 
111 rs970548 156-SNPs 10q11.21 HDL MARCH8, ALOX5 Mar-08 Imputation C 2.00E-10 




C10orf107 Imputation T 1.00E-09 
113 rs10761731 51-SNPs 10q21.3 Triglycerides JMJD1C JMJD1C Imputation T 8.00E-12 
114 rs1802295 156-SNPs 10q22.1 Type 2 diabetes VPS26A VPS26A Genotype A 4.00E-08 
115 rs5015480 156-SNPs 10q23.33 Type 2 diabetes HHEX, IDE HHEX - EXOC6 Genotype C 1.00E-15 
116 rs2068888 51-SNPs 10q23.33 Triglycerides CYP26A1 CYP26A1 - NIP7P1 Genotype A 2.00E-11 
117 rs11191580 156-SNPs 10q24.33 BMI NT5C2 NT5C2 Imputation C 4.00E-08 
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119 rs3817334 156-SNPs 11p11.2 BMI 
MTCH2, NDUFS3, 
CUGBP1 
MTCH2 Imputation T 2.00E-12 
120 rs652722 51-SNPs 11p13 BMI PAX6 DKFZp686K1684 Genotype C 8.00E-08 
121 rs6265 156-SNPs 11p14.1 BMI BDNF BDNF; BDNF-AS Genotype G 5.00E-10 
122 rs381815 156-SNPs 11p15.1 SBP PLEKHA7 PLEKHA7 Genotype T 2.00E-09 
123 rs5215 156-SNPs 11p15.1 Type 2 diabetes KCNJ11 KCNJ11 Genotype C 3.00E-11 
124 rs11024074 51-SNPs 11p15.1 DBP PLEKHA7 PLEKHA7 Genotype T 1.00E-06 
125 rs11042023 156-SNPs 11p15.4 Obesity RPL27A TRIM66 Genotype C 1.00E-11 
126 rs163184 156-SNPs 11p15.4 Type 2 diabetes KCNQ1 KCNQ1 Genotype G 2.00E-14 
127 rs2923084 156-SNPs 11p15.4 HDL AMPD3 CAND1.11 Genotype G 5.00E-08 
128 rs174546 156-SNPs 11q12.2 HDL FADS1, FADS2, FADS3 FADS1 Genotype T 2.00E-39 
129 rs1552224 156-SNPs 11q13.4 Type 2 diabetes CENTD2 ARAP1 Genotype A 1.00E-22 
130 rs499974 156-SNPs 11q13.5 HDL MOGAT2, DGAT2 MOGAT2 - DGAT2 Genotype A 1.00E-08 
131 rs1387153 156-SNPs 11q14.3 Type 2 diabetes MTNR1B RPS3AP42 - MTNR1B Genotype T 8.00E-15 
132 rs633185 156-SNPs 11q22.1 SBP FLJ32810, TMEM133 ARHGAP42 Imputation G 1.00E-17 
133 rs974819 18-SNPs/156-SNPs 11q22.3 CHD PDGFD MTND1P36 - MIR4693 Genotype T 2.00E-09 
134 rs603446 156-SNPs 11q23.3 Triglycerides 
ZNF259, APOA1, 
APOC3, APOA4, APOA5, 
BUD13 
ZPR1 Imputation T 2.00E-86 
135 rs2266788 51-SNPs 11q23.3 HDL/TG APOA5 ZPR1; APOA5 Genotype C 5.00E-13 
136 rs964184 13-SNPs 11q23.3 CHD 
ZNF259, APOA5, 
APOA4, APOC3, APOA1 
ZPR1 Imputation G 1.00E-17 
137 rs7134375 156-SNPs 12p12.2 HDL PDE3A TCP1P3 - PDE3A Genotype A 1.00E-08 
138 rs10875976 156-SNPs 12q13.12 Obesity LOC144233 BCDIN3D-AS1 Genotype A 2.00E-10 
139 rs2261181 156-SNPs 12q14.3 Type 2 diabetes HMGA2 RPSAP52 Genotype T 4.00E-08 
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140 rs7961581 156-SNPs 12q21.1 Type 2 diabetes TSPAN8, LGR5 TSPAN8 - LGR5 Genotype C 1.00E-09 
141 rs1495377 51-SNPs 12q21.1 Type 2 diabetes NR TSPAN8 - LGR5 Imputation G 7.00E-06 
142 rs2681492 156-SNPs 12q21.33 SBP ATP2B1 ATP2B1 Genotype T 4.00E-11 
143 rs2384550 51-SNPs 12q24.21 DBP TBX3, TBX5 TBX3 - UBA52P7 Genotype A 4.00E-08 
144 rs2259816 18-SNPs 12q24.31 CHD HNF1A, C12orf43 HNF1A Genotype T 5.00E-07 
145 rs1727313 156-SNPs 12q24.31 Type 2 diabetes MPHOSPH9 MPHOSPH9 Imputation C 1.00E-08 
146 rs7979473 156-SNPs 12q24.31 CRP HNF1A HNF1A Genotype A 1.00E-10 
147 rs7989336 156-SNPs 13q32.1 Obesity HS6ST3 HS6ST3 Imputation A 1.00E-08 
148 rs8017377 156-SNPs 14q12 LDL NYNRIN NYNRIN Genotype A 3.00E-15 
149 rs7141420 156-SNPs 14q31.1 Obesity NRXN3 NRXN3 Genotype T 1.00E-17 
150 rs4983559 156-SNPs 14q32.33 HDL ZBTB42, AKT1 ZBTB42 - LINC00638 Genotype G 1.00E-08 
151 rs7403531 156-SNPs 15q14 Type 2 diabetes RASGRP1 RASGRP1 Genotype T 4.00E-09 
152 rs2929282 156-SNPs 15q15.3 Triglycerides FRMD5 FRMD5 Imputation T 2.00E-09 
153 rs1532085 156-SNPs/51-SNPs 15q21.3 HDL LIPC LOC102724766 Genotype A 1.00E-188 
154 rs2241423 156-SNPs 15q23 BMI MAP2K5, LBXCOR1 MAP2K5 Genotype G 1.00E-18 
155 rs6495122 156-SNPs 15q24.1 DBP CSK, ULK3 CPLX3 - ULK3 Genotype A 2.00E-10 
156 rs7178572 156-SNPs 15q24.3 Type 2 diabetes HMG20A HMG20A Imputation G 2.00E-11 
157 rs3825807 18-SNPs/156-SNPs 15q25.1 CHD ADAMTS7 ADAMTS7 Imputation A 1.00E-12 
158 rs4380028 18-SNPs/13-SNPs/156-SNPs/51-SNPs 15q25.1 CHD ADAMTS7, MORF4L1 ADAMTS7 - TRNAK6 Genotype C 4.00E-09 
159 rs2028299 156-SNPs 15q26.1 Type 2 diabetes AP3S2 AP3S2;C15orf38-AP3S2 Genotype C 2.00E-11 
160 rs11649653 156-SNPs 16p11.2 Triglycerides CTF1 CTF2P Genotype G 3.00E-08 
161 rs7498665 156-SNPs 16p11.2 BMI SH2B1 SH2B1 Imputation G 5.00E-11 
162 rs12597579 156-SNPs 16p12.3 BMI GP2 SNRPEP3 - GP2 Imputation C 1.00E-08 
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164 rs11642841 156-SNPs 16q12.2 Type 2 diabetes FTO FTO Genotype A 3.00E-08 
165 rs6499640 156-SNPs 16q12.2 BMI FTO FTO Genotype A 4.00E-13 
166 rs12708980 156-SNPs 16q13 HDL CETP CETP Genotype C 2.00E-28 
167 rs3764261 156-SNPs 16q13 HDL CETP HERPUD1 - CETP Genotype A 1E-769 
168 rs16965039 13-SNPs/51-SNPs 16q13 CHD CETP NLRC5 Imputation T 6.00E-07 
169 rs3729639 18-SNPs/13-SNPs/156-SNPs/51-SNPs 16q22.1 CHD LCAT E2F4; EXOC3L1 Genotype T 2.00E-11 
170 rs8060686 13-SNPs/51-SNPs 16q22.1 HDL/TG EDC4 EDC4 Genotype T 8.00E-06 
171 rs16955379 51-SNPs 16q23.2 Type 2 diabetes CMIP CMIP Imputation C 3.00E-07 
172 rs623323 51-SNPs 17p13.3 Type 2 diabetes NXN RNMTL1 - NXN Genotype T 4.00E-06 
173 rs4430796 156-SNPs 17q12 Type 2 diabetes HNF1B HNF1B Genotype G 9.00E-10 
174 rs12946454 156-SNPs 17q21.31 SBP 
PLCD3, ACBD4, 
HEXIM1, HEXIM2 
ACBD4; PLCD3 Imputation T 1.00E-08 
175 rs46522 18-SNPs/13-SNPs/156-SNPs/51-SNPs 17q21.32 CHD 
UBE2Z, GIP, ATP5G1, 
SNF8 
UBE2Z Imputation T 2.00E-08 
176 rs7206971 156-SNPs 17q21.32 LDL OSBPL7 EFCAB13 Imputation A 4.00E-09 
177 rs4129767 156-SNPs/51-SNPs 17q25.3 HDL PGS1 PGS1 Imputation G 2.00E-11 
178 rs7503807 51-SNPs 17q25.3 Obesity RPTOR RPTOR Genotype A 2.00E-08 
179 rs17697518 51-SNPs 18q12.3 Obesity KC6 RPL17P45 - KC6 Imputation - 7.00E-07 
180 rs2156552 156-SNPs 18q21.1 HDL LIPG SMUG1P1 - ACAA2 Imputation T 2.00E-12 
181 rs17782313 156-SNPs 18q21.32 BMI MC4R RPS3AP49 - MC4R Genotype C 5.00E-18 
182 rs2304130 156-SNPs 19p13.11 Triglycerides CILP2, ZNF101 ZNF101 Genotype G 4.00E-08 
183 rs10401969 51-SNPs 19p13.11 LDL NCAN, CILP2, PBX4 SUGP1 Genotype C 2.00E-08 
184 rs12979813 156-SNPs 19p13.2 HDL LOC55908 DOCK6 Imputation T 2.00E-09 
185 rs7248104 156-SNPs 19p13.2 Triglycerides INSR INSR; LOC100996405 Genotype A 5.00E-10 
186 rs11668477 51-SNPs 19p13.2 LDL LDLR SMARCA4 - LDLR Genotype G 2.00E-07 
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187 rs3803915 13-SNPs/51-SNPs 19p13.3 BMI NR AP3D1 - DOT1L Genotype C 5.00E-06 
188 rs11084753 156-SNPs 19q13.11 BMI KCTD15 KCTD15 - RPS4XP20 Genotype G 2.00E-08 
189 rs731839 156-SNPs 19q13.11 HDL PEPD PEPD Genotype G 3.00E-09 
190 rs1160985 156-SNPs 19q13.32 LDL APOE TOMM40 Genotype C 2.00E-21 
191 rs11671664 156-SNPs/51-SNPs 19q13.32 BMI GIPR, QPCTL GIPR Genotype G 3.00E-12 
HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol (LDL-C), BP: blood pressure; BMI: body mass index; CRP: 
C-reactive protein; CHD: coronary heart disease; DBP: diastolic blood pressure; SBP: systolic blood pressure 
 
Table 12: Comparison of the risk prediction models 
Model Risk predictors Coefficients Advantages Disadvantages 







Coefficients are more reliable and 
demonstrated to be applicable to 
Asian populations. 
Coefficients are not available for 
hsCRP and creatinine. 






Coefficients are estimated from the 
local cohort. 
Coefficients were derived from a 
smaller sample size compared to 
FHS. 
M2 + hsCRP + creatinine (M3) 
Traditional risk 
predictors from 
ATPIII model + 
hsCRP + creatinine 
Estimate from 
SCHS 
Coefficients are estimated from the 
local cohort. Coefficients for 
hsCRP and creatinine could also be 
estimated. 
Coefficients were derived from a 
smaller sample size compared to 
FHS. 
hsCRP: High-sensitive C-reactive protein; ATPIII: Adult Treatment Panel III; SCHS: Singapore Chinese Health Study 
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5.2.7 Statistical analysis 
Selecting only a subset of nested case-control (NCC) study participants would 
normally be problematic had our statistical analysis used the traditional conditional 
logistic regression that retain the matched-set property of the case-control pairs 
because some matched-set will be without case or control in the subset.  To 
overcome this potential problem, we used the pseudo-likelihood approach [236] 
where the matching sets are ‘broken’ prior to subset selection and each subject is 
considered as independent individual with their contribution to the study weighted by 
the inverse of their probability of being included into the NCC study.  In our case, to 
estimate the absolute risk, we fitted a weighted Cox proportional hazards model to 
estimate the regression coefficients and baseline hazards in which the sampling 
weight for each case is one and for controls, is the inverse of the probability of being 
selected into the nested case-control study.  Weighted means and SD were 
calculated for baseline risk factors in cases and controls separately. 
 
The GRS was added to the Cox’s proportional hazards model, which contained all the 
risk factors and the interaction terms from ATPIII model as a categorical variable by 
using quartiles as cut-off.  To assess whether the addition of the GRS improved the 
model performance, we evaluated the model discrimination by c-statistic [237] and 
weighted net reclassification improvement (NRI) index [203] was calculated 
separately for cases and controls [238] to assess the extent to which adding the GRS 
re-assigned individuals to risk categories that better reflected their actual outcome.  
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Among the cases, a shift to higher risk categories is classified as improved 
reclassification while in controls a shift to lower risk categories is classified as 
improved reclassification.  Individuals were classified into four risk categories 
according to their estimated 10-year ‘hard’ CHD risks (0-4.99%; 5-9.99% 10-19.99%; 
20% and above) to assess the reclassification.  As NRI statistic can be prone to 
model over-fitting [239], we performed leave-one-out (LOO) cross-validation for 
NRI index and reported the NRI index using the cross-validated models. 
 
All statistical analyses were performed in R3.2.0 (www.r-project.org).  A 5% type I 
error was set to indicate statistical significance. 
 
5.3 Results 
5.3.1 Baseline characteristics of study participants 
The baseline characteristics of the subjects included in the analysis are presented in 
Table 13.  Cases were older, had higher levels total cholesterol, systolic blood 
pressure, hsCRP, creatinine; lower levels of HDL cholesterol, more likely to be 
smokers and be on anti-hypertensive medication for both men and women.  Women 
had higher HDL cholesterol level and higher total cholesterol level compared to men, 
but the proportion of smokers was lower.  All the GRS were higher among the cases 





Table 13: Characteristics of participants of the Singapore Chinese Health Study 
nested case control study of coronary heart disease† 
 
Men (N =836) Women (N =470) 
  Cases (N= 267) Controls (N= 569) Cases (N= 128) Controls (N= 342) 
Age at blood collection (years) 65.57(7.69) 63.00(7.57) 69.19(7.74) 63.00(7.12) 
Total cholesterol (mg/dL) 202.21(37.15) 195.61(33.20) 217.89(39.87) 210.56(33.28) 
HDL-C (mg/dL) 47.50(9.81) 49.43(11.46) 55.83(12.65) 58.71(12.21) 
Systolic blood pressure (mm Hg) 145.69(23.05) 136.64(19.59) 148.71(22.39) 134.16(21.19) 
Anti-hypertensive treatment 0.38(0.49) 0.25(0.43) 0.34(0.47) 0.27(0.44) 
Current smoking 0.41(0.49) 0.32(0.47) 0.16(0.36) 0.05(0.21) 
hsCRP (mg/L) 2.13(2.21) 1.31(1.48) 2.00(2.13) 1.55(1.68) 
Serum creatinine (mg/dL) 0.94(0.26) 0.86(0.16) 0.68(0.29) 0.62(0.15) 
Genetic Risk Score (unweighted) 10.64(1.91) 10.16(2.00) 10.70(1.74) 10.08(2.14) 
Genetic Risk Score (weighted) 10.77(2.29) 10.24(2.34) 10.87(2.10) 10.21(2.59) 
Genetic Risk Score (18 SNPs) 18.42(2.44) 17.82(2.41) 18.50(2.36) 17.62(2.43) 
Genetic Risk Score (13 SNPs) 12.54(2.18) 11.96(2.00) 12.71(1.99) 11.75(2.26) 
Genetic Risk Score (156 SNPs) 128.24(7.41) 124.66(7.19) 128.36(7.51) 125.19(7.11) 
Genetic Risk Score (51 SNPs) 50.47(4.06) 47.53(3.98) 50.63(3.92) 47.44(3.99) 
† Figures are weighted means (weighted SD), calculated using nested case-control data with 
inverse of probability of inclusions as sampling weights. 
hsCRP: high-sensitivity C-reactive protein 
 
5.3.2 Comparison between unweighted and weighted GRS 
We first investigated whether there was a significant difference between unweighted 
and weighted GRS regarding their contribution to the improvement of model 
performance.  As can be seen in Table 14, there was no obvious difference in 
c-statistics in all three models and in both men and women.  When compared the 
model with weighted GRS to the model with unweighted GRS, no significant change 
in NRI index was observed in all situations.  The two GRS acted most differently in 
M2 in females, the weighted GRS had a net gain of 7.8% (p-value = 0.056) cases 
being reclassified into higher risk categories.  Thus a weighted GRS was not 




5.3.3 Results for men 
5.3.3.1 18-SNPs GRS 
Table 15 shows the performance of the various prediction models before and after 
including the 18-SNPs GRS.  The best model was M3, which included all the 
predictors from ATPIII model as well as the biomarkers creatinine and hsCRP.  The 
18-SNPs GRS were strongly associated with incident ‘hard’ CHD in all three models 
with various adjustments for the effects of confounding factors such as traditional risk 
factors, hsCRP and creatinine.  Men in the highest quartile of the 18-SNPs GRS 
(>20) had a higher CHD risk, varying from 1.80-fold for M3 to 1.93-fold for M2 than 
those in the lowest quartile (<17). 
 
Improvements in discrimination were assessed for inclusion of the GRS to the three 
models predicting risk of ‘hard’ CHD in men.  In all three models, adding the 
18-SNPs GRS into the base models slightly improved the c-statistics (Table 15).  
The largest increase occurred when adding the 18-SNPs GRS to the recalibrated 
Framingham risk model (M1).  The c-statistic improved from 0.663 to 0.678.  The 
best performing model is M3, for which the c-statistic reached 0.704 after the 








 Models C-statistic Cases NRI Controls NRI C-statistic Cases NRI Controls NRI 
  (SE) (p-value) (p-value) (SE) (p-value) (p-value) 
 M1: Recalibrated Framingham Risk Model       
  M1 + unweighted GRS 0.677(0.018) -0.004(0.879) 0.021(0.252) 0.782(0.026) -0.023(0.631) 0.018(0.499) 
 M1 + weighted GRS 0.677(0.018) 0.775(0.026) 
 M2: ATPIII covariates       
 M2 + unweighted GRS 0.685(0.018) 0.004(0.873) -0.013(0.431) 
0.788(0.026) 
0.078(0.056) -0.001(0.958)  M2 + weighted GRS 0.684(0.018) 0.781(0.026) 
 M3: ATPIII covariates + hsCRP + creatinine       
 M3 + unweighted GRS 0.703(0.018) -0.045(0.064) 0.001(0.952) 
0.784(0.026) 
-0.023(0.590) -0.003(0.865)  M3 + weighted GRS 0.700(0.018) 0.780(0.026) 
NRI: net reclassification improvement; SE: standard error 




Table 15: Performance of various prediction models of coronary heart disease with and without 18-SNPs Genetic Risk Score for men 
 Models Quartiles of Hazard Ratio P-value C-statistic Cases NRI Controls NRI 
  GRS[Range] 95% CI  (SE) (p-value) (p-value) 
 M1: Recalibrated Framingham Risk Model    0.663(0.021) - - 
  Q1[10, 16] 1.000 -    
  Q2[17, 18] 1.122(0.801, 1.572) 0.503 
0.678(0.018) 0.019(0.569) -0.031(0.178)  M1 + GRS Q3[19, 20] 1.425(1.027, 1.978) 0.034 
  Q4[21, 26] 1.895(1.301, 2.759) 0.001 
 M2: ATPIII covariates    0.679(0.018) - - 
  Q1[10, 16] 1.000 -    
  Q2[17, 18] 1.135(0.809, 1.594) 0.463 
0.687(0.018) -0.007(0.800) -0.002(0.904)  M2 + GRS Q3[19, 20] 1.405(1.010, 1.956) 0.044 
  Q4[21, 26] 1.934(1.318, 2.837) 0.001 
 M3: ATPIII covariates + hsCRP + creatinine    0.695(0.018) - - 
  Q1[10, 16] 1.000 -    
  Q2[17, 18] 1.109(0.790, 1.557) 0.548 
0.704(0.018) 0.030(0.310) -0.014(0.519)  M3 + GRS Q3[19, 20] 1.497(1.072, 2.092) 0.018 
  Q4[21, 26] 1.797(1.221, 2.644) 0.003 
Cl: Confidence Interval; NRI: net reclassification improvement; SE: standard error 
hsCRP: high-sensitivity C-reactive protein 
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In terms of absolute risk, including 18-SNPs GRS into the base models led to lower 
absolute risks for individuals in the first two quartiles while predicting higher 
absolute risks for individuals in the latter two quartiles (Figure 3).  This greater 
separation between individuals in the lower and higher quartiles enabled the new 
model to identify potential ‘hard’ CHD cases from the rest of the population.  As 
shown in Table 15, the risk classification was not significantly changed for all three 
models in both cases and controls.  Table 16 shows that the improved 
reclassification for cases occurs when individuals classified as lower risk group by 
models without the 18-SNPs GRS were reclassified into the higher risk group by 
models with the GRS in men. 
 
Table 16: Risk reclassification table (base model with and without 18-SNPs GRS) for 
male cases of coronary heart disease 
 
0-5% 5-10% 10-20% 20% above 
M1: Recalibrated Framingham Risk Model Recalibrated Framingham Risk Model + 18 SNPs 
0-5% 61 18 0 0 
5-10% 25 110 21 0 
10-20% 0 11 19 2 
20% above 0 0 0 0 
M2: ATPIII covariates ATPIII covariates + 18 SNPs 
0-5% 107 14 0 0 
5-10% 21 75 11 0 
10-20% 0 9 22 5 
20% above 0 0 2 1 
M3: ATPIII covariates + hsCRP + creatinine ATPIII covariates + hsCRP + creatinine + 18 SNPs 
0-5% 99 16 0 0 
5-10% 20 71 16 0 
10-20% 0 7 27 3 
20% above 0 0 0 5 




Figure 3: Boxplots of 10-year of coronary heart disease risk estimated using different 
models with and without 18-SNPs GRS, by quartiles of 18-SNPs GRS in men. (A) 
Recalibrated Framingham Risk Model (M1); (B) ATPIII covariates (M2); (C) ATPIII 
covariates + hsCRP + creatinine (M3) 
(A)   (B)  
(C)  
 
5.3.3.2 13-SNPs GRS 
Table 17 shows the performance of the various prediction models before and after 
including the 13-SNPs GRS.  The best model was M3.  The 13-SNPs GRS were 
strongly associated with incident ‘hard’ CHD in all three models.  Men in the 
highest quartile of the 13-SNPs GRS (>14) had a higher CHD risk, varying from 
2.77-fold for M1 to 3.07-fold for M3 than those in the lowest quartile (<12). 
 
Improvements in discrimination were assessed for inclusion of the GRS to the three 
models predicting risk of ‘hard’ CHD in men.  In all three models, adding the 
13-SNPs GRS into the base models improved the c-statistics (Table 17).  The largest 
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Table 17: Performance of various prediction models of coronary heart disease with and without 13-SNPs Genetic Risk Score for men 
 Models Quartiles of Hazard Ratio P-value C-statistic Cases NRI Controls NRI 
  GRS[Range] 95% CI  (SE) (p-value) (p-value) 
 M1: Recalibrated Framingham Risk Model    0.663(0.021) - - 
  Q1[06, 11] 1.000 -    
  Q2[12, 12] 0.916(0.646, 1.300) 0.624 
0.691(0.018) 0.026(0.468) 0.033(0.166)  M1 + GRS Q3[13, 14] 1.222(0.902, 1.656) 0.195 
  Q4[15, 19] 2.769(1.964, 3.903) 6.09x10-9 
 M2: ATPIII covariates    0.679(0.018) - - 
  Q1[06, 11] 1.000 -    
  Q2[12, 12] 0.894(0.627, 1.273) 0.533 
0.696(0.018) 0.037(0.286) 0.019(0.371)  M2 + GRS Q3[13, 14] 1.256(0.924, 1.707) 0.145 
  Q4[15, 19] 2.874(2.033, 4.064) 2.27x10-9 
 M3: ATPIII covariates + hsCRP + creatinine    0.695(0.018) - - 
  Q1[06, 11] 1.000 -    
  Q2[12, 12] 0.903(1.108, 1.291) 0.576 
0.706(0.018) 0.087(0.012) 0.020(0.362)  M3 + GRS Q3[13, 14] 1.325(0.974, 1.803) 0.074 
  Q4[15, 19] 3.074(2.164, 4.366) 3.58x10-10 
Cl: Confidence Interval; NRI: net reclassification improvement; SE: standard error 
hsCRP: high-sensitivity C-reactive protein
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increase occurred when adding the 13-SNPs GRS to the recalibrated Framingham risk 
model (M1).  The c-statistic improved from 0.663 to 0.691.  The best performing 
model is M3, for which the c-statistic reached 0.706 after the inclusion of 13-SNPs 
GRS. 
 
In terms of absolute risk, including 13-SNPs GRS into the base models led to lower 
absolute risks for individuals in the first two quartiles while predicting higher 
absolute risks for individuals in the latter two quartiles (Figure 4).  As shown in 
Table 17, the risk classification was improved only in M3 with a net gain of 8.70% 
(p-value = 0.012) cases being reclassified into higher risk categories, while it did not 
significantly reduce the classification accuracy for controls.  Table 18 shows that the 
improved reclassification for cases occurs when individuals classified as lower risk  
 
Table 18: Risk reclassification table (base model with and without 13-SNPs GRS) for 
male cases of coronary heart disease 
 
0-5% 5-10% 10-20% 20% above 
M1: Recalibrated Framingham Risk Model Recalibrated Framingham Risk Model + 13 SNPs 
0-5% 61 11 7 0 
5-10% 28 101 25 2 
10-20% 0 15 12 5 
20% above 0 0 0 0 
M2: ATPIII covariates ATPIII covariates + 13 SNPs 
0-5% 102 16 3 0 
5-10% 24 59 22 2 
10-20% 0 13 17 6 
20% above 0 0 2 1 
M3: ATPIII covariates + hsCRP + creatinine ATPIII covariates + hsCRP + creatinine + 13 SNPs 
0-5% 101 12 2 0 
5-10% 22 58 18 9 
10-20% 0 8 17 15 
20% above 0 0 0 5 
hsCRP: high-sensitivity C-reactive protein  
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group by models without the 13-SNPs GRS were reclassified into the higher risk 
group by models with the GRS in men. 
 
Figure 4: Boxplots of 10-year of coronary heart disease risk estimated using different 
models with and without 13-SNPs GRS, by quartiles of 13-SNPs GRS in men. (A) 
Recalibrated Framingham Risk Model (M1); (B) ATPIII covariates (M2); (C) ATPIII 
covariates + hsCRP + creatinine (M3) 
(A)   (B)  
(C)  
 
5.3.3.3 156-SNPs GRS 
Table 19 shows the performance of the various prediction models before and after 
including the 156-SNPs GRS.  The best model was M3.  The 156-SNPs GRS were 
strongly associated with incident ‘hard’ CHD in all three models with various 
adjustments for the effects of confounding factors.  Men in the highest quartile of 
the 156-SNPs GRS (>131) had a higher CHD risk, varying from 3.54-fold for M3 to 
3.70-fold for M2 than those in the lowest quartile (<122).
98 
 
Table 19: Performance of various prediction models of coronary heart disease with and without 156-SNPs Genetic Risk Score for men 
 Models Quartiles of Hazard Ratio P-value C-statistic Cases NRI Controls NRI 
  GRS[Range] 95% CI  (SE) (p-value) (p-value) 
 M1: Recalibrated Framingham Risk Model    0.663(0.021) - - 
  Q1[100,121] 1.000 -    
  Q2[122,126] 1.421(0.965,2.095) 
 
0.076 
 0.705(0.018) 0.124(0.007) 0.007(0.840)  M1+ GRS Q3[127,131] 2.337(1.624,3.363)
 
4.81x10-6
  Q4[132,149] 3.554(2.493,5.065)
 
2.35x10-12 
 M2: ATPIII covariates    0.679(0.018) - - 
  Q1[100,121] 1.000 -    
  Q2[122,126] 1.286(0.866,1.908) 
 
0.212 
 0.713(0.018) 0.176(4.02x10-5) -0.013(0.659)  M2 + GRS Q3[127,131] 2.328(1.614,3.356)
 
6.06x10-6 
  Q4[132,149] 3.696(2.587,5.282)
 
7.04x10-13 
 M3: ATPIII covariates + hsCRP + creatinine    0.695(0.018) - - 
  Q1[100,121] 1.000 -    
  Q2[122,126] 1.351(0.907,2.011) 
 
0.138 
 0.724(0.018) 0.159(1.26x10-4) -0.041(0.167)  M3 + GRS Q3[127,131] 2.270(1.568,3.288)
 
1.43x10-5
  Q4[132,149] 3.537(2.463,5.079)
 
7.69x10-12 
Cl: Confidence Interval; NRI: net reclassification improvement; SE: standard error 





Improvements in discrimination were assessed for inclusion of the GRS to the three 
models predicting risk of ‘hard’ CHD in men.  In all three models, adding the 
156-SNPs GRS into the base models greatly improved the c-statistics (Table 19).  
The largest increase occurred when adding the 156-SNPs GRS to the recalibrated 
Framingham risk model (M1).  The c-statistic improved from 0.663 to 0.705.  The 
best performing model is M3, for which the c-statistic reached 0.724 after the 
inclusion of 156-SNPs GRS. 
 
In terms of absolute risk, including 156-SNPs GRS into the base models led to lower 
absolute risks for individuals in the first two quartiles while predicting higher 
absolute risks for individuals in the latter two quartiles (Figure 5).  As shown in 
Table 19, the risk classification was improved for all three models with a net gain of 
cases being reclassified into higher risk categories (NRI index: 12.4% (M1) - 17.6% 
(M2); p-value: 4.02 x10-5(M2) - 0.007 (M1)), while it did not significantly reduce the 
classification accuracy for controls.  Table 20 shows that the improved 
reclassification for cases occurs when individuals classified as lower risk group by 
models without the 156-SNPs GRS were reclassified into the higher risk group by 





Table 20: Risk reclassification table (base model with and without 156-SNPs GRS) 
for male cases of coronary heart disease 
 
0-5% 5-10% 10-20% 20% above 
M1: Recalibrated Framingham Risk Model Recalibrated Framingham Risk Model + 156 SNPs 
0-5% 50 29 0 0 
5-10% 42 54 60 0 
10-20% 0 16 14 2 
20% above 0 0 0 0 
M2: ATPIII covariates ATPIII covariates + 156 SNPs 
0-5% 83 38 0 0 
5-10% 29 39 39 0 
10-20% 0 12 12 12 
20% above 0 0 1 2 
M3: ATPIII covariates + hsCRP + creatinine ATPIII covariates + hsCRP + creatinine + 156 SNPs 
0-5% 83 32 0 0 
5-10% 31 41 35 0 
10-20% 0 8 15 14 
20% above 0 0 0 5 
hsCRP: high-sensitivity C-reactive protein 
 
Figure 5: Boxplots of 10-year of coronary heart disease risk estimated using different 
models with and without 156-SNPs GRS, by quartiles of 156-SNPs GRS in men. (A) 
Recalibrated Framingham Risk Model (M1); (B) ATPIII covariates (M2); (C) ATPIII 
covariates + hsCRP + creatinine (M3) 




5.3.3.4 51-SNPs GRS 
Table 21 shows the performance of the various prediction models before and after 
including the 51-SNPs GRS.  The best model was M3.  The 156-SNPs GRS were 
strongly associated with incident ‘hard’ CHD in all three models.  Men in the 
highest quartile of the 51-SNPs GRS (>52) had a higher CHD risk, varying from 
3.54-fold for M3 to 3.70-fold for M2 than those in the lowest quartile (<46). 
 
Improvements in discrimination were assessed for inclusion of the GRS to the three 
models predicting risk of ‘hard’ CHD in men.  In all three models, adding the 
51-SNPs GRS into the base models extremely improved the c-statistics (Table 21).  
The largest increase occurred when adding the 51-SNPs GRS to the recalibrated 
Framingham risk model (M1).  The c-statistic improved from 0.663 to 0.749.  The 
best performing model is M3, for which the c-statistic reached 0.758 after the 
inclusion of 51-SNPs GRS. 
 
In terms of absolute risk, including 51-SNPs GRS into the base models led to lower 
absolute risks for individuals in the first two quartiles while predicting higher 
absolute risks for individuals in the latter two quartiles (Figure 6).  As shown in 
Table 21, the risk classification was improved for all three models with a net gain of 
cases being reclassified into higher risk categories (NRI index: 30.3% (M1) – 39.4% 
(M3); p-value: 2.22 x10-16(M3) – 1.14 x10-9 (M1)), while it did not significantly reduce 
the classification accuracy for controls.  Table 22 shows that the improved 
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Table 21: Performance of various prediction models of coronary heart disease with and without 51-SNPs Genetic Risk Score for men 
 Models Quartiles of Hazard Ratio P-value C-statistic Cases NRI Controls NRI 
  GRS[Range] (95% Cl)  (SE) (p-value) (p-value) 
 M1: Recalibrated Framingham Risk Model    0.663(0.021) - - 
  Q1[35, 45] 1.000 -    
  Q2[46, 48] 2.010(1.307,3.092) 
 
0.001 
0.749(0.018) 0.303(1.14 x10-09) 0.034(0.341)  M1+ GRS Q3[49, 52] 3.858(2.683,5.548)
 
3.15x10-13 
  Q4[53, 61] 7.838(5.389,11.400)
 
<2x10-16 
 M2: ATPIII covariates   0.679(0.018) - - 
  Q1[35, 45] 1.000 -    
  Q2[46, 48] 2.154(1.396,3.324) 
 
5.29x10-4 
0.753(0.018) 0.318(4.61 x10-12) -0.028(0.401)  M2 + GRS Q3[49, 52] 4.145(2.873,5.981)
 
2.92x10-14 
  Q4[53, 61] 8.342(5.708,12.190)
 
<2x10-16 
 M3: ATPIII covariates + hsCRP + creatinine   0.695(0.018) - - 
  Q1[35, 45] 1.000 -    
  Q2[46, 48] 2.497(1.612,3.870) 
 
4.21x10-5 
0.758(0.018) 0.394(2.22 x10-16) -0.047(0.156)  M3 + GRS Q3[49, 52] 4.877(3.354,7.094)
 
<2x10-16 
  Q4[53, 61] 9.109(6.201,13.380)
 
<2x10-16 
Cl: Confidence Interval; NRI: net reclassification improvement; SE: standard error 
hsCRP: high-sensitivity C-reactive protein 
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Table 22: Risk reclassification table (base model with and without 51-SNPs GRS) for 
male cases of coronary heart disease 
 
0-5% 5-10% 10-20% 20% above 
M1: Recalibrated Framingham Risk Model Recalibrated Framingham Risk Model + 51 SNPs 
0-5% 37 30 12 0 
5-10% 37 42 57 20 
10-20% 1 10 11 10 
20% above 0 0 0 0 
M2: ATPIII covariates ATPIII covariates + 51 SNPs 
0-5% 71 36 14 0 
5-10% 26 29 38 14 
10-20% 1 5 14 16 
20% above 0 1 0 2 
M3: ATPIII covariates + hsCRP + creatinine ATPIII covariates + hsCRP + creatinine + 51 SNPs 
0-5% 66 39 10 0 
5-10% 24 25 38 20 
10-20% 0 2 11 24 
20% above 0 1 0 4 
hsCRP: high-sensitivity C-reactive protein 
 
Figure 6: Boxplots of 10-year of coronary heart disease risk estimated using different 
models with and without 51-SNPs GRS, by quartiles of 51-SNPs GRS in men. (A) 
Recalibrated Framingham Risk Model (M1); (B) ATPIII covariates (M2); (C) ATPIII 
covariates + hsCRP + creatinine (M3) 




reclassification for cases occurs when individuals classified as lower risk group by 
models without the 51-SNPs GRS were reclassified into the higher risk group by 
models with the GRS in men. 
 
5.3.4 Results for women 
5.3.4.1 18-SNPs GRS 
Table 22 shows the performance of the various prediction models before and after 
including the 18-SNPs GRS in women.  The best model was M2.  The 18-SNPs 
GRS were strongly associated with incident ‘hard’ CHD in all three models with 
different adjustment.  Women in the highest quartile of the 18-SNPs GRS (>20) had 
a higher CHD risk, varying from 4.18-fold in M1 to 5.28-fold in M3 than those in the 
lowest quartile (<17). 
 
Improvements in discrimination were evaluated for the inclusion of the GRS to the 
three models predicting risk of ‘hard’ CHD in women.  In all three models, adding 
the 18-SNPs GRS into the base models provided slight improvement in c-statistics 
(Table 23).  The largest increase also occurred when adding the 18-SNPs GRS to M1, 
the recalibrated Framingham risk model, the same as in men.  The c-statistic 
increased from 0.765 to 0.775.  The c-statistic of the best performing model, M2, 




Table 23: Performance of various prediction models of coronary heart disease with and without 18-SNPs Genetic Risk Score for women 
 Models Quartiles of Hazard Ratio P-value C-statistic Cases NRI Controls NRI 
  GRS[Range] (95% CI)  (SE) (p-value) (p-value) 
 M1: Recalibrated Framingham Risk Model    0.765(0.026) - - 
  Q1[09, 16] 1.000 -    
  Q2[17, 18] 1.699(1.003, 2.878) 0.049 
0.775(0.026) 0.078(0.096) -0.002(0.932)  M1 + GRS Q3[19, 20] 2.158(1.256, 3.709) 0.005 
  Q4[21, 25] 4.178(2.317, 7.533) 2.00x10-6 
 M2: ATPIII covariates    0.773(0.026) - - 
  Q1[09, 16] 1.000 -    
  Q2[17, 18] 1.540(0.895, 2.649) 0.119 
0.782(0.026) 0.141(0.004) -0.023(0.287)  M2 + GRS Q3[19, 20] 2.081(1.200, 3.607) 0.009 
  Q4[21, 25] 4.526(2.489, 8.229) 7.40x10-7 
 M3: ATPIII covariates + hsCRP + creatinine    0.771(0.026) - - 
  Q1[09, 16] 1.000 -    
  Q2[17, 18] 1.639(0.938, 2.865) 0.083 
0.780(0.026) 0.102(0.024) 0.001(0.946)  M3 + GRS Q3[19, 20] 2.197(1.246, 3.872) 0.006 
  Q4[21, 25] 5.275(2.856, 9.743) 1.08x10-7 
Cl: Confidence Interval; NRI: net reclassification improvement; SE: standard error 




In terms of absolute risk, adding the 18-SNPs GRS into the base models also led to 
lower absolute risks for individuals in the first two quartiles while higher absolute 
risks for individuals in the latter two quartiles (Figure 7), which was a similar 
observation in men.  As shown in Table 23, the risk classification was improved for 
M2 and M3 with a net gain of 14.1% (p-value = 0.004) and 10.2% (p-value = 0.024) 
cases, respectively being reclassified into higher risk categories, while it did not 
significantly reduce the classification accuracy for controls in these two models.  
Table 24 shows that the improved reclassification for female cases occurs when 
individuals classified as lower risk group by models without the 18-SNPs GRS were 
reclassified into a higher risk group by models with the GRS. 
 
Table 24: Risk reclassification table (base model with and without 18-SNPs GRS) for 
female cases of coronary heart disease 
 
0-5% 5-10% 10-20% 20% above 
M1: Recalibrated Framingham Risk Model Recalibrated Framingham Risk Model + 18 SNPs 
0-5% 48 5 1 0 
5-10% 8 27 8 1 
10-20% 0 5 13 8 
20% above 0 0 0 4 
M2: ATPIII covariates ATPIII covariates + 18 SNPs 
0-5% 74 10 2 0 
5-10% 8 14 11 1 
10-20% 0 2 2 4 
20% above 0 0 0 0 
M3: ATPIII covariates + hsCRP + creatinine ATPIII covariates + hsCRP + creatinine + 18 SNPs 
0-5% 74 8 4 0 
5-10% 7 12 2 3 
10-20% 0 2 6 6 
20% above 0 0 1 3 
hsCRP: high-sensitivity C-reactive protein  
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Figure 7: Boxplots of 10-year of coronary heart disease risk estimated using different 
models with and without 18-SNPs GRS, by quartiles of 18-SNPs GRS in women. (A) 
Recalibrated Framingham Risk Model (M1); (B) ATPIII covariates (M2); (C) ATPIII 
covariates + hsCRP + creatinine (M3) 
(A)   (B)  
(C)  
 
5.3.4.2 13-SNPs GRS 
Table 25 shows the performance of the various prediction models before and after 
including the 13-SNPs GRS in women.  The 13-SNPs GRS were strongly associated 
with incident ‘hard’ CHD in all three models with different adjustment.  Women in 
the highest quartile of the 13-SNPs GRS (>20) had a higher CHD risk, varying from 
3.63-fold in M1 to 3.88-fold in M3 than those in the lowest quartile (<17). 
 
Improvements in discrimination were evaluated for the inclusion of the GRS to the 
three models predicting risk of ‘hard’ CHD in women.  In all three models, adding  
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Table 25: Performance of various prediction models of coronary heart disease with and without 13-SNPs Genetic Risk Score for women 
 Models Quartiles of Hazard Ratio P-value C-statistic Cases NRI Controls NRI 
  GRS[Range] (95% CI)  (SE) (p-value) (p-value) 
 M1: Recalibrated Framingham Risk Model    0.765(0.026) - - 
  Q1[09, 16] 1.000 -    
  Q2[17, 18] 1.705(0.983, 2.959) 0.058 
0.791(0.026) 0.133(0.024) -0.011(0.737)  M1 + GRS Q3[19, 20] 2.597(1.591, 4.240) 1.36 x10-4 
  Q4[21, 25] 3.626(2.291, 5.738) 3.83 x10-8 
 M2: ATPIII covariates    0.773(0.026) - - 
  Q1[09, 16] 1.000 -    
  Q2[17, 18] 1.750(0.994, 3.082) 0.052 
0.798(0.026) 0.156(0.003) -0.005(0.848)  M2 + GRS Q3[19, 20] 2.707(1.643, 4.460) 9.22 x10-5 
  Q4[21, 25] 3.786(2.372, 6.043) 2.39 x10-8 
 M3: ATPIII covariates + hsCRP + creatinine    0.771(0.026) - - 
  Q1[09, 16] 1.000 -    
  Q2[17, 18] 1.660(0.932, 2.954) 0.085 
0.798(0.026) 0.141(0.007) 0.014(0.612)  M3 + GRS Q3[19, 20] 2.864(1.728, 4.745) 4.44 x10-5 
  Q4[21, 25] 3.883(2.417, 6.237) 2.03 x10-8 
 Cl: Confidence Interval; NRI: net reclassification improvement; SE: standard error 




the 13-SNPs GRS into the base models provided great improvement in c-statistics 
(Table 25).  The largest increase also occurred when adding the 13-SNPs GRS to M3, 
which included all the predictors from ATPIII model as well as the biomarkers 
creatinine and hsCRP.  The c-statistic increased from 0.771 to 0.798. 
 
In terms of absolute risk, adding the 13-SNPs GRS into the base models also led to 
lower absolute risks for individuals in the first two quartiles while higher absolute 
risks for individuals in the latter two quartiles (Figure 8).  As shown in Table 25, the 
risk classification was improved for all three models with a net gain of cases being 
reclassified into higher risk categories (NRI index: 13.3% (M1) – 15.6% (M2); p-value: 
0.003 (M2) - 0.024 (M1)), while it did not significantly reduce the classification 
accuracy for controls.  Table 26 shows that the improved reclassification for female 
cases occurs when individuals classified as lower risk group by models without the 
13-SNPs GRS were reclassified into a higher risk group by models with the GRS. 
 
5.3.4.3 156-SNPs GRS 
Table 27 shows the performance of the various prediction models before and after 
including the 156-SNPs GRS in women.  The best model was M2.  The 156-SNPs 
GRS were strongly associated with incident ‘hard’ CHD in all three models.  
Women in the highest quartile of the 156-SNPs GRS (>131) had a higher CHD risk, 




Table 26: Risk reclassification table (base model with and without 13-SNPs GRS) for 
female cases of coronary heart disease 
 
0-5% 5-10% 10-20% 20% above 
M1: Recalibrated Framingham Risk Model Recalibrated Framingham Risk Model + 13 SNPs 
0-5% 38 16 0 0 
5-10% 12 13 19 0 
10-20% 0 8 16 2 
20% above 0 0 0 4 
M2: ATPIII covariates ATPIII covariates + 13 SNPs 
0-5% 67 19 0 0 
5-10% 11 11 10 2 
10-20% 0 2 4 2 
20% above 0 0 0 0 
M3: ATPIII covariates + hsCRP + creatinine ATPIII covariates + hsCRP + creatinine + 13 SNPs 
0-5% 70 16 0  
5-10% 8 7 8 1 
10-20% 0 4 4 6 
20% above 0 1 0 3 
hsCRP: high-sensitivity C-reactive protein 
 
Figure 8: Boxplots of 10-year of coronary heart disease risk estimated using different 
models with and without 13-SNPs GRS, by quartiles of 13-SNPs GRS in women. (A) 
Recalibrated Framingham Risk Model (M1); (B) ATPIII covariates (M2); (C) ATPIII 
covariates + hsCRP + creatinine (M3) 




Table 27: Performance of various prediction models of coronary heart disease with and without 156-SNPs Genetic Risk Score for women 
 Models Quartiles of Hazard Ratio P-value C-statistic Cases NRI Controls NRI 
  GRS[Range] (95% CI)  (SE) (p-value) (p-value) 
 M1: Recalibrated Framingham Risk Model    0.765(0.026) - - 
  Q1[104,121] 1.000 -    
  Q2[122,126] 0.546(0.288,1.038) 
 
0.065 
 0.794(0.026) 0.117(0.036) 0.016(0.609)  M1+ GRS Q3[127,131] 1.608(1.002,2.581)
 
0.049
   Q4[132,144] 2.412(1.491,3.902)
 
3.35x10-4
 M2: ATPIII covariates   0.773(0.026) - - 
  Q1[104,121] 1.000 -    
  Q2[122,126] 0.495(0.258,0.949) 
 
0.034 
 0.798(0.026) 0.117(0.011) -0.021(0.377)  M2+ GRS Q3[127,131] 1.507(0.926,2.452)
 
0.099
   Q4[132,144] 2.194(1.344,3.582)
 
0.002
 M3: ATPIII covariates + hsCRP + creatinine   0.771(0.026) - - 
  Q1[104,121] 1.000 -    
  Q2[122,126] 0.454(0.234,0.880) 
 
0.019 
 0.794(0.026) 0.148(0.001) 0.002(0.949)  M3 + GRS Q3[127,131] 1.584(0.974,2.575)
 
0.064
   Q4[132,144] 2.304(1.408,3.771)
 
9.01x10-4
Cl: Confidence Interval; NRI: net reclassification improvement; SE: standard error 
hsCRP: high-sensitivity C-reactive protein 
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Improvements in discrimination were evaluated for the inclusion of the GRS to the 
three models predicting risk of ‘hard’ CHD in women.  In all three models, adding 
the 156-SNPs GRS into the base models provided great improvement in c-statistics 
(Table 27).  The largest increase also occurred when adding the 156-SNPs GRS to 
M1, the recalibrated Framingham risk model, the same as in men.  The c-statistic 
increased from 0.765 to 0.794.  The c-statistic of the best performing model, M2, 
reached 0.798 after adding the 156-SNPs GRS.  The addition of the 156-SNPs GRS 
to all three models resulted in attaining c-statistics that are very close to 0.80, which 
is the threshold for excellent discrimination according to the gauge for interpretation 
set by Hosmer et al [240]. 
 
In terms of absolute risk, adding the 156-SNPs GRS into the base models also led to 
lower absolute risks for individuals in the first two quartiles while higher absolute 
risks for individuals in the latter two quartiles (Figure 9), which was a similar 
observation in men.  As shown in Table 27, the risk classification was improved for 
all three models with a net gain of cases being reclassified into higher risk categories 
(NRI index: 11.7% (M1 and M2) - 14.8% (M3); p-value: 0.001 (M3) - 0.036 (M1)), 
while it did not significantly reduce the classification accuracy for controls.  Table 
28 shows that the improved reclassification for female cases occurs when individuals 
classified as lower risk group by models without the 156-SNPs GRS were reclassified 




Table 28: Risk reclassification table (base model with and without 156-SNPs GRS) 
for female cases of coronary heart disease 
 
0-5% 5-10% 10-20% 20% above 
M1: Recalibrated Framingham Risk Model Recalibrated Framingham Risk Model + 156 SNPs 
0-5% 41 13 0 0 
5-10% 11 19 14 0 
10-20% 0 6 14 6 
20% above 0 0 1 3 
M2: ATPIII covariates ATPIII covariates + 156 SNPs 
0-5% 72 14 0 0 
5-10% 7 20 7 0 
10-20% 0 3 1 4 
20% above 0 0 0 0 
M3: ATPIII covariates + hsCRP + creatinine ATPIII covariates + hsCRP + creatinine + 156 SNPs 
0-5% 70 16 0 0 
5-10% 5 12 7 0 
10-20% 0 3 7 4 
20% above 0 0 0 4 
hsCRP: high-sensitivity C-reactive protein 
 
Figure 9: Boxplots of 10-year of coronary heart disease risk estimated using different 
models with and without 156-SNPs GRS, by quartiles of 156-SNPs GRS in women. 
(A) Recalibrated Framingham Risk Model (M1); (B) ATPIII covariates (M2); (C) 
ATPIII covariates + hsCRP + creatinine (M3) 
(A)   (B)  
(C)   
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5.3.4.4 51-SNPs GRS 
Table 29 shows the performance of the various prediction models before and after 
including the 51-SNPs GRS in women.  The best model was M3.  The 51-SNPs 
GRS were strongly associated with incident ‘hard’ CHD in all three models with 
different adjustment.  Women in the highest quartile of the 51-SNPs GRS (>51) had 
a higher CHD risk, varying from 11.24-fold in M1 to 12.37-fold in M3 than those in 
the lowest quartile (<46). 
 
Improvements in discrimination were evaluated for the inclusion of the GRS to the 
three models predicting risk of ‘hard’ CHD in women.  In all three models, adding 
the 51-SNPs GRS into the base models improved c-statistics to a great extent (Table 
28).  The largest increase also occurred when adding the 51-SNPs GRS to M3.  The 
c-statistic increased from 0.771 to 0.828.  The c-statistic of the best performing 
model, M3, reached 0.828 after adding the 51-SNPs GRS.  The addition of the 
51-SNPs GRS into all three different models reached 0.80 which indicated the new 
models provided excellent discrimination according to the gauge for interpretation set 
by Hosmer et al [240]. 
 
In terms of absolute risk, adding the 51-SNPs GRS into the base models also led to 
lower absolute risks for individuals in the first two quartiles while higher absolute 
risks for individuals in the latter two quartiles (Figure 10).  As shown in Table 29, 
the risk classification was improved for all three models with a net gain of cases 
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Table 29: Performance of various prediction models of coronary heart disease with and without 51-SNPs Genetic Risk Score for women 
 Models Quartiles of Hazard Ratio P-value C-statistic Cases NRI Controls NRI 
  GRS[Range] (95% CI)  (SE) (p-value) (p-value) 
 M1: Recalibrated Framingham Risk Model    0.765(0.026) - - 
  Q1[35, 45] 1.000 -    
  Q2[46, 48] 4.148(2.085,8.253) 
 
5.06 x10-5 
0.821(0.026) 0.258(2.43 x10-6) 0.003(0.921)  M1+ GRS Q3[49, 51] 3.998(2.030,7.871)
 
6.11 x10-5 
  Q4[52, 64] 11.236(5.855,21.562)
 
3.49 x10-13 
 M2: ATPIII covariates   0.773(0.026) - - 
  Q1[35, 45] 1.000 -    
  Q2[46, 48] 4.856(2.404,9.808) 
 
1.05 x10-5 
0.825(0.026) 0.313(7.76 x10-9) -0.020(0.422)  M2 + GRS Q3[49, 51] 5.089(2.543,10.180)
 
4.30 x10-6 
  Q4[52, 64] 12.310(6.371,23.800)
 
8.13 x10-14 
 M3: ATPIII covariates + hsCRP + creatinine   0.771(0.026) - - 
  Q1[35, 45] 1.000 -    
  Q2[46, 48] 4.939(2.439,10.000) 
 
9.11 x10-6 
0.828(0.026) 0.281(2.03 x10-7) -0.002(0.925)  M3 + GRS Q3[49, 51] 5.128(2.554,10.300)
 
4.29 x10-6 
  Q4[52, 64] 12.370(6.393,23.930)
 
8.08 x10-14 
Cl: Confidence Interval; NRI: net reclassification improvement; SE: standard error 
hsCRP: high-sensitivity C-reactive protein
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Table 30: Risk reclassification table (base model with and without 51-SNPs GRS) for 
female cases of coronary heart disease 
 
0-5% 5-10% 10-20% 20% above 
M1: Recalibrated Framingham Risk Model Recalibrated Framingham Risk Model + 51 SNPs 
0-5% 38 9 7 0 
5-10% 5 22 10 7 
10-20% 2 0 16 8 
20% above 0 1 0 3 
M2: ATPIII covariates ATPIII covariates + 51 SNPs 
0-5% 62 16 8 0 
5-10% 3 14 14 3 
10-20% 1 0 4 3 
20% above 0 0 0 0 
M3: ATPIII covariates + hsCRP + creatinine ATPIII covariates + hsCRP + creatinine + 51 SNPs 
0-5% 63 16 7 0 
5-10% 1 12 9 2 
10-20% 2 2 2 8 
20% above 1 0 0 3 
hsCRP: high-sensitivity C-reactive protein 
 
Figure 10: Boxplots of 10-year of coronary heart disease risk estimated using 
different models with and without 51-SNPs GRS, by quartiles of 51-SNPs GRS in 
women. (A) Recalibrated Framingham Risk Model (M1); (B) ATPIII covariates (M2); 
(C) ATPIII covariates + hsCRP + creatinine (M3) 




being reclassified into higher risk categories (NRI index: 25.8% (M1) – 31.3% (M2); 
p-value: 7.76 x10-9 (M2) - 2.43 x10-6 (M1)), while it did not significantly reduce the 
classification accuracy for controls.  Table 30 shows that the improved 
reclassification for female cases occurs when individuals classified as lower risk 
group by models without the 51-SNPs GRS were reclassified into a higher risk group 
by models with the GRS. 
 
5.4 Discussion 
The aim of this study was to evaluate whether genetic factors could provide 
additional information for the prediction of incident ‘hard’ CHD beyond the use of 
traditional risk factors and biomarkers.  We found that all the GRS were 
significantly associated with incident ‘hard’ CHD after adjustment for traditional risk 
factors and recent ones such as hsCRP and creatinine.  In addition to the significant 
association, the inclusion of the GRS into the phenotypic risk models led to the 
improvement in discrimination and risk classification in most situations.  The 
significant association and the improvement in discrimination and classification 
suggested that the GRS was constituted with the appropriate predictive SNPs 
associated with CHD and its risk factors.  It is hence an independent predictor of 
‘hard’ CHD over and above traditional risk factors as shown by comparison with M2.  
The GRS remains as an independent predictor even when compared with model M3 




Several previous studies have incorporated genetic factors into the non-genetic based 
model.  Investigators began by adding a single SNP into the model and the SNPs 
most frequently used were from 9p21.3, a region reported to be highly associated 
with CHD.  However, the results were controversial [167, 241].  We have also 
tested the predictiveness of the SNPs in this region but found no improvement for 
both model discrimination and risk classification (Table 31).  We also constructed 
two sets of GRS containing different number of SNPs.  One set only included SNPs 
reported to be associated with CHD or MI in GWAS publications.  The other set 
included SNPs associated with CHD related traits on the basis of the prior set.  We 
found that the performance of the GRS containing larger number of SNPs was better 
(18-SNPs vs 156-SNPs; 13-SNPs vs 51-SNPs) than the GRS including only a small 
set of SNPs in terms of their effect sizes, model discrimination and risk classifications 
in both men and women.  One possibility could be due to the modest effect of the 
single SNP and it has been suggested that hundreds of SNPs with modest effect size 
would be needed to improve risk prediction [242, 243]. 
 
In our study, all the SNPs were retrieved from the GWAS catalog [78] and had been 
reported to be associated with CHD and its risk factors.  We used two different 
selection criteria to choose SNPs included in the GRS.  It is found that the 
performance of the GRS containing SNPs selected using the second approach (SNPs 
filtered by the Cox proportional hazards models with adjustments for age and gender) 
performed much better (13-SNPs vs 18-SNPs; 51-SNPs vs 156-SNPs) than the GRS
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C-statistic Cases NRI Controls NRI C-statistic Cases NRI Controls NRI 
 (SE) (p-value) (p-value) (SE) (p-value) (p-value) 
 M1: Recalibrated Framingham Risk Model 0.663(0.021) - - 0.765(0.026) - - 
M1+ GRS 0.675(0.018) 0.011(0.639) 0.004(0.791) 0.775(0.026) 0.008(0.835) 0.008(0.720) 
 M2: ATPIII covariates 0.679(0.018) - - 0.773(0.026) - - 
M2 + GRS 0.683(0.018) -0.022(0.317) -0.011(0.423) 0.778(0.026) 0(1.000) -0.005(0.689) 
 M3: ATPIII covariates + hsCRP + creatinine 0.695(0.018) - - 0.771(0.026) - - 
M3 + GRS 0.699(0.018) 0.008(0.758) 0.011(0.513) 0.776(0.026) 0.016(0.593) 0.008(0.637) 
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containing SNPs selected using the first approach (SNPs robustly associated with 
CHD and its risk factors).  Although the extent of improvement of c-statistics was 
smaller in women than those in men when compared to the same base model and the 
same GRS, the addition of GRS to all models resulted in better c-statistics in women.  
After incorporating the 51-SNPs GRS into the three base models in women, 
c-statistics were all above 0.80, indicating the new model with 51-SNPs GRS could 
provide excellent discrimination.  However, since we selected the SNPs and did the 
analysis in the same population and with our relatively small sample size, we believe 
that these models may be over-fitted and may not represent its true predictive 
performance.  Hence, additional Chinese cohorts will be needed to confirm if the 
13-SNPs and 51-SNPs GRS could perform consistently well across independent 
populations. 
 
Some studies have shown that newer biomarkers, such as hsCRP are independent risk 
predictors in addition to traditional risk factors [54, 244].  It was found previously in 
the SCHS that hsCRP and creatinine but not HbA1c, could improve risk prediction 
when combined with conventional risk factors [203].  Hence we were interested in 
the improvement of prediction accuracy by adding the GRS to a model that included 
conventional risk factors (M2), and even one that included hsCRP and creatinine (M3).  
We found that the inclusion of GRS could indeed further improve the model 
discrimination compared to the model that already included traditional risk factors 
and the two additional biomarkers.  The comparisons were made with the 
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recalibrated ATPIII model as the base model (M1).  Compared with the coefficients 
generated from the local cohort, those from the FHS were more reliable since they 
were generated from a much larger cohort and have been demonstrated to be 
applicable to Asian populations [165].  We found that incorporating the GRS into 
the recalibrated ATPIII model resulted in improvement in discrimination and 
classification in both men and women.  Indeed, the c-statistic and NRI indices 
achieved were almost as good as when the GRS score was incorporated into the 
locally-fitted model.  Since recalibrated ATP III model is widely-used in clinical 
settings, this result suggests the potential of including GRS in clinical use, especially 
with the increasing number of SNPs being identified to be associated with the 
disease. 
 
Some limitations of our study are as follow.  First, the genotypes of the SNPs 
included in this analysis were obtained from a previous genome-wide association 
study for ‘hard’ CHD in the Singaporean Chinese [209, 245, 246].  We did not carry 
out any specific genotyping for any SNPs needed in the prediction study.  For those 
SNPs without genotype information, we made use of imputation data which has not 
been confirmed by genotyping and thus could be less accurate.  Second, we only 
considered the direct effect of genetic factors.  It is believed that gene-gene and 
gene-environment interactions could also play a role in the etiology of the disease.  
Thus the interaction might also be able to improve prediction accuracy.  However, 
there are no results for interactions that have been robustly confirmed in large scale 
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analysis thus far.  Third, we estimated and tested the GRS effects in the same sample 
set.  Since our sample size is relatively small, we could not afford to split it into a 
separate training and validation dataset.  We realized there can be over-fitting with 
our results and have tried to minimize this by performing internal cross-validation 
when reporting the results.  However, external replication in independent cohorts is 
ultimately needed for further validation of the GRS.  Forth, in our study, only SNPs 
from GWAS studies for CHD and its related traits were included and individually 
they only explain a small proportion of the variance / heritability of these traits.  We 
believe that with additional studies to identify more common variants and other 
variants not effectively captured by GWAS, such as rare variants and structural 
variants, and include them in future models may further improve risk prediction 
accuracy. 
 
In summary, we have shown that the GRS could be an independent predictor for the 
risk of incident ‘hard’ CHD in addition to the conventional risk factors and 
biomarkers.  All the GRS were found to be significantly associated with ‘hard’ CHD 
and improved for model discrimination and risk classification when added to 
phenotype based models.  Our results suggest the potential of applying genetic 
factors in the clinical setting.  Additional research should be done to further confirm 





Chapter 6: Interactions between genes and dietary intake and 
their effect on body mass index in the Singaporean Chinese 
population 
6.1 Introduction 
Overweight and obesity, which are defined as the excessive accumulation of fat, are 
major health problems all over the world.  According to the report from the World 
Health Organization updated in 2015, worldwide obesity has been more than two 
times higher since 1980.  More than 1.9 billion (39%) adults aged 18 years old and 
above were overweight, and over 600 million (13%) were obese in 2014 [31].  
Individuals who are overweight or obese have significantly higher mortality and 
morbidity rate than those with normal weight due to various health disorders such as 
type 2 diabetes, cardiovascular diseases, hypertension, musculoskeletal disorders, 
respiratory complications and certain types of cancer [247-249].  The substantial 
increase of overweight and obesity prevalence in recent decades is mainly due to 
widespread adoption of westernized lifestyles, which is characterized by increased 
energy intake (excessive diet intake) and decreased energy expenditure (lack of 
physical activity and sedentary lifestyle) [247].  It presents enormous health and 
finance burdens on individuals, societies and health care systems worldwide, 
including Asia [250]. 
 
Obesity is a complex disease, which is associated with both environmental factors, 
such as dietary intake and physical inactivity and genetic factors [31-33].  With the 
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rapid development of GWAS, it is possible to assess many SNPs across the genome 
and uncover SNPs that are associated with obesity.  Recent GWAS has identified 97 
independent loci that were associated with BMI, a commonly used measurement to 
access overweight and obesity.  The BMI variation accounted by these 97 loci was 
estimated to be around 2.7% and it is suggested that the variation explained by 
genome-wide common variants could be more than 20% [251].  However, previous 
observations reported that BMI has an estimated heritability around 40%–70% [32, 
252].  The ‘missing’ heritability of BMI might be partially explained by 
gene-environment interaction studies. 
 
Previous studies were mostly focused on investigating whether the association 
between BMI and genetic components could be affected by physical activity, smoking 
or a certain type of dietary factors [253-258].  In addition, these studies usually only 
chose SNPs from regions that were reported to be strongly associated with BMI or 
obesity, such as FTO and melanocortin 4 receptor (MC4R) and were conducted in 
European-ancestry populations [36-39].  Limited study systematically investigates 
whether dietary intake could modify BMI associations at known GWAS BMI risk loci, 
especially in East-Asians. 
 
The study was conducted in 3,758 subjects from two independent Singaporean 
Chinese cohorts, the SCHS and the SP2.  The aims of this study were to investigate: 
(1) the association between dietary variables and BMI; (2) the association between 
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these dietary components and genetic factors; (3) whether the association between 
BMI and BMI risk loci could be modified by dietary intake. 
 
6.2 Methods 
6.2.1 Study population 
We studied 3,758 participants from two independent adult Singaporean Chinese 
cohorts (SCHS: N = 1,664; SP2: N = 2,094).  All study subjects gave written 
informed consent.  Detailed information regarding these two cohorts was described 
previously in chapter 3. 
 
6.2.2 Body composition and dietary data 
In SCHS, weight and height were self-reported via in-person interviews [259, 260] 
and were shown to be highly valid across populations [261] including Asians [262].  
Since BMI was used as outcome in our study, we excluded those without information 
for both height and weight to improve the accuracy of the analysis.  In SP2, a wall 
mounted measuring tape and a digital scale were used to measure height and weight 
respectively [263].  BMI was calculated as weight in kilograms (kg) divided by 
height in meter square (m2). 
 
In SCHS, information on dietary components was collected by using a 
semi-quantitative food-frequency questionnaire (FFQ) specifically developed for this 
population during the baseline interview.  A total of 165 food items commonly 
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consumed in the Singapore Chinese were assessed by the questionnaire, and the study 
participants provided the usual frequency and portion size on each of the food and 
beverage items referring to accompanying photographs to select from 8 
food-frequency categories (ranging from never or hardly ever to two or more times/d) 
and 3 portion sizes.  The FFQ was subsequently validated against a series of 24-hour 
dietary recall interviews [188].  The corrected correlation coefficients for selected 
energy or nutrients ranged from 0.24 to 0.79 [188, 264]. 
  
In SP2, a semi-quantitative FFQ, which contains 169 validated food items and used in 
the National Nutrition Surveys was utilized to collect dietary intake information 
during the month prior to the interview [263, 265].  The estimation of the frequency 
for consuming each food, based on a standard portion size specific for that food group 
was requested from the participants.  The consumption frequency could be reported 
as per day, per week, per month, rarely or never.  Nutrient intakes were computed by 
the Health Promotion Board of Singapore by use of their in-house database. 
 
Ten dietary variables examined in this study were total calories (kcal/day), cholesterol 
(mg/day), starch (g/day), dietary fiber (g/day), percentage of energy from protein 
(%protein), percentage of energy from fat (%fat), percentage of energy from SFA 
(%SFA), percentage of energy from MFA (%MFA), percentage of energy from PFA 




6.2.3 SNP selection and genotyping 
Large scale GWAS study has identified 97 independent BMI-associated loci in 
European ancestry population [251].  Among them, 64 SNPs were either genotyped 
or imputed both in SCHS and SP2.  The procedure of genotyping and quality control 
were described in detail previously in chapter 3. 
 
6.2.4 Statistical analysis 
A weighted genetic risk score (wGRS) was calculated based on the 64 
BMI-associated variants, where the number of BMI increasing alleles were weighted 
by their reported effect estimates from recent large-scale GWAS studies [251].  We 
converted macronutrients (protein, fat, saturated fatty acid (SFA), monounsaturated 
fatty acid (MFA), polyunsaturated fatty acid (PFA) and carbohydrate) to nutrient 
density expressed as percent calories or weight per 1,000 kcal and the micronutrients 
(cholesterol, starch and fiber) to calorie-adjusted nutrient value based on the method 
of residuals [266].  BMI and all the dietary factors were Z-score transformed as they 
were not normally distributed.  Continuous variables were presented as mean ± SD 
while categorical variables were displayed as N (%).  Differences between means of 
continuous variables were evaluated by Kruskal-Wallis rank test and differences in 
frequencies of categorical variables were evaluated by Pearson’s χ2 test.  Linear 
regression analyses between Z-BMI and dietary factors were performed and adjusted 
for age, sex and calorie intake.  Association between the 64 SNPs and BMI/dietary 
components were evaluated by linear regression with adjustment for age and gender.  
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Interaction analyses were performed by introducing the interaction term (dietary 
factor x SNP) with the specific dietary factor and SNP included as covariates in the 
same regression model.  Analysis was carried out in each cohort individually and 
subsequently meta-analyzed using the inverse-variance weighted method.  Since it is 
not advisable to study gene-environment interactions in subjects with disease [255], 
we conducted meta-analysis both in SCHS + SP2 (4 datasets: SCHS cases, SCHS 
controls, SP2610 and SP21m) and SCHS controls + SP2 (3 datasets: SCHS controls, 
SP2610 and SP21m).  Cochran’s Q test was used to measure between-study 
heterogeneity (P < 0.1) [267].  All analyses were performed using STATA (version 
12.1, Statacorp, College Station, TX, USA).  Adjusted P value of <0.05 (2 tailed) 
was considered statistically significant after adjusting for multiple comparison.  The 
power to detect the associations was estimated by QUANTO (Version 1.2.4) 




The study was conducted to investigate the association between dietary components 
and BMI.  In addition, we were also interested in whether intake of various dietary 
components modifies the association between known index variants at obesity risk 





Table 32: Power Estimation of gene-diet interaction for BMI 
Minor allele frequency Modifying factor Beta for genotype Beta for Diet Beta for interaction Power (%) 




























6.3.1 Demographic and clinical characteristics of study populations 
The main demographic and clinical characteristics of the study subjects are presented 
in Table 33.  In total, 3,758 individuals (1,664 from SCHS, 2,094 from SP2) had 
data available for analysis.  As can be seen, BMI level was significantly higher in 
SCHS, especially in CHD cases (P<0.001).  Subjects in SCHS had significant lower 
intake of total calories (P<0.001), %fat (P<0.001), %SFA (P<0.001), %MFA 
(P<0.001), %PFA (P<0.001), cholesterol (P<0.001) and fiber (P<0.001) but 
significantly higher intake of %carbohydrate (P<0.001) than those in SP2.  Levels 
of %protein (P=0.130) and starch (P=0.069) intake were similar in these two cohorts.  
Individuals in SCHS were much older than those from SP2 (P<0.001) and the 
percentage of male was significantly lower in SP2 (P<0.001), especially in SP2610.  
Thus age and gender were included in the model as covariates in subsequent analysis.  
The weighted GRS was similar across study cohorts (P=0.650). 
 
Table 33: Clinical characteristics of the study participants 
 SCHS cases 
   
SCHS controls 
   
SP2610 
   
SP21m 
   BMI (kg/m2) 23.25 ± 3.48 22.83 ± 3.27 22.62 ± 3.88 22.89 ± 3.47 
Age (years) 66.14 ± 7.83 65.98 ± 7.78 48.48 ± 11.42 46.76 ± 10.36 
Gender (male %) 389 (65.49%) 699 (65.33%) 268 (23.41%) 605 (63.75%) 
Calories (kcal/day) 1642.12 ± 600.70 1638.09 ± 561.71 1853.89 ± 761.45 2115.58 ± 839.03 
%Protein1 15.02 ± 2.51 15.09 ± 2.50 15.08 ± 2.02 14.80 ± 1.95 
%Fat1 24.86 ± 5.80 24.90 ± 5.56 28.30 ±5.70 28.63 ± 5.63 
%SFA1 8.75 ± 2.50 8.73 ± 2.55 10.58 ± 2.62 10.77 ± 2.67 
%MFA1 8.49 ± 2.13 8.41 ± 2.07 9.87 ± 2.63 10.01 ± 2.57 
%PFA1 4.98 ± 1.82 5.13 ± 1.85 6.04 ±2.52 5.97 ± 2.44 
Cholesterol (mg/day) 184.69 ± 114.18 184.35 ± 116.00 225.94 ± 139.26 260.61 ± 150.56 
%Carbohydrate1 59.38 ± 7.57 59.14 ± 7.23 56.40 ± 6.57 56.17 ± 6.59 
Starch (g/day) 174.54 ± 71.07 170.89 ± 66.31 163.67 ± 70.18 189.93 ± 78.11 
Fiber (g/day) 12.86 ± 5.43 13.19 ± 5.75 19.77 ± 8.50 21.92 ± 9.29 
wGRS 58.65 ± 4.72 58.73 ± 4.92 58.48 ± 4.76 58.49 ± 4.76 
Data was presented as Mean ± SD or N (%). 1 Represented as a % of Total Energy. 
wGRS: weighted Genetic Risk Score; PUFA: Polyunsaturated Fatty Acids; SFA: Saturated 
Fatty Acids; MUFA: Monounsaturated Fatty Acids 
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6.3.2 Main effect of SNP on BMI 
We first tested the association between BMI susceptibility loci and Z-BMI.  Among 
the 64 overlapping SNPs, 54 of them showed directionally consistent association with 
BMI as reported previously [251] of which 5 loci (GNPDA2, KCNK3, NT5C2, 
QPCTL and MC4R) were significantly associated with the outcome (P < 0.05, Table 
34).  Differing from previous studies conducted in European and Pakistan 
populations [251, 255], in our meta-analysis, the locus that was most strongly 
associated with BMI in our Singaporean Chinese populations was rs10938397 on 
GNPDA2 (β=0.078, SE=0.026, P=0.002).  While for MC4R rs6567160, the 
strongest associated locus in European and Pakistan only showed nominal significant 
association with BMI (β=0.062, SE=0.031, P=0.043) in our population. 
 
6.3.3 Main effect of dietary components on BMI 
The association between dietary components and Z-BMI was also evaluated by linear 
regression.  Total calories (P=0.004), starch (P=0.006), %protein (P=0.019), %fat 
(P=0.009), %MFA (P=0.009) showed statistically significant positive associations 
with BMI (P<0.05).  Cholesterol (P=0.011) and %carbohydrate (P=0.034) were 
significantly associated with BMI negatively (Figure 11).  Fiber, %SFA and %PFA 
were not associated with the outcome (Table 35). 
 
After adjusting for multiple comparison, only total calories intake was significantly 
associated with Z-BMI (β=0.049, SE=0.017, Padjust=0.040), which showed that a 
0.049 change in Z-BMI for every 1 SD change in total calories. 
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Table 34: Association between 64 SNPs and BMI 
 SNPs Chr Position TA TAF SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
      Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Qpvalue Beta SE P Qpvalue 
1 rs1000940 17 5223976 G 0.634 -0.021 0.059 0.728 0.091 0.045 0.042 -0.036 0.041 0.383 0.022 0.047 0.643 0.015 0.023 0.508 0.186 0.022 0.025 0.385 0.112 
2 rs1016287 2 59159129 T 0.247 0.012 0.064 0.853 4.84E-04 0.049 0.992 -0.003 0.049 0.947 -0.048 0.050 0.345 -0.012 0.026 0.657 0.865 -0.016 0.029 0.569 0.750 
3 rs10182181 2 25003800 G 0.427 0.057 0.058 0.326 0.043 0.044 0.327 0.018 0.042 0.671 -0.055 0.045 0.217 0.012 0.023 0.615 0.336 0.003 0.025 0.902 0.265 
4 rs10733682 9 128500735 A 0.761 0.023 0.065 0.731 0.017 0.052 0.736 0.005 0.047 0.919 0.093 0.055 0.095 0.032 0.027 0.236 0.651 0.034 0.029 0.253 0.447 
5 rs10938397 4 44877284 G 0.271 0.081 0.065 0.209 0.091 0.048 0.059 0.001 0.047 0.988 0.155 0.051 0.003 0.078 0.026 0.002 0.165 0.078 0.028 0.006 0.078 
6 rs10968576 9 28404339 G 0.171 0.044 0.077 0.570 0.015 0.058 0.798 -0.063 0.054 0.237 0.047 0.060 0.439 0.002 0.030 0.937 0.497 -0.005 0.033 0.875 0.360 
7 rs11030104 11 27641093 A 0.504 0.034 0.056 0.548 0.033 0.042 0.438 0.090 0.040 0.025 0.002 0.044 0.973 0.043 0.022 0.056 0.503 0.044 0.024 0.069 0.314 
8 rs11126666 2 26782315 A 0.703 0.126 0.061 0.040 0.040 0.047 0.389 0.011 0.046 0.810 0.093 0.049 0.059 0.059 0.025 0.017 0.396 0.046 0.027 0.091 0.466 
9 rs11191560 10 104859028 C 0.275 -0.029 0.066 0.663 0.149 0.049 0.002 0.070 0.045 0.121 -0.026 0.053 0.620 0.054 0.026 0.038 0.051 0.069 0.028 0.015 0.052 
10 rs11583200 1 50332407 C 0.920 0.014 0.094 0.885 0.187 0.079 0.017 0.003 0.076 0.964 0.014 0.088 0.870 0.060 0.042 0.152 0.297 0.071 0.047 0.127 0.184 
11 rs11688816 2 62906552 G 0.704 0.049 0.063 0.438 0.039 0.048 0.423 -0.057 0.045 0.200 0.013 0.050 0.795 0.003 0.025 0.891 0.402 -0.005 0.027 0.851 0.314 
12 rs12286929 11 114527614 G 0.271 -0.042 0.068 0.542 -0.024 0.048 0.620 0.092 0.047 0.049 0.092 0.050 0.067 0.039 0.026 0.126 0.137 0.053 0.028 0.057 0.144 
13 rs12429545 13 53000207 A 0.243 0.128 0.068 0.060 -0.046 0.048 0.336 0.078 0.048 0.103 0.055 0.055 0.313 0.042 0.026 0.110 0.133 0.027 0.029 0.350 0.155 
14 rs12566985 1 74774781 G 0.820 0.016 0.074 0.825 -0.003 0.056 0.952 0.127 0.053 0.018 0.011 0.060 0.857 0.044 0.030 0.141 0.313 0.049 0.033 0.130 0.183 
15 rs12940622 17 76230166 G 0.697 0.096 0.062 0.120 -0.005 0.047 0.924 0.043 0.044 0.333 0.009 0.048 0.858 0.030 0.025 0.229 0.581 0.017 0.027 0.526 0.750 
16 rs13021737 2 622348 G 0.928 0.036 0.113 0.748 0.115 0.082 0.162 0.093 0.076 0.221 0.028 0.090 0.753 0.076 0.044 0.084 0.879 0.083 0.048 0.082 0.766 
17 rs13201877 6 137717234 G 0.038 0.055 0.182 0.764 0.111 0.108 0.303 0.121 0.105 0.253 -0.019 0.117 0.871 0.074 0.060 0.215 0.813 0.077 0.063 0.227 0.625 
18 rs1441264 13 78478920 A 0.604 0.114 0.060 0.056 0.035 0.044 0.429 -0.029 0.041 0.483 -0.048 0.046 0.299 0.005 0.023 0.812 0.121 -0.014 0.025 0.583 0.388 
19 rs1460676 2 164275935 C 0.372 -0.009 0.060 0.884 -0.030 0.045 0.510 0.080 0.041 0.055 0.094 0.046 0.043 0.040 0.023 0.085 0.151 0.049 0.026 0.053 0.105 
20 rs1516725 3 187306698 C 0.922 -0.110 0.105 0.296 0.139 0.085 0.102 0.138 0.073 0.058 -0.042 0.085 0.623 0.053 0.042 0.209 0.110 0.085 0.046 0.067 0.207 
21 rs1528435 2 181259207 T 0.664 0.056 0.062 0.369 0.032 0.045 0.479 -0.031 0.044 0.485 0.045 0.048 0.352 0.020 0.024 0.415 0.572 0.013 0.026 0.614 0.449 
22 rs1558902 16 52361075 A 0.126 -0.172 0.082 0.036 0.024 0.064 0.713 0.044 0.064 0.489 0.139 0.072 0.056 0.021 0.035 0.547 0.040 0.064 0.038 0.099 0.460 
23 rs16851483 3 142758126 T 0.242 -0.006 0.064 0.932 0.019 0.050 0.701 -0.016 0.046 0.726 0.099 0.053 0.060 0.024 0.026 0.364 0.390 0.029 0.029 0.303 0.251 
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Table 34 (continued): Association between 64 SNPs and BMI 
 SNPs Chr Position TA TAF SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
      Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Qpvalue Beta SE P Qpvalue 
24 rs16951275 15 65864222 T 0.407 0.085 0.060 0.157 0.038 0.042 0.368 0.022 0.042 0.603 0.029 0.046 0.531 0.038 0.023 0.102 0.849 0.029 0.025 0.237 0.963 
25 rs17203016 2 207963763 G 0.140 0.102 0.087 0.239 0.135 0.063 0.031 0.084 0.057 0.142 -0.057 0.064 0.377 0.064 0.033 0.050 0.163 0.058 0.035 0.101 0.086 
26 rs17405819 8 76969139 T 0.536 -0.134 0.059 0.024 -0.061 0.043 0.158 0.017 0.041 0.676 0.104 0.045 0.022 -0.005 0.023 0.814 0.006 0.018 0.025 0.481 0.031 
27 rs17724992 19 18315825 A 0.528 0.101 0.057 0.076 0.041 0.044 0.349 -0.015 0.040 0.707 0.023 0.045 0.617 0.028 0.023 0.216 0.407 0.014 0.025 0.568 0.624 
28 rs1928295 9 119418304 T 0.607 0.007 0.058 0.900 0.043 0.044 0.336 -0.021 0.040 0.598 0.051 0.046 0.265 0.018 0.023 0.422 0.611 0.021 0.025 0.412 0.412 
29 rs2033529 6 40456631 G 0.167 0.111 0.084 0.189 -0.079 0.060 0.188 0.025 0.052 0.632 0.084 0.060 0.159 0.025 0.031 0.421 0.170 0.012 0.033 0.726 0.148 
30 rs2033732 8 85242264 C 0.601 0.021 0.057 0.708 0.036 0.045 0.430 0.026 0.042 0.538 -0.019 0.045 0.671 0.016 0.023 0.494 0.836 0.015 0.025 0.561 0.655 
31 rs205262 6 34671142 G 0.135 0.065 0.077 0.397 -0.024 0.062 0.696 0.018 0.061 0.769 0.024 0.066 0.713 0.016 0.033 0.620 0.838 0.005 0.036 0.882 0.838 
32 rs2075650 19 50087459 A 0.919 -0.059 0.106 0.576 0.232 0.079 0.003 -0.069 0.072 0.334 -0.039 0.081 0.633 0.021 0.041 0.604 0.020 0.035 0.044 0.427 0.010 
33 rs2080454 16 47620091 C 0.489 -0.051 0.060 0.394 -0.016 0.044 0.714 0.059 0.041 0.147 -0.054 0.045 0.234 -0.007 0.023 0.761 0.232 0.001 0.025 0.980 0.161 
34 rs2112347 5 75050998 T 0.440 0.003 0.057 0.964 0.010 0.044 0.822 0.109 0.041 0.008 -0.009 0.045 0.847 0.035 0.023 0.126 0.183 0.041 0.025 0.099 0.107 
35 rs2176040 2 226801046 A 0.071 -0.112 0.110 0.310 -0.042 0.085 0.622 -0.070 0.080 0.381 0.019 0.086 0.822 -0.046 0.044 0.302 0.794 -0.033 0.048 0.495 0.742 
36 rs2207139 6 50953449 G 0.132 -0.032 0.078 0.679 0.070 0.063 0.266 -0.077 0.063 0.222 0.122 0.066 0.066 0.023 0.033 0.485 0.121 0.036 0.037 0.332 0.075 
37 rs2287019 19 50894012 C 0.812 0.029 0.072 0.686 0.102 0.054 0.062 0.076 0.051 0.138 0.082 0.060 0.174 0.077 0.029 0.008 0.883 0.086 0.032 0.006 0.937 
38 rs2365389 3 61211502 C 0.129 0.029 0.082 0.722 -0.077 0.063 0.222 0.143 0.064 0.026 0.016 0.067 0.805 0.027 0.034 0.434 0.111 0.026 0.037 0.485 0.050 
39 rs2820292 1 200050910 C 0.200 0.082 0.069 0.236 -0.092 0.057 0.105 0.012 0.051 0.819 0.075 0.056 0.178 0.014 0.029 0.622 0.129 3.70E-05 0.031 0.999 0.105 
40 rs2836754 21 39213610 C 0.376 -0.070 0.059 0.241 -0.047 0.045 0.290 -0.007 0.042 0.874 0.028 0.047 0.553 -0.019 0.023 0.414 0.530 -0.010 0.026 0.700 0.509 
41 rs29941 19 39001372 G 0.209 0.008 0.073 0.908 0.006 0.052 0.909 -0.009 0.051 0.860 0.052 0.056 0.354 0.013 0.028 0.634 0.875 0.014 0.031 0.639 0.710 
42 rs3101336 1 72523773 C 0.919 -0.084 0.109 0.444 0.070 0.080 0.382 0.096 0.072 0.184 0.077 0.086 0.374 0.058 0.042 0.170 0.565 0.082 0.046 0.071 0.967 
43 rs3817334 11 47607569 T 0.286 0.001 0.063 0.992 0.091 0.047 0.053 -0.002 0.046 0.957 0.012 0.050 0.806 0.029 0.025 0.258 0.470 0.034 0.028 0.218 0.318 
44 rs3849570 3 81874802 A 0.505 0.059 0.057 0.298 0.023 0.044 0.591 0.032 0.040 0.432 -0.015 0.046 0.742 0.022 0.023 0.329 0.766 0.015 0.025 0.541 0.726 
45 rs3888190 16 28796987 A 0.086 0.018 0.100 0.860 -0.194 0.077 0.012 0.091 0.072 0.205 -0.013 0.081 0.874 -0.024 0.040 0.544 0.055 -0.033 0.044 0.459 0.025 
46 rs4256980 11 8630515 C 0.594 0.034 0.061 0.571 -0.003 0.044 0.939 0.014 0.041 0.737 -0.093 0.046 0.041 -0.016 0.023 0.500 0.243 -0.024 0.025 0.334 0.185 
134 
 
Table 34 (continued): Association between 64 SNPs and BMI 
 SNPs Chr Position TA TAF SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
      Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Qpvalue Beta SE P Qpvalue 
47 rs4740619 9 15624326 T 0.239 0.161 0.065 0.013 -0.054 0.051 0.294 -0.028 0.046 0.548 0.044 0.054 0.419 0.014 0.026 0.605 0.045 -0.016 0.029 0.586 0.402 
48 rs4787491 16 29922838 G 0.447 0.028 0.058 0.635 0.056 0.042 0.183 -0.027 0.041 0.512 -0.030 0.046 0.507 0.005 0.023 0.835 0.419 0.001 0.025 0.980 0.267 
49 rs492400 2 219057996 C 0.215 0.075 0.073 0.303 -0.032 0.052 0.543 0.066 0.049 0.181 0.055 0.054 0.310 0.037 0.028 0.179 0.484 0.031 0.030 0.303 0.344 
50 rs6567160 18 55980115 C 0.164 0.161 0.079 0.041 0.079 0.056 0.163 0.042 0.055 0.441 0.005 0.062 0.937 0.062 0.031 0.043 0.450 0.044 0.033 0.183 0.679 
51 rs6804842 3 25081441 G 0.660 0.043 0.060 0.476 0.051 0.046 0.266 0.035 0.044 0.431 -0.040 0.047 0.389 0.020 0.024 0.396 0.496 0.016 0.026 0.538 0.329 
52 rs7138803 12 48533735 A 0.256 0.124 0.067 0.065 0.055 0.049 0.270 -0.019 0.046 0.679 -0.094 0.053 0.076 0.005 0.026 0.854 0.048 -0.017 0.028 0.561 0.122 
53 rs7141420 14 78969207 T 0.479 0.094 0.057 0.101 -0.053 0.043 0.224 -0.023 0.041 0.580 -0.015 0.044 0.741 -0.010 0.023 0.645 0.224 -0.030 0.025 0.225 0.809 
54 rs7164727 15 70881044 T 0.252 0.070 0.067 0.295 -0.039 0.049 0.431 0.040 0.047 0.402 0.091 0.051 0.073 0.036 0.026 0.169 0.289 0.030 0.028 0.294 0.178 
55 rs7239883 18 38401669 G 0.305 0.097 0.062 0.117 0.002 0.046 0.969 0.009 0.043 0.844 -0.034 0.049 0.489 0.010 0.024 0.687 0.421 -0.006 0.027 0.815 0.793 
56 rs7243357 18 55034299 T 0.794 0.053 0.070 0.443 0.029 0.052 0.579 0.083 0.054 0.128 -0.063 0.055 0.253 0.023 0.028 0.409 0.279 0.017 0.031 0.575 0.163 
57 rs7599312 2 213121476 G 0.978 -0.227 0.219 0.299 0.396 0.160 0.014 0.034 0.125 0.789 -0.119 0.161 0.459 0.051 0.078 0.520 0.060 0.092 0.084 0.276 0.062 
58 rs7715256 5 153518086 G 0.965 -0.031 0.151 0.840 0.100 0.117 0.392 -0.098 0.115 0.394 -0.040 0.117 0.732 -0.017 0.061 0.788 0.672 -0.014 0.067 0.838 0.464 
59 rs7903146 10 114748339 C 0.978 -0.031 0.198 0.874 0.116 0.136 0.394 -0.034 0.146 0.816 0.028 0.153 0.858 0.030 0.077 0.697 0.876 0.041 0.083 0.625 0.750 
60 rs9374842 6 120227364 T 0.913 0.093 0.107 0.384 0.071 0.074 0.339 0.038 0.072 0.596 0.067 0.080 0.403 0.063 0.040 0.118 0.976 0.058 0.043 0.182 0.943 
61 rs9400239 6 109084356 C 0.705 -0.038 0.064 0.556 0.039 0.047 0.410 0.032 0.045 0.467 0.045 0.051 0.380 0.026 0.025 0.294 0.747 0.038 0.027 0.163 0.982 
62 rs9641123 7 93035668 C 0.313 0.011 0.063 0.856 0.067 0.046 0.149 -0.047 0.043 0.277 0.075 0.048 0.118 0.025 0.024 0.310 0.194 0.027 0.026 0.305 0.097 
63 rs977747 1 47457264 T 0.959 -0.108 0.158 0.494 -0.081 0.111 0.468 0.127 0.109 0.242 -0.045 0.103 0.663 -0.014 0.058 0.803 0.476 5.57E-05 0.062 0.999 0.352 
64 rs9914578 17 1951886 G 0.210 -0.022 0.071 0.760 -0.040 0.053 0.447 0.039 0.051 0.453 0.017 0.058 0.764 0.001 0.028 0.977 0.723 0.005 0.031 0.868 0.548 
Chr: chromosome; TA: test allele; TAF: test allele frequency; Q (Cochran’s Q test) was used to measure between-study heterogeneity.  Significant Z-score BMI associations 





Table 35: Association between dietary components and BMI 
 SCHS cases SCHS controls SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
 Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qp-value Beta SE P Padjust Qp-value 
Calories 0.142 0.045 0.002 0.083 0.033 0.012 -0.002 0.030 0.952 0.026 0.033 0.437 0.049 0.017 0.004 0.040 0.034 0.033 0.019 0.071 0.710 0.161 
Cholesterol -0.037 0.056 0.514 0.006 0.043 0.890 -0.095 0.037 0.010 -0.064 0.037 0.099 -0.054 0.021 0.011 0.110 0.346 -0.057 0.023 0.013 0.130 0.201 
Starch -0.010 0.047 0.824 0.100 0.037 0.007 0.013 0.034 0.690 0.090 0.038 0.017 0.052 0.019 0.006 0.060 0.123 0.064 0.021 0.002 0.020 0.159 
Fiber -0.060 0.056 0.280 -0.018 0.043 0.671 0.027 0.035 0.441 -0.049 0.038 0.206 -0.017 0.021 0.407 1.000 0.414 -0.010 0.022 0.644 1.000 0.338 
%Protein1 0.049 0.041 0.234 0.031 0.031 0.325 0.033 0.029 0.264 0.048 0.033 0.147 0.039 0.016 0.019 0.190 0.971 0.037 0.018 0.041 0.410 0.921 
%Fat1 -0.008 0.042 0.848 0.084 0.032 0.008 0.009 0.033 0.773 0.080 0.036 0.028 0.045 0.017 0.009 0.090 0.155 0.057 0.019 0.003 0.030 0.198 
%SFA1 -0.001 0.041 0.985 0.075 0.031 0.017 -0.004 0.032 0.904 0.042 0.037 0.248 0.031 0.017 0.072 0.720 0.280 0.038 0.019 0.046 0.460 0.212 
%MFA1 0.002 0.042 0.967 0.044 0.032 0.162 0.035 0.031 0.258 0.086 0.035 0.013 0.045 0.019 0.009 0.090 0.454 0.053 0.019 0.004 0.040 0.509 
%PFA1 -0.049 0.041 0.232 0.054 0.031 0.080 -0.011 0.030 0.721 0.079 0.033 0.017 0.024 0.017 0.147 1.000 0.041 0.038 0.019 0.035 0.350 0.107 
%Carbohydrate1 0.005 0.042 0.904 -0.065 0.032 0.039 -0.010 0.032 0.762 -0.063 0.035 0.071 -0.037 0.017 0.034 0.340 0.374 -0.045 0.019 0.017 0.170 0.381 
Q (Cochran’s Q test) was used to measure between-study heterogeneity.  Significant associations (Padjust < 0 .05) and heterogeneity (Qpvalue < 0.1) findings are in bold.
136 
 
Figure 11: Regression coefficients for the associations between dietary components 
and Z-BMI adjusted for total calories, age, and sex. Components with the red square 
markers have significant associations with Z-BMI (P <0.05) 
 
 
6.3.4 Main effect of weighted GRS on various dietary components 
The wGRS was significantly associated with Z-BMI in all dataset.  After 
meta-analysis, each unit increase in the wGRS was positively associated with the 
outcome as shown in Table 36 (β=0.023, SE=0.003, P<0.001). 
 
We also tested the association between wGRS and various dietary components.  No 
significant association was observed as shown in Figure 12 and Table 36. 
 
6.3.5 Interaction between weighted GRS and dietary intake for BMI 
After checking the main effect of genetic factors/dietary components on BMI, we 
tested the interaction between wGRS and various dietary factors on BMI. 
 















Table 36: Association between weighted GRS and dietary factors or BMI 
 SCHS cases SCHS controls SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
 Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qp-value Beta SE P Padjust Qp-value 
BMI 0.025 0.008 0.003 0.025 0.006 7.05E-05 0.022 0.006 3.35E-04 0.023 0.007 0.001 0.023 0.003 2.51E-12 - 0.984 0.023 0.004 2.00E-10 - 0.944 
Calories 0.006 0.008 0.414 -0.010 0.006 0.087 0.003 0.006 0.580 -0.003 0.007 0.622 -0.002 0.003 0.577 1.000 0.280 -0.003 0.004 0.328 1.000 0.283 
Cholesterol -0.014 0.009 0.102 0.004 0.006 0.551 0.009 0.006 0.118 -0.004 0.007 0.548 0.001 0.003 0.801 1.000 0.123 0.004 0.004 0.334 1.000 0.328 
Starch 0.002 0.009 0.777 -0.001 0.006 0.893 -0.005 0.006 0.442 0.003 0.007 0.651 -0.001 0.003 0.871 1.000 0.833 -0.001 0.004 0.767 1.000 0.696 
Fiber 0.002 0.009 0.805 -0.002 0.006 0.794 -0.006 0.006 0.277 0.004 0.007 0.530 -0.001 0.003 0.736 1.000 0.660 -0.002 0.004 0.640 1.000 0.490 
%Protein1 -0.011 0.009 0.219 -0.001 0.006 0.927 0.005 0.006 0.432 0.002 0.007 0.744 2.08E-04 0.003 0.950 1.000 0.523 0.002 0.004 0.556 1.000 0.825 
%Fat1 0.001 0.009 0.881 0.002 0.006 0.790 0.007 0.006 0.219 -0.006 0.007 0.372 0.001 0.003 0.662 1.000 0.529 0.001 0.004 0.682 1.000 0.331 
%SFA1 0.003 0.009 0.745 0.001 0.006 0.818 0.004 0.006 0.472 -0.004 0.006 0.522 0.001 0.003 0.744 1.000 0.806 0.001 0.004 0.827 1.000 0.627 
%MFA1 0.005 0.009 0.560 -0.001 0.006 0.890 0.009 0.006 0.135 -0.008 0.007 0.261 0.001 0.003 0.671 1.000 0.298 0.001 0.004 0.830 1.000 0.176 
%PFA1 -0.007 0.009 0.445 -4.70E-04 0.006 0.938 -0.001 0.006 0.908 -0.002 0.007 0.749 -0.002 0.003 0.573 1.000 0.942 -0.001 0.004 0.773 1.000 0.981 
%Carbohydrate1 0.003 0.008 0.749 -4.60E-04 0.006 0.940 -0.008 0.006 0.158 0.005 0.007 0.481 -0.001 0.003 0.729 1.000 0.480 -0.002 0.004 0.610 1.000 0.327 
Q (Cochran’s Q test) was used to measure between-study heterogeneity.  Significant associations (Padjust < 0 .05) and heterogeneity (Qpvalue < 0.1) findings are in bold. 
 
Table 37: Interaction between weighted GRS and dietary factors on BMI 
 SCHS cases SCHS controls SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
 Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qp-value Beta SE P Padjust Qp-value 
Calories 0.007 0.009 0.419 -0.005 0.006 0.407 -0.001 0.006 0.847 1.22E-04 0.007 0.985 -0.001 0.003 0.828 1.000 0.721 -0.002 0.004 0.555 1.000 0.828 
Cholesterol 0.009 0.008 0.297 -2.90E-04 0.006 0.963 -0.004 0.006 0.496 -0.012 0.007 0.086 -0.003 0.003 0.426 1.000 0.275 -0.004 0.004 0.181 1.000 0.445 
Starch 0.015 0.009 0.086 -2.90E-04 0.006 0.962 0.004 0.006 0.557 0.018 0.007 0.011 0.008 0.003 0.028 0.279 0.176 0.006 0.004 0.097 0.970 0.132 
Fiber -0.018 0.009 0.055 4.74E-04 0.006 0.938 -0.005 0.006 0.388 0.005 0.007 0.439 -0.002 0.003 0.440 1.000 0.215 -2.70E-04 0.004 0.940 1.000 0.510 
%Protein1 -0.002 0.009 0.823 -0.007 0.006 0.268 0.007 0.006 0.219 -0.020 0.007 0.004 -0.005 0.003 0.162 1.000 0.027 -0.005 0.004 0.154 1.000 0.011 
%Fat1 -0.017 0.009 0.056 0.002 0.006 0.796 -0.003 0.006 0.594 -0.019 0.007 0.004 -0.008 0.003 0.020 0.200 0.078 -0.006 0.004 0.086 0.860 0.061 
%SFA1 -0.017 0.009 0.051 0.002 0.006 0.780 -2.50E-04 0.006 0.968 -0.011 0.007 0.118 -0.005 0.003 0.156 1.000 0.228 -0.003 0.004 0.471 1.000 0.366 
%MFA1 -0.008 0.009 0.374 0.003 0.006 0.645 -0.001 0.006 0.803 -0.019 0.007 0.005 -0.005 0.003 0.105 1.000 0.097 -0.005 0.004 0.165 1.000 0.044 
%PFA1 -0.012 0.009 0.196 0.006 0.006 0.326 -0.005 0.006 0.446 -0.013 0.007 0.058 -0.004 0.003 0.195 1.000 0.161 -0.003 0.004 0.383 1.000 0.111 
%Carbohydrate1 0.012 0.009 0.175 0.001 0.006 0.852 -0.002 0.006 0.723 0.022 0.007 0.002 0.007 0.003 0.048 0.480 0.044 0.006 0.004 0.113 1.000 0.021 
Q (Cochran’s Q test) was used to measure between-study heterogeneity.  Significant interactions (Padjust < 0 .05) and heterogeneity (Qpvalue < 0.1) findings are in bold. 
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Figure 12: Regression coefficients for the associations between weighted GRS and 
Z-BMI adjusted for age, and sex. 
 
 
None of the interaction remained statistically significant after adjusting for multiple 
testing (P<0.005=0.05/10 tests).  Nominal evidence of interaction between wGRS 
with starch (β=0.008, SE=0.003, P=0.028), %fat (β=-0.008, SE=0.003, P=0.020) 
and %carbohydrate (β=-0.007, SE=0.003, P=0.048) on BMI was observed as shown 
in Table 37.  In the case of %carbohydrate and starch intake, the association of the 
wGRS on BMI was stronger among individuals who consumed more starch 
/ %carbohydrate as compared to individuals who had less intake of these two dietary 
components.  While for %fat intake, the association of the wGRS on BMI was 
stronger among individuals who consumed less %fat. 
 
6.3.6 Main effect of 64 SNPs on various dietary components 
The association between the 64 SNPs and various dietary components was evaluated 
by linear regression with adjustment for age, gender and total calories intake (except 
using total calories as outcome).  The analysis was conducted in each cohort 
















individually and subsequently meta-analyzed both in SCHS+SP2 and SCHS controls 
+SP2. 
 
Results are summarized in Table 38 to Table 47.  After meta-analysis, none of the 
association remained statistically significant after adjusting for multiple testing 
(P<0.0007=0.05/74 tests). 
 
6.3.6.1 Total calories 
After meta-analysis, rs1016287 on FLJ30838 (β=-0.052, SE=0.025, P=0.034), 
rs3888190 on ATP2A1 (β=-0.086, SE=0.038, P=0.026) and rs6804842 on RARB 
(β=0.074, SE=0.023, P=0.001) were found to be associated with total calories intake 
(Table 38).  BMI risk allele T of rs1016287 and A of rs3888190 would decrease 
calories intake while G of rs6804842 increased intake of calories.  In addition, if 
meta-analysis was conducted only in SCHS controls and SP2, the association 
between rs6804842 and total calories would still be significant after correction for 
multiple testing (β=0.091, SE=0.025, P=3.11×10-4, Padjust=0.023). 
 
6.3.6.2 Cholesterol 
After meta-analysis, rs1000940 on RABEP1 (β=0.049, SE=0.023, P=0.034) were 
found to be positively associated with cholesterol intake (Table 39).  BMI risk allele 




Table 38: Association between 64 SNPs and calories intake 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
1 rs1000940 -0.007 0.054 0.901 -0.015 0.042 0.718 -0.034 0.041 0.401 0.017 0.046 0.704 -0.012 0.022 0.601 1.000 0.868 -0.013 0.025 0.604 1.000 0.701 
2 rs1016287 -0.044 0.058 0.450 -0.068 0.045 0.131 -0.071 0.048 0.142 -0.021 0.049 0.666 -0.052 0.025 0.034 1.000 0.873 -0.054 0.027 0.047 1.000 0.714 
3 rs10182181 0.010 0.053 0.855 -0.049 0.041 0.225 0.033 0.041 0.419 -0.079 0.044 0.071 -0.023 0.022 0.291 1.000 0.230 -0.030 0.024 0.213 1.000 0.147 
4 rs10733682 0.004 0.059 0.947 0.055 0.048 0.257 0.004 0.046 0.937 0.024 0.054 0.650 0.023 0.026 0.373 1.000 0.871 0.027 0.028 0.340 1.000 0.746 
5 rs10938397 0.067 0.058 0.253 -0.028 0.045 0.533 -0.023 0.046 0.622 0.062 0.050 0.214 0.012 0.025 0.627 1.000 0.354 1.47E-04 0.027 0.996 1.000 0.336 
6 rs10968576 0.093 0.070 0.184 -0.009 0.054 0.864 0.046 0.053 0.383 0.017 0.059 0.774 0.031 0.029 0.282 1.000 0.686 0.018 0.032 0.564 1.000 0.763 
7 rs11030104 0.056 0.050 0.267 0.003 0.039 0.941 -0.015 0.040 0.700 -0.032 0.043 0.464 -0.001 0.021 0.954 1.000 0.589 -0.014 0.023 0.562 1.000 0.838 
8 rs11126666 0.067 0.056 0.233 -0.003 0.043 0.953 -0.027 0.045 0.544 0.013 0.048 0.792 0.007 0.024 0.777 1.000 0.617 -0.006 0.026 0.806 1.000 0.827 
9 rs11191560 0.033 0.060 0.587 -0.012 0.046 0.788 0.044 0.045 0.322 0.012 0.051 0.817 0.018 0.025 0.459 1.000 0.836 0.015 0.027 0.571 1.000 0.674 
10 rs11583200 0.018 0.086 0.830 -0.076 0.073 0.297 -0.008 0.076 0.917 -0.063 0.086 0.463 -0.034 0.040 0.389 1.000 0.815 -0.049 0.045 0.278 1.000 0.794 
11 rs11688816 -0.036 0.057 0.530 0.004 0.045 0.926 -0.007 0.044 0.872 0.027 0.048 0.582 -0.001 0.024 0.976 1.000 0.866 0.007 0.026 0.797 1.000 0.873 
12 rs12286929 -0.036 0.062 0.558 -0.023 0.045 0.606 -0.060 0.046 0.191 0.098 0.049 0.044 -0.005 0.025 0.844 1.000 0.095 0.001 0.027 0.969 1.000 0.048 
13 rs12429545 0.043 0.062 0.481 -0.073 0.045 0.102 -0.034 0.047 0.465 0.098 0.053 0.066 -0.004 0.025 0.876 1.000 0.069 -0.013 0.028 0.627 1.000 0.041 
14 rs12566985 -0.055 0.067 0.414 0.012 0.052 0.824 0.035 0.053 0.504 0.065 0.058 0.268 0.019 0.028 0.501 1.000 0.585 0.035 0.031 0.260 1.000 0.795 
15 rs12940622 0.060 0.056 0.283 -0.001 0.044 0.988 -0.054 0.043 0.217 0.011 0.047 0.818 -0.003 0.023 0.910 1.000 0.437 -0.016 0.026 0.536 1.000 0.549 
16 rs13021737 -0.089 0.103 0.384 0.006 0.076 0.941 0.032 0.075 0.667 0.129 0.088 0.144 0.026 0.042 0.536 1.000 0.440 0.049 0.046 0.287 1.000 0.552 
17 rs13201877 -0.207 0.165 0.211 0.083 0.100 0.409 0.183 0.104 0.077 -0.142 0.115 0.216 0.023 0.057 0.692 1.000 0.080 0.054 0.061 0.376 1.000 0.102 
18 rs1441264 -0.076 0.054 0.162 0.032 0.041 0.442 0.039 0.040 0.336 -0.075 0.045 0.092 -0.010 0.022 0.642 1.000 0.107 0.003 0.024 0.910 1.000 0.114 
19 rs1460676 0.064 0.054 0.234 -0.058 0.042 0.170 0.044 0.041 0.281 0.077 0.045 0.089 0.027 0.022 0.227 1.000 0.116 0.019 0.025 0.434 1.000 0.069 
20 rs1516725 -0.058 0.095 0.544 -0.096 0.079 0.223 0.061 0.072 0.394 -0.111 0.083 0.181 -0.043 0.040 0.290 1.000 0.353 -0.039 0.045 0.378 1.000 0.199 
21 rs1528435 -0.042 0.058 0.463 -0.032 0.042 0.451 -0.023 0.043 0.589 -0.048 0.047 0.304 -0.035 0.023 0.131 1.000 0.982 -0.034 0.025 0.184 1.000 0.926 
22 rs1558902 -0.086 0.074 0.250 0.031 0.060 0.605 0.079 0.063 0.210 -0.146 0.071 0.040 -0.017 0.033 0.602 1.000 0.069 -3.70E-04 0.037 0.992 1.000 0.048 
23 rs16851483 -0.011 0.059 0.852 -0.034 0.047 0.460 -0.016 0.046 0.719 -0.057 0.051 0.267 -0.030 0.025 0.226 1.000 0.924 -0.034 0.028 0.211 1.000 0.841 
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Table 38 (Continued): Association between 64 SNPs and calories intake 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
24 rs16951275 0.023 0.055 0.677 0.005 0.039 0.899 0.066 0.041 0.110 -0.026 0.045 0.562 0.018 0.022 0.421 1.000 0.488 0.017 0.024 0.486 1.000 0.298 
25 rs17203016 -0.027 0.079 0.735 0.054 0.058 0.355 -0.017 0.056 0.759 -0.173 0.063 0.006 -0.037 0.031 0.235 1.000 0.063 -0.039 0.034 0.252 1.000 0.027 
26 rs17405819 -0.006 0.054 0.905 -0.004 0.041 0.928 -0.082 0.040 0.043 -0.054 0.044 0.224 -0.040 0.022 0.071 1.000 0.506 -0.047 0.024 0.054 1.000 0.392 
27 rs17724992 -0.002 0.052 0.969 0.062 0.041 0.127 0.051 0.040 0.196 0.006 0.044 0.886 0.034 0.022 0.115 1.000 0.671 0.042 0.024 0.079 1.000 0.622 
28 rs1928295 0.099 0.053 0.060 0.036 0.041 0.382 0.006 0.040 0.875 -0.069 0.045 0.123 0.013 0.022 0.559 1.000 0.094 -0.005 0.024 0.824 1.000 0.209 
29 rs2033529 0.075 0.076 0.325 -0.026 0.056 0.641 -0.003 0.052 0.950 -0.011 0.058 0.854 1.39E-04 0.029 0.996 1.000 0.747 -0.013 0.032 0.685 1.000 0.955 
30 rs2033732 0.110 0.052 0.034 -0.043 0.042 0.301 0.010 0.041 0.816 0.007 0.044 0.876 0.012 0.022 0.572 1.000 0.148 -0.009 0.024 0.704 1.000 0.604 
31 rs205262 0.091 0.070 0.193 -0.035 0.057 0.537 0.051 0.060 0.396 -0.121 0.064 0.059 -0.007 0.031 0.814 1.000 0.097 -0.032 0.035 0.363 1.000 0.146 
32 rs2075650 -0.028 0.097 0.772 0.131 0.074 0.074 0.018 0.071 0.796 0.097 0.079 0.216 0.062 0.039 0.112 1.000 0.504 0.080 0.043 0.062 1.000 0.522 
33 rs2080454 -0.060 0.054 0.270 0.023 0.041 0.570 0.007 0.040 0.866 0.011 0.044 0.798 0.002 0.022 0.935 1.000 0.653 0.014 0.024 0.565 1.000 0.958 
34 rs2112347 0.062 0.052 0.232 0.008 0.041 0.841 0.007 0.040 0.869 0.041 0.044 0.353 0.025 0.022 0.246 1.000 0.797 0.017 0.024 0.470 1.000 0.814 
35 rs2176040 -0.147 0.100 0.142 -0.040 0.079 0.618 0.061 0.078 0.436 -0.086 0.083 0.303 -0.041 0.042 0.326 1.000 0.374 -0.019 0.046 0.687 1.000 0.415 
36 rs2207139 -0.063 0.071 0.372 -0.166 0.059 0.005 -0.054 0.062 0.391 0.071 0.065 0.272 -0.058 0.032 0.067 1.000 0.061 -0.057 0.036 0.110 1.000 0.025 
37 rs2287019 -0.028 0.065 0.672 -0.123 0.051 0.015 0.034 0.050 0.493 0.075 0.059 0.198 -0.014 0.028 0.602 1.000 0.047 -0.012 0.030 0.705 1.000 0.019 
38 rs2365389 0.020 0.074 0.786 0.112 0.058 0.054 -0.055 0.064 0.391 -0.047 0.065 0.471 0.013 0.032 0.693 1.000 0.180 0.011 0.036 0.759 1.000 0.087 
39 rs2820292 0.134 0.063 0.033 -0.023 0.053 0.660 -0.007 0.051 0.897 -0.078 0.055 0.152 -0.002 0.027 0.934 1.000 0.078 -0.035 0.030 0.257 1.000 0.610 
40 rs2836754 -0.036 0.054 0.501 -0.003 0.041 0.946 -0.008 0.041 0.842 -0.066 0.046 0.153 -0.025 0.022 0.263 1.000 0.732 -0.023 0.025 0.356 1.000 0.539 
41 rs29941 -0.045 0.066 0.495 0.066 0.048 0.169 0.048 0.050 0.345 -0.090 0.054 0.097 0.005 0.027 0.862 1.000 0.113 0.014 0.029 0.623 1.000 0.071 
42 rs3101336 -0.033 0.099 0.739 0.013 0.074 0.862 -0.083 0.071 0.248 -0.021 0.084 0.801 -0.033 0.040 0.417 1.000 0.829 -0.032 0.044 0.459 1.000 0.643 
43 rs3817334 0.057 0.057 0.313 -0.085 0.044 0.053 0.044 0.045 0.327 0.070 0.049 0.155 0.014 0.024 0.557 1.000 0.060 0.005 0.027 0.860 1.000 0.035 
44 rs3849570 -0.030 0.051 0.561 -0.037 0.041 0.364 0.069 0.039 0.082 0.043 0.045 0.330 0.015 0.022 0.482 1.000 0.199 0.025 0.024 0.295 1.000 0.156 
45 rs3888190 0.120 0.091 0.185 -0.047 0.072 0.516 -0.087 0.071 0.219 -0.282 0.078 3.23E-04 -0.086 0.038 0.026 1.000 0.008 -0.130 0.042 0.002 0.128 0.064 
46 rs4256980 -0.045 0.055 0.409 -0.054 0.041 0.183 -0.050 0.041 0.221 0.009 0.045 0.836 -0.036 0.022 0.105 1.000 0.711 -0.034 0.024 0.160 1.000 0.511 
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Table 38 (Continued): Association between 64 SNPs and calories intake 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
47 rs4740619 -0.002 0.059 0.973 0.020 0.047 0.678 -0.041 0.045 0.366 -0.056 0.053 0.291 -0.020 0.025 0.425 1.000 0.689 -0.024 0.028 0.386 1.000 0.508 
48 rs4787491 -0.030 0.053 0.575 0.004 0.039 0.922 0.020 0.041 0.614 -0.025 0.044 0.576 -0.004 0.022 0.857 1.000 0.836 0.001 0.024 0.957 1.000 0.751 
49 rs492400 -0.083 0.066 0.208 -0.027 0.049 0.586 0.044 0.048 0.365 0.095 0.052 0.071 0.016 0.026 0.546 1.000 0.132 0.035 0.029 0.227 1.000 0.230 
50 rs6567160 -0.028 0.072 0.692 0.006 0.053 0.911 -0.015 0.054 0.776 0.065 0.060 0.286 0.008 0.029 0.791 1.000 0.724 0.015 0.032 0.640 1.000 0.602 
51 rs6804842 -0.006 0.055 0.907 0.119 0.043 0.006 0.036 0.043 0.402 0.120 0.045 0.008 0.074 0.023 0.001 0.074 0.169 0.091 0.025 3.11E-04 0.023 0.297 
52 rs7138803 0.048 0.061 0.437 0.002 0.046 0.971 0.034 0.046 0.451 -0.064 0.051 0.215 0.004 0.025 0.884 1.000 0.441 -0.005 0.027 0.850 1.000 0.355 
53 rs7141420 -0.051 0.052 0.325 0.059 0.040 0.144 -0.015 0.040 0.702 0.035 0.043 0.417 0.013 0.022 0.562 1.000 0.311 0.026 0.024 0.277 1.000 0.414 
54 rs7164727 0.055 0.061 0.368 -0.082 0.046 0.073 -0.026 0.047 0.576 -0.066 0.050 0.183 -0.039 0.025 0.115 1.000 0.304 -0.058 0.027 0.033 1.000 0.682 
55 rs7239883 0.140 0.056 0.013 0.007 0.043 0.880 0.001 0.043 0.978 -0.026 0.048 0.588 0.020 0.023 0.388 1.000 0.124 -0.005 0.026 0.853 1.000 0.868 
56 rs7243357 -0.027 0.063 0.672 0.021 0.048 0.670 0.049 0.053 0.362 0.056 0.054 0.303 0.028 0.027 0.301 1.000 0.757 0.040 0.030 0.179 1.000 0.874 
57 rs7599312 0.235 0.198 0.237 0.065 0.149 0.663 -0.233 0.123 0.059 0.015 0.157 0.922 -0.033 0.075 0.658 1.000 0.172 -0.078 0.081 0.336 1.000 0.239 
58 rs7715256 0.121 0.137 0.378 0.108 0.109 0.323 -0.069 0.113 0.543 0.147 0.113 0.195 0.074 0.058 0.207 1.000 0.528 0.063 0.065 0.327 1.000 0.355 
59 rs7903146 0.160 0.179 0.371 -0.369 0.125 0.003 -0.007 0.144 0.962 -0.139 0.149 0.353 -0.133 0.073 0.068 1.000 0.072 -0.191 0.080 0.017 1.000 0.151 
60 rs9374842 0.031 0.097 0.751 0.092 0.069 0.180 0.049 0.071 0.491 -0.011 0.078 0.889 0.045 0.038 0.240 1.000 0.798 0.048 0.042 0.253 1.000 0.610 
61 rs9400239 -0.008 0.058 0.890 -0.004 0.044 0.929 -0.033 0.044 0.447 -0.071 0.050 0.158 -0.029 0.024 0.229 1.000 0.763 -0.033 0.026 0.208 1.000 0.607 
62 rs9641123 0.027 0.057 0.639 -0.022 0.043 0.615 0.029 0.043 0.506 0.047 0.047 0.317 0.018 0.023 0.436 1.000 0.726 0.016 0.026 0.520 1.000 0.526 
63 rs977747 -0.068 0.143 0.634 -0.066 0.103 0.523 0.114 0.107 0.287 0.200 0.101 0.047 0.062 0.055 0.264 1.000 0.214 0.084 0.060 0.159 1.000 0.173 
64 rs9914578 0.042 0.064 0.515 -0.009 0.049 0.847 0.005 0.051 0.918 0.032 0.056 0.572 0.013 0.027 0.620 1.000 0.908 0.007 0.030 0.808 1.000 0.857 





Table 39: Association between 64 SNPs and cholesterol intake 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
1 rs1000940 0.017 0.059 0.781 0.079 0.044 0.074 0.027 0.041 0.518 0.066 0.047 0.158 0.049 0.023 0.034 1.000 0.755 0.055 0.025 0.029 1.000 0.660 
2 rs1016287 0.015 0.064 0.818 -0.049 0.048 0.307 -0.030 0.049 0.541 0.019 0.050 0.699 -0.015 0.026 0.561 1.000 0.734 -0.021 0.028 0.460 1.000 0.601 
3 rs10182181 -0.083 0.058 0.150 -0.050 0.043 0.246 0.068 0.042 0.104 -0.129 0.045 0.004 -0.041 0.023 0.075 1.000 0.010 -0.033 0.025 0.189 1.000 0.005 
4 rs10733682 0.045 0.065 0.487 -0.035 0.051 0.493 -0.066 0.047 0.162 -0.005 0.055 0.925 -0.024 0.027 0.360 1.000 0.556 -0.039 0.029 0.188 1.000 0.704 
5 rs10938397 0.037 0.064 0.566 0.011 0.048 0.816 -0.063 0.046 0.172 -0.018 0.051 0.725 -0.015 0.026 0.565 1.000 0.564 -0.024 0.028 0.381 1.000 0.528 
6 rs10968576 0.014 0.077 0.855 0.052 0.057 0.363 0.055 0.054 0.304 0.041 0.060 0.499 0.044 0.030 0.142 1.000 0.975 0.050 0.033 0.129 1.000 0.983 
7 rs11030104 -0.043 0.056 0.441 -0.016 0.041 0.704 0.055 0.040 0.173 0.082 0.044 0.063 0.026 0.022 0.240 1.000 0.197 0.039 0.024 0.106 1.000 0.239 
8 rs11126666 -0.126 0.061 0.040 -0.047 0.046 0.302 0.005 0.045 0.907 0.017 0.049 0.723 -0.028 0.025 0.252 1.000 0.249 -0.009 0.027 0.731 1.000 0.581 
9 rs11191560 0.043 0.066 0.515 -0.016 0.048 0.748 -0.019 0.045 0.677 -0.067 0.052 0.199 -0.020 0.026 0.433 1.000 0.628 -0.032 0.028 0.259 1.000 0.721 
10 rs11583200 -0.004 0.094 0.970 -0.075 0.078 0.332 -0.127 0.076 0.098 -0.069 0.088 0.432 -0.075 0.042 0.070 1.000 0.793 -0.092 0.046 0.046 1.000 0.853 
11 rs11688816 0.036 0.063 0.569 0.016 0.047 0.741 -0.084 0.044 0.060 0.015 0.050 0.764 -0.013 0.025 0.613 1.000 0.282 -0.022 0.027 0.426 1.000 0.211 
12 rs12286929 0.038 0.068 0.579 -0.031 0.047 0.512 -0.009 0.047 0.849 0.033 0.050 0.509 0.002 0.026 0.927 1.000 0.752 -0.004 0.028 0.897 1.000 0.642 
13 rs12429545 -0.063 0.068 0.356 0.034 0.047 0.477 0.063 0.048 0.188 -0.055 0.054 0.315 0.007 0.026 0.781 1.000 0.258 0.020 0.029 0.489 1.000 0.250 
14 rs12566985 -0.037 0.074 0.616 0.050 0.055 0.368 -0.006 0.053 0.913 -0.025 0.060 0.678 4.24E-04 0.030 0.989 1.000 0.741 0.008 0.032 0.813 1.000 0.625 
15 rs12940622 -0.085 0.062 0.168 0.054 0.047 0.244 0.007 0.044 0.874 0.008 0.048 0.864 0.006 0.025 0.811 1.000 0.354 0.023 0.027 0.391 1.000 0.713 
16 rs13021737 -0.091 0.113 0.420 0.164 0.081 0.042 0.078 0.076 0.306 0.080 0.090 0.374 0.079 0.044 0.071 1.000 0.335 0.108 0.047 0.022 1.000 0.692 
17 rs13201877 0.016 0.182 0.928 0.012 0.106 0.910 0.141 0.106 0.183 -0.073 0.117 0.534 0.031 0.060 0.598 1.000 0.592 0.033 0.063 0.598 1.000 0.387 
18 rs1441264 -0.014 0.060 0.820 -0.017 0.044 0.704 -0.087 0.041 0.034 0.031 0.046 0.497 -0.026 0.023 0.253 1.000 0.278 -0.029 0.025 0.253 1.000 0.150 
19 rs1460676 -0.059 0.059 0.320 0.006 0.044 0.888 0.033 0.041 0.423 1.57E-04 0.046 0.997 0.003 0.023 0.893 1.000 0.652 0.015 0.025 0.566 1.000 0.847 
20 rs1516725 -0.198 0.104 0.057 -0.018 0.084 0.827 0.066 0.073 0.362 -0.044 0.085 0.605 -0.026 0.042 0.541 1.000 0.220 0.008 0.046 0.859 1.000 0.573 
21 rs1528435 0.058 0.063 0.357 0.016 0.045 0.712 -0.036 0.044 0.418 -0.028 0.048 0.559 -0.005 0.024 0.851 1.000 0.584 -0.015 0.026 0.557 1.000 0.675 
22 rs1558902 -0.076 0.082 0.353 -0.016 0.063 0.799 -0.027 0.064 0.676 -0.053 0.073 0.468 -0.038 0.035 0.269 1.000 0.939 -0.030 0.038 0.432 1.000 0.928 
23 rs16851483 -0.055 0.064 0.391 0.051 0.050 0.305 0.079 0.046 0.091 -0.012 0.053 0.812 0.027 0.026 0.306 1.000 0.300 0.043 0.028 0.134 1.000 0.422 
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Table 39 (continued): Association between 64 SNPs and cholesterol intake 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
24 rs16951275 0.063 0.060 0.293 0.028 0.041 0.505 -0.031 0.042 0.451 0.046 0.046 0.309 0.020 0.023 0.387 1.000 0.492 0.012 0.025 0.617 1.000 0.407 
25 rs17203016 -0.087 0.086 0.313 0.041 0.062 0.510 0.053 0.057 0.354 -0.002 0.065 0.974 0.016 0.033 0.632 1.000 0.555 0.033 0.035 0.353 1.000 0.805 
26 rs17405819 -0.085 0.059 0.145 0.038 0.043 0.385 0.052 0.041 0.206 -0.068 0.045 0.133 -0.004 0.023 0.869 1.000 0.081 0.011 0.025 0.659 1.000 0.109 
27 rs17724992 0.049 0.057 0.384 -0.005 0.043 0.912 0.035 0.040 0.377 0.006 0.045 0.900 0.019 0.023 0.394 1.000 0.840 0.014 0.025 0.583 1.000 0.777 
28 rs1928295 0.019 0.058 0.742 -0.019 0.044 0.665 0.025 0.040 0.535 0.091 0.046 0.049 0.028 0.023 0.216 1.000 0.385 0.030 0.025 0.228 1.000 0.221 
29 rs2033529 0.116 0.084 0.168 0.025 0.059 0.677 -0.050 0.052 0.337 0.026 0.060 0.667 0.012 0.031 0.706 1.000 0.385 -0.004 0.033 0.893 1.000 0.532 
30 rs2033732 -0.105 0.057 0.065 0.007 0.044 0.869 0.033 0.042 0.426 -0.086 0.045 0.057 -0.028 0.023 0.232 1.000 0.099 -0.012 0.025 0.625 1.000 0.133 
31 rs205262 0.005 0.077 0.951 -0.070 0.061 0.246 0.071 0.061 0.242 -0.001 0.066 0.992 0.001 0.033 0.978 1.000 0.437 3.29E-05 0.036 0.999 1.000 0.257 
32 rs2075650 -0.157 0.106 0.139 -0.078 0.078 0.321 0.038 0.072 0.593 0.089 0.081 0.273 -0.009 0.041 0.818 1.000 0.202 0.016 0.044 0.712 1.000 0.310 
33 rs2080454 0.028 0.060 0.638 0.013 0.043 0.770 -0.028 0.041 0.488 0.005 0.045 0.920 -6.73E-05 0.023 0.998 1.000 0.850 -0.005 0.025 0.843 1.000 0.764 
34 rs2112347 0.060 0.057 0.292 0.011 0.043 0.792 0.017 0.041 0.675 0.012 0.045 0.797 0.021 0.023 0.355 1.000 0.903 0.014 0.025 0.584 1.000 0.994 
35 rs2176040 0.050 0.110 0.649 0.004 0.084 0.965 0.006 0.079 0.941 0.050 0.086 0.558 0.024 0.044 0.585 1.000 0.967 0.019 0.048 0.691 1.000 0.908 
36 rs2207139 -0.023 0.078 0.765 -0.030 0.062 0.631 0.014 0.063 0.820 0.018 0.066 0.782 -0.004 0.033 0.901 1.000 0.933 1.02E-04 0.037 0.998 1.000 0.836 
37 rs2287019 -0.053 0.072 0.459 0.029 0.054 0.586 0.131 0.051 0.010 0.037 0.060 0.535 0.050 0.029 0.080 1.000 0.189 0.070 0.031 0.025 1.000 0.318 
38 rs2365389 -0.022 0.081 0.783 -0.060 0.062 0.328 0.028 0.064 0.666 0.021 0.067 0.755 -0.009 0.034 0.789 1.000 0.742 -0.006 0.037 0.867 1.000 0.545 
39 rs2820292 -0.073 0.069 0.291 -0.002 0.056 0.974 -0.054 0.051 0.292 0.023 0.056 0.686 -0.024 0.029 0.406 1.000 0.636 -0.014 0.031 0.664 1.000 0.581 
40 rs2836754 -0.011 0.059 0.855 -0.067 0.044 0.125 -0.051 0.041 0.215 -0.005 0.047 0.918 -0.038 0.023 0.101 1.000 0.741 -0.043 0.025 0.088 1.000 0.607 
41 rs29941 0.018 0.073 0.803 -0.019 0.051 0.711 -0.022 0.051 0.671 0.023 0.056 0.682 -0.004 0.028 0.893 1.000 0.912 -0.008 0.030 0.803 1.000 0.809 
42 rs3101336 -0.123 0.108 0.257 -0.161 0.079 0.040 -0.046 0.072 0.521 0.013 0.086 0.877 -0.076 0.042 0.068 1.000 0.455 -0.068 0.045 0.132 1.000 0.301 
43 rs3817334 -0.037 0.063 0.549 0.016 0.047 0.731 0.004 0.046 0.933 0.023 0.050 0.649 0.005 0.025 0.828 1.000 0.886 0.014 0.027 0.617 1.000 0.960 
44 rs3849570 -0.064 0.057 0.264 0.055 0.043 0.198 0.037 0.040 0.356 0.012 0.046 0.792 0.020 0.023 0.377 1.000 0.384 0.036 0.025 0.147 1.000 0.786 
45 rs3888190 -0.019 0.100 0.847 0.001 0.076 0.986 -0.028 0.072 0.701 0.094 0.081 0.246 0.012 0.040 0.769 1.000 0.694 0.018 0.044 0.685 1.000 0.513 
46 rs4256980 0.035 0.060 0.559 -0.035 0.043 0.425 0.015 0.041 0.709 -0.023 0.046 0.609 -0.006 0.023 0.801 1.000 0.725 -0.013 0.025 0.606 1.000 0.680 
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Table 39 (continued): Association between 64 SNPs and cholesterol intake 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
47 rs4740619 -0.136 0.065 0.036 0.013 0.050 0.796 0.058 0.046 0.207 0.046 0.054 0.397 0.011 0.026 0.681 1.000 0.085 0.040 0.029 0.166 1.000 0.796 
48 rs4787491 0.015 0.058 0.802 0.041 0.042 0.325 -0.001 0.041 0.981 -0.086 0.045 0.059 -0.007 0.023 0.747 1.000 0.213 -0.011 0.025 0.648 1.000 0.115 
49 rs492400 0.073 0.072 0.317 -0.068 0.052 0.188 -0.017 0.049 0.725 -0.019 0.054 0.721 -0.019 0.027 0.484 1.000 0.476 -0.035 0.030 0.244 1.000 0.732 
50 rs6567160 0.081 0.079 0.306 0.056 0.056 0.317 0.015 0.055 0.783 -0.097 0.062 0.119 0.010 0.031 0.742 1.000 0.216 -0.002 0.033 0.941 1.000 0.173 
51 rs6804842 -0.021 0.060 0.731 0.048 0.046 0.291 0.002 0.044 0.956 -0.016 0.047 0.726 0.006 0.024 0.789 1.000 0.732 0.012 0.026 0.659 1.000 0.592 
52 rs7138803 0.010 0.067 0.882 0.013 0.049 0.791 -0.004 0.046 0.934 -0.004 0.053 0.935 0.003 0.026 0.911 1.000 0.993 0.002 0.028 0.953 1.000 0.961 
53 rs7141420 0.016 0.057 0.774 0.002 0.043 0.953 0.028 0.041 0.494 0.056 0.044 0.209 0.026 0.023 0.245 1.000 0.854 0.028 0.025 0.254 1.000 0.689 
54 rs7164727 -0.125 0.066 0.059 -0.057 0.048 0.240 -0.008 0.047 0.863 0.072 0.051 0.154 -0.019 0.026 0.460 1.000 0.090 6.97E-05 0.028 0.998 1.000 0.179 
55 rs7239883 0.010 0.062 0.877 -0.014 0.046 0.756 -0.025 0.043 0.568 -0.034 0.049 0.492 -0.019 0.024 0.442 1.000 0.954 -0.024 0.026 0.368 1.000 0.958 
56 rs7243357 0.199 0.069 0.004 -0.036 0.051 0.482 0.070 0.054 0.198 -0.070 0.055 0.203 0.023 0.028 0.417 1.000 0.010 -0.012 0.031 0.686 1.000 0.164 
57 rs7599312 0.286 0.218 0.191 0.060 0.158 0.707 -0.162 0.125 0.196 -0.407 0.160 0.011 -0.109 0.078 0.162 1.000 0.045 -0.167 0.084 0.046 1.000 0.116 
58 rs7715256 -0.037 0.151 0.805 -0.080 0.115 0.486 -0.133 0.115 0.246 -0.021 0.116 0.855 -0.072 0.061 0.238 1.000 0.911 -0.079 0.067 0.238 1.000 0.790 
59 rs7903146 0.356 0.197 0.071 -0.211 0.135 0.119 -0.233 0.146 0.110 -0.029 0.153 0.848 -0.086 0.077 0.263 1.000 0.070 -0.164 0.083 0.048 1.000 0.571 
60 rs9374842 -0.309 0.106 0.004 0.049 0.073 0.498 -0.008 0.072 0.907 -0.011 0.080 0.889 -0.035 0.040 0.387 1.000 0.040 0.011 0.043 0.799 1.000 0.808 
61 rs9400239 0.059 0.063 0.355 -0.007 0.047 0.875 0.003 0.044 0.949 0.061 0.051 0.235 0.023 0.025 0.369 1.000 0.684 0.016 0.027 0.562 1.000 0.575 
62 rs9641123 0.047 0.062 0.448 0.024 0.046 0.597 -0.068 0.043 0.116 -0.098 0.048 0.043 -0.032 0.024 0.186 1.000 0.128 -0.046 0.026 0.079 1.000 0.152 
63 rs977747 -0.208 0.157 0.187 -0.100 0.110 0.366 0.103 0.108 0.340 -0.140 0.103 0.173 -0.070 0.057 0.225 1.000 0.276 -0.048 0.062 0.433 1.000 0.226 
64 rs9914578 0.034 0.071 0.629 -0.001 0.052 0.980 0.023 0.051 0.653 0.038 0.058 0.512 0.021 0.028 0.453 1.000 0.959 0.019 0.031 0.543 1.000 0.876 




After meta-analysis, rs205262 on C6orf106 (β=0.070, SE=0.032, P=0.031) were 
found to be positively associated with starch intake (Table 40).  BMI risk allele G of 
rs205262 would increase starch intake. 
 
6.3.6.4 Fiber 
After meta-analysis, nominal significance were found between rs1000940 on 
RABEP1 (β=-0.061, SE=0.023, P=0.008), rs1016287 on FLJ30838 (β=-0.070, 
SE=0.026, P=0.006), rs10968576 on LINGO (β=-0.061, SE=0.030, P=0.042), 
rs11030104 on BDNF (β=-0.048, SE=0.022, P=0.030), rs1928295 on TLR4 
(β=-0.049, SE=0.023, P=0.031) and rs9374842 on LOC285762 (β=-0.079, SE=0.040, 
P=0.046) and fiber intake (Table 41).  BMI risk allele G of rs1000940, T of 
rs1016287, G of rs10968576, A of rs11030104, T of rs1928295 and T of rs9374842 
were all negatively associated with dietary fiber intake. 
 
6.3.6.5 %Protein 
After meta-analysis, rs2287019 on QPCTL (β=0.057, SE=0.029, P=0.047), 
rs2365389 on FHIT (β=-0.070, SE=0.034, P=0.037) and rs3101336 on NEGR1 
(β=-0.123, SE=0.042, P=0.003) were found to be associated with %protein intake 
(Table 42).  BMI risk allele C of rs2287019 was positively associated while C of 
rs2365389 and C of rs3101336 were negatively associated with %protein intake.
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Table 40: Association between 64 SNPs and starch intake 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
1 rs1000940 -0.014 0.059 0.819 -0.053 0.044 0.231 -0.003 0.041 0.939 0.046 0.047 0.322 -0.006 0.023 0.783 1.000 0.494 -0.005 0.025 0.840 1.000 0.304 
2 rs1016287 0.008 0.064 0.899 0.012 0.048 0.804 0.016 0.049 0.749 0.002 0.050 0.964 0.010 0.026 0.706 1.000 0.998 0.010 0.028 0.721 1.000 0.981 
3 rs10182181 -0.043 0.058 0.459 0.054 0.043 0.216 0.020 0.042 0.639 -0.023 0.045 0.614 0.008 0.023 0.717 1.000 0.489 0.018 0.025 0.476 1.000 0.472 
4 rs10733682 -0.155 0.065 0.017 -0.081 0.051 0.108 -0.003 0.047 0.950 -0.047 0.055 0.399 -0.060 0.027 0.024 1.000 0.274 -0.041 0.029 0.159 1.000 0.518 
5 rs10938397 0.014 0.064 0.827 0.076 0.047 0.109 -0.033 0.046 0.481 0.081 0.051 0.118 0.034 0.026 0.179 1.000 0.287 0.038 0.028 0.171 1.000 0.161 
6 rs10968576 0.054 0.077 0.486 -0.035 0.056 0.540 -0.038 0.053 0.471 0.084 0.060 0.162 0.007 0.030 0.810 1.000 0.351 -0.001 0.033 0.972 1.000 0.241 
7 rs11030104 0.036 0.056 0.515 0.053 0.041 0.200 -0.085 0.040 0.035 -0.028 0.044 0.530 -0.012 0.022 0.594 1.000 0.085 -0.021 0.024 0.389 1.000 0.056 
8 rs11126666 0.132 0.061 0.031 -0.014 0.046 0.760 0.060 0.045 0.183 0.050 0.049 0.314 0.048 0.025 0.053 1.000 0.284 0.031 0.027 0.244 1.000 0.465 
9 rs11191560 -0.064 0.066 0.335 -0.002 0.048 0.974 0.016 0.045 0.723 -0.037 0.052 0.479 -0.014 0.026 0.589 1.000 0.737 -0.005 0.028 0.859 1.000 0.743 
10 rs11583200 -0.015 0.094 0.875 0.104 0.077 0.177 0.133 0.076 0.081 -0.082 0.088 0.348 0.048 0.041 0.245 1.000 0.219 0.063 0.046 0.170 1.000 0.144 
11 rs11688816 -0.025 0.063 0.684 0.025 0.047 0.600 -0.004 0.044 0.927 0.028 0.049 0.564 0.009 0.025 0.724 1.000 0.883 0.015 0.027 0.575 1.000 0.860 
12 rs12286929 0.122 0.067 0.071 -0.073 0.047 0.124 -0.044 0.047 0.353 -0.079 0.050 0.115 -0.038 0.026 0.143 1.000 0.077 -0.064 0.028 0.020 1.000 0.855 
13 rs12429545 0.004 0.068 0.954 0.087 0.047 0.066 -0.060 0.048 0.210 0.045 0.054 0.411 0.020 0.026 0.450 1.000 0.167 0.023 0.029 0.426 1.000 0.082 
14 rs12566985 0.066 0.073 0.370 -0.117 0.055 0.033 -0.096 0.053 0.070 0.046 0.060 0.444 -0.042 0.029 0.159 1.000 0.065 -0.062 0.032 0.053 1.000 0.097 
15 rs12940622 0.047 0.062 0.450 0.012 0.046 0.795 -0.025 0.044 0.567 0.071 0.048 0.144 0.021 0.024 0.392 1.000 0.500 0.016 0.027 0.544 1.000 0.340 
16 rs13021737 -0.081 0.113 0.472 -0.116 0.080 0.150 0.017 0.076 0.827 -0.113 0.090 0.209 -0.067 0.043 0.124 1.000 0.602 -0.064 0.047 0.172 1.000 0.399 
17 rs13201877 0.175 0.182 0.335 0.024 0.106 0.823 0.014 0.106 0.898 -0.011 0.117 0.927 0.028 0.059 0.640 1.000 0.852 0.010 0.063 0.873 1.000 0.976 
18 rs1441264 0.015 0.060 0.805 0.017 0.043 0.691 -0.003 0.041 0.933 0.019 0.046 0.680 0.011 0.023 0.641 1.000 0.981 0.010 0.025 0.687 1.000 0.917 
19 rs1460676 -0.005 0.059 0.937 -0.079 0.044 0.076 0.065 0.041 0.113 -0.030 0.046 0.514 -0.009 0.023 0.695 1.000 0.114 -0.010 0.025 0.695 1.000 0.051 
20 rs1516725 0.007 0.104 0.949 0.014 0.083 0.863 -0.055 0.072 0.443 0.082 0.085 0.331 0.006 0.042 0.880 1.000 0.672 0.006 0.046 0.891 1.000 0.462 
21 rs1528435 -0.084 0.063 0.182 -0.025 0.045 0.568 -0.004 0.044 0.934 -0.024 0.048 0.615 -0.027 0.024 0.262 1.000 0.773 -0.017 0.026 0.510 1.000 0.928 
22 rs1558902 0.069 0.082 0.399 -0.071 0.063 0.264 -0.020 0.064 0.755 0.003 0.073 0.971 -0.014 0.035 0.683 1.000 0.594 -0.032 0.038 0.399 1.000 0.727 
23 rs16851483 -0.066 0.064 0.302 -0.075 0.049 0.129 0.009 0.046 0.846 -0.068 0.052 0.197 -0.045 0.026 0.080 1.000 0.568 -0.041 0.028 0.145 1.000 0.388 
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Table 40 (continued): Association between 64 SNPs and starch intake 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
24 rs16951275 0.064 0.059 0.279 0.007 0.041 0.873 0.011 0.041 0.795 0.009 0.046 0.841 0.017 0.023 0.455 1.000 0.861 0.009 0.025 0.720 1.000 0.997 
25 rs17203016 -0.039 0.086 0.651 0.040 0.062 0.517 0.065 0.057 0.253 0.050 0.064 0.434 0.040 0.033 0.223 1.000 0.788 0.053 0.035 0.134 1.000 0.956 
26 rs17405819 0.058 0.059 0.324 0.016 0.043 0.706 -0.015 0.041 0.714 -0.004 0.045 0.935 0.008 0.023 0.736 1.000 0.766 -0.001 0.025 0.960 1.000 0.869 
27 rs17724992 -0.008 0.057 0.893 -0.084 0.043 0.051 0.053 0.040 0.186 0.056 0.045 0.220 0.006 0.023 0.779 1.000 0.072 0.009 0.025 0.716 1.000 0.031 
28 rs1928295 -0.038 0.058 0.517 0.038 0.043 0.382 0.006 0.040 0.889 0.040 0.046 0.385 0.016 0.023 0.475 1.000 0.693 0.026 0.025 0.292 1.000 0.807 
29 rs2033529 -0.026 0.084 0.758 0.036 0.059 0.534 0.087 0.052 0.094 -0.091 0.059 0.126 0.012 0.030 0.684 1.000 0.141 0.018 0.033 0.578 1.000 0.073 
30 rs2033732 -0.003 0.057 0.954 0.002 0.044 0.968 -0.059 0.041 0.153 -0.001 0.045 0.984 -0.019 0.023 0.420 1.000 0.706 -0.021 0.025 0.393 1.000 0.519 
31 rs205262 0.071 0.077 0.356 0.044 0.060 0.462 0.032 0.060 0.600 0.144 0.065 0.028 0.070 0.032 0.031 1.000 0.603 0.070 0.036 0.051 1.000 0.395 
32 rs2075650 0.097 0.106 0.361 0.032 0.078 0.683 -0.076 0.071 0.291 -0.081 0.081 0.315 -0.022 0.041 0.585 1.000 0.418 -0.043 0.044 0.332 1.000 0.508 
33 rs2080454 -0.008 0.060 0.887 0.063 0.043 0.140 -0.013 0.040 0.756 0.028 0.045 0.535 0.020 0.023 0.384 1.000 0.588 0.025 0.025 0.317 1.000 0.435 
34 rs2112347 0.057 0.057 0.316 -0.022 0.043 0.606 -0.010 0.041 0.809 0.097 0.045 0.032 0.024 0.023 0.285 1.000 0.188 0.018 0.025 0.466 1.000 0.111 
35 rs2176040 -0.077 0.110 0.485 -0.113 0.083 0.175 0.011 0.079 0.886 -0.131 0.085 0.125 -0.074 0.044 0.089 1.000 0.608 -0.074 0.048 0.122 1.000 0.400 
36 rs2207139 -0.001 0.079 0.992 -0.003 0.062 0.963 0.057 0.063 0.370 0.006 0.066 0.923 0.016 0.033 0.622 1.000 0.903 0.020 0.037 0.583 1.000 0.773 
37 rs2287019 -0.071 0.072 0.321 -0.035 0.054 0.515 -0.026 0.051 0.613 0.062 0.060 0.308 -0.016 0.029 0.583 1.000 0.492 -0.005 0.031 0.870 1.000 0.428 
38 rs2365389 -0.120 0.081 0.142 0.001 0.061 0.992 -0.012 0.065 0.850 0.063 0.066 0.341 -0.007 0.034 0.830 1.000 0.383 0.016 0.037 0.665 1.000 0.685 
39 rs2820292 0.024 0.069 0.733 0.101 0.056 0.070 -0.034 0.051 0.500 0.027 0.056 0.624 0.027 0.028 0.347 1.000 0.359 0.027 0.031 0.380 1.000 0.200 
40 rs2836754 0.020 0.059 0.738 0.020 0.044 0.645 -0.041 0.041 0.317 -0.112 0.047 0.018 -0.032 0.023 0.173 1.000 0.163 -0.041 0.025 0.105 1.000 0.121 
41 rs29941 -0.009 0.073 0.904 -0.025 0.051 0.625 0.069 0.051 0.177 -0.053 0.056 0.343 -0.001 0.028 0.963 1.000 0.396 5.79E-07 0.030 1.000 1.000 0.227 
42 rs3101336 -0.064 0.109 0.558 0.121 0.078 0.123 -0.042 0.072 0.558 -0.015 0.086 0.862 0.007 0.042 0.862 1.000 0.381 0.019 0.045 0.666 1.000 0.277 
43 rs3817334 0.072 0.062 0.248 -0.009 0.046 0.844 -0.032 0.046 0.481 -0.033 0.050 0.511 -0.009 0.025 0.721 1.000 0.536 -0.024 0.027 0.371 1.000 0.920 
44 rs3849570 -0.024 0.057 0.669 -0.048 0.043 0.256 0.009 0.040 0.822 0.004 0.046 0.926 -0.014 0.023 0.549 1.000 0.759 -0.011 0.025 0.640 1.000 0.568 
45 rs3888190 -0.024 0.100 0.810 0.078 0.076 0.306 0.077 0.071 0.281 0.043 0.081 0.593 0.053 0.040 0.189 1.000 0.843 0.067 0.044 0.124 1.000 0.938 
46 rs4256980 -0.015 0.060 0.803 -0.010 0.043 0.823 0.016 0.041 0.700 -0.025 0.046 0.591 -0.006 0.023 0.786 1.000 0.924 -0.005 0.025 0.849 1.000 0.797 
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Table 40 (continued): Association between 64 SNPs and starch intake 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
47 rs4740619 0.154 0.064 0.017 0.050 0.050 0.321 -0.052 0.046 0.254 -0.053 0.054 0.329 0.01 0.026 0.715 1.000 0.032 -0.019 0.029 0.509 1.000 0.246 
48 rs4787491 0.014 0.058 0.805 0.008 0.041 0.844 0.011 0.041 0.790 0.021 0.045 0.642 0.013 0.023 0.561 1.000 0.997 0.013 0.024 0.599 1.000 0.976 
49 rs492400 0.091 0.072 0.208 0.064 0.051 0.211 0.049 0.049 0.320 -0.010 0.054 0.855 0.044 0.027 0.108 1.000 0.661 0.036 0.030 0.221 1.000 0.578 
50 rs6567160 -0.057 0.079 0.471 0.043 0.055 0.436 0.020 0.055 0.714 0.034 0.062 0.587 0.019 0.030 0.536 1.000 0.759 0.032 0.033 0.330 1.000 0.957 
51 rs6804842 -0.051 0.060 0.398 -0.030 0.045 0.504 -0.027 0.044 0.532 0.092 0.046 0.048 -1.97E-04 0.024 0.993 1.000 0.141 0.009 0.026 0.721 1.000 0.099 
52 rs7138803 0.056 0.067 0.404 -0.035 0.049 0.469 0.025 0.046 0.582 0.013 0.053 0.799 0.010 0.026 0.710 1.000 0.693 0.001 0.028 0.959 1.000 0.641 
53 rs7141420 -0.020 0.057 0.727 -0.075 0.042 0.077 0.006 0.041 0.880 -0.046 0.044 0.296 -0.034 0.022 0.127 1.000 0.564 -0.037 0.024 0.131 1.000 0.375 
54 rs7164727 0.057 0.067 0.394 -0.021 0.048 0.656 0.050 0.047 0.292 0.014 0.051 0.777 0.021 0.026 0.417 1.000 0.693 0.015 0.028 0.601 1.000 0.573 
55 rs7239883 0.023 0.062 0.708 0.017 0.045 0.707 -0.017 0.043 0.701 0.021 0.049 0.663 0.008 0.024 0.728 1.000 0.919 0.006 0.026 0.826 1.000 0.806 
56 rs7243357 -0.087 0.069 0.213 -0.007 0.051 0.898 -0.109 0.054 0.043 -0.030 0.055 0.582 -0.054 0.028 0.055 1.000 0.510 -0.047 0.031 0.123 1.000 0.359 
57 rs7599312 -0.048 0.218 0.825 0.008 0.157 0.958 -0.203 0.125 0.106 0.058 0.160 0.716 -0.069 0.078 0.377 1.000 0.568 -0.072 0.084 0.389 1.000 0.366 
58 rs7715256 0.216 0.150 0.151 -0.050 0.115 0.666 -0.045 0.115 0.695 0.063 0.116 0.588 0.026 0.061 0.668 1.000 0.472 -0.011 0.066 0.868 1.000 0.739 
59 rs7903146 -0.248 0.197 0.207 0.075 0.133 0.575 0.148 0.145 0.308 0.087 0.154 0.575 0.049 0.076 0.518 1.000 0.416 0.102 0.083 0.218 1.000 0.927 
60 rs9374842 0.231 0.106 0.030 -0.012 0.072 0.867 -0.029 0.071 0.687 -0.062 0.079 0.436 0.004 0.040 0.914 1.000 0.138 -0.033 0.043 0.447 1.000 0.896 
61 rs9400239 -0.132 0.063 0.037 0.046 0.047 0.324 0.041 0.044 0.362 -0.039 0.051 0.450 -0.004 0.025 0.878 1.000 0.082 0.020 0.027 0.463 1.000 0.399 
62 rs9641123 -0.093 0.062 0.136 0.030 0.045 0.513 -0.032 0.043 0.460 -0.024 0.048 0.621 -0.022 0.024 0.372 1.000 0.449 -0.009 0.026 0.734 1.000 0.576 
63 rs977747 0.225 0.157 0.153 0.149 0.109 0.173 0.026 0.108 0.813 0.105 0.103 0.307 0.111 0.057 0.053 1.000 0.736 0.093 0.061 0.129 1.000 0.717 
64 rs9914578 -0.137 0.070 0.052 0.042 0.052 0.422 0.011 0.051 0.836 0.044 0.058 0.450 0.004 0.028 0.888 1.000 0.170 0.031 0.031 0.315 1.000 0.884 





Table 41: Association between 64 SNPs and fiber intake 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
1 rs1000940 -0.057 0.059 0.339 -0.096 0.044 0.029 -0.048 0.040 0.235 -0.042 0.046 0.366 -0.061 0.023 0.008 0.512 0.822 -0.062 0.025 0.014 0.896 0.635 
2 rs1016287 -0.061 0.064 0.338 -0.104 0.048 0.030 -0.073 0.048 0.130 -0.036 0.049 0.472 -0.070 0.026 0.006 0.384 0.799 -0.072 0.028 0.010 0.640 0.610 
3 rs10182181 0.049 0.058 0.395 0.007 0.044 0.874 0.018 0.041 0.667 -0.017 0.044 0.694 0.010 0.023 0.651 1.000 0.829 0.003 0.025 0.899 1.000 0.840 
4 rs10733682 0.078 0.065 0.232 0.020 0.051 0.696 0.057 0.046 0.219 0.042 0.054 0.446 0.047 0.026 0.078 1.000 0.904 0.041 0.029 0.162 1.000 0.866 
5 rs10938397 -0.018 0.065 0.778 -0.030 0.048 0.522 -0.008 0.046 0.862 -0.068 0.051 0.184 -0.031 0.025 0.224 1.000 0.848 -0.033 0.028 0.230 1.000 0.683 
6 rs10968576 -0.133 0.077 0.085 0.003 0.057 0.959 -0.089 0.053 0.092 -0.052 0.059 0.385 -0.061 0.030 0.042 1.000 0.483 -0.048 0.032 0.140 1.000 0.491 
7 rs11030104 -0.091 0.056 0.104 -0.056 0.041 0.179 -0.012 0.040 0.769 -0.056 0.044 0.201 -0.048 0.022 0.030 1.000 0.686 -0.040 0.024 0.097 1.000 0.679 
8 rs11126666 0.026 0.062 0.677 -0.026 0.046 0.565 -0.026 0.045 0.562 -0.025 0.049 0.611 -0.018 0.025 0.474 1.000 0.899 -0.026 0.027 0.336 1.000 1.000 
9 rs11191560 0.037 0.066 0.573 0.083 0.048 0.086 -0.012 0.045 0.786 0.048 0.052 0.349 0.037 0.026 0.151 1.000 0.540 0.037 0.028 0.187 1.000 0.340 
10 rs11583200 0.114 0.094 0.227 -0.047 0.077 0.547 0.062 0.075 0.414 -0.010 0.087 0.912 0.025 0.041 0.547 1.000 0.543 0.004 0.046 0.935 1.000 0.596 
11 rs11688816 0.002 0.063 0.974 -0.070 0.047 0.137 -0.021 0.044 0.628 -0.036 0.049 0.464 -0.035 0.025 0.159 1.000 0.800 -0.042 0.027 0.122 1.000 0.741 
12 rs12286929 -0.072 0.068 0.290 0.084 0.047 0.076 0.032 0.046 0.491 0.033 0.049 0.511 0.032 0.025 0.202 1.000 0.314 0.049 0.027 0.071 1.000 0.673 
13 rs12429545 0.099 0.068 0.147 -0.076 0.047 0.108 -0.048 0.047 0.305 0.114 0.054 0.034 0.003 0.026 0.897 1.000 0.017 -0.013 0.028 0.643 1.000 0.019 
14 rs12566985 -0.084 0.074 0.254 0.070 0.055 0.203 -0.002 0.053 0.967 -0.014 0.059 0.807 0.002 0.029 0.937 1.000 0.394 0.019 0.032 0.561 1.000 0.510 
15 rs12940622 0.032 0.062 0.604 -0.041 0.047 0.382 0.012 0.044 0.789 -0.005 0.048 0.915 -0.004 0.024 0.874 1.000 0.779 -0.010 0.026 0.694 1.000 0.707 
16 rs13021737 0.196 0.113 0.083 -0.048 0.081 0.550 -0.002 0.075 0.983 -0.100 0.089 0.264 -0.009 0.043 0.831 1.000 0.206 -0.044 0.047 0.343 1.000 0.701 
17 rs13201877 -0.048 0.182 0.792 -0.059 0.106 0.575 -0.064 0.105 0.538 -0.069 0.115 0.549 -0.062 0.059 0.292 1.000 1.000 -0.064 0.063 0.305 1.000 0.998 
18 rs1441264 0.011 0.060 0.859 -0.032 0.043 0.465 0.044 0.040 0.276 0.045 0.045 0.319 0.018 0.023 0.421 1.000 0.552 0.020 0.025 0.425 1.000 0.354 
19 rs1460676 0.006 0.059 0.924 0.058 0.045 0.192 -0.037 0.041 0.362 0.080 0.046 0.078 0.025 0.023 0.276 1.000 0.216 0.029 0.025 0.253 1.000 0.115 
20 rs1516725 0.030 0.106 0.779 -0.114 0.083 0.171 0.015 0.072 0.835 0.053 0.084 0.529 -0.006 0.042 0.888 1.000 0.498 -0.013 0.046 0.784 1.000 0.326 
21 rs1528435 0.062 0.062 0.321 -0.006 0.045 0.894 0.013 0.043 0.759 0.040 0.047 0.392 0.022 0.024 0.360 1.000 0.803 0.015 0.026 0.563 1.000 0.775 
22 rs1558902 0.004 0.082 0.960 0.123 0.063 0.052 -0.107 0.063 0.090 0.027 0.072 0.704 0.012 0.034 0.733 1.000 0.082 0.013 0.038 0.725 1.000 0.035 
23 rs16851483 0.076 0.064 0.240 0.037 0.049 0.456 0.090 0.046 0.051 -0.018 0.052 0.724 0.046 0.026 0.074 1.000 0.441 0.040 0.028 0.151 1.000 0.295 
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Table 41 (continued): Association between 64 SNPs and fiber intake 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
24 rs16951275 0.012 0.061 0.840 -0.015 0.041 0.715 0.005 0.041 0.899 -0.037 0.045 0.407 -0.011 0.023 0.636 1.000 0.884 -0.015 0.025 0.553 1.000 0.784 
25 rs17203016 -0.070 0.087 0.420 -0.049 0.062 0.427 0.032 0.056 0.576 -0.069 0.064 0.278 -0.031 0.032 0.343 1.000 0.599 -0.024 0.035 0.485 1.000 0.441 
26 rs17405819 0.053 0.059 0.370 -0.029 0.043 0.506 0.009 0.041 0.819 0.022 0.045 0.618 0.009 0.023 0.703 1.000 0.705 0.001 0.025 0.972 1.000 0.690 
27 rs17724992 0.037 0.057 0.517 0.054 0.043 0.211 -0.053 0.040 0.184 0.002 0.045 0.966 0.004 0.022 0.859 1.000 0.292 -0.002 0.024 0.931 1.000 0.189 
28 rs1928295 -0.073 0.058 0.207 -0.071 0.044 0.102 -0.070 0.040 0.077 0.019 0.045 0.679 -0.049 0.023 0.031 1.000 0.399 -0.044 0.025 0.071 1.000 0.254 
29 rs2033529 -0.032 0.084 0.704 -0.030 0.059 0.608 0.044 0.052 0.399 0.022 0.059 0.708 0.009 0.030 0.774 1.000 0.759 0.015 0.032 0.650 1.000 0.635 
30 rs2033732 0.053 0.057 0.354 0.041 0.044 0.354 -0.049 0.041 0.230 0.026 0.045 0.556 0.011 0.023 0.627 1.000 0.352 0.003 0.025 0.900 1.000 0.268 
31 rs205262 -0.146 0.077 0.059 0.079 0.060 0.194 -0.071 0.060 0.233 -0.101 0.065 0.118 -0.049 0.032 0.128 1.000 0.078 -0.029 0.036 0.422 1.000 0.086 
32 rs2075650 0.015 0.107 0.885 0.042 0.078 0.586 0.013 0.071 0.854 -0.034 0.080 0.672 0.009 0.041 0.820 1.000 0.923 0.008 0.044 0.852 1.000 0.788 
33 rs2080454 0.009 0.060 0.882 -0.067 0.043 0.117 0.054 0.040 0.179 -0.017 0.045 0.707 -0.005 0.023 0.840 1.000 0.222 -0.007 0.024 0.780 1.000 0.114 
34 rs2112347 -0.102 0.057 0.072 -0.034 0.043 0.430 0.063 0.040 0.117 0.076 0.045 0.091 0.014 0.023 0.548 1.000 0.031 0.035 0.025 0.151 1.000 0.143 
35 rs2176040 0.043 0.110 0.699 0.032 0.084 0.700 0.032 0.078 0.686 -0.058 0.084 0.494 0.010 0.044 0.823 1.000 0.831 0.004 0.047 0.938 1.000 0.679 
36 rs2207139 0.010 0.078 0.899 -0.022 0.062 0.728 0.022 0.063 0.724 -0.021 0.065 0.749 -0.004 0.033 0.915 1.000 0.950 -0.006 0.036 0.860 1.000 0.854 
37 rs2287019 0.077 0.072 0.283 0.033 0.054 0.540 -0.084 0.050 0.097 0.066 0.059 0.264 0.010 0.029 0.727 1.000 0.144 -0.003 0.031 0.932 1.000 0.112 
38 rs2365389 0.065 0.081 0.427 0.130 0.062 0.035 0.008 0.063 0.894 -0.157 0.065 0.017 0.010 0.033 0.754 1.000 0.013 -0.001 0.037 0.989 1.000 0.006 
39 rs2820292 -0.038 0.069 0.581 -0.061 0.056 0.274 -0.029 0.051 0.573 2.04E-04 0.055 0.997 -0.031 0.028 0.274 1.000 0.891 -0.029 0.031 0.342 1.000 0.736 
40 rs2836754 0.018 0.060 0.769 -0.004 0.044 0.928 0.035 0.041 0.391 -0.028 0.047 0.545 0.006 0.023 0.801 1.000 0.769 0.004 0.025 0.881 1.000 0.580 
41 rs29941 -0.017 0.073 0.812 0.112 0.051 0.028 -0.031 0.050 0.534 0.100 0.055 0.069 0.047 0.028 0.093 1.000 0.125 0.057 0.030 0.056 1.000 0.089 
42 rs3101336 0.203 0.109 0.062 -0.025 0.078 0.746 -0.011 0.072 0.882 0.033 0.085 0.694 0.027 0.041 0.517 1.000 0.340 -0.003 0.045 0.945 1.000 0.871 
43 rs3817334 0.011 0.063 0.866 0.025 0.047 0.593 0.013 0.045 0.771 -0.025 0.050 0.612 0.006 0.025 0.795 1.000 0.899 0.006 0.027 0.833 1.000 0.747 
44 rs3849570 0.046 0.057 0.420 -0.043 0.043 0.313 -0.032 0.040 0.417 0.012 0.045 0.795 -0.012 0.022 0.588 1.000 0.552 -0.023 0.024 0.350 1.000 0.647 
45 rs3888190 0.005 0.100 0.957 0.058 0.076 0.446 0.054 0.071 0.449 0.004 0.080 0.962 0.035 0.040 0.384 1.000 0.940 0.040 0.044 0.354 1.000 0.861 
46 rs4256980 -0.071 0.060 0.242 0.109 0.043 0.011 -0.001 0.041 0.981 -0.033 0.045 0.470 0.012 0.023 0.595 1.000 0.045 0.026 0.025 0.292 1.000 0.053 
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Table 41 (continued): Association between 64 SNPs and fiber intake 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
47 rs4740619 0.052 0.065 0.425 -0.036 0.050 0.470 -0.009 0.046 0.836 -0.038 0.054 0.480 -0.014 0.026 0.604 1.000 0.699 -0.026 0.029 0.360 1.000 0.894 
48 rs4787491 -0.018 0.058 0.759 -0.020 0.041 0.623 -0.040 0.041 0.330 0.011 0.045 0.802 -0.018 0.023 0.425 1.000 0.871 -0.018 0.024 0.462 1.000 0.701 
49 rs492400 -0.121 0.073 0.095 -0.015 0.051 0.774 2.17E-04 0.048 0.996 0.091 0.053 0.085 0.003 0.027 0.912 1.000 0.120 0.023 0.029 0.427 1.000 0.299 
50 rs6567160 -0.026 0.079 0.744 -0.020 0.056 0.713 -0.052 0.054 0.336 0.058 0.061 0.341 -0.012 0.030 0.697 1.000 0.588 -0.009 0.033 0.775 1.000 0.388 
51 rs6804842 0.082 0.060 0.174 0.072 0.046 0.116 0.004 0.043 0.925 -0.056 0.046 0.220 0.018 0.024 0.439 1.000 0.154 0.007 0.026 0.797 1.000 0.140 
52 rs7138803 0.010 0.068 0.881 0.055 0.049 0.262 -0.030 0.046 0.519 0.018 0.052 0.730 0.012 0.026 0.643 1.000 0.658 0.012 0.028 0.660 1.000 0.449 
53 rs7141420 -0.030 0.057 0.604 0.043 0.043 0.309 0.033 0.040 0.414 0.008 0.044 0.852 0.020 0.022 0.378 1.000 0.745 0.029 0.024 0.239 1.000 0.838 
54 rs7164727 -0.020 0.067 0.763 0.112 0.048 0.021 -0.010 0.047 0.834 0.059 0.050 0.237 0.041 0.026 0.109 1.000 0.233 0.052 0.028 0.062 1.000 0.194 
55 rs7239883 0.030 0.063 0.631 -0.037 0.045 0.422 0.016 0.043 0.711 0.057 0.048 0.237 0.014 0.024 0.574 1.000 0.553 0.011 0.026 0.683 1.000 0.366 
56 rs7243357 0.063 0.070 0.370 -0.035 0.051 0.489 -0.049 0.053 0.360 0.124 0.054 0.023 0.019 0.028 0.500 1.000 0.077 0.010 0.031 0.731 1.000 0.041 
57 rs7599312 0.102 0.219 0.641 0.029 0.158 0.855 0.007 0.123 0.957 -0.116 0.158 0.463 -0.006 0.077 0.943 1.000 0.853 -0.021 0.083 0.800 1.000 0.775 
58 rs7715256 -0.256 0.151 0.091 0.105 0.115 0.362 0.232 0.114 0.043 0.039 0.115 0.731 0.064 0.061 0.288 1.000 0.078 0.126 0.066 0.057 1.000 0.482 
59 rs7903146 0.102 0.198 0.607 0.099 0.134 0.457 0.003 0.144 0.983 0.284 0.150 0.060 0.120 0.076 0.114 1.000 0.598 0.123 0.082 0.134 1.000 0.393 
60 rs9374842 -0.144 0.107 0.178 -0.060 0.073 0.408 -0.111 0.071 0.118 -0.027 0.078 0.729 -0.079 0.040 0.046 1.000 0.782 -0.069 0.043 0.107 1.000 0.721 
61 rs9400239 -0.001 0.064 0.991 -0.053 0.047 0.262 0.022 0.044 0.621 -0.013 0.051 0.804 -0.011 0.025 0.659 1.000 0.713 -0.013 0.027 0.635 1.000 0.512 
62 rs9641123 0.055 0.063 0.379 -0.098 0.045 0.031 0.025 0.043 0.561 0.013 0.048 0.788 -0.008 0.024 0.728 1.000 0.126 -0.019 0.026 0.458 1.000 0.104 
63 rs977747 -0.183 0.158 0.246 -0.059 0.110 0.594 -0.140 0.107 0.192 -0.079 0.101 0.436 -0.104 0.057 0.067 1.000 0.897 -0.093 0.061 0.130 1.000 0.857 
64 rs9914578 0.041 0.071 0.561 -0.043 0.052 0.409 0.024 0.051 0.634 0.017 0.057 0.768 0.005 0.028 0.847 1.000 0.730 -0.001 0.031 0.966 1.000 0.608 






Table 42: Association between 64 SNPs and %protein intake 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
1 rs1000940 0.021 0.060 0.728 0.035 0.044 0.424 -0.026 0.041 0.531 -0.091 0.047 0.053 -0.018 0.023 0.448 1.000 0.227 -0.025 0.025 0.331 1.000 0.146 
2 rs1016287 -0.015 0.064 0.811 -0.019 0.048 0.692 -0.076 0.049 0.125 0.019 0.050 0.708 -0.024 0.026 0.355 1.000 0.602 -0.026 0.028 0.365 1.000 0.399 
3 rs10182181 -0.005 0.058 0.934 -0.028 0.043 0.510 0.008 0.042 0.851 -0.049 0.045 0.269 -0.020 0.023 0.395 1.000 0.807 -0.022 0.025 0.373 1.000 0.638 
4 rs10733682 -0.039 0.065 0.550 0.023 0.051 0.648 -0.057 0.047 0.227 0.103 0.055 0.060 0.006 0.027 0.820 1.000 0.138 0.015 0.029 0.605 1.000 0.085 
5 rs10938397 0.018 0.065 0.781 -0.054 0.047 0.258 0.003 0.047 0.942 -0.074 0.051 0.150 -0.030 0.026 0.236 1.000 0.564 -0.039 0.028 0.158 1.000 0.503 
6 rs10968576 -0.024 0.077 0.758 0.041 0.057 0.468 0.006 0.054 0.917 0.021 0.060 0.729 0.015 0.030 0.619 1.000 0.918 0.022 0.033 0.501 1.000 0.902 
7 rs11030104 -0.047 0.056 0.399 -0.058 0.041 0.160 0.052 0.041 0.204 0.036 0.044 0.412 3.15E-04 0.022 0.989 1.000 0.173 0.009 0.024 0.703 1.000 0.127 
8 rs11126666 -0.129 0.061 0.035 -0.005 0.046 0.912 0.135 0.046 0.003 0.006 0.049 0.904 0.019 0.025 0.454 1.000 0.005 0.047 0.027 0.080 1.000 0.057 
9 rs11191560 0.050 0.066 0.444 0.031 0.048 0.520 4.18E-04 0.046 0.993 0.058 0.052 0.268 0.031 0.026 0.232 1.000 0.849 0.027 0.028 0.330 1.000 0.706 
10 rs11583200 0.015 0.094 0.878 -0.120 0.077 0.122 -0.020 0.077 0.800 -0.025 0.088 0.779 -0.043 0.042 0.301 1.000 0.684 -0.057 0.046 0.219 1.000 0.597 
11 rs11688816 0.009 0.063 0.891 -0.008 0.047 0.862 -0.042 0.045 0.345 -0.003 0.049 0.951 -0.015 0.025 0.554 1.000 0.898 -0.019 0.027 0.481 1.000 0.807 
12 rs12286929 -0.033 0.069 0.628 0.023 0.047 0.630 0.069 0.047 0.147 0.051 0.050 0.309 0.036 0.026 0.162 1.000 0.646 0.047 0.028 0.089 1.000 0.786 
13 rs12429545 0.003 0.068 0.970 -0.020 0.047 0.674 0.019 0.048 0.693 0.033 0.054 0.541 0.008 0.026 0.770 1.000 0.891 0.009 0.029 0.763 1.000 0.735 
14 rs12566985 0.068 0.074 0.354 0.065 0.055 0.242 0.052 0.054 0.334 -0.055 0.060 0.360 0.032 0.030 0.280 1.000 0.417 0.025 0.032 0.440 1.000 0.280 
15 rs12940622 -0.038 0.062 0.539 0.060 0.046 0.200 0.009 0.045 0.843 0.049 0.048 0.313 0.026 0.025 0.289 1.000 0.581 0.038 0.027 0.156 1.000 0.707 
16 rs13021737 -0.024 0.113 0.832 0.097 0.081 0.231 0.069 0.077 0.374 0.014 0.090 0.879 0.050 0.044 0.252 1.000 0.805 0.063 0.047 0.183 1.000 0.786 
17 rs13201877 -0.265 0.182 0.145 0.054 0.106 0.612 0.053 0.107 0.618 -0.121 0.117 0.300 -0.027 0.060 0.656 1.000 0.319 0.002 0.063 0.972 1.000 0.454 
18 rs1441264 0.040 0.060 0.502 -0.036 0.043 0.407 0.067 0.041 0.105 0.005 0.046 0.918 0.018 0.023 0.438 1.000 0.365 0.014 0.025 0.575 1.000 0.222 
19 rs1460676 -0.022 0.059 0.702 0.059 0.045 0.190 -0.070 0.042 0.092 0.041 0.046 0.371 0.001 0.023 0.964 1.000 0.138 0.005 0.025 0.831 1.000 0.070 
20 rs1516725 -0.203 0.105 0.054 0.003 0.084 0.976 0.138 0.073 0.061 -0.021 0.085 0.805 0.008 0.042 0.848 1.000 0.064 0.049 0.046 0.287 1.000 0.295 
21 rs1528435 0.043 0.062 0.492 0.088 0.045 0.050 -0.003 0.044 0.952 0.022 0.048 0.642 0.037 0.024 0.126 1.000 0.533 0.036 0.026 0.170 1.000 0.335 
22 rs1558902 -0.025 0.082 0.761 0.025 0.063 0.693 -0.031 0.065 0.628 0.052 0.072 0.471 0.006 0.035 0.861 1.000 0.808 0.013 0.038 0.738 1.000 0.671 
23 rs16851483 -0.036 0.064 0.577 0.024 0.049 0.620 -0.016 0.047 0.738 -0.007 0.052 0.900 -0.006 0.026 0.832 1.000 0.887 4.36E-04 0.029 0.988 1.000 0.830 
154 
 
Table 42 (continued): Association between 64 SNPs and %protein intake 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
24 rs16951275 -0.012 0.060 0.848 0.031 0.041 0.456 -0.061 0.042 0.151 0.097 0.045 0.032 0.015 0.023 0.521 1.000 0.077 0.019 0.025 0.440 1.000 0.036 
25 rs17203016 -0.165 0.086 0.056 0.003 0.062 0.967 0.056 0.058 0.333 0.013 0.064 0.840 -0.002 0.033 0.958 1.000 0.200 0.026 0.035 0.469 1.000 0.796 
26 rs17405819 -0.076 0.059 0.202 0.056 0.043 0.195 0.029 0.042 0.484 -0.089 0.045 0.050 -0.010 0.023 0.678 1.000 0.058 0.002 0.025 0.930 1.000 0.050 
27 rs17724992 -0.003 0.057 0.958 0.056 0.043 0.194 -0.007 0.041 0.861 -0.090 0.045 0.047 -0.010 0.023 0.662 1.000 0.138 -0.011 0.025 0.650 1.000 0.064 
28 rs1928295 -0.026 0.058 0.655 -0.018 0.044 0.685 -0.033 0.041 0.417 0.010 0.046 0.836 -0.017 0.023 0.456 1.000 0.916 -0.015 0.025 0.536 1.000 0.785 
29 rs2033529 0.071 0.084 0.397 0.046 0.059 0.436 -0.088 0.053 0.094 0.021 0.060 0.718 -0.002 0.031 0.942 1.000 0.235 -0.013 0.033 0.683 1.000 0.185 
30 rs2033732 -0.005 0.057 0.934 -0.022 0.044 0.620 0.051 0.042 0.231 -0.052 0.045 0.251 -0.005 0.023 0.822 1.000 0.398 -0.005 0.025 0.834 1.000 0.228 
31 rs205262 -0.074 0.077 0.340 -0.033 0.061 0.590 -0.011 0.061 0.856 -0.037 0.065 0.576 -0.035 0.033 0.285 1.000 0.939 -0.026 0.036 0.462 1.000 0.953 
32 rs2075650 -0.062 0.106 0.558 0.006 0.078 0.943 -0.048 0.072 0.507 0.096 0.080 0.234 0.002 0.041 0.965 1.000 0.530 0.013 0.044 0.770 1.000 0.410 
33 rs2080454 0.111 0.060 0.065 -0.001 0.043 0.975 0.011 0.041 0.782 -0.006 0.045 0.895 0.018 0.023 0.436 1.000 0.405 0.002 0.025 0.939 1.000 0.956 
34 rs2112347 0.021 0.057 0.712 -0.035 0.043 0.409 0.034 0.041 0.403 -0.009 0.045 0.834 0.002 0.023 0.947 1.000 0.669 -0.002 0.025 0.929 1.000 0.492 
35 rs2176040 -0.064 0.110 0.560 -0.004 0.084 0.959 0.044 0.080 0.579 -0.037 0.085 0.660 -0.008 0.044 0.855 1.000 0.847 0.003 0.048 0.957 1.000 0.778 
36 rs2207139 0.032 0.079 0.687 0.037 0.062 0.552 0.011 0.064 0.864 -0.018 0.066 0.788 0.015 0.033 0.656 1.000 0.936 0.011 0.037 0.762 1.000 0.834 
37 rs2287019 -0.148 0.072 0.039 0.057 0.054 0.286 0.098 0.051 0.058 0.146 0.060 0.015 0.057 0.029 0.047 1.000 0.012 0.097 0.032 0.002 0.128 0.547 
38 rs2365389 -0.100 0.081 0.216 -0.156 0.061 0.011 0.002 0.065 0.976 -0.023 0.066 0.724 -0.070 0.034 0.037 1.000 0.282 -0.064 0.037 0.084 1.000 0.161 
39 rs2820292 0.022 0.069 0.755 -0.092 0.056 0.102 0.025 0.052 0.629 0.021 0.056 0.707 -0.007 0.029 0.806 1.000 0.377 -0.013 0.031 0.680 1.000 0.236 
40 rs2836754 0.014 0.060 0.818 -0.029 0.044 0.508 -0.033 0.042 0.431 -0.030 0.047 0.527 -0.024 0.023 0.309 1.000 0.924 -0.031 0.025 0.228 1.000 0.998 
41 rs29941 0.004 0.073 0.958 0.028 0.051 0.587 -0.055 0.051 0.285 0.011 0.056 0.838 -0.004 0.028 0.873 1.000 0.692 -0.006 0.030 0.845 1.000 0.486 
42 rs3101336 -0.201 0.109 0.067 -0.244 0.078 0.002 -0.025 0.073 0.737 -0.066 0.085 0.442 -0.123 0.042 0.003 0.192 0.160 -0.110 0.045 0.015 1.000 0.101 
43 rs3817334 9.05E-05 0.063 0.999 0.027 0.047 0.561 0.012 0.046 0.803 -0.033 0.050 0.511 0.003 0.025 0.903 1.000 0.845 0.004 0.027 0.894 1.000 0.665 
44 rs3849570 0.001 0.057 0.985 0.019 0.043 0.654 -0.036 0.041 0.374 0.005 0.045 0.904 -0.004 0.023 0.847 1.000 0.808 -0.005 0.025 0.828 1.000 0.619 
45 rs3888190 0.041 0.100 0.679 0.040 0.076 0.603 -0.035 0.072 0.625 -0.026 0.080 0.748 3.17E-04 0.040 0.994 1.000 0.853 -0.008 0.044 0.863 1.000 0.747 
46 rs4256980 0.023 0.061 0.708 -0.009 0.043 0.828 -0.025 0.042 0.557 0.014 0.046 0.761 -0.003 0.023 0.886 1.000 0.895 -0.008 0.025 0.756 1.000 0.824 
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Table 42 (continued): Association between 64 SNPs and %protein intake 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
47 rs4740619 -0.091 0.065 0.160 -0.030 0.050 0.546 -0.003 0.047 0.946 0.033 0.054 0.537 -0.017 0.026 0.531 1.000 0.506 -0.002 0.029 0.952 1.000 0.688 
48 rs4787491 0.051 0.058 0.380 -0.023 0.041 0.576 0.025 0.042 0.550 -0.057 0.045 0.209 -0.006 0.023 0.787 1.000 0.399 -0.016 0.025 0.506 1.000 0.405 
49 rs492400 -0.035 0.073 0.631 -0.012 0.051 0.821 -0.040 0.049 0.422 0.057 0.054 0.292 -0.006 0.028 0.835 1.000 0.573 -0.001 0.030 0.976 1.000 0.405 
50 rs6567160 0.034 0.079 0.664 -0.042 0.056 0.449 0.008 0.056 0.887 -0.004 0.062 0.943 -0.006 0.031 0.837 1.000 0.862 -0.013 0.033 0.685 1.000 0.805 
51 rs6804842 0.054 0.061 0.373 0.007 0.046 0.872 0.074 0.044 0.097 -0.052 0.046 0.260 0.018 0.024 0.451 1.000 0.233 0.011 0.026 0.664 1.000 0.145 
52 rs7138803 -0.077 0.067 0.254 0.012 0.049 0.801 -0.055 0.047 0.245 0.002 0.052 0.969 -0.024 0.026 0.349 1.000 0.606 -0.015 0.028 0.593 1.000 0.568 
53 rs7141420 -0.008 0.057 0.890 0.029 0.043 0.489 0.005 0.041 0.908 0.022 0.044 0.625 0.014 0.023 0.530 1.000 0.949 0.018 0.025 0.457 1.000 0.914 
54 rs7164727 -0.101 0.067 0.133 0.014 0.048 0.778 -0.041 0.048 0.396 -0.018 0.051 0.723 -0.028 0.026 0.283 1.000 0.565 -0.015 0.028 0.595 1.000 0.725 
55 rs7239883 0.049 0.062 0.434 -0.054 0.045 0.236 0.044 0.044 0.314 -0.066 0.049 0.171 -0.011 0.024 0.647 1.000 0.195 -0.022 0.026 0.408 1.000 0.164 
56 rs7243357 0.068 0.070 0.330 0.004 0.051 0.934 0.136 0.055 0.013 -0.008 0.055 0.881 0.047 0.028 0.098 1.000 0.216 0.043 0.031 0.168 1.000 0.114 
57 rs7599312 0.063 0.219 0.773 0.103 0.158 0.513 -0.074 0.126 0.556 -0.355 0.159 0.026 -0.081 0.078 0.301 1.000 0.190 -0.102 0.084 0.224 1.000 0.119 
58 rs7715256 -0.312 0.150 0.038 -0.075 0.115 0.514 -0.044 0.116 0.708 -0.045 0.116 0.697 -0.098 0.061 0.110 1.000 0.473 -0.055 0.067 0.413 1.000 0.977 
59 rs7903146 0.009 0.198 0.963 -0.018 0.135 0.897 0.004 0.147 0.981 -0.017 0.152 0.913 -0.008 0.077 0.921 1.000 0.999 -0.011 0.083 0.899 1.000 0.993 
60 rs9374842 -0.283 0.106 0.008 0.043 0.073 0.557 -0.015 0.073 0.833 0.023 0.079 0.770 -0.026 0.040 0.517 1.000 0.067 0.017 0.043 0.702 1.000 0.849 
61 rs9400239 0.111 0.063 0.080 -0.031 0.047 0.502 -0.013 0.045 0.767 -0.028 0.051 0.582 -0.002 0.025 0.923 1.000 0.271 -0.024 0.027 0.385 1.000 0.957 
62 rs9641123 0.089 0.062 0.156 0.020 0.046 0.660 -0.060 0.044 0.175 0.010 0.048 0.832 0.004 0.024 0.885 1.000 0.253 -0.012 0.026 0.655 1.000 0.390 
63 rs977747 -0.120 0.158 0.447 -0.124 0.109 0.257 0.018 0.110 0.868 0.116 0.102 0.259 -0.009 0.057 0.878 1.000 0.370 0.008 0.062 0.894 1.000 0.276 
64 rs9914578 0.053 0.070 0.454 -0.002 0.052 0.972 0.012 0.052 0.814 0.096 0.058 0.097 0.035 0.028 0.221 1.000 0.597 0.031 0.031 0.314 1.000 0.406 





Table 43: Association between 64 SNPs and %fat intake 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
1 rs1000940 0.002 0.059 0.967 0.040 0.043 0.351 0.04 0.037 0.279 -0.004 0.042 0.933 0.023 0.022 0.283 1.000 0.825 0.027 0.023 0.255 1.000 0.686 
2 rs1016287 0.006 0.063 0.919 -0.015 0.047 0.749 -0.033 0.044 0.456 0.003 0.045 0.940 -0.012 0.024 0.623 1.000 0.933 -0.015 0.026 0.565 1.000 0.846 
3 rs10182181 0.114 0.057 0.046 -0.022 0.043 0.610 0.006 0.038 0.881 -0.010 0.040 0.795 0.009 0.021 0.659 1.000 0.245 -0.008 0.023 0.737 1.000 0.888 
4 rs10733682 0.067 0.064 0.296 0.023 0.050 0.651 -0.056 0.043 0.185 -0.046 0.049 0.352 -0.015 0.025 0.536 1.000 0.316 -0.030 0.027 0.266 1.000 0.451 
5 rs10938397 0.074 0.064 0.248 -0.037 0.047 0.424 -0.042 0.042 0.327 -0.074 0.046 0.108 -0.033 0.024 0.171 1.000 0.302 -0.051 0.026 0.051 1.000 0.826 
6 rs10968576 -0.017 0.076 0.825 0.006 0.056 0.911 0.048 0.049 0.324 -0.006 0.054 0.906 0.014 0.028 0.628 1.000 0.846 0.019 0.030 0.542 1.000 0.730 
7 rs11030104 -0.048 0.055 0.388 -0.079 0.041 0.051 -1.73E-04 0.037 0.996 0.032 0.040 0.425 -0.019 0.021 0.364 1.000 0.225 -0.014 0.022 0.530 1.000 0.132 
8 rs11126666 -0.114 0.060 0.061 -0.043 0.045 0.337 -0.089 0.041 0.031 -0.063 0.044 0.152 -0.073 0.023 0.001 0.064 0.777 -0.067 0.025 0.008 0.512 0.749 
9 rs11191560 0.072 0.065 0.269 -0.034 0.048 0.472 -0.032 0.041 0.430 -0.047 0.047 0.316 -0.022 0.024 0.352 1.000 0.475 -0.037 0.026 0.149 1.000 0.970 
10 rs11583200 0.095 0.093 0.307 -0.169 0.076 0.026 -0.013 0.070 0.850 -0.141 0.078 0.074 -0.067 0.039 0.087 1.000 0.097 -0.101 0.043 0.018 1.000 0.266 
11 rs11688816 0.036 0.062 0.565 0.046 0.047 0.322 -0.019 0.041 0.640 -0.038 0.044 0.396 -7.47E-05 0.023 0.997 1.000 0.522 -0.006 0.025 0.812 1.000 0.394 
12 rs12286929 -0.108 0.067 0.109 0.033 0.047 0.477 -0.018 0.043 0.669 0.022 0.045 0.625 -0.004 0.024 0.853 1.000 0.324 0.011 0.026 0.677 1.000 0.685 
13 rs12429545 0.038 0.067 0.566 -0.006 0.046 0.901 0.018 0.043 0.682 -0.053 0.049 0.277 -0.004 0.025 0.862 1.000 0.645 -0.011 0.027 0.679 1.000 0.550 
14 rs12566985 -0.089 0.073 0.223 0.130 0.054 0.017 0.067 0.049 0.166 -0.071 0.054 0.186 0.024 0.028 0.388 1.000 0.017 0.043 0.030 0.150 1.000 0.025 
15 rs12940622 -0.069 0.061 0.259 0.037 0.046 0.420 0.054 0.040 0.179 0.001 0.043 0.989 0.017 0.023 0.451 1.000 0.367 0.032 0.025 0.203 1.000 0.658 
16 rs13021737 0.028 0.111 0.798 0.105 0.079 0.183 0.025 0.070 0.721 0.099 0.081 0.220 0.066 0.041 0.107 1.000 0.834 0.072 0.044 0.102 1.000 0.692 
17 rs13201877 -0.246 0.179 0.171 0.056 0.104 0.592 0.021 0.097 0.824 -0.097 0.105 0.355 -0.028 0.056 0.614 1.000 0.420 -0.005 0.059 0.934 1.000 0.552 
18 rs1441264 6.53E-05 0.059 0.999 -0.060 0.043 0.157 0.029 0.037 0.442 -0.048 0.041 0.237 -0.019 0.022 0.371 1.000 0.362 -0.022 0.023 0.337 1.000 0.215 
19 rs1460676 0.029 0.058 0.620 0.076 0.044 0.085 0.026 0.038 0.488 0.033 0.041 0.421 0.041 0.022 0.062 1.000 0.837 0.043 0.024 0.070 1.000 0.669 
20 rs1516725 -0.097 0.103 0.347 -0.014 0.082 0.866 0.030 0.066 0.647 -0.066 0.076 0.387 -0.024 0.039 0.537 1.000 0.684 -0.012 0.043 0.780 1.000 0.635 
21 rs1528435 0.109 0.062 0.078 0.058 0.044 0.189 -0.013 0.040 0.751 0.026 0.043 0.542 0.033 0.023 0.143 1.000 0.365 0.021 0.024 0.379 1.000 0.490 
22 rs1558902 -0.001 0.081 0.992 0.094 0.062 0.129 -0.035 0.058 0.547 0.034 0.065 0.601 0.023 0.033 0.474 1.000 0.488 0.028 0.036 0.431 1.000 0.313 
23 rs16851483 -0.018 0.064 0.774 0.072 0.048 0.140 -0.003 0.042 0.946 0.051 0.047 0.278 0.028 0.024 0.248 1.000 0.551 0.036 0.026 0.170 1.000 0.477 
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Table 43 (continued): Association between 64 SNPs and %fat intake 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
24 rs16951275 -0.038 0.059 0.522 -0.008 0.041 0.851 0.033 0.038 0.392 0.003 0.041 0.942 0.004 0.021 0.849 1.000 0.766 0.010 0.023 0.651 1.000 0.753 
25 rs17203016 -0.093 0.085 0.277 -0.023 0.061 0.707 0.010 0.052 0.846 -0.066 0.058 0.250 -0.033 0.030 0.284 1.000 0.673 -0.024 0.033 0.465 1.000 0.616 
26 rs17405819 -0.065 0.058 0.267 -0.023 0.042 0.594 0.053 0.037 0.155 -0.007 0.041 0.858 0.001 0.021 0.965 1.000 0.311 0.011 0.023 0.626 1.000 0.348 
27 rs17724992 -0.009 0.056 0.871 0.028 0.043 0.514 0.023 0.037 0.523 -0.020 0.041 0.626 0.008 0.021 0.703 1.000 0.812 0.011 0.023 0.633 1.000 0.655 
28 rs1928295 1.71E-04 0.057 0.998 -0.042 0.043 0.327 0.032 0.037 0.389 0.074 0.041 0.074 0.020 0.021 0.346 1.000 0.259 0.023 0.023 0.310 1.000 0.144 
29 rs2033529 0.076 0.083 0.362 0.062 0.058 0.282 -0.142 0.047 0.003 0.048 0.053 0.365 -0.013 0.028 0.637 1.000 0.009 -0.025 0.030 0.404 1.000 0.006 
30 rs2033732 0.028 0.056 0.621 -0.002 0.044 0.962 0.041 0.038 0.278 -0.058 0.040 0.149 1.93E-04 0.022 0.993 1.000 0.320 -0.005 0.023 0.845 1.000 0.200 
31 rs205262 -0.026 0.076 0.733 -0.050 0.060 0.400 0.030 0.055 0.591 -0.098 0.059 0.096 -0.035 0.031 0.254 1.000 0.459 -0.036 0.033 0.274 1.000 0.276 
32 rs2075650 -0.238 0.104 0.023 -0.098 0.077 0.201 0.015 0.065 0.813 0.071 0.072 0.328 -0.031 0.038 0.416 1.000 0.066 0.001 0.041 0.984 1.000 0.266 
33 rs2080454 0.059 0.059 0.321 0.029 0.042 0.487 -0.044 0.037 0.234 0.027 0.041 0.508 0.008 0.021 0.713 1.000 0.364 2.46E-04 0.023 0.991 1.000 0.311 
34 rs2112347 0.015 0.056 0.792 -0.002 0.042 0.962 -0.023 0.037 0.542 0.015 0.041 0.707 -0.002 0.021 0.940 1.000 0.901 -0.004 0.023 0.850 1.000 0.787 
35 rs2176040 0.053 0.109 0.629 0.037 0.082 0.656 0.092 0.072 0.201 -0.014 0.076 0.855 0.042 0.041 0.302 1.000 0.792 0.041 0.044 0.359 1.000 0.599 
36 rs2207139 0.017 0.077 0.822 0.027 0.061 0.660 0.035 0.058 0.544 -0.036 0.059 0.543 0.010 0.031 0.746 1.000 0.831 0.009 0.034 0.799 1.000 0.648 
37 rs2287019 -0.013 0.071 0.857 0.043 0.053 0.418 0.052 0.047 0.261 0.013 0.054 0.812 0.030 0.027 0.263 1.000 0.860 0.038 0.029 0.199 1.000 0.851 
38 rs2365389 0.108 0.080 0.180 -0.051 0.060 0.394 -0.001 0.059 0.984 -0.001 0.060 0.982 0.002 0.032 0.952 1.000 0.470 -0.018 0.034 0.610 1.000 0.791 
39 rs2820292 0.010 0.068 0.887 -0.083 0.055 0.129 0.011 0.047 0.812 -0.044 0.050 0.373 -0.027 0.027 0.306 1.000 0.546 -0.034 0.029 0.241 1.000 0.410 
40 rs2836754 -0.013 0.059 0.826 -0.062 0.043 0.152 0.030 0.038 0.423 0.045 0.042 0.292 0.004 0.022 0.843 1.000 0.282 0.007 0.024 0.763 1.000 0.156 
41 rs29941 0.051 0.072 0.483 -0.016 0.050 0.752 -0.039 0.046 0.400 0.057 0.050 0.256 0.006 0.026 0.831 1.000 0.466 -0.001 0.028 0.963 1.000 0.350 
42 rs3101336 -0.081 0.107 0.450 -0.074 0.077 0.338 -0.029 0.066 0.665 -0.047 0.077 0.545 -0.052 0.039 0.185 1.000 0.963 -0.047 0.042 0.259 1.000 0.904 
43 rs3817334 -0.053 0.062 0.393 -0.004 0.046 0.925 0.046 0.042 0.272 -0.005 0.045 0.914 0.004 0.024 0.849 1.000 0.589 0.014 0.025 0.577 1.000 0.632 
44 rs3849570 0.027 0.056 0.628 0.049 0.042 0.247 -0.018 0.037 0.631 -0.023 0.041 0.580 0.004 0.021 0.842 1.000 0.557 3.92E-04 0.023 0.986 1.000 0.391 
45 rs3888190 -0.085 0.099 0.388 -0.025 0.075 0.736 -0.023 0.065 0.726 0.015 0.072 0.834 -0.022 0.038 0.554 1.000 0.879 -0.012 0.041 0.776 1.000 0.905 
46 rs4256980 0.068 0.060 0.254 0.024 0.042 0.564 -0.006 0.038 0.868 -0.001 0.041 0.980 0.013 0.022 0.549 1.000 0.728 0.005 0.023 0.842 1.000 0.851 
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Table 43 (continued): Association between 64 SNPs and %fat intake 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
47 rs4740619 -0.138 0.064 0.031 -0.054 0.049 0.271 0.007 0.042 0.865 0.044 0.049 0.365 -0.020 0.025 0.408 1.000 0.108 2.87E-04 0.027 0.991 1.000 0.357 
48 rs4787491 0.031 0.058 0.592 0.024 0.041 0.560 0.013 0.038 0.738 -0.056 0.041 0.168 -0.001 0.021 0.976 1.000 0.450 -0.006 0.023 0.806 1.000 0.317 
49 rs492400 -0.009 0.072 0.902 -0.067 0.051 0.187 0.012 0.045 0.787 -0.007 0.048 0.884 -0.016 0.026 0.525 1.000 0.694 -0.017 0.027 0.526 1.000 0.487 
50 rs6567160 0.059 0.078 0.451 0.027 0.055 0.618 0.096 0.050 0.057 0.023 0.055 0.678 0.053 0.029 0.066 1.000 0.743 0.052 0.031 0.093 1.000 0.540 
51 rs6804842 0.029 0.060 0.630 0.011 0.045 0.803 0.032 0.040 0.423 -0.088 0.042 0.033 -0.009 0.022 0.692 1.000 0.150 -0.015 0.024 0.534 1.000 0.088 
52 rs7138803 -0.098 0.066 0.142 0.066 0.048 0.169 -1.07E-04 0.042 0.998 -0.039 0.047 0.401 -0.007 0.024 0.783 1.000 0.196 0.008 0.026 0.775 1.000 0.284 
53 rs7141420 0.007 0.056 0.898 0.031 0.042 0.465 0.020 0.037 0.595 0.032 0.039 0.415 0.024 0.021 0.249 1.000 0.983 0.027 0.023 0.234 1.000 0.970 
54 rs7164727 -0.079 0.066 0.234 4.24E-04 0.047 0.993 -0.006 0.043 0.890 0.074 0.045 0.103 0.009 0.024 0.717 1.000 0.264 0.022 0.026 0.390 1.000 0.377 
55 rs7239883 -0.009 0.062 0.880 -0.009 0.045 0.834 0.008 0.040 0.846 -0.017 0.044 0.697 -0.006 0.023 0.800 1.000 0.979 -0.005 0.025 0.832 1.000 0.910 
56 rs7243357 0.081 0.069 0.240 -0.025 0.050 0.621 0.016 0.050 0.741 0.019 0.049 0.697 0.015 0.027 0.562 1.000 0.671 0.004 0.029 0.892 1.000 0.784 
57 rs7599312 0.072 0.216 0.739 0.013 0.155 0.935 0.034 0.114 0.764 -0.069 0.143 0.631 0.007 0.073 0.922 1.000 0.934 -0.001 0.077 0.988 1.000 0.849 
58 rs7715256 -0.250 0.148 0.093 -0.005 0.113 0.966 -0.114 0.105 0.277 0.006 0.104 0.953 -0.070 0.057 0.220 1.000 0.472 -0.039 0.062 0.529 1.000 0.672 
59 rs7903146 0.194 0.195 0.320 -0.180 0.131 0.171 -0.234 0.133 0.077 -0.186 0.137 0.174 -0.147 0.072 0.040 1.000 0.303 -0.200 0.077 0.009 0.576 0.951 
60 rs9374842 -0.234 0.105 0.026 0.054 0.072 0.448 -0.051 0.066 0.439 -0.002 0.071 0.976 -0.032 0.037 0.393 1.000 0.144 -0.003 0.040 0.948 1.000 0.556 
61 rs9400239 0.134 0.063 0.032 -0.039 0.046 0.397 -0.027 0.041 0.507 -0.008 0.046 0.868 -0.002 0.024 0.926 1.000 0.122 -0.025 0.025 0.330 1.000 0.888 
62 rs9641123 0.028 0.062 0.652 0.007 0.045 0.869 0.031 0.040 0.436 -0.050 0.043 0.248 0.002 0.023 0.927 1.000 0.539 -0.002 0.024 0.935 1.000 0.375 
63 rs977747 -0.164 0.155 0.291 -0.181 0.107 0.091 -0.094 0.099 0.342 -0.004 0.092 0.964 -0.094 0.054 0.080 1.000 0.611 -0.084 0.057 0.140 1.000 0.453 
64 rs9914578 0.087 0.070 0.210 -0.015 0.051 0.766 0.005 0.047 0.918 -0.010 0.052 0.844 0.008 0.027 0.778 1.000 0.652 -0.006 0.029 0.830 1.000 0.955 




After meta-analysis, nominal significance were found between rs11126666 on 
KCNK3 (β=-0.073, SE=0.023, P=0.001) and rs7903146 on TCF7L2 (β=-0.147, 
SE=0.072, P=0.040) and intake of %fat (Table 43).  BMI risk allele A of rs11126666 
and C of rs7903146 were all negatively associated with the outcome. 
 
6.3.6.7 %SFA 
After meta-analysis, nominal association were observed between rs1000940 on 
RABEP1 (β=0.051, SE=0.022, P=0.020), rs11126666 on KCNK3 (β=-0.051, 
SE=0.023, P=0.028) and rs977747 on TAL1 (β=-0.120, SE=0.054, P=0.025) were 
found to be associated with %SFA intake (Table 44).  BMI risk allele G of 
rs1000940 was positively associated while A of rs11126666 and T of rs977747 were 
negatively associated with %SFA intake. 
 
6.3.6.8 %MFA 
After meta-analysis, rs11126666 on KCNK3 (β=-0.055, SE=0.024, P=0.020), 
rs11583200 on ELAVL4 (β=-0.088, SE=0.040, P=0.029), rs1460676 on FIGN 
(β=0.052, SE=0.023, P=0.020), rs2176040 on LOC646736 (β=0.091, SE=0.042, 
P=0.032) and rs6567160 on MC4R (β=0.069, SE=0.029, P=0.019) were found to be 
associated with %MFA intake (Table 45).  BMI risk allele A of rs11126666 and C of 
rs11583200 would reduce while C of rs1460676, A of rs2176040 and C of rs6567160 
would increase %MFA intake.
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Table 44: Association between 64 SNPs and %SFA intake 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
1 rs1000940 0.018 0.059 0.765 0.021 0.043 0.621 0.055 0.038 0.147 0.090 0.042 0.031 0.051 0.022 0.020 1.000 0.643 0.056 0.024 0.017 1.000 0.521 
2 rs1016287 0.025 0.063 0.695 -0.044 0.047 0.355 -0.007 0.045 0.875 -0.036 0.045 0.424 -0.021 0.024 0.398 1.000 0.810 -0.028 0.026 0.281 1.000 0.835 
3 rs10182181 0.092 0.058 0.111 -0.036 0.043 0.409 -3.86E-04 0.038 0.992 -0.004 0.040 0.911 0.003 0.022 0.906 1.000 0.357 -0.012 0.023 0.604 1.000 0.808 
4 rs10733682 0.049 0.065 0.446 0.047 0.050 0.351 -0.006 0.043 0.896 -0.040 0.049 0.415 0.007 0.025 0.789 1.000 0.560 -0.001 0.027 0.976 1.000 0.460 
5 rs10938397 0.039 0.064 0.546 -0.019 0.047 0.684 -0.031 0.043 0.468 0.027 0.046 0.555 -0.002 0.024 0.936 1.000 0.706 -0.009 0.026 0.739 1.000 0.628 
6 rs10968576 0.018 0.076 0.813 0.005 0.056 0.926 0.052 0.049 0.294 -0.001 0.054 0.991 0.021 0.028 0.465 1.000 0.889 0.021 0.030 0.488 1.000 0.729 
7 rs11030104 -0.040 0.055 0.473 -0.014 0.041 0.728 0.027 0.037 0.463 0.002 0.039 0.963 -2.50E-04 0.021 0.990 1.000 0.759 0.006 0.023 0.780 1.000 0.747 
8 rs11126666 -0.093 0.061 0.125 0.032 0.045 0.474 -0.102 0.042 0.015 -0.051 0.044 0.243 -0.051 0.023 0.028 1.000 0.146 -0.044 0.025 0.082 1.000 0.090 
9 rs11191560 0.017 0.065 0.792 -0.023 0.048 0.630 -0.036 0.042 0.390 -0.074 0.047 0.113 -0.035 0.024 0.142 1.000 0.705 -0.044 0.026 0.092 1.000 0.724 
10 rs11583200 -1.95E-05 0.093 1.000 -0.151 0.076 0.048 0.010 0.070 0.892 -0.071 0.078 0.365 -0.055 0.039 0.163 1.000 0.420 -0.066 0.043 0.125 1.000 0.300 
11 rs11688816 0.004 0.062 0.953 0.036 0.047 0.443 -0.037 0.041 0.371 0.014 0.044 0.751 0.001 0.023 0.950 1.000 0.684 0.001 0.025 0.965 1.000 0.475 
12 rs12286929 -0.066 0.068 0.329 0.065 0.047 0.166 -0.030 0.043 0.490 -0.009 0.045 0.849 -0.003 0.024 0.902 1.000 0.338 0.006 0.026 0.809 1.000 0.306 
13 rs12429545 0.039 0.067 0.558 -0.026 0.046 0.572 0.008 0.044 0.850 -0.106 0.048 0.028 -0.027 0.025 0.269 1.000 0.230 -0.038 0.027 0.155 1.000 0.205 
14 rs12566985 0.017 0.073 0.817 0.074 0.054 0.175 0.027 0.049 0.585 -0.082 0.053 0.123 0.008 0.028 0.775 1.000 0.213 0.006 0.030 0.831 1.000 0.106 
15 rs12940622 -0.055 0.061 0.374 -0.011 0.046 0.810 0.015 0.041 0.703 0.028 0.043 0.513 0.003 0.023 0.911 1.000 0.703 0.012 0.025 0.631 1.000 0.819 
16 rs13021737 -0.070 0.112 0.534 0.073 0.079 0.356 0.076 0.071 0.286 0.087 0.081 0.283 0.058 0.041 0.157 1.000 0.675 0.078 0.044 0.077 1.000 0.992 
17 rs13201877 -0.141 0.180 0.434 0.122 0.105 0.243 0.064 0.097 0.512 -0.103 0.105 0.327 0.013 0.056 0.813 1.000 0.346 0.030 0.059 0.614 1.000 0.286 
18 rs1441264 -5.87E-05 0.059 0.999 -0.046 0.043 0.284 0.019 0.038 0.609 -0.004 0.041 0.926 -0.006 0.022 0.765 1.000 0.722 -0.007 0.023 0.749 1.000 0.518 
19 rs1460676 0.027 0.059 0.651 0.059 0.044 0.180 0.031 0.038 0.410 -0.034 0.041 0.408 0.019 0.022 0.382 1.000 0.456 0.018 0.024 0.447 1.000 0.274 
20 rs1516725 -0.097 0.104 0.349 0.015 0.083 0.856 0.033 0.067 0.626 -0.007 0.076 0.930 -0.001 0.040 0.979 1.000 0.764 0.015 0.043 0.721 1.000 0.927 
21 rs1528435 0.108 0.062 0.082 0.085 0.044 0.054 -0.013 0.040 0.753 0.008 0.043 0.844 0.035 0.023 0.120 1.000 0.214 0.024 0.024 0.325 1.000 0.237 
22 rs1558902 0.004 0.081 0.960 0.094 0.062 0.134 -0.021 0.059 0.726 0.032 0.065 0.624 0.028 0.033 0.390 1.000 0.598 0.033 0.036 0.359 1.000 0.412 
23 rs16851483 -0.026 0.064 0.682 0.048 0.049 0.323 -0.088 0.043 0.038 0.045 0.047 0.333 -0.008 0.024 0.730 1.000 0.099 -0.005 0.026 0.839 1.000 0.045 
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Table 44 (continued): Association between 64 SNPs and %SFA intake 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
24 rs16951275 -0.045 0.059 0.449 0.001 0.041 0.985 0.040 0.038 0.302 -0.013 0.041 0.750 0.003 0.021 0.884 1.000 0.633 0.010 0.023 0.652 1.000 0.618 
25 rs17203016 0.014 0.086 0.872 -0.081 0.061 0.184 0.061 0.053 0.246 0.039 0.057 0.492 0.013 0.031 0.667 1.000 0.330 0.013 0.033 0.690 1.000 0.180 
26 rs17405819 -0.060 0.059 0.310 -0.047 0.043 0.274 0.036 0.038 0.347 -0.022 0.040 0.585 -0.015 0.022 0.496 1.000 0.399 -0.008 0.023 0.741 1.000 0.322 
27 rs17724992 -0.007 0.056 0.895 -0.002 0.043 0.955 0.013 0.037 0.731 0.025 0.040 0.531 0.010 0.021 0.653 1.000 0.954 0.012 0.023 0.590 1.000 0.895 
28 rs1928295 -3.57E-04 0.058 0.995 0.004 0.043 0.928 0.054 0.037 0.147 0.035 0.041 0.397 0.029 0.021 0.183 1.000 0.786 0.033 0.023 0.151 1.000 0.680 
29 rs2033529 0.086 0.083 0.300 0.038 0.058 0.508 -0.075 0.048 0.119 0.030 0.053 0.570 0.002 0.029 0.952 1.000 0.235 -0.010 0.030 0.753 1.000 0.213 
30 rs2033732 0.001 0.057 0.983 0.004 0.044 0.921 0.075 0.038 0.051 -0.067 0.040 0.095 0.006 0.022 0.796 1.000 0.087 0.006 0.023 0.787 1.000 0.038 
31 rs205262 -0.011 0.077 0.884 -0.066 0.060 0.269 0.046 0.056 0.410 -0.027 0.058 0.648 -0.013 0.031 0.680 1.000 0.580 -0.013 0.033 0.699 1.000 0.375 
32 rs2075650 -0.123 0.105 0.243 -0.151 0.077 0.051 -0.018 0.066 0.780 0.098 0.072 0.171 -0.032 0.038 0.406 1.000 0.091 -0.018 0.041 0.664 1.000 0.061 
33 rs2080454 0.041 0.059 0.493 0.020 0.042 0.638 -0.094 0.037 0.012 0.009 0.040 0.827 -0.018 0.021 0.391 1.000 0.094 -0.027 0.023 0.237 1.000 0.073 
34 rs2112347 0.086 0.056 0.127 0.005 0.042 0.911 -0.023 0.038 0.546 0.026 0.040 0.518 0.014 0.021 0.525 1.000 0.436 0.001 0.023 0.953 1.000 0.673 
35 rs2176040 -0.025 0.109 0.820 0.031 0.083 0.707 0.099 0.073 0.176 0.068 0.076 0.371 0.055 0.041 0.177 1.000 0.799 0.069 0.044 0.121 1.000 0.828 
36 rs2207139 -0.071 0.078 0.357 -0.053 0.061 0.389 -0.017 0.058 0.767 0.003 0.059 0.965 -0.030 0.031 0.342 1.000 0.855 -0.022 0.034 0.528 1.000 0.806 
37 rs2287019 -0.001 0.071 0.991 0.041 0.053 0.441 0.036 0.047 0.446 -0.107 0.053 0.045 -0.005 0.027 0.853 1.000 0.161 -0.006 0.029 0.845 1.000 0.076 
38 rs2365389 0.049 0.081 0.541 -0.017 0.061 0.778 -0.016 0.059 0.791 0.026 0.059 0.661 0.006 0.032 0.853 1.000 0.877 -0.002 0.034 0.952 1.000 0.844 
39 rs2820292 0.010 0.069 0.880 0.011 0.055 0.843 -0.012 0.047 0.796 -0.023 0.050 0.650 -0.006 0.027 0.813 1.000 0.964 -0.009 0.029 0.749 1.000 0.900 
40 rs2836754 -0.013 0.059 0.826 -0.052 0.043 0.233 0.016 0.038 0.684 0.022 0.042 0.597 -0.004 0.022 0.859 1.000 0.596 -0.002 0.024 0.918 1.000 0.394 
41 rs29941 0.008 0.072 0.915 -0.033 0.051 0.518 0.020 0.047 0.674 0.051 0.050 0.306 0.013 0.026 0.631 1.000 0.699 0.013 0.028 0.635 1.000 0.492 
42 rs3101336 -0.028 0.108 0.795 0.011 0.077 0.884 -0.091 0.067 0.174 -0.010 0.076 0.896 -0.035 0.039 0.374 1.000 0.760 -0.036 0.042 0.394 1.000 0.559 
43 rs3817334 -0.052 0.062 0.406 -0.037 0.046 0.425 0.055 0.042 0.188 -0.003 0.045 0.943 -0.001 0.024 0.980 1.000 0.381 0.008 0.026 0.753 1.000 0.320 
44 rs3849570 0.086 0.056 0.126 0.036 0.042 0.393 -2.01E-04 0.037 0.996 0.010 0.041 0.810 0.024 0.021 0.257 1.000 0.605 0.014 0.023 0.550 1.000 0.806 
45 rs3888190 -0.042 0.099 0.668 -0.029 0.075 0.703 -0.052 0.066 0.429 0.010 0.072 0.894 -0.028 0.038 0.460 1.000 0.934 -0.025 0.041 0.534 1.000 0.817 
46 rs4256980 0.132 0.060 0.028 0.004 0.043 0.926 -0.008 0.038 0.839 -0.008 0.041 0.839 0.014 0.022 0.532 1.000 0.206 -0.004 0.023 0.850 1.000 0.973 
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Table 44 (continued): Association between 64 SNPs and %SFA intake 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
47 rs4740619 -0.124 0.064 0.054 -0.055 0.049 0.262 0.031 0.042 0.468 0.068 0.048 0.162 -0.004 0.025 0.869 1.000 0.059 0.017 0.027 0.531 1.000 0.187 
48 rs4787491 0.013 0.058 0.816 0.026 0.041 0.525 -0.023 0.038 0.542 -0.078 0.040 0.052 -0.020 0.021 0.342 1.000 0.295 -0.026 0.023 0.265 1.000 0.191 
49 rs492400 0.071 0.072 0.323 -0.048 0.051 0.343 0.032 0.045 0.473 0.058 0.048 0.220 0.024 0.026 0.345 1.000 0.390 0.017 0.027 0.527 1.000 0.283 
50 rs6567160 -0.041 0.078 0.604 0.018 0.055 0.747 0.077 0.051 0.131 0.020 0.055 0.723 0.029 0.029 0.310 1.000 0.626 0.040 0.031 0.194 1.000 0.662 
51 rs6804842 0.001 0.060 0.989 -0.003 0.045 0.955 -0.041 0.040 0.314 -0.014 0.041 0.738 -0.017 0.023 0.444 1.000 0.910 -0.020 0.024 0.405 1.000 0.805 
52 rs7138803 -0.017 0.067 0.801 0.031 0.048 0.519 0.006 0.043 0.892 -0.044 0.047 0.345 -0.004 0.025 0.858 1.000 0.716 -0.002 0.026 0.926 1.000 0.517 
53 rs7141420 0.045 0.057 0.427 0.065 0.042 0.119 0.064 0.038 0.088 -0.011 0.039 0.781 0.040 0.021 0.058 1.000 0.482 0.039 0.023 0.085 1.000 0.293 
54 rs7164727 -0.007 0.067 0.912 -0.069 0.047 0.144 -0.008 0.044 0.862 0.086 0.045 0.057 0.003 0.024 0.888 1.000 0.122 0.005 0.026 0.846 1.000 0.056 
55 rs7239883 0.045 0.062 0.464 -0.023 0.045 0.606 0.005 0.040 0.908 -0.016 0.043 0.709 -0.003 0.023 0.903 1.000 0.816 -0.010 0.025 0.673 1.000 0.887 
56 rs7243357 0.129 0.069 0.061 -0.024 0.051 0.639 0.054 0.050 0.279 0.013 0.049 0.787 0.032 0.027 0.229 1.000 0.314 0.015 0.029 0.606 1.000 0.549 
57 rs7599312 -0.105 0.217 0.627 -0.123 0.156 0.431 -0.019 0.115 0.868 -0.036 0.143 0.801 -0.056 0.073 0.442 1.000 0.949 -0.050 0.078 0.521 1.000 0.861 
58 rs7715256 -0.248 0.149 0.097 0.052 0.114 0.647 -0.098 0.106 0.353 -0.091 0.103 0.378 -0.080 0.057 0.162 1.000 0.447 -0.051 0.062 0.409 1.000 0.557 
59 rs7903146 0.312 0.195 0.111 -0.074 0.132 0.574 0.002 0.134 0.988 -0.238 0.136 0.080 -0.046 0.072 0.525 1.000 0.137 -0.102 0.077 0.188 1.000 0.439 
60 rs9374842 -0.136 0.106 0.198 0.089 0.072 0.215 -0.038 0.066 0.569 -0.024 0.071 0.732 -0.012 0.037 0.755 1.000 0.315 0.006 0.040 0.877 1.000 0.376 
61 rs9400239 0.156 0.063 0.013 -0.028 0.046 0.545 -0.012 0.041 0.769 -0.005 0.046 0.906 0.009 0.024 0.690 1.000 0.089 -0.015 0.025 0.560 1.000 0.938 
62 rs9641123 -0.073 0.062 0.241 -0.004 0.045 0.922 -0.015 0.040 0.706 -0.038 0.043 0.372 -0.027 0.023 0.242 1.000 0.811 -0.019 0.025 0.427 1.000 0.853 
63 rs977747 -0.208 0.156 0.182 -0.193 0.108 0.073 -0.019 0.100 0.851 -0.122 0.091 0.183 -0.120 0.054 0.025 1.000 0.614 -0.108 0.057 0.058 1.000 0.487 
64 rs9914578 0.055 0.070 0.433 -0.050 0.051 0.332 0.004 0.048 0.940 -0.053 0.052 0.301 -0.019 0.027 0.484 1.000 0.543 -0.031 0.029 0.280 1.000 0.654 





Table 45: Association between 64 SNPs and %MFA intake 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
1 rs1000940 0.018 0.059 0.755 0.029 0.043 0.503 0.041 0.039 0.296 -0.009 0.044 0.838 0.022 0.023 0.337 1.000 0.859 0.022 0.024 0.362 1.000 0.686 
2 rs1016287 0.017 0.063 0.789 -0.030 0.047 0.520 -0.068 0.047 0.145 0.057 0.047 0.229 -0.009 0.025 0.705 1.000 0.271 -0.014 0.027 0.597 1.000 0.156 
3 rs10182181 0.082 0.057 0.153 -0.036 0.043 0.404 0.050 0.040 0.213 -0.041 0.042 0.334 0.007 0.022 0.759 1.000 0.162 -0.007 0.024 0.787 1.000 0.211 
4 rs10733682 0.073 0.065 0.261 0.009 0.050 0.865 -0.076 0.045 0.090 -0.012 0.052 0.826 -0.014 0.026 0.583 1.000 0.270 -0.031 0.028 0.276 1.000 0.413 
5 rs10938397 0.081 0.064 0.205 -0.042 0.047 0.374 -0.063 0.045 0.160 -0.051 0.049 0.300 -0.032 0.025 0.198 1.000 0.285 -0.052 0.027 0.053 1.000 0.948 
6 rs10968576 -0.035 0.076 0.647 0.012 0.056 0.833 0.006 0.051 0.907 -0.052 0.057 0.362 -0.014 0.029 0.641 1.000 0.830 -0.010 0.031 0.752 1.000 0.673 
7 rs11030104 -0.035 0.055 0.528 -0.081 0.041 0.046 0.014 0.039 0.712 0.056 0.042 0.183 -0.009 0.021 0.682 1.000 0.105 -0.004 0.023 0.859 1.000 0.053 
8 rs11126666 -0.067 0.061 0.271 -0.044 0.045 0.326 -0.078 0.044 0.075 -0.035 0.046 0.450 -0.055 0.024 0.020 1.000 0.908 -0.053 0.026 0.040 1.000 0.776 
9 rs11191560 0.099 0.065 0.129 -0.032 0.048 0.499 -0.056 0.043 0.197 -0.047 0.049 0.340 -0.025 0.025 0.322 1.000 0.225 -0.046 0.027 0.089 1.000 0.935 
10 rs11583200 0.083 0.093 0.371 -0.169 0.076 0.027 -0.062 0.073 0.395 -0.159 0.083 0.056 -0.088 0.040 0.029 1.000 0.146 -0.127 0.045 0.004 0.256 0.541 
11 rs11688816 -0.003 0.062 0.958 0.061 0.047 0.194 0.007 0.043 0.879 -0.058 0.047 0.216 0.002 0.024 0.921 1.000 0.356 0.003 0.026 0.897 1.000 0.199 
12 rs12286929 -0.127 0.067 0.060 0.035 0.047 0.450 -0.009 0.045 0.835 0.020 0.047 0.667 -0.004 0.025 0.857 1.000 0.230 0.015 0.027 0.580 1.000 0.781 
13 rs12429545 0.038 0.067 0.576 -0.025 0.047 0.587 0.036 0.046 0.427 -0.017 0.051 0.745 0.005 0.025 0.844 1.000 0.727 -4.78E-04 0.028 0.986 1.000 0.596 
14 rs12566985 -0.106 0.072 0.146 0.091 0.054 0.093 0.048 0.051 0.347 -0.043 0.057 0.451 0.013 0.029 0.651 1.000 0.102 0.035 0.031 0.263 1.000 0.220 
15 rs12940622 -0.046 0.061 0.456 0.018 0.046 0.695 0.047 0.042 0.264 0.019 0.046 0.675 0.018 0.024 0.449 1.000 0.668 0.029 0.026 0.256 1.000 0.865 
16 rs13021737 0.107 0.111 0.337 0.106 0.079 0.182 -0.023 0.073 0.757 -0.019 0.085 0.825 0.033 0.042 0.431 1.000 0.526 0.021 0.045 0.647 1.000 0.423 
17 rs13201877 -0.211 0.180 0.240 0.072 0.104 0.494 0.049 0.101 0.632 -0.043 0.111 0.698 0.004 0.058 0.942 1.000 0.527 0.029 0.061 0.635 1.000 0.732 
18 rs1441264 -0.008 0.059 0.898 -0.034 0.043 0.430 -0.013 0.039 0.738 -0.057 0.043 0.189 -0.030 0.022 0.185 1.000 0.869 -0.033 0.024 0.168 1.000 0.756 
19 rs1460676 0.040 0.059 0.501 0.084 0.044 0.055 0.057 0.040 0.152 0.023 0.044 0.601 0.052 0.023 0.020 1.000 0.792 0.055 0.024 0.025 1.000 0.613 
20 rs1516725 -0.133 0.103 0.200 -0.054 0.082 0.511 0.021 0.070 0.768 -0.128 0.080 0.112 -0.060 0.041 0.142 1.000 0.468 -0.047 0.044 0.294 1.000 0.376 
21 rs1528435 0.111 0.062 0.073 0.039 0.044 0.381 0.012 0.042 0.768 0.036 0.045 0.427 0.040 0.023 0.086 1.000 0.622 0.028 0.025 0.261 1.000 0.893 
22 rs1558902 -0.002 0.081 0.981 0.089 0.062 0.154 -0.040 0.061 0.518 0.041 0.069 0.546 0.023 0.034 0.484 1.000 0.507 0.029 0.037 0.436 1.000 0.331 
23 rs16851483 -0.015 0.064 0.817 0.057 0.049 0.242 0.004 0.045 0.927 -0.016 0.050 0.751 0.010 0.025 0.686 1.000 0.713 0.015 0.027 0.589 1.000 0.552 
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Table 45 (continued): Association between 64 SNPs and %MFA intake 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue      Beta SE P Padjust Qpvalue 
24 rs16951275 -0.040 0.059 0.499 0.004 0.041 0.919 0.025 0.040 0.526 0.038 0.043 0.378 0.013 0.022 0.544 1.000 0.734 0.022 0.024 0.355 1.000 0.845 
25 rs17203016 -0.108 0.085 0.207 -0.037 0.061 0.547 0.022 0.055 0.691 -0.067 0.061 0.272 -0.035 0.031 0.264 1.000 0.557 -0.024 0.034 0.483 1.000 0.538 
26 rs17405819 -0.075 0.058 0.194 -0.035 0.043 0.413 0.023 0.039 0.564 -0.001 0.043 0.981 -0.014 0.022 0.541 1.000 0.509 -0.003 0.024 0.901 1.000 0.610 
27 rs17724992 -0.017 0.056 0.767 0.015 0.043 0.719 0.025 0.039 0.523 0.015 0.043 0.731 0.013 0.022 0.544 1.000 0.946 0.019 0.024 0.432 1.000 0.981 
28 rs1928295 0.026 0.057 0.654 -0.013 0.043 0.754 0.036 0.039 0.357 0.044 0.044 0.315 0.023 0.022 0.293 1.000 0.788 0.023 0.024 0.341 1.000 0.591 
29 rs2033529 0.055 0.083 0.507 0.034 0.058 0.560 -0.110 0.050 0.028 -0.005 0.056 0.923 -0.024 0.029 0.416 1.000 0.175 -0.035 0.031 0.262 1.000 0.140 
30 rs2033732 0.022 0.056 0.691 -0.019 0.044 0.662 0.113 0.040 0.005 -0.050 0.043 0.243 0.020 0.022 0.364 1.000 0.030 0.020 0.024 0.414 1.000 0.011 
31 rs205262 -0.002 0.076 0.978 -0.032 0.060 0.591 0.086 0.058 0.139 -0.068 0.062 0.273 -0.002 0.031 0.959 1.000 0.299 -0.002 0.035 0.965 1.000 0.159 
32 rs2075650 -0.169 0.105 0.107 -0.165 0.077 0.032 0.056 0.069 0.419 0.038 0.076 0.617 -0.039 0.039 0.325 1.000 0.068 -0.017 0.043 0.684 1.000 0.069 
33 rs2080454 0.061 0.059 0.306 0.037 0.042 0.387 -0.077 0.039 0.046 -0.032 0.043 0.456 -0.015 0.022 0.489 1.000 0.117 -0.027 0.024 0.248 1.000 0.137 
34 rs2112347 0.036 0.056 0.523 0.015 0.042 0.725 -0.025 0.039 0.526 0.029 0.043 0.493 0.009 0.022 0.668 1.000 0.748 0.005 0.024 0.846 1.000 0.619 
35 rs2176040 0.086 0.109 0.427 0.101 0.082 0.222 0.148 0.076 0.052 0.020 0.081 0.804 0.091 0.042 0.032 1.000 0.720 0.092 0.046 0.046 1.000 0.513 
36 rs2207139 0.039 0.077 0.611 0.020 0.061 0.741 0.022 0.061 0.721 -0.045 0.062 0.469 0.007 0.032 0.840 1.000 0.806 -3.65E-04 0.035 0.992 1.000 0.683 
37 rs2287019 -0.006 0.071 0.931 0.033 0.053 0.533 0.037 0.049 0.449 0.010 0.057 0.857 0.023 0.028 0.415 1.000 0.953 0.028 0.030 0.355 1.000 0.932 
38 rs2365389 0.127 0.080 0.114 -0.047 0.060 0.434 -0.036 0.062 0.563 -0.030 0.063 0.638 -0.011 0.033 0.743 1.000 0.313 -0.038 0.036 0.289 1.000 0.978 
39 rs2820292 -4.85E-04 0.068 0.994 -0.071 0.055 0.194 -0.003 0.049 0.946 -0.056 0.053 0.284 -0.034 0.028 0.211 1.000 0.735 -0.041 0.030 0.172 1.000 0.614 
40 rs2836754 0.004 0.059 0.945 -0.064 0.043 0.136 0.033 0.040 0.404 0.031 0.045 0.484 0.002 0.023 0.943 1.000 0.331 0.001 0.024 0.961 1.000 0.181 
41 rs29941 0.050 0.072 0.484 -0.025 0.050 0.618 0.006 0.049 0.902 0.038 0.053 0.474 0.012 0.027 0.667 1.000 0.782 0.005 0.029 0.857 1.000 0.689 
42 rs3101336 -0.087 0.108 0.418 -0.057 0.077 0.459 -0.045 0.069 0.515 -0.031 0.081 0.705 -0.051 0.040 0.208 1.000 0.979 -0.045 0.044 0.303 1.000 0.972 
43 rs3817334 -0.050 0.062 0.422 -0.008 0.046 0.861 0.004 0.044 0.925 -0.017 0.048 0.722 -0.013 0.024 0.590 1.000 0.914 -0.006 0.026 0.809 1.000 0.947 
44 rs3849570 0.037 0.056 0.508 0.038 0.042 0.376 -0.031 0.039 0.415 -0.052 0.043 0.225 -0.008 0.022 0.716 1.000 0.358 -0.016 0.024 0.500 1.000 0.291 
45 rs3888190 -0.102 0.099 0.301 -0.024 0.075 0.754 -0.029 0.069 0.671 0.032 0.076 0.674 -0.023 0.039 0.552 1.000 0.760 -0.009 0.042 0.838 1.000 0.813 
46 rs4256980 0.073 0.060 0.222 0.018 0.042 0.664 -0.023 0.040 0.557 -0.041 0.043 0.347 -0.003 0.022 0.895 1.000 0.408 -0.015 0.024 0.525 1.000 0.602 
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Table 45 (continued): Association between 64 SNPs and %MFA intake 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
47 rs4740619 -0.116 0.064 0.071 -0.053 0.049 0.280 0.036 0.044 0.414 0.012 0.051 0.820 -0.018 0.025 0.488 1.000 0.197 0.001 0.028 0.977 1.000 0.390 
48 rs4787491 0.056 0.058 0.329 0.009 0.041 0.827 0.018 0.040 0.649 -0.014 0.043 0.744 0.013 0.022 0.566 1.000 0.805 0.005 0.024 0.827 1.000 0.855 
49 rs492400 -0.003 0.072 0.962 -0.053 0.051 0.296 -0.019 0.047 0.689 -0.021 0.051 0.681 -0.027 0.026 0.315 1.000 0.937 -0.030 0.028 0.288 1.000 0.862 
50 rs6567160 0.049 0.078 0.528 0.036 0.055 0.517 0.141 0.053 0.008 0.031 0.059 0.594 0.069 0.029 0.019 1.000 0.438 0.073 0.032 0.022 1.000 0.268 
51 rs6804842 0.028 0.060 0.643 0.023 0.045 0.614 0.049 0.042 0.242 -0.067 0.044 0.128 0.007 0.023 0.779 1.000 0.252 0.003 0.025 0.914 1.000 0.140 
52 rs7138803 -0.081 0.066 0.225 0.069 0.048 0.152 0.006 0.044 0.884 -0.012 0.050 0.805 0.006 0.025 0.802 1.000 0.315 0.021 0.027 0.442 1.000 0.463 
53 rs7141420 -0.027 0.056 0.632 0.016 0.042 0.707 0.047 0.039 0.231 0.062 0.042 0.139 0.032 0.022 0.147 1.000 0.593 0.042 0.024 0.076 1.000 0.729 
54 rs7164727 -0.096 0.066 0.147 -0.030 0.048 0.531 -0.004 0.045 0.925 0.064 0.048 0.184 -0.006 0.025 0.812 1.000 0.238 0.009 0.027 0.734 1.000 0.357 
55 rs7239883 0.002 0.062 0.975 -0.007 0.045 0.883 0.021 0.042 0.618 -0.070 0.046 0.131 -0.013 0.024 0.578 1.000 0.522 -0.016 0.025 0.539 1.000 0.336 
56 rs7243357 0.108 0.069 0.115 -0.020 0.051 0.697 4.42E-05 0.052 0.999 -0.020 0.052 0.697 0.006 0.027 0.831 1.000 0.433 -0.013 0.030 0.652 1.000 0.951 
57 rs7599312 0.135 0.216 0.533 -0.017 0.156 0.911 -0.071 0.120 0.555 -0.106 0.151 0.485 -0.042 0.075 0.578 1.000 0.818 -0.066 0.080 0.409 1.000 0.919 
58 rs7715256 -0.237 0.149 0.111 -0.036 0.113 0.750 0.026 0.111 0.818 0.045 0.109 0.680 -0.027 0.059 0.649 1.000 0.446 0.012 0.064 0.846 1.000 0.866 
59 rs7903146 0.142 0.195 0.468 -0.246 0.132 0.062 -0.105 0.140 0.452 -0.042 0.144 0.773 -0.098 0.074 0.187 1.000 0.402 -0.138 0.080 0.085 1.000 0.556 
60 rs9374842 -0.198 0.105 0.060 0.078 0.072 0.276 -0.028 0.069 0.682 -9.24E-05 0.075 0.999 -0.013 0.039 0.739 1.000 0.186 0.016 0.041 0.699 1.000 0.547 
61 rs9400239 0.099 0.063 0.114 -0.009 0.046 0.849 -0.048 0.043 0.259 0.037 0.048 0.449 0.006 0.024 0.801 1.000 0.228 -0.010 0.026 0.695 1.000 0.420 
62 rs9641123 0.039 0.062 0.526 0.037 0.045 0.413 0.051 0.042 0.221 -0.044 0.046 0.340 0.020 0.023 0.386 1.000 0.435 0.017 0.025 0.499 1.000 0.269 
63 rs977747 -0.123 0.156 0.429 -0.098 0.108 0.366 -0.065 0.104 0.532 -0.030 0.097 0.758 -0.070 0.055 0.210 1.000 0.949 -0.062 0.059 0.298 1.000 0.896 
64 rs9914578 0.059 0.070 0.399 -0.007 0.051 0.896 0.035 0.050 0.486 -0.004 0.055 0.949 0.017 0.027 0.538 1.000 0.840 0.009 0.030 0.758 1.000 0.814 




After meta-analysis, nominal significance were found between rs11030104 on BDNF 
(β=-0.049, SE=0.022, P=0.026), rs11126666 on KCNK3 (β=-0.063, SE=0.024, 
P=0.010), rs17203016 on CREB1 (β=-0.108, SE=0.032, P=0.001), rs2080454 on 
CBLN1 (β=0.052, SE=0.023, P=0.022) and rs9374842 on LOC285762 (β=-0.089, 
SE=0.040, P=0.024) and intake of %PFA (Table 46).  BMI risk allele A of 
rs11030104, A of rs11126666, G of rs17203016 and T of rs9374842 would decrease 
while C of rs2080454 would increase intake of %PFA. 
 
6.3.6.10 %Carbohydrate 
After meta-analysis, nominal significance were found between rs11126666 on 
KCNK3 (β=0.070, SE=0.024, P=0.003) and rs3101336 on NEGR1 (β=0.089, 
SE=0.040, P=0.026) and intake of %carbohydrate (Table 47).  BMI risk allele A of 
rs11126666 and C of rs3101336 were all positively associated with %carbohydrate 
intake. 
 
6.3.7 Interaction between 64 SNPs and dietary intake for BMI 
We tested each of the 64 BMI risk loci for interaction with various dietary 




Table 46: Association between 64 SNPs and %PFA intake 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
1 rs1000940 0.008 0.059 0.897 0.023 0.044 0.600 -0.045 0.041 0.271 -0.073 0.046 0.113 -0.025 0.023 0.271 1.000 0.421 -0.031 0.025 0.211 1.000 0.294 
2 rs1016287 -0.030 0.063 0.638 0.055 0.048 0.247 -0.048 0.048 0.318 0.012 0.049 0.803 0.001 0.026 0.978 1.000 0.454 0.007 0.028 0.812 1.000 0.310 
3 rs10182181 0.089 0.058 0.124 0.036 0.043 0.410 0.029 0.041 0.487 -0.003 0.044 0.940 0.031 0.023 0.167 1.000 0.651 0.021 0.025 0.399 1.000 0.796 
4 rs10733682 0.040 0.065 0.537 -0.017 0.051 0.733 -0.040 0.046 0.391 -0.018 0.054 0.737 -0.015 0.026 0.561 1.000 0.799 -0.026 0.029 0.362 1.000 0.934 
5 rs10938397 0.067 0.064 0.298 -0.015 0.048 0.760 -0.011 0.046 0.805 -0.170 0.050 0.001 -0.040 0.025 0.113 1.000 0.018 -0.060 0.028 0.030 1.000 0.034 
6 rs10968576 -0.006 0.077 0.940 0.004 0.057 0.947 0.002 0.053 0.967 0.027 0.059 0.648 0.008 0.030 0.795 1.000 0.985 0.010 0.032 0.753 1.000 0.943 
7 rs11030104 -0.058 0.056 0.298 -0.102 0.041 0.014 -0.053 0.040 0.188 0.020 0.043 0.650 -0.049 0.022 0.026 1.000 0.241 -0.047 0.024 0.049 1.000 0.125 
8 rs11126666 -0.112 0.061 0.068 -0.100 0.046 0.028 -0.030 0.045 0.498 -0.027 0.048 0.569 -0.063 0.024 0.010 0.640 0.498 -0.053 0.027 0.045 1.000 0.448 
9 rs11191560 0.047 0.066 0.477 -0.004 0.048 0.939 -0.028 0.045 0.528 0.020 0.051 0.700 0.002 0.026 0.947 1.000 0.788 -0.006 0.028 0.821 1.000 0.778 
10 rs11583200 0.141 0.094 0.133 -0.049 0.078 0.526 -0.052 0.076 0.494 -0.121 0.086 0.159 -0.030 0.041 0.469 1.000 0.204 -0.071 0.046 0.123 1.000 0.785 
11 rs11688816 0.109 0.062 0.081 0.061 0.047 0.199 -0.014 0.044 0.751 -0.030 0.049 0.535 0.021 0.025 0.386 1.000 0.218 0.005 0.027 0.848 1.000 0.350 
12 rs12286929 -0.073 0.068 0.284 -0.002 0.047 0.961 -0.026 0.046 0.569 0.024 0.049 0.629 -0.012 0.025 0.624 1.000 0.689 -0.003 0.027 0.924 1.000 0.759 
13 rs12429545 -0.003 0.068 0.962 0.035 0.047 0.461 -0.009 0.047 0.845 0.045 0.053 0.398 0.018 0.026 0.487 1.000 0.846 0.022 0.028 0.439 1.000 0.706 
14 rs12566985 -0.176 0.073 0.016 0.105 0.055 0.058 0.024 0.053 0.652 0.005 0.059 0.937 0.010 0.029 0.741 1.000 0.024 0.045 0.032 0.157 1.000 0.406 
15 rs12940622 -0.056 0.062 0.362 0.082 0.047 0.078 0.038 0.044 0.386 -0.017 0.047 0.720 0.021 0.024 0.389 1.000 0.252 0.035 0.026 0.184 1.000 0.326 
16 rs13021737 0.032 0.113 0.780 0.064 0.081 0.426 -0.085 0.075 0.259 0.119 0.088 0.177 0.024 0.043 0.584 1.000 0.320 0.022 0.047 0.633 1.000 0.173 
17 rs13201877 -0.244 0.181 0.178 -0.141 0.106 0.183 -0.002 0.104 0.988 -0.098 0.115 0.391 -0.096 0.059 0.103 1.000 0.644 -0.079 0.062 0.208 1.000 0.630 
18 rs1441264 0.005 0.060 0.938 -0.100 0.043 0.022 0.026 0.041 0.518 -0.027 0.045 0.554 -0.026 0.023 0.264 1.000 0.185 -0.031 0.025 0.214 1.000 0.104 
19 rs1460676 -0.011 0.059 0.848 0.038 0.045 0.401 -0.008 0.041 0.854 0.051 0.045 0.257 0.019 0.023 0.405 1.000 0.713 0.025 0.025 0.323 1.000 0.591 
20 rs1516725 -0.030 0.105 0.773 -0.013 0.084 0.879 0.037 0.072 0.610 -0.071 0.083 0.391 -0.014 0.042 0.743 1.000 0.802 -0.011 0.046 0.817 1.000 0.617 
21 rs1528435 0.002 0.062 0.976 -0.014 0.045 0.759 -0.040 0.043 0.357 0.014 0.047 0.769 -0.012 0.024 0.611 1.000 0.856 -0.015 0.026 0.572 1.000 0.701 
22 rs1558902 0.011 0.082 0.894 -0.014 0.063 0.821 -0.042 0.063 0.507 -0.025 0.071 0.726 -0.021 0.034 0.551 1.000 0.964 -0.027 0.038 0.472 1.000 0.952 
23 rs16851483 -0.009 0.064 0.889 0.058 0.049 0.241 0.045 0.046 0.333 0.042 0.052 0.414 0.039 0.026 0.131 1.000 0.868 0.048 0.028 0.087 1.000 0.971 
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Table 46 (continued): Association between 64 SNPs and %PFA intake 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
24 rs16951275 -3.04E-04 0.060 0.996 -0.018 0.042 0.664 0.019 0.041 0.641 0.027 0.045 0.549 0.007 0.023 0.748 1.000 0.882 0.009 0.024 0.728 1.000 0.725 
25 rs17203016 -0.183 0.086 0.033 0.060 0.062 0.332 -0.119 0.057 0.035 -0.226 0.063 3.30E-04 -0.108 0.032 0.001 0.064 0.008 -0.095 0.035 0.006 0.384 0.004 
26 rs17405819 -0.015 0.059 0.806 0.006 0.043 0.898 -0.001 0.041 0.989 0.023 0.044 0.609 0.005 0.023 0.821 1.000 0.962 0.009 0.025 0.728 1.000 0.925 
27 rs17724992 -0.027 0.056 0.634 0.059 0.043 0.173 0.017 0.040 0.671 -0.027 0.044 0.546 0.010 0.022 0.650 1.000 0.488 0.017 0.024 0.483 1.000 0.384 
28 rs1928295 -0.033 0.058 0.573 -0.114 0.044 0.009 -0.035 0.040 0.377 0.077 0.045 0.089 -0.028 0.023 0.219 1.000 0.025 -0.027 0.025 0.273 1.000 0.009 
29 rs2033529 0.009 0.084 0.916 0.080 0.059 0.176 -0.091 0.052 0.077 0.024 0.059 0.680 -0.003 0.030 0.929 1.000 0.162 -0.004 0.032 0.891 1.000 0.078 
30 rs2033732 0.042 0.057 0.460 -0.027 0.044 0.543 -0.063 0.041 0.126 0.029 0.044 0.517 -0.012 0.023 0.595 1.000 0.334 -0.023 0.025 0.366 1.000 0.314 
31 rs205262 -0.035 0.077 0.649 -0.027 0.061 0.658 -0.039 0.060 0.512 -0.122 0.064 0.057 -0.056 0.032 0.083 1.000 0.696 -0.060 0.036 0.089 1.000 0.510 
32 rs2075650 -0.195 0.106 0.066 0.062 0.078 0.429 -0.035 0.071 0.622 -0.010 0.079 0.897 -0.026 0.040 0.522 1.000 0.278 0.003 0.044 0.947 1.000 0.644 
33 rs2080454 0.057 0.060 0.340 0.062 0.043 0.148 0.039 0.040 0.332 0.053 0.044 0.232 0.052 0.023 0.022 1.000 0.983 0.051 0.024 0.038 1.000 0.924 
34 rs2112347 -0.089 0.056 0.116 0.008 0.043 0.852 -0.007 0.040 0.856 -0.057 0.044 0.200 -0.029 0.023 0.200 1.000 0.468 -0.018 0.025 0.475 1.000 0.548 
35 rs2176040 0.092 0.110 0.400 -0.012 0.084 0.888 0.062 0.079 0.427 -0.111 0.084 0.186 0.001 0.043 0.989 1.000 0.374 -0.016 0.047 0.728 1.000 0.319 
36 rs2207139 0.108 0.078 0.165 0.094 0.062 0.129 0.078 0.063 0.214 -0.056 0.065 0.393 0.054 0.033 0.105 1.000 0.273 0.041 0.036 0.256 1.000 0.193 
37 rs2287019 -0.008 0.072 0.908 0.024 0.054 0.660 0.044 0.051 0.382 0.117 0.059 0.047 0.047 0.029 0.099 1.000 0.531 0.058 0.031 0.064 1.000 0.475 
38 rs2365389 0.132 0.081 0.102 -0.078 0.062 0.204 -0.054 0.064 0.397 0.016 0.065 0.812 -0.011 0.033 0.741 1.000 0.175 -0.041 0.037 0.268 1.000 0.560 
39 rs2820292 0.043 0.069 0.532 -0.150 0.056 0.008 0.015 0.051 0.773 -0.044 0.055 0.424 -0.038 0.028 0.178 1.000 0.092 -0.055 0.031 0.079 1.000 0.091 
40 rs2836754 -0.031 0.059 0.601 -0.035 0.044 0.422 0.008 0.041 0.846 0.042 0.046 0.369 -0.002 0.023 0.945 1.000 0.623 0.004 0.025 0.883 1.000 0.479 
41 rs29941 0.076 0.073 0.297 -0.017 0.051 0.747 -0.063 0.050 0.211 0.024 0.055 0.660 -0.007 0.028 0.810 1.000 0.408 -0.021 0.030 0.488 1.000 0.501 
42 rs3101336 -0.117 0.108 0.281 -0.181 0.079 0.021 0.077 0.072 0.283 -0.064 0.084 0.447 -0.057 0.041 0.167 1.000 0.097 -0.047 0.045 0.294 1.000 0.051 
43 rs3817334 0.010 0.062 0.878 0.026 0.047 0.576 0.023 0.045 0.614 0.007 0.049 0.880 0.018 0.025 0.476 1.000 0.991 0.019 0.027 0.477 1.000 0.958 
44 rs3849570 -0.029 0.057 0.610 0.048 0.043 0.266 0.014 0.040 0.719 -0.029 0.045 0.510 0.006 0.022 0.803 1.000 0.573 0.012 0.024 0.623 1.000 0.459 
45 rs3888190 -0.042 0.100 0.674 0.003 0.076 0.966 -0.029 0.071 0.681 0.057 0.079 0.470 -0.001 0.040 0.990 1.000 0.833 0.007 0.043 0.865 1.000 0.717 
46 rs4256980 -0.049 0.060 0.418 0.017 0.043 0.701 0.014 0.041 0.740 0.061 0.045 0.176 0.018 0.023 0.439 1.000 0.541 0.029 0.025 0.242 1.000 0.696 
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Table 46 (continued): Association between 64 SNPs and %PFA intake 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
47 rs4740619 -0.098 0.064 0.130 -0.003 0.050 0.945 -0.017 0.046 0.709 0.012 0.053 0.827 -0.020 0.026 0.451 1.000 0.590 -0.004 0.029 0.877 1.000 0.920 
48 rs4787491 0.045 0.058 0.435 0.016 0.041 0.696 0.040 0.041 0.329 0.002 0.044 0.969 0.024 0.022 0.284 1.000 0.903 0.020 0.024 0.405 1.000 0.813 
49 rs492400 -0.126 0.072 0.081 -0.024 0.052 0.635 -0.006 0.048 0.902 -0.052 0.053 0.328 -0.040 0.027 0.138 1.000 0.561 -0.026 0.029 0.374 1.000 0.816 
50 rs6567160 0.146 0.078 0.063 0.003 0.056 0.951 0.022 0.055 0.682 0.031 0.061 0.607 0.037 0.030 0.216 1.000 0.499 0.018 0.033 0.575 1.000 0.941 
51 rs6804842 0.035 0.060 0.560 0.008 0.046 0.857 0.093 0.044 0.032 -0.081 0.046 0.077 0.014 0.024 0.570 1.000 0.051 0.010 0.026 0.713 1.000 0.022 
52 rs7138803 -0.180 0.067 0.007 0.066 0.049 0.174 -0.021 0.046 0.647 0.016 0.052 0.751 -0.011 0.026 0.672 1.000 0.026 0.019 0.028 0.500 1.000 0.427 
53 rs7141420 -0.017 0.057 0.761 -0.034 0.043 0.429 -0.021 0.041 0.598 0.027 0.043 0.531 -0.011 0.022 0.616 1.000 0.768 -0.010 0.024 0.677 1.000 0.570 
54 rs7164727 -0.116 0.067 0.082 0.116 0.048 0.016 0.070 0.047 0.132 0.014 0.050 0.782 0.041 0.026 0.115 1.000 0.034 0.068 0.028 0.015 0.960 0.335 
55 rs7239883 -0.090 0.062 0.150 0.014 0.046 0.752 0.043 0.043 0.315 0.013 0.048 0.784 0.007 0.024 0.756 1.000 0.366 0.025 0.026 0.345 1.000 0.863 
56 rs7243357 -0.047 0.069 0.494 -0.016 0.051 0.757 0.020 0.054 0.714 -0.016 0.054 0.774 -0.011 0.028 0.687 1.000 0.892 -0.004 0.031 0.890 1.000 0.863 
57 rs7599312 0.283 0.218 0.195 0.163 0.158 0.302 0.101 0.124 0.415 -0.146 0.157 0.353 0.079 0.077 0.309 1.000 0.356 0.049 0.083 0.551 1.000 0.326 
58 rs7715256 -0.164 0.150 0.275 -0.068 0.115 0.555 -0.100 0.114 0.381 -0.011 0.114 0.922 -0.077 0.060 0.205 1.000 0.869 -0.060 0.066 0.367 1.000 0.856 
59 rs7903146 -0.066 0.197 0.737 -0.139 0.134 0.299 -0.225 0.144 0.119 -0.002 0.151 0.989 -0.117 0.076 0.122 1.000 0.746 -0.126 0.082 0.125 1.000 0.563 
60 rs9374842 -0.319 0.106 0.003 -0.089 0.073 0.223 -0.059 0.071 0.406 -0.002 0.078 0.984 -0.089 0.040 0.024 1.000 0.104 -0.052 0.043 0.222 1.000 0.710 
61 rs9400239 0.043 0.064 0.500 -0.025 0.047 0.593 -0.017 0.044 0.699 -0.003 0.050 0.952 -0.007 0.025 0.788 1.000 0.844 -0.016 0.027 0.563 1.000 0.949 
62 rs9641123 0.067 0.062 0.282 -0.010 0.046 0.835 0.028 0.043 0.521 -0.044 0.047 0.356 0.005 0.024 0.843 1.000 0.489 -0.006 0.026 0.812 1.000 0.535 
63 rs977747 -0.062 0.157 0.695 -0.087 0.110 0.424 -0.016 0.107 0.881 0.073 0.101 0.469 -0.013 0.057 0.820 1.000 0.732 -0.006 0.061 0.927 1.000 0.555 
64 rs9914578 0.103 0.070 0.141 0.052 0.052 0.314 -0.003 0.051 0.957 0.004 0.057 0.951 0.032 0.028 0.254 1.000 0.594 0.018 0.031 0.551 1.000 0.717 





Table 47: Association between 64 SNPs and %Carbohydrate intake 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
1 rs1000940 -0.035 0.059 0.552 -0.049 0.043 0.262 -0.028 0.039 0.468 0.027 0.044 0.537 -0.020 0.022 0.365 1.000 0.637 -0.018 0.024 0.462 1.000 0.443 
2 rs1016287 -0.015 0.062 0.815 -0.025 0.047 0.589 0.037 0.046 0.417 -0.008 0.047 0.856 -0.001 0.025 0.974 1.000 0.792 0.002 0.027 0.948 1.000 0.612 
3 rs10182181 -0.081 0.057 0.154 0.031 0.043 0.470 -0.013 0.039 0.742 0.028 0.042 0.506 -3.74E-04 0.022 0.986 1.000 0.375 0.014 0.024 0.561 1.000 0.692 
4 rs10733682 -0.050 0.064 0.434 -0.028 0.050 0.580 0.063 0.044 0.153 0.001 0.052 0.992 0.006 0.026 0.806 1.000 0.406 0.017 0.028 0.544 1.000 0.371 
5 rs10938397 -0.056 0.063 0.374 0.044 0.047 0.348 0.048 0.044 0.273 0.087 0.048 0.070 0.041 0.024 0.091 1.000 0.347 0.059 0.027 0.027 1.000 0.777 
6 rs10968576 0.014 0.075 0.854 -0.035 0.056 0.529 -0.042 0.050 0.399 0.023 0.056 0.679 -0.015 0.029 0.598 1.000 0.792 -0.020 0.031 0.518 1.000 0.650 
7 rs11030104 0.008 0.055 0.889 0.064 0.041 0.117 -0.024 0.038 0.533 -0.027 0.041 0.514 0.004 0.021 0.851 1.000 0.354 0.003 0.023 0.885 1.000 0.197 
8 rs11126666 0.140 0.060 0.020 0.055 0.045 0.223 0.058 0.043 0.178 0.059 0.046 0.197 0.070 0.024 0.003 0.192 0.658 0.057 0.026 0.026 1.000 0.998 
9 rs11191560 -0.068 0.065 0.290 0.015 0.048 0.745 0.023 0.042 0.587 0.036 0.049 0.461 0.011 0.025 0.652 1.000 0.602 0.025 0.027 0.356 1.000 0.955 
10 rs11583200 -0.083 0.092 0.370 0.131 0.077 0.089 0.037 0.072 0.610 0.089 0.082 0.277 0.052 0.040 0.190 1.000 0.329 0.083 0.044 0.060 1.000 0.666 
11 rs11688816 -0.027 0.062 0.667 -0.008 0.047 0.855 0.038 0.042 0.367 0.021 0.046 0.653 0.012 0.024 0.627 1.000 0.802 0.018 0.026 0.479 1.000 0.760 
12 rs12286929 0.052 0.067 0.434 -0.037 0.047 0.425 -0.004 0.044 0.924 -0.044 0.047 0.345 -0.017 0.025 0.494 1.000 0.641 -0.028 0.026 0.297 1.000 0.798 
13 rs12429545 -0.029 0.067 0.670 0.013 0.046 0.784 -0.023 0.045 0.612 0.041 0.051 0.417 0.003 0.025 0.915 1.000 0.762 0.008 0.027 0.772 1.000 0.635 
14 rs12566985 5.90E-05 0.072 0.999 -0.112 0.054 0.039 -0.057 0.050 0.254 0.067 0.056 0.231 -0.031 0.028 0.267 1.000 0.124 -0.037 0.031 0.228 1.000 0.063 
15 rs12940622 0.058 0.061 0.339 -0.034 0.046 0.453 -0.059 0.041 0.154 -0.014 0.045 0.755 -0.023 0.023 0.325 1.000 0.449 -0.037 0.025 0.142 1.000 0.761 
16 rs13021737 -0.025 0.111 0.818 -0.130 0.079 0.100 -0.042 0.072 0.560 -0.096 0.084 0.252 -0.078 0.042 0.062 1.000 0.812 -0.086 0.045 0.055 1.000 0.707 
17 rs13201877 0.245 0.178 0.170 -0.069 0.104 0.510 -0.015 0.100 0.883 0.122 0.109 0.265 0.033 0.057 0.564 1.000 0.354 0.009 0.060 0.884 1.000 0.431 
18 rs1441264 0.010 0.059 0.866 0.038 0.043 0.377 -0.039 0.038 0.317 0.039 0.043 0.360 0.009 0.022 0.676 1.000 0.480 0.009 0.024 0.702 1.000 0.290 
19 rs1460676 -0.019 0.058 0.748 -0.043 0.044 0.323 0.010 0.039 0.807 -0.030 0.043 0.494 -0.019 0.022 0.402 1.000 0.824 -0.019 0.024 0.439 1.000 0.636 
20 rs1516725 0.121 0.103 0.239 -0.044 0.083 0.598 -0.070 0.068 0.303 0.049 0.079 0.533 -0.003 0.040 0.932 1.000 0.375 -0.026 0.044 0.552 1.000 0.503 
21 rs1528435 -0.061 0.061 0.322 -0.060 0.044 0.172 0.011 0.041 0.794 -0.037 0.044 0.408 -0.032 0.023 0.170 1.000 0.631 -0.027 0.025 0.281 1.000 0.482 
22 rs1558902 -0.007 0.080 0.927 -0.055 0.062 0.377 0.026 0.060 0.660 -0.010 0.068 0.883 -0.011 0.033 0.735 1.000 0.828 -0.012 0.036 0.742 1.000 0.641 
23 rs16851483 0.054 0.063 0.391 -0.065 0.048 0.177 -0.003 0.044 0.953 -0.020 0.049 0.679 -0.015 0.025 0.550 1.000 0.498 -0.028 0.027 0.308 1.000 0.619 
171 
 
Table 47 (continued): Association between 64 SNPs and %Carbohydrate intake 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
24 rs16951275 0.038 0.059 0.514 0.016 0.041 0.696 -0.011 0.039 0.780 -0.014 0.043 0.735 0.003 0.022 0.902 1.000 0.860 -0.003 0.024 0.897 1.000 0.848 
25 rs17203016 0.081 0.085 0.338 0.035 0.061 0.569 -0.027 0.054 0.613 0.021 0.060 0.721 0.017 0.031 0.592 1.000 0.719 0.007 0.033 0.843 1.000 0.716 
26 rs17405819 0.077 0.058 0.183 -0.025 0.043 0.549 -0.060 0.039 0.120 0.010 0.042 0.812 -0.012 0.022 0.571 1.000 0.231 -0.027 0.024 0.247 1.000 0.472 
27 rs17724992 0.007 0.056 0.904 -0.031 0.043 0.463 -0.040 0.038 0.290 0.033 0.042 0.430 -0.011 0.022 0.596 1.000 0.569 -0.015 0.023 0.531 1.000 0.389 
28 rs1928295 -0.004 0.057 0.949 0.022 0.043 0.606 -0.029 0.038 0.442 -0.051 0.043 0.235 -0.018 0.022 0.418 1.000 0.656 -0.020 0.024 0.395 1.000 0.462 
29 rs2033529 -0.048 0.082 0.561 -0.055 0.058 0.344 0.122 0.049 0.013 -0.052 0.056 0.353 0.009 0.029 0.760 1.000 0.042 0.017 0.031 0.585 1.000 0.022 
30 rs2033732 0.008 0.056 0.881 0.017 0.044 0.692 -0.033 0.039 0.402 0.077 0.042 0.066 0.017 0.022 0.450 1.000 0.296 0.018 0.024 0.449 1.000 0.159 
31 rs205262 0.036 0.076 0.634 0.078 0.060 0.190 0.007 0.057 0.896 0.115 0.061 0.060 0.059 0.031 0.056 1.000 0.604 0.064 0.034 0.060 1.000 0.420 
32 rs2075650 0.140 0.104 0.180 0.087 0.077 0.258 -0.012 0.067 0.858 -0.114 0.075 0.129 0.007 0.039 0.853 1.000 0.145 -0.014 0.042 0.732 1.000 0.173 
33 rs2080454 -0.035 0.059 0.547 -0.034 0.042 0.415 0.031 0.038 0.420 -0.006 0.042 0.884 -0.006 0.022 0.795 1.000 0.652 -0.001 0.024 0.969 1.000 0.512 
34 rs2112347 0.017 0.056 0.760 0.024 0.042 0.577 0.014 0.038 0.720 0.001 0.042 0.982 0.013 0.022 0.535 1.000 0.985 0.013 0.024 0.586 1.000 0.930 
35 rs2176040 0.017 0.108 0.874 -0.082 0.082 0.317 -0.092 0.075 0.217 0.014 0.080 0.864 -0.044 0.042 0.293 1.000 0.687 -0.055 0.045 0.228 1.000 0.577 
36 rs2207139 -0.052 0.076 0.493 -0.015 0.061 0.806 -0.008 0.060 0.887 0.021 0.062 0.731 -0.010 0.032 0.754 1.000 0.903 -0.001 0.035 0.976 1.000 0.906 
37 rs2287019 0.048 0.070 0.492 -0.048 0.053 0.367 -0.057 0.048 0.238 -0.043 0.056 0.447 -0.035 0.028 0.209 1.000 0.641 -0.050 0.030 0.097 1.000 0.981 
38 rs2365389 -0.079 0.079 0.323 0.094 0.061 0.123 -0.044 0.061 0.464 0.007 0.062 0.906 0.003 0.032 0.926 1.000 0.271 0.019 0.035 0.589 1.000 0.266 
39 rs2820292 0.002 0.068 0.979 0.084 0.055 0.127 -0.012 0.048 0.795 0.023 0.052 0.654 0.023 0.027 0.393 1.000 0.601 0.027 0.030 0.357 1.000 0.418 
40 rs2836754 0.023 0.058 0.692 0.049 0.043 0.260 0.007 0.039 0.850 -0.037 0.044 0.396 0.009 0.022 0.679 1.000 0.569 0.007 0.024 0.777 1.000 0.377 
41 rs29941 -0.094 0.071 0.188 0.029 0.050 0.569 0.041 0.048 0.387 -0.031 0.052 0.548 -4.10E-04 0.027 0.988 1.000 0.366 0.015 0.029 0.606 1.000 0.557 
42 rs3101336 0.157 0.107 0.143 0.169 0.077 0.028 0.020 0.068 0.771 0.059 0.080 0.465 0.089 0.040 0.026 1.000 0.445 0.078 0.043 0.072 1.000 0.334 
43 rs3817334 0.070 0.061 0.256 -0.011 0.046 0.818 -0.048 0.043 0.266 -0.016 0.047 0.725 -0.011 0.024 0.633 1.000 0.480 -0.026 0.026 0.317 1.000 0.815 
44 rs3849570 -0.030 0.056 0.597 -0.036 0.042 0.397 0.014 0.038 0.705 0.014 0.042 0.750 -0.006 0.022 0.795 1.000 0.759 -0.001 0.023 0.953 1.000 0.619 
45 rs3888190 0.089 0.098 0.365 0.036 0.075 0.627 0.047 0.067 0.482 0.001 0.075 0.987 0.039 0.038 0.311 1.000 0.913 0.03 0.042 0.474 1.000 0.896 
46 rs4256980 -0.043 0.059 0.468 0.026 0.042 0.544 0.022 0.039 0.566 -0.019 0.043 0.656 0.003 0.022 0.887 1.000 0.705 0.011 0.024 0.658 1.000 0.704 
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Table 47 (continued): Association between 64 SNPs and %Carbohydrate intake 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
47 rs4740619 0.167 0.063 0.008 0.048 0.049 0.333 -0.018 0.043 0.685 -0.048 0.051 0.340 0.021 0.025 0.405 1.000 0.040 -0.006 0.027 0.813 1.000 0.375 
48 rs4787491 0.013 0.057 0.817 0.009 0.041 0.819 -0.012 0.039 0.757 0.059 0.042 0.162 0.016 0.022 0.451 1.000 0.660 0.017 0.023 0.472 1.000 0.451 
49 rs492400 0.023 0.071 0.743 0.038 0.051 0.453 -0.009 0.046 0.852 -0.021 0.050 0.679 0.005 0.026 0.853 1.000 0.839 0.002 0.028 0.945 1.000 0.682 
50 rs6567160 -0.090 0.077 0.243 -0.008 0.055 0.879 -0.066 0.052 0.204 -0.022 0.058 0.700 -0.042 0.029 0.152 1.000 0.778 -0.034 0.031 0.284 1.000 0.726 
51 rs6804842 -0.090 0.059 0.131 -0.016 0.045 0.720 -0.067 0.041 0.104 0.088 0.043 0.042 -0.014 0.023 0.552 1.000 0.031 -2.31E-04 0.025 0.993 1.000 0.031 
52 rs7138803 0.132 0.066 0.047 -0.039 0.048 0.411 -0.001 0.044 0.973 0.031 0.049 0.523 0.016 0.025 0.530 1.000 0.199 -0.004 0.027 0.895 1.000 0.586 
53 rs7141420 0.016 0.056 0.769 -0.035 0.042 0.409 -0.007 0.038 0.849 -0.031 0.041 0.449 -0.018 0.022 0.415 1.000 0.870 -0.023 0.023 0.315 1.000 0.868 
54 rs7164727 0.126 0.065 0.054 -0.001 0.047 0.986 0.020 0.045 0.652 -0.064 0.047 0.177 0.007 0.025 0.791 1.000 0.128 -0.013 0.027 0.615 1.000 0.412 
55 rs7239883 0.005 0.061 0.940 -0.006 0.045 0.887 -0.040 0.041 0.321 0.035 0.045 0.441 -0.005 0.023 0.827 1.000 0.669 -0.007 0.025 0.790 1.000 0.465 
56 rs7243357 -0.060 0.068 0.378 -0.017 0.050 0.732 -0.056 0.051 0.273 -0.024 0.051 0.643 -0.037 0.027 0.174 1.000 0.925 -0.032 0.029 0.272 1.000 0.848 
57 rs7599312 -0.006 0.215 0.977 0.009 0.155 0.952 -0.024 0.117 0.836 0.171 0.149 0.252 0.034 0.074 0.646 1.000 0.765 0.040 0.079 0.617 1.000 0.574 
58 rs7715256 0.290 0.149 0.052 0.001 0.113 0.990 0.117 0.108 0.280 -0.020 0.108 0.856 0.073 0.058 0.209 1.000 0.330 0.034 0.063 0.593 1.000 0.632 
59 rs7903146 -0.188 0.194 0.331 0.176 0.132 0.180 0.200 0.137 0.143 0.109 0.142 0.446 0.113 0.073 0.121 1.000 0.382 0.164 0.079 0.038 1.000 0.891 
60 rs9374842 0.248 0.104 0.018 -0.060 0.071 0.399 0.040 0.067 0.552 -0.012 0.074 0.876 0.026 0.038 0.499 1.000 0.098 -0.009 0.041 0.835 1.000 0.592 
61 rs9400239 -0.112 0.062 0.072 0.026 0.046 0.573 0.047 0.042 0.263 0.014 0.048 0.770 0.009 0.024 0.701 1.000 0.190 0.031 0.026 0.241 1.000 0.868 
62 rs9641123 -0.075 0.061 0.219 -0.018 0.045 0.694 -0.020 0.041 0.622 0.013 0.045 0.772 -0.019 0.023 0.422 1.000 0.717 -0.009 0.025 0.717 1.000 0.839 
63 rs977747 0.119 0.154 0.443 0.205 0.107 0.057 0.075 0.102 0.464 0.004 0.096 0.965 0.091 0.055 0.096 1.000 0.572 0.087 0.059 0.137 1.000 0.374 
64 rs9914578 -0.040 0.069 0.566 0.007 0.051 0.898 -0.006 0.049 0.903 -0.005 0.054 0.932 -0.007 0.027 0.788 1.000 0.961 -0.001 0.030 0.963 1.000 0.982 
Q (Cochran’s Q test) was used to measure between-study heterogeneity.  Significant associations (Padjust < 0 .05) and heterogeneity (Qpvalue < 0.1) findings are in bold.
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Results are summarized and displayed in Table 48 to Table 58.  The interaction 
between %fat and rs205262 (C6orf106) (β=0.122, SE=0.033, adjusted 
Pinteraction=0.015), %SFA and rs11126666 (KCNK3) (β=-0.086, SE=0.025, adjusted 
Pinteraction=0.044) and cholesterol and rs4740619 (CCDC171) (β=0.094, SE=0.027, 
adjusted Pinteraction =0.047) on BMI remained significant after correction for multiple 
testing (P<0.0007=0.05/74 tests). 
 
6.3.7.1 Total calories 
Table 48 shows the interaction results between 64 SNPs and total calories intake on 
Z-BMI.  None of the interaction remained statistically significant after adjusting for 
multiple testing.  Nominal significant negative SNP × calories interaction on BMI 
was observed for GNPDA2 rs10938397 (β=-0.056, SE=0.026, Pinteraction=0.033) and 
NRXN3 rs7141420 (β=-0.057, SE=0.023, Pinteraction= 0.014).  The BMI level 
decreased as the number of reported BMI risk alleles and calories intake increased. 
 
6.3.7.2 Cholesterol 
Table 49 shows the interaction results between 64 SNPs and cholesterol intake on 
Z-BMI.  Nominal significant SNP × cholesterol interaction on BMI was observed 
for RABEP1 rs1000940 (β=-0.056, SE=0.024, Pinteraction=0.020), TDRG1 rs2033529 
(β=-0.092, SE=0.032, Pinteraction=0.004), C6orf106 rs205262 (β=0.080, SE=0.033, 
Pinteraction=0.017), ETS2 rs2836754 (β=-0.052, SE=0.024, Pinteraction=0.030) and NEGR1 
rs3101336 (β=-0.092, SE=0.042, Pinteraction=0.029).  In the case of rs205262, the 
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interaction term was found to be positively associated with Z-BMI.  Thus BMI level 
increased as the number of G allele and the intake of total calories increased.  For 
the rest SNPs, the interaction terms were negatively associated with Z-BMI so that 
the BMI level decreased as the number of reported BMI risk alleles and the intake of 
cholesterol increased. 
 
The interaction effect of CCDC171 rs4740619 with cholesterol was found to be 
significant on Z-BMI even after adjusting for multiple comparisons (β=0.094, 
SE=0.027, Pinteraction=6.40×10-4, adjusted Pinteraction =0.047).  The positive association 
between cholesterol intake and BMI tended to be stronger among individuals who are 
homozygous for the reported BMI risk allele T of CCDC171 rs4740619 as compared 
to individuals who have less copies of the T allele.  Figure 13 showed the 
association between rs4740619 and BMI depending on cholesterol intake using 
population mean as the cut-off (Mean ± SD: 216.33 ± 135.96 mg/day). 
 





















Table 48: Interaction between 64 SNPs and calories intake on BMI 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
1 rs1000940 0.091 0.064 0.153 0.044 0.045 0.329 0.040 0.042 0.342 -0.013 0.049 0.786 0.036 0.024 0.139 1.000 0.617 0.026 0.026 0.310 1.000 0.637 
2 rs1016287 0.131 0.061 0.033 -0.050 0.049 0.303 -0.027 0.052 0.604 0.030 0.052 0.570 0.010 0.027 0.693 1.000 0.108 -0.018 0.030 0.553 1.000 0.521 
3 rs10182181 4.03E-04 0.056 0.994 0.006 0.045 0.885 0.005 0.044 0.902 -0.045 0.045 0.323 -0.009 0.023 0.714 1.000 0.830 -0.010 0.026 0.684 1.000 0.654 
4 rs10733682 0.085 0.068 0.213 -0.081 0.053 0.125 0.003 0.047 0.942 -0.039 0.056 0.484 -0.016 0.027 0.553 1.000 0.255 -0.035 0.030 0.235 1.000 0.485 
5 rs10938397 0.004 0.066 0.957 -0.109 0.048 0.022 -0.037 0.049 0.451 -0.053 0.054 0.323 -0.056 0.026 0.033 1.000 0.529 -0.068 0.029 0.019 1.000 0.540 
6 rs10968576 0.011 0.075 0.882 -0.068 0.055 0.216 0.053 0.055 0.336 -0.136 0.062 0.028 -0.035 0.030 0.243 1.000 0.114 -0.044 0.033 0.180 1.000 0.064 
7 rs11030104 0.033 0.057 0.561 0.025 0.044 0.566 0.015 0.041 0.720 0.032 0.045 0.479 0.025 0.023 0.275 1.000 0.991 0.023 0.025 0.349 1.000 0.960 
8 rs11126666 0.073 0.062 0.236 0.005 0.047 0.922 -0.049 0.045 0.282 -0.045 0.050 0.361 -0.013 0.025 0.601 1.000 0.371 -0.030 0.027 0.273 1.000 0.670 
9 rs11191560 0.056 0.067 0.402 -0.047 0.052 0.370 -0.018 0.046 0.693 -0.092 0.054 0.085 -0.032 0.027 0.228 1.000 0.364 -0.048 0.029 0.093 1.000 0.572 
10 rs11583200 -0.012 0.097 0.905 -0.093 0.080 0.244 0.031 0.075 0.686 0.066 0.089 0.460 -0.004 0.042 0.930 1.000 0.557 -0.002 0.047 0.968 1.000 0.356 
11 rs11688816 -0.055 0.060 0.359 -0.025 0.047 0.605 -0.013 0.046 0.773 0.009 0.050 0.850 -0.018 0.025 0.473 1.000 0.870 -0.010 0.028 0.712 1.000 0.882 
12 rs12286929 0.042 0.064 0.511 -0.042 0.048 0.384 -0.124 0.049 0.011 -0.034 0.052 0.516 -0.049 0.026 0.060 1.000 0.214 -0.067 0.029 0.019 1.000 0.359 
13 rs12429545 -0.009 0.071 0.904 0.034 0.048 0.480 -0.039 0.046 0.404 0.046 0.055 0.402 0.007 0.026 0.785 1.000 0.606 0.010 0.028 0.732 1.000 0.410 
14 rs12566985 -0.052 0.081 0.524 0.055 0.056 0.326 -0.095 0.055 0.084 0.084 0.060 0.160 0.002 0.031 0.958 1.000 0.096 0.010 0.033 0.752 1.000 0.054 
15 rs12940622 0.058 0.060 0.338 -0.016 0.047 0.728 0.015 0.045 0.743 -0.075 0.051 0.142 -0.008 0.025 0.747 1.000 0.362 -0.021 0.027 0.431 1.000 0.414 
16 rs13021737 -0.085 0.093 0.359 0.027 0.087 0.760 0.009 0.075 0.907 0.016 0.088 0.859 -0.005 0.043 0.904 1.000 0.809 0.016 0.048 0.736 1.000 0.988 
17 rs13201877 -0.287 0.198 0.148 -0.139 0.106 0.193 -0.081 0.104 0.436 0.366 0.121 0.003 -0.007 0.060 0.907 1.000 0.004 0.022 0.063 0.733 1.000 0.003 
18 rs1441264 -0.036 0.058 0.531 0.021 0.045 0.641 0.057 0.042 0.176 -0.020 0.047 0.665 0.012 0.024 0.603 1.000 0.500 0.022 0.026 0.395 1.000 0.468 
19 rs1460676 -0.030 0.062 0.630 0.020 0.047 0.674 0.013 0.042 0.765 0.075 0.047 0.111 0.024 0.024 0.310 1.000 0.570 0.034 0.026 0.191 1.000 0.576 
20 rs1516725 0.045 0.099 0.652 0.033 0.087 0.700 0.137 0.079 0.084 0.085 0.087 0.327 0.080 0.044 0.066 1.000 0.816 0.088 0.048 0.068 1.000 0.677 
21 rs1528435 -0.030 0.062 0.631 0.023 0.046 0.623 0.036 0.044 0.412 0.003 0.047 0.946 0.014 0.024 0.578 1.000 0.839 0.022 0.027 0.418 1.000 0.877 
22 rs1558902 -0.051 0.089 0.569 1.45E-04 0.070 0.998 -0.050 0.067 0.453 0.110 0.077 0.154 0.001 0.037 0.976 1.000 0.404 0.012 0.041 0.768 1.000 0.285 
23 rs16851483 -0.027 0.060 0.659 -0.068 0.050 0.169 0.035 0.048 0.468 0.005 0.051 0.922 -0.012 0.026 0.644 1.000 0.492 -0.009 0.029 0.763 1.000 0.311 
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Table 48 (continued): Interaction between 64 SNPs and calories intake on BMI 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
24 rs16951275 -0.005 0.062 0.941 -0.007 0.043 0.876 -0.029 0.043 0.495 0.011 0.047 0.810 -0.009 0.024 0.710 1.000 0.937 -0.009 0.025 0.710 1.000 0.814 
25 rs17203016 0.173 0.088 0.049 0.009 0.062 0.888 0.061 0.061 0.318 -0.028 0.062 0.650 0.037 0.033 0.263 1.000 0.277 0.014 0.036 0.685 1.000 0.589 
26 rs17405819 0.033 0.062 0.593 -0.045 0.045 0.314 -0.096 0.042 0.024 0.015 0.049 0.764 -0.036 0.024 0.140 1.000 0.226 -0.048 0.026 0.068 1.000 0.232 
27 rs17724992 -0.043 0.056 0.443 0.094 0.045 0.035 -0.018 0.042 0.676 0.031 0.045 0.496 0.021 0.023 0.369 1.000 0.180 0.034 0.025 0.182 1.000 0.189 
28 rs1928295 0.039 0.059 0.515 -0.097 0.045 0.033 0.020 0.041 0.630 -0.008 0.048 0.870 -0.015 0.024 0.513 1.000 0.186 -0.026 0.026 0.319 1.000 0.147 
29 rs2033529 0.118 0.086 0.169 0.007 0.061 0.905 -0.072 0.055 0.192 0.029 0.060 0.630 0.002 0.032 0.938 1.000 0.279 -0.016 0.034 0.645 1.000 0.420 
30 rs2033732 0.066 0.057 0.248 0.026 0.045 0.565 -0.022 0.043 0.619 -0.001 0.047 0.982 0.012 0.024 0.617 1.000 0.644 0.001 0.026 0.982 1.000 0.749 
31 rs205262 -0.177 0.079 0.025 -0.043 0.060 0.474 0.106 0.060 0.077 0.095 0.066 0.151 0.011 0.032 0.729 1.000 0.014 0.05 0.036 0.161 1.000 0.153 
32 rs2075650 0.155 0.106 0.146 0.020 0.075 0.790 -0.049 0.073 0.507 -0.061 0.078 0.431 -0.003 0.040 0.941 1.000 0.355 -0.029 0.043 0.499 1.000 0.714 
33 rs2080454 0.024 0.060 0.683 0.033 0.044 0.455 -0.001 0.041 0.981 -0.040 0.044 0.359 0.001 0.023 0.954 1.000 0.668 -0.003 0.025 0.916 1.000 0.499 
34 rs2112347 -0.092 0.056 0.100 -0.048 0.045 0.283 0.072 0.041 0.083 -0.013 0.045 0.767 -0.010 0.023 0.678 1.000 0.079 0.007 0.025 0.775 1.000 0.124 
35 rs2176040 0.047 0.117 0.690 0.029 0.080 0.717 0.050 0.080 0.531 -0.111 0.087 0.201 0.002 0.044 0.962 1.000 0.509 -0.005 0.048 0.912 1.000 0.342 
36 rs2207139 0.065 0.084 0.438 0.010 0.065 0.874 0.007 0.066 0.911 -0.071 0.064 0.270 -0.004 0.034 0.897 1.000 0.605 -0.018 0.038 0.625 1.000 0.601 
37 rs2287019 0.138 0.067 0.040 0.024 0.056 0.670 0.052 0.056 0.349 -0.060 0.059 0.308 0.033 0.029 0.266 1.000 0.163 0.008 0.033 0.818 1.000 0.359 
38 rs2365389 -0.020 0.085 0.810 0.015 0.066 0.820 0.071 0.066 0.283 -0.013 0.068 0.846 0.017 0.035 0.624 1.000 0.787 0.025 0.039 0.517 1.000 0.663 
39 rs2820292 -0.028 0.071 0.699 -0.100 0.059 0.092 0.063 0.054 0.244 0.135 0.057 0.018 0.026 0.030 0.387 1.000 0.027 0.037 0.033 0.259 1.000 0.014 
40 rs2836754 0.017 0.061 0.778 -0.007 0.043 0.871 0.040 0.041 0.337 -0.036 0.049 0.466 0.005 0.024 0.830 1.000 0.679 0.003 0.025 0.909 1.000 0.480 
41 rs29941 -0.008 0.072 0.912 0.065 0.054 0.230 0.080 0.051 0.117 -0.152 0.060 0.011 0.007 0.029 0.808 1.000 0.016 0.010 0.032 0.754 1.000 0.006 
42 rs3101336 0.036 0.104 0.728 -0.030 0.083 0.717 0.053 0.076 0.485 0.073 0.092 0.426 0.032 0.044 0.465 1.000 0.839 0.031 0.048 0.519 1.000 0.657 
43 rs3817334 -0.008 0.061 0.901 -0.016 0.049 0.739 -0.003 0.047 0.944 -0.060 0.050 0.226 -0.023 0.025 0.376 1.000 0.845 -0.026 0.028 0.360 1.000 0.688 
44 rs3849570 0.090 0.055 0.105 -0.007 0.046 0.878 0.013 0.043 0.764 -0.067 0.047 0.153 0.001 0.024 0.953 1.000 0.187 -0.018 0.026 0.485 1.000 0.434 
45 rs3888190 0.124 0.114 0.276 0.029 0.081 0.716 0.067 0.076 0.379 -0.046 0.079 0.556 0.032 0.042 0.444 1.000 0.603 0.018 0.045 0.697 1.000 0.577 
46 rs4256980 0.009 0.060 0.882 0.039 0.044 0.373 0.035 0.042 0.404 0.001 0.047 0.979 0.024 0.024 0.311 1.000 0.921 0.027 0.026 0.299 1.000 0.813 
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Table 48 (continued): Interaction between 64 SNPs and calories intake on BMI 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
47 rs4740619 -0.088 0.064 0.169 -0.013 0.053 0.799 0.011 0.047 0.823 0.032 0.054 0.551 -0.008 0.027 0.779 1.000 0.515 0.010 0.030 0.746 1.000 0.833 
48 rs4787491 0.009 0.060 0.879 -0.052 0.043 0.228 0.044 0.041 0.276 -0.042 0.045 0.348 -0.010 0.023 0.657 1.000 0.341 -0.013 0.025 0.587 1.000 0.199 
49 rs492400 0.071 0.071 0.317 0.034 0.054 0.527 -0.009 0.048 0.849 -0.009 0.053 0.862 0.014 0.027 0.611 1.000 0.751 0.004 0.030 0.894 1.000 0.799 
50 rs6567160 -0.024 0.071 0.740 0.080 0.059 0.171 -0.010 0.055 0.854 0.077 0.063 0.224 0.032 0.031 0.290 1.000 0.496 0.045 0.034 0.184 1.000 0.444 
51 rs6804842 -0.002 0.060 0.973 0.009 0.047 0.855 -0.067 0.045 0.137 0.036 0.046 0.429 -0.007 0.024 0.762 1.000 0.425 -0.008 0.027 0.752 1.000 0.249 
52 rs7138803 0.047 0.072 0.512 0.010 0.050 0.847 -0.040 0.047 0.395 0.091 0.055 0.103 0.018 0.027 0.511 1.000 0.331 0.013 0.029 0.658 1.000 0.199 
53 rs7141420 -0.076 0.056 0.179 0.004 0.045 0.927 -0.104 0.042 0.014 -0.054 0.047 0.254 -0.057 0.023 0.014 1.000 0.357 -0.053 0.026 0.038 1.000 0.212 
54 rs7164727 -0.041 0.068 0.550 -0.040 0.050 0.428 0.023 0.049 0.641 0.039 0.054 0.463 -0.001 0.027 0.970 1.000 0.628 0.006 0.029 0.828 1.000 0.512 
55 rs7239883 -0.008 0.061 0.895 0.032 0.047 0.503 -0.021 0.045 0.633 0.029 0.049 0.555 0.008 0.025 0.740 1.000 0.817 0.011 0.027 0.673 1.000 0.654 
56 rs7243357 -0.008 0.070 0.910 0.050 0.052 0.331 -0.037 0.057 0.515 0.056 0.056 0.318 0.020 0.029 0.494 1.000 0.590 0.025 0.032 0.422 1.000 0.422 
57 rs7599312 -0.133 0.230 0.561 0.147 0.160 0.357 -0.008 0.125 0.951 -0.025 0.181 0.889 0.013 0.081 0.872 1.000 0.757 0.034 0.087 0.696 1.000 0.698 
58 rs7715256 0.169 0.160 0.292 0.066 0.121 0.585 -0.081 0.123 0.509 -0.019 0.115 0.872 0.017 0.063 0.783 1.000 0.616 -0.011 0.069 0.878 1.000 0.692 
59 rs7903146 -0.177 0.207 0.394 -0.151 0.139 0.279 0.055 0.146 0.707 -0.323 0.189 0.088 -0.123 0.082 0.133 1.000 0.439 -0.113 0.089 0.205 1.000 0.269 
60 rs9374842 -0.043 0.115 0.712 -0.054 0.072 0.453 -0.101 0.075 0.182 0.121 0.080 0.131 -0.021 0.041 0.608 1.000 0.212 -0.018 0.044 0.683 1.000 0.108 
61 rs9400239 -0.023 0.062 0.706 -0.058 0.048 0.222 0.096 0.046 0.037 -0.012 0.052 0.818 0.006 0.025 0.820 1.000 0.112 0.012 0.028 0.675 1.000 0.057 
62 rs9641123 0.033 0.061 0.595 -0.060 0.048 0.210 -0.031 0.046 0.498 0.030 0.048 0.527 -0.012 0.025 0.639 1.000 0.476 -0.020 0.027 0.453 1.000 0.392 
63 rs977747 -0.099 0.141 0.483 0.097 0.111 0.381 0.140 0.108 0.193 -0.033 0.097 0.735 0.036 0.056 0.523 1.000 0.447 0.060 0.060 0.320 1.000 0.452 
64 rs9914578 0.064 0.066 0.329 -0.013 0.054 0.805 -0.096 0.053 0.073 -0.030 0.060 0.614 -0.027 0.029 0.357 1.000 0.302 -0.048 0.032 0.133 1.000 0.524 





Table 49: Interaction between 64 SNPs and cholesterol intake on BMI 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
1 rs1000940 -0.129 0.064 0.043 -0.111 0.046 0.015 0.006 0.042 0.878 -0.036 0.048 0.452 -0.056 0.024 0.020 1.000 0.158 -0.044 0.026 0.091 1.000 0.161 
2 rs1016287 0.071 0.064 0.266 -0.041 0.050 0.413 -0.040 0.052 0.438 0.055 0.052 0.288 0.005 0.027 0.863 1.000 0.307 -0.010 0.030 0.747 1.000 0.317 
3 rs10182181 0.035 0.057 0.536 0.050 0.045 0.269 -0.055 0.042 0.187 -0.052 0.046 0.257 -0.011 0.023 0.630 1.000 0.221 -0.021 0.026 0.419 1.000 0.166 
4 rs10733682 -0.009 0.072 0.905 -0.006 0.054 0.907 -0.073 0.048 0.129 -0.015 0.056 0.792 -0.031 0.028 0.264 1.000 0.764 -0.035 0.030 0.246 1.000 0.594 
5 rs10938397 0.142 0.065 0.031 0.055 0.049 0.267 -0.041 0.047 0.381 -0.070 0.053 0.187 0.008 0.026 0.749 1.000 0.039 -0.017 0.029 0.549 1.000 0.184 
6 rs10968576 -0.046 0.074 0.539 -0.001 0.058 0.984 -0.096 0.058 0.097 -0.082 0.064 0.207 -0.056 0.031 0.074 1.000 0.672 -0.058 0.035 0.092 1.000 0.468 
7 rs11030104 -0.031 0.057 0.584 -0.027 0.041 0.509 -0.039 0.041 0.342 0.025 0.045 0.587 -0.019 0.022 0.406 1.000 0.742 -0.016 0.024 0.503 1.000 0.553 
8 rs11126666 -0.105 0.058 0.071 -0.010 0.046 0.835 -0.002 0.045 0.960 -0.025 0.051 0.619 -0.028 0.025 0.252 1.000 0.523 -0.011 0.027 0.675 1.000 0.943 
9 rs11191560 -0.040 0.067 0.550 0.047 0.053 0.371 -0.020 0.044 0.646 -0.027 0.054 0.623 -0.008 0.026 0.764 1.000 0.677 -0.002 0.029 0.945 1.000 0.535 
10 rs11583200 0.164 0.093 0.077 0.003 0.083 0.974 0.027 0.081 0.743 0.132 0.092 0.153 0.074 0.043 0.090 1.000 0.491 0.048 0.049 0.327 1.000 0.551 
11 rs11688816 0.161 0.062 0.009 -0.003 0.047 0.943 0.005 0.045 0.913 0.013 0.051 0.801 0.030 0.025 0.225 1.000 0.140 0.004 0.027 0.873 1.000 0.973 
12 rs12286929 0.087 0.067 0.193 -0.013 0.050 0.799 0.026 0.049 0.594 -0.108 0.052 0.038 -0.010 0.026 0.697 1.000 0.101 -0.029 0.029 0.323 1.000 0.157 
13 rs12429545 0.008 0.068 0.908 0.019 0.049 0.699 -0.048 0.049 0.326 0.076 0.055 0.165 0.011 0.027 0.691 1.000 0.408 0.011 0.029 0.702 1.000 0.235 
14 rs12566985 0.014 0.073 0.845 0.078 0.057 0.173 0.042 0.055 0.446 0.004 0.059 0.950 0.037 0.030 0.214 1.000 0.816 0.042 0.033 0.202 1.000 0.665 
15 rs12940622 -0.159 0.062 0.011 0.002 0.048 0.970 -0.081 0.046 0.076 0.021 0.050 0.680 -0.045 0.025 0.073 1.000 0.084 -0.023 0.028 0.407 1.000 0.266 
16 rs13021737 -0.067 0.116 0.563 -0.098 0.088 0.269 0.104 0.075 0.168 0.107 0.088 0.224 0.029 0.044 0.515 1.000 0.211 0.045 0.048 0.346 1.000 0.156 
17 rs13201877 -0.225 0.176 0.201 0.104 0.103 0.314 0.171 0.109 0.118 -0.104 0.122 0.398 0.036 0.060 0.551 1.000 0.141 0.070 0.064 0.271 1.000 0.227 
18 rs1441264 0.064 0.058 0.276 -0.030 0.044 0.486 -0.018 0.044 0.679 0.009 0.047 0.854 -0.002 0.024 0.946 1.000 0.599 -0.014 0.026 0.578 1.000 0.826 
19 rs1460676 0.006 0.061 0.922 -0.010 0.045 0.827 0.066 0.042 0.112 0.003 0.045 0.951 0.020 0.023 0.393 1.000 0.602 0.022 0.025 0.377 1.000 0.407 
20 rs1516725 -0.078 0.109 0.472 -0.069 0.081 0.395 0.247 0.082 0.003 0.091 0.086 0.292 0.061 0.044 0.161 1.000 0.023 0.089 0.048 0.065 1.000 0.023 
21 rs1528435 4.74E-04 0.063 0.994 -0.035 0.045 0.437 -0.040 0.045 0.377 0.014 0.048 0.767 -0.018 0.024 0.454 1.000 0.822 -0.022 0.027 0.415 1.000 0.667 
22 rs1558902 -0.011 0.083 0.891 0.002 0.063 0.976 0.136 0.067 0.042 0.120 0.080 0.136 0.062 0.036 0.085 1.000 0.328 0.079 0.040 0.048 1.000 0.289 
23 rs16851483 0.067 0.066 0.308 0.037 0.051 0.470 -0.028 0.047 0.551 -0.041 0.057 0.474 0.003 0.027 0.908 1.000 0.490 -0.010 0.030 0.740 1.000 0.527 
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Table 49 (continued): Interaction between 64 SNPs and cholesterol intake on BMI 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
24 rs16951275 0.071 0.057 0.209 -0.067 0.042 0.110 -0.046 0.043 0.279 0.035 0.048 0.462 -0.014 0.023 0.550 1.000 0.139 -0.031 0.025 0.222 1.000 0.249 
25 rs17203016 -0.040 0.092 0.667 -0.090 0.062 0.146 -0.106 0.062 0.085 0.071 0.070 0.308 -0.049 0.034 0.151 1.000 0.234 -0.051 0.037 0.170 1.000 0.119 
26 rs17405819 -0.046 0.058 0.427 -0.049 0.046 0.292 0.054 0.042 0.196 0.040 0.046 0.384 0.008 0.024 0.747 1.000 0.254 0.018 0.026 0.482 1.000 0.217 
27 rs17724992 -0.055 0.057 0.342 -0.062 0.042 0.144 0.022 0.041 0.581 0.004 0.045 0.930 -0.018 0.023 0.422 1.000 0.439 -0.011 0.025 0.640 1.000 0.328 
28 rs1928295 -0.062 0.061 0.315 0.061 0.045 0.169 0.030 0.042 0.473 0.033 0.046 0.467 0.026 0.023 0.264 1.000 0.439 0.041 0.025 0.105 1.000 0.857 
29 rs2033529 -0.088 0.087 0.312 -0.081 0.061 0.184 -0.053 0.056 0.348 -0.152 0.062 0.014 -0.092 0.032 0.004 0.296 0.684 -0.093 0.034 0.007 0.516 0.475 
30 rs2033732 0.026 0.058 0.657 0.004 0.046 0.925 0.049 0.044 0.269 -0.032 0.046 0.488 0.011 0.024 0.642 1.000 0.639 0.008 0.026 0.756 1.000 0.446 
31 rs205262 -0.085 0.079 0.282 0.206 0.065 0.002 0.065 0.060 0.274 0.082 0.068 0.230 0.080 0.033 0.017 1.000 0.042 0.116 0.037 0.002 0.124 0.236 
32 rs2075650 0.201 0.108 0.065 0.013 0.088 0.884 -0.070 0.079 0.374 0.120 0.089 0.179 0.045 0.045 0.311 1.000 0.170 0.013 0.049 0.787 1.000 0.280 
33 rs2080454 -1.30E-04 0.059 0.998 -0.012 0.043 0.788 -0.010 0.040 0.797 0.044 0.046 0.340 0.004 0.023 0.852 1.000 0.797 0.005 0.025 0.839 1.000 0.604 
34 rs2112347 0.066 0.057 0.244 -0.007 0.046 0.878 -0.111 0.043 0.010 -0.034 0.047 0.472 -0.033 0.024 0.164 1.000 0.082 -0.054 0.026 0.039 1.000 0.223 
35 rs2176040 0.029 0.121 0.814 -0.125 0.088 0.155 -0.024 0.079 0.764 0.003 0.087 0.973 -0.036 0.045 0.427 1.000 0.674 -0.046 0.049 0.342 1.000 0.546 
36 rs2207139 0.028 0.084 0.734 -0.059 0.067 0.385 0.086 0.063 0.171 -0.062 0.062 0.323 -0.003 0.034 0.923 1.000 0.294 -0.009 0.037 0.799 1.000 0.170 
37 rs2287019 0.165 0.077 0.032 0.092 0.052 0.078 -0.039 0.055 0.478 -0.024 0.059 0.692 0.037 0.030 0.210 1.000 0.077 0.015 0.032 0.647 1.000 0.169 
38 rs2365389 0.115 0.080 0.152 -0.039 0.061 0.519 0.053 0.064 0.407 -0.069 0.070 0.328 0.007 0.034 0.834 1.000 0.254 -0.016 0.037 0.664 1.000 0.393 
39 rs2820292 0.094 0.066 0.154 -0.023 0.060 0.694 0.026 0.054 0.633 -0.080 0.056 0.156 -0.001 0.029 0.968 1.000 0.218 -0.025 0.033 0.452 1.000 0.399 
40 rs2836754 -0.098 0.058 0.092 -0.012 0.047 0.798 -0.086 0.042 0.043 -0.019 0.049 0.695 -0.052 0.024 0.030 1.000 0.479 -0.043 0.026 0.106 1.000 0.423 
41 rs29941 0.072 0.074 0.329 0.073 0.052 0.158 -0.040 0.051 0.426 0.042 0.056 0.459 0.030 0.028 0.284 1.000 0.394 0.023 0.030 0.449 1.000 0.271 
42 rs3101336 -0.088 0.113 0.440 -0.164 0.079 0.037 -0.126 0.071 0.077 0.054 0.091 0.549 -0.092 0.042 0.029 1.000 0.299 -0.093 0.046 0.041 1.000 0.159 
43 rs3817334 0.048 0.062 0.432 -0.012 0.047 0.792 -0.008 0.048 0.873 -0.108 0.051 0.034 -0.024 0.025 0.338 1.000 0.233 -0.039 0.028 0.159 1.000 0.273 
44 rs3849570 0.043 0.059 0.464 0.014 0.045 0.756 -0.008 0.040 0.851 -0.049 0.046 0.290 -0.005 0.023 0.845 1.000 0.626 -0.013 0.025 0.602 1.000 0.612 
45 rs3888190 -0.108 0.110 0.326 -0.056 0.093 0.548 0.100 0.077 0.193 0.039 0.078 0.621 0.015 0.043 0.735 1.000 0.368 0.037 0.047 0.429 1.000 0.433 
46 rs4256980 0.012 0.064 0.854 -0.017 0.044 0.702 0.043 0.043 0.311 -0.078 0.045 0.079 -0.012 0.023 0.613 1.000 0.257 -0.016 0.025 0.537 1.000 0.144 
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Table 49 (continued): Interaction between 64 SNPs and cholesterol intake on BMI 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
47 rs4740619 0.087 0.066 0.186 0.109 0.053 0.039 0.077 0.049 0.119 0.103 0.056 0.064 0.094 0.027 6.40E-04 0.047 0.971 0.095 0.030 0.002 0.121 0.893 
48 rs4787491 -0.017 0.058 0.770 0.034 0.043 0.420 0.024 0.041 0.554 -0.043 0.046 0.349 0.004 0.023 0.861 1.000 0.587 0.008 0.025 0.752 1.000 0.411 
49 rs492400 0.018 0.074 0.807 0.118 0.056 0.035 0.007 0.051 0.892 -0.048 0.052 0.356 0.021 0.028 0.462 1.000 0.182 0.021 0.030 0.487 1.000 0.088 
50 rs6567160 -0.010 0.076 0.891 -0.018 0.061 0.762 -0.051 0.055 0.353 -0.124 0.062 0.046 -0.054 0.031 0.082 1.000 0.584 -0.063 0.034 0.065 1.000 0.461 
51 rs6804842 0.043 0.062 0.485 -0.037 0.047 0.433 0.039 0.045 0.388 0.015 0.048 0.759 0.012 0.025 0.616 1.000 0.639 0.007 0.027 0.809 1.000 0.497 
52 rs7138803 0.072 0.072 0.313 -0.006 0.050 0.900 0.052 0.046 0.261 0.068 0.055 0.219 0.042 0.027 0.120 1.000 0.708 0.037 0.029 0.203 1.000 0.556 
53 rs7141420 0.174 0.059 0.004 -0.002 0.045 0.959 -0.032 0.042 0.455 -0.018 0.044 0.678 0.011 0.023 0.625 1.000 0.029 -0.018 0.025 0.477 1.000 0.892 
54 rs7164727 -0.082 0.070 0.243 0.036 0.050 0.476 -0.034 0.049 0.491 -0.024 0.049 0.632 -0.018 0.026 0.486 1.000 0.553 -0.008 0.029 0.783 1.000 0.566 
55 rs7239883 -0.032 0.065 0.621 -0.026 0.048 0.593 -0.018 0.043 0.683 -0.065 0.050 0.193 -0.034 0.025 0.175 1.000 0.907 -0.034 0.027 0.207 1.000 0.758 
56 rs7243357 -0.156 0.073 0.033 0.025 0.050 0.611 0.086 0.057 0.134 -0.045 0.056 0.426 -0.006 0.029 0.838 1.000 0.053 0.022 0.031 0.486 1.000 0.265 
57 rs7599312 0.105 0.249 0.672 -0.166 0.176 0.345 -0.162 0.122 0.184 -0.119 0.161 0.458 -0.124 0.080 0.122 1.000 0.800 -0.151 0.085 0.076 1.000 0.973 
58 rs7715256 0.245 0.173 0.158 0.059 0.138 0.667 -0.049 0.113 0.662 -0.215 0.124 0.084 -0.029 0.066 0.666 1.000 0.159 -0.075 0.072 0.293 1.000 0.322 
59 rs7903146 -0.206 0.219 0.346 -0.030 0.119 0.801 -0.225 0.195 0.249 0.042 0.136 0.755 -0.058 0.076 0.443 1.000 0.616 -0.038 0.081 0.641 1.000 0.529 
60 rs9374842 -0.295 0.124 0.018 0.027 0.078 0.728 -0.032 0.072 0.659 -0.070 0.082 0.389 -0.054 0.042 0.192 1.000 0.175 -0.024 0.044 0.588 1.000 0.682 
61 rs9400239 0.146 0.065 0.025 0.024 0.047 0.602 -0.066 0.046 0.155 -0.081 0.052 0.123 -0.010 0.026 0.709 1.000 0.023 -0.038 0.028 0.173 1.000 0.245 
62 rs9641123 -0.061 0.065 0.349 0.030 0.048 0.529 -0.016 0.044 0.721 0.038 0.049 0.441 0.004 0.025 0.880 1.000 0.577 0.015 0.027 0.579 1.000 0.667 
63 rs977747 0.020 0.176 0.912 0.190 0.109 0.081 -0.084 0.109 0.441 0.036 0.100 0.721 0.044 0.058 0.446 1.000 0.361 0.047 0.061 0.442 1.000 0.203 
64 rs9914578 0.032 0.069 0.638 0.067 0.054 0.219 0.065 0.053 0.214 -0.126 0.059 0.032 0.014 0.029 0.635 1.000 0.053 0.010 0.032 0.761 1.000 0.022 





As can be seen, the minor risk allele T would decrease the BMI level in the 
individuals in the lower cholesterol intake group while increased BMI level in the 
higher cholesterol intake group. 
 
6.3.7.3 Starch 
Table 50 shows the interaction results between 64 SNPs and starch intake on Z-BMI.  
None of the interaction remained statistically significant after adjusting for multiple 
testing.  Nominal significant positive SNP × starch interaction on BMI was observed 
for KCNK3 rs11126666 (β=0.059, SE=0.025, Pinteraction=0.017), CREB1 rs17203016 
(β=0.065, SE=0.033, Pinteraction= 0.045), INO80E rs4787491 (β=0.055, SE=0.023, 
Pinteraction= 0.016) and LOC646736 rs2176040 (β=0.105, SE=0.047, Pinteraction= 0.024).  




Table 51 shows the interaction results between 64 SNPs and fiber intake on Z-BMI.  
None of the interaction remained statistically significant after adjusting for multiple 
testing.  Nominal significant SNP × fiber interaction on BMI was observed for 
IFNGR1 rs13201877 (β=-0.132, SE=0.063, Pinteraction=0.038) and MC4R rs6567160 
(β=0.068, SE=0.032, Pinteraction= 0.032).  In the case of rs13201877, BMI level 
decreased as the number of G allele and the intake of fiber increased while for 
rs6567160, BMI level increased as the number of C allele and fiber intake increased.
182 
 
Table 50: Interaction between 64 SNPs and starch intake on BMI 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
1 rs1000940 0.090 0.062 0.147 0.018 0.045 0.693 -0.057 0.043 0.185 0.077 0.047 0.104 0.020 0.024 0.392 1.000 0.115 0.008 0.026 0.749 1.000 0.107 
2 rs1016287 -0.047 0.066 0.478 0.025 0.050 0.626 0.126 0.049 0.011 -0.009 0.053 0.862 0.034 0.027 0.201 1.000 0.129 0.050 0.029 0.086 1.000 0.146 
3 rs10182181 -0.061 0.059 0.307 -0.069 0.044 0.118 0.025 0.044 0.560 0.002 0.044 0.965 -0.021 0.023 0.373 1.000 0.385 -0.014 0.025 0.595 1.000 0.286 
4 rs10733682 0.172 0.069 0.013 0.027 0.052 0.601 0.023 0.046 0.621 0.027 0.056 0.629 0.048 0.027 0.076 1.000 0.282 0.025 0.029 0.387 1.000 0.997 
5 rs10938397 -0.012 0.064 0.855 0.031 0.051 0.543 -0.001 0.047 0.980 1.69E-04 0.053 0.997 0.006 0.026 0.821 1.000 0.950 0.010 0.029 0.740 1.000 0.878 
6 rs10968576 0.063 0.075 0.406 0.048 0.058 0.409 -0.016 0.056 0.773 0.063 0.054 0.242 0.037 0.030 0.215 1.000 0.732 0.032 0.032 0.321 1.000 0.563 
7 rs11030104 0.019 0.056 0.736 0.010 0.043 0.812 -0.004 0.041 0.928 0.113 0.045 0.013 0.033 0.023 0.144 1.000 0.232 0.036 0.025 0.147 1.000 0.122 
8 rs11126666 0.041 0.060 0.497 0.012 0.047 0.805 0.042 0.047 0.368 0.142 0.048 0.004 0.059 0.025 0.017 1.000 0.245 0.063 0.027 0.021 1.000 0.132 
9 rs11191560 -0.023 0.068 0.731 -0.063 0.050 0.204 -0.048 0.046 0.293 -0.047 0.053 0.377 -0.048 0.026 0.065 1.000 0.973 -0.053 0.028 0.064 1.000 0.967 
10 rs11583200 -0.085 0.092 0.354 0.038 0.079 0.631 -0.079 0.074 0.281 -0.004 0.095 0.966 -0.033 0.042 0.424 1.000 0.655 -0.020 0.047 0.672 1.000 0.544 
11 rs11688816 -0.015 0.061 0.803 0.044 0.048 0.356 -0.042 0.047 0.372 0.017 0.052 0.738 0.002 0.025 0.947 1.000 0.611 0.005 0.028 0.851 1.000 0.422 
12 rs12286929 0.065 0.068 0.336 -0.046 0.047 0.333 0.015 0.049 0.769 0.010 0.052 0.849 0.002 0.026 0.928 1.000 0.577 -0.009 0.029 0.758 1.000 0.617 
13 rs12429545 0.039 0.071 0.585 -0.067 0.049 0.172 -0.028 0.049 0.565 -0.071 0.054 0.188 -0.041 0.027 0.128 1.000 0.590 -0.054 0.029 0.062 1.000 0.799 
14 rs12566985 0.078 0.074 0.290 -0.063 0.055 0.258 -0.033 0.056 0.551 0.035 0.064 0.584 -0.008 0.030 0.802 1.000 0.392 -0.025 0.033 0.450 1.000 0.505 
15 rs12940622 0.036 0.060 0.556 0.084 0.046 0.067 0.006 0.044 0.883 0.006 0.050 0.908 0.033 0.024 0.175 1.000 0.594 0.033 0.027 0.222 1.000 0.387 
16 rs13021737 0.189 0.107 0.077 0.019 0.090 0.833 0.028 0.076 0.717 0.013 0.098 0.892 0.051 0.045 0.257 1.000 0.565 0.021 0.050 0.671 1.000 0.993 
17 rs13201877 -0.114 0.157 0.469 0.082 0.104 0.430 -0.149 0.105 0.154 0.142 0.112 0.205 0.003 0.057 0.965 1.000 0.188 0.020 0.062 0.740 1.000 0.125 
18 rs1441264 0.023 0.059 0.693 0.033 0.046 0.475 -0.069 0.042 0.105 0.015 0.046 0.736 -0.005 0.024 0.836 1.000 0.338 -0.010 0.026 0.690 1.000 0.213 
19 rs1460676 -0.019 0.060 0.757 0.006 0.048 0.901 -0.021 0.041 0.601 0.037 0.046 0.427 0.001 0.024 0.967 1.000 0.798 0.005 0.026 0.860 1.000 0.641 
20 rs1516725 0.117 0.100 0.244 0.102 0.080 0.200 -0.097 0.072 0.179 -0.057 0.090 0.531 0.004 0.042 0.924 1.000 0.158 -0.020 0.046 0.666 1.000 0.160 
21 rs1528435 0.037 0.061 0.539 -0.001 0.047 0.984 -0.057 0.045 0.210 0.004 0.048 0.940 -0.010 0.025 0.685 1.000 0.617 -0.019 0.027 0.474 1.000 0.587 
22 rs1558902 0.021 0.085 0.810 -0.026 0.064 0.687 0.024 0.065 0.710 0.139 0.072 0.054 0.036 0.035 0.307 1.000 0.384 0.039 0.039 0.311 1.000 0.222 
23 rs16851483 0.022 0.070 0.750 0.008 0.052 0.882 0.003 0.048 0.956 0.054 0.054 0.318 0.020 0.027 0.461 1.000 0.901 0.020 0.030 0.506 1.000 0.748 
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Table 50 (continued): Interaction between 64 SNPs and starch intake on BMI 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
24 rs16951275 0.029 0.058 0.615 0.024 0.042 0.569 0.016 0.043 0.705 -0.026 0.047 0.577 0.010 0.023 0.655 1.000 0.841 0.007 0.025 0.788 1.000 0.702 
25 rs17203016 0.126 0.085 0.139 0.030 0.059 0.610 0.045 0.059 0.446 0.099 0.066 0.135 0.065 0.033 0.045 1.000 0.745 0.055 0.035 0.119 1.000 0.726 
26 rs17405819 0.085 0.059 0.152 0.041 0.046 0.379 0.012 0.042 0.771 -0.027 0.046 0.549 0.021 0.024 0.382 1.000 0.472 0.008 0.026 0.741 1.000 0.574 
27 rs17724992 0.056 0.060 0.351 0.019 0.043 0.665 0.012 0.040 0.758 -0.049 0.046 0.288 0.005 0.023 0.814 1.000 0.526 -0.003 0.025 0.894 1.000 0.497 
28 rs1928295 -0.036 0.060 0.552 -0.053 0.044 0.234 0.051 0.043 0.234 0.036 0.048 0.450 0.004 0.024 0.868 1.000 0.292 0.011 0.026 0.661 1.000 0.201 
29 rs2033529 0.140 0.079 0.077 0.018 0.061 0.771 -0.036 0.052 0.481 0.009 0.062 0.880 0.015 0.031 0.629 1.000 0.321 -0.007 0.033 0.829 1.000 0.756 
30 rs2033732 -0.027 0.059 0.649 0.106 0.047 0.023 0.005 0.043 0.908 0.073 0.045 0.100 0.045 0.024 0.056 1.000 0.215 0.059 0.026 0.023 1.000 0.258 
31 rs205262 -0.012 0.079 0.878 -0.067 0.063 0.291 -0.036 0.060 0.554 -0.074 0.072 0.302 -0.049 0.034 0.148 1.000 0.927 -0.057 0.037 0.127 1.000 0.903 
32 rs2075650 0.052 0.113 0.646 -0.081 0.082 0.326 0.050 0.071 0.484 0.002 0.087 0.986 0.004 0.042 0.927 1.000 0.646 -0.004 0.046 0.931 1.000 0.485 
33 rs2080454 -0.026 0.061 0.670 0.040 0.044 0.353 0.040 0.041 0.330 -0.035 0.045 0.437 0.011 0.023 0.634 1.000 0.499 0.017 0.025 0.493 1.000 0.378 
34 rs2112347 -0.017 0.059 0.769 0.010 0.047 0.832 0.012 0.042 0.778 0.056 0.045 0.209 0.019 0.023 0.419 1.000 0.768 0.026 0.025 0.314 1.000 0.708 
35 rs2176040 0.192 0.114 0.092 -0.008 0.088 0.929 0.155 0.085 0.069 0.114 0.093 0.222 0.105 0.047 0.024 1.000 0.460 0.088 0.051 0.086 1.000 0.389 
36 rs2207139 0.027 0.084 0.748 0.074 0.066 0.264 0.011 0.068 0.871 -0.004 0.067 0.948 0.027 0.035 0.436 1.000 0.855 0.027 0.039 0.478 1.000 0.678 
37 rs2287019 -0.079 0.075 0.289 -0.087 0.054 0.109 0.017 0.052 0.740 -0.043 0.062 0.483 -0.043 0.030 0.149 1.000 0.528 -0.036 0.032 0.265 1.000 0.381 
38 rs2365389 -0.094 0.087 0.281 0.037 0.059 0.534 0.009 0.067 0.896 0.024 0.074 0.743 0.005 0.035 0.875 1.000 0.648 0.024 0.038 0.521 1.000 0.952 
39 rs2820292 -0.087 0.070 0.217 -0.021 0.061 0.733 0.02 0.052 0.705 0.096 0.058 0.098 0.011 0.030 0.704 1.000 0.222 0.032 0.033 0.323 1.000 0.363 
40 rs2836754 0.026 0.058 0.655 -0.004 0.046 0.931 0.019 0.042 0.655 -0.027 0.049 0.580 0.003 0.024 0.903 1.000 0.874 -0.002 0.026 0.947 1.000 0.775 
41 rs29941 -0.250 0.078 0.001 -0.035 0.050 0.481 0.032 0.050 0.519 0.024 0.057 0.673 -0.028 0.028 0.326 1.000 0.016 0.006 0.030 0.853 1.000 0.590 
42 rs3101336 0.054 0.107 0.617 0.066 0.083 0.431 0.087 0.079 0.269 -0.060 0.090 0.506 0.040 0.044 0.361 1.000 0.636 0.037 0.048 0.437 1.000 0.431 
43 rs3817334 -0.023 0.061 0.700 -0.017 0.049 0.726 0.087 0.046 0.059 -0.001 0.052 0.985 0.018 0.025 0.492 1.000 0.338 0.026 0.028 0.349 1.000 0.244 
44 rs3849570 0.028 0.057 0.627 0.034 0.042 0.425 -2.60E-04 0.041 0.995 0.067 0.048 0.161 0.030 0.023 0.193 1.000 0.765 0.030 0.025 0.227 1.000 0.563 
45 rs3888190 0.006 0.104 0.958 -0.049 0.079 0.530 0.004 0.078 0.956 0.021 0.080 0.794 -0.006 0.042 0.884 1.000 0.930 -0.008 0.046 0.855 1.000 0.806 
46 rs4256980 -0.018 0.064 0.772 -0.063 0.044 0.153 -0.053 0.042 0.209 0.012 0.046 0.801 -0.034 0.024 0.147 1.000 0.643 -0.037 0.026 0.148 1.000 0.449 
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Table 50 (continued): Interaction between 64 SNPs and starch intake on BMI 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
47 rs4740619 -0.069 0.067 0.302 -0.024 0.053 0.654 0.003 0.048 0.958 -0.044 0.054 0.417 -0.028 0.027 0.302 1.000 0.834 -0.020 0.030 0.504 1.000 0.812 
48 rs4787491 0.134 0.059 0.025 0.032 0.042 0.456 0.004 0.041 0.924 0.101 0.046 0.029 0.055 0.023 0.016 1.000 0.207 0.042 0.025 0.093 1.000 0.282 
49 rs492400 0.012 0.077 0.874 -0.011 0.052 0.840 -0.013 0.049 0.790 -0.033 0.053 0.531 -0.015 0.028 0.597 1.000 0.969 -0.019 0.030 0.530 1.000 0.946 
50 rs6567160 -0.004 0.078 0.958 0.024 0.059 0.686 0.027 0.056 0.625 0.040 0.065 0.538 0.024 0.031 0.441 1.000 0.979 0.030 0.034 0.388 1.000 0.982 
51 rs6804842 -0.028 0.062 0.650 0.004 0.048 0.938 0.060 0.048 0.210 0.020 0.046 0.661 0.019 0.025 0.453 1.000 0.702 0.028 0.027 0.309 1.000 0.692 
52 rs7138803 -0.007 0.069 0.914 -0.087 0.051 0.091 0.068 0.046 0.139 -0.034 0.055 0.539 -0.009 0.027 0.724 1.000 0.150 -0.010 0.029 0.735 1.000 0.070 
53 rs7141420 0.006 0.058 0.920 -0.016 0.043 0.718 -0.003 0.042 0.934 0.017 0.046 0.718 -4.20E-04 0.023 0.986 1.000 0.964 -0.002 0.025 0.949 1.000 0.876 
54 rs7164727 0.060 0.071 0.392 0.007 0.051 0.889 -0.025 0.048 0.598 -0.060 0.053 0.258 -0.013 0.027 0.635 1.000 0.555 -0.025 0.029 0.385 1.000 0.663 
55 rs7239883 -0.032 0.064 0.613 0.005 0.046 0.917 -0.047 0.044 0.284 0.024 0.050 0.631 -0.013 0.025 0.612 1.000 0.708 -0.009 0.027 0.736 1.000 0.528 
56 rs7243357 0.132 0.067 0.049 0.021 0.054 0.696 -0.020 0.057 0.719 0.077 0.059 0.192 0.045 0.029 0.124 1.000 0.320 0.024 0.032 0.453 1.000 0.492 
57 rs7599312 -0.197 0.194 0.312 -0.016 0.143 0.911 -0.185 0.127 0.147 0.032 0.162 0.841 -0.092 0.076 0.222 1.000 0.638 -0.074 0.082 0.369 1.000 0.508 
58 rs7715256 -0.113 0.155 0.465 -0.162 0.160 0.310 0.092 0.107 0.390 0.027 0.126 0.832 -0.006 0.066 0.926 1.000 0.504 0.018 0.073 0.810 1.000 0.415 
59 rs7903146 0.232 0.226 0.306 -0.016 0.114 0.889 -0.180 0.143 0.208 0.082 0.162 0.612 -0.013 0.074 0.860 1.000 0.410 -0.042 0.078 0.589 1.000 0.456 
60 rs9374842 0.084 0.124 0.496 0.047 0.078 0.546 -0.089 0.072 0.217 0.036 0.082 0.659 0.002 0.042 0.954 1.000 0.467 -0.008 0.044 0.855 1.000 0.358 
61 rs9400239 0.040 0.063 0.528 0.020 0.048 0.680 -0.069 0.045 0.128 -0.077 0.050 0.122 -0.029 0.025 0.248 1.000 0.267 -0.042 0.027 0.125 1.000 0.283 
62 rs9641123 0.049 0.061 0.428 -0.039 0.046 0.400 0.024 0.043 0.575 -0.005 0.049 0.921 0.003 0.024 0.889 1.000 0.650 -0.005 0.026 0.850 1.000 0.607 
63 rs977747 0.269 0.163 0.098 -0.164 0.126 0.192 0.023 0.123 0.852 -0.083 0.107 0.440 -0.023 0.063 0.711 1.000 0.176 -0.074 0.068 0.275 1.000 0.565 
64 rs9914578 -0.054 0.075 0.468 -0.028 0.055 0.618 -0.032 0.053 0.547 0.043 0.058 0.453 -0.015 0.029 0.615 1.000 0.693 -0.008 0.032 0.813 1.000 0.571 





Table 51: Interaction between 64 SNPs and fiber intake on BMI 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
1 rs1000940 -0.058 0.063 0.357 -0.004 0.044 0.921 -0.067 0.041 0.106 0.057 0.048 0.231 -0.017 0.024 0.464 1.000 0.223 -0.011 0.026 0.677 1.000 0.143 
2 rs1016287 0.045 0.066 0.497 -0.026 0.049 0.589 0.079 0.050 0.117 0.078 0.054 0.147 0.041 0.027 0.123 1.000 0.401 0.041 0.029 0.165 1.000 0.230 
3 rs10182181 0.084 0.059 0.151 -0.091 0.044 0.040 0.041 0.042 0.331 0.036 0.046 0.427 0.010 0.023 0.663 1.000 0.054 -0.004 0.025 0.880 1.000 0.056 
4 rs10733682 -0.137 0.069 0.046 0.024 0.053 0.650 -0.047 0.049 0.340 -0.024 0.059 0.688 -0.037 0.028 0.188 1.000 0.317 -0.017 0.031 0.583 1.000 0.614 
5 rs10938397 -0.147 0.068 0.030 -0.021 0.050 0.678 0.086 0.048 0.076 0.037 0.050 0.465 0.008 0.026 0.769 1.000 0.036 0.035 0.029 0.215 1.000 0.311 
6 rs10968576 0.028 0.077 0.719 0.018 0.062 0.767 0.005 0.054 0.919 0.053 0.058 0.361 0.025 0.031 0.408 1.000 0.945 0.025 0.033 0.455 1.000 0.828 
7 rs11030104 -0.031 0.056 0.585 0.043 0.042 0.310 -0.030 0.043 0.477 -0.018 0.045 0.685 -0.006 0.023 0.796 1.000 0.586 -0.001 0.025 0.967 1.000 0.427 
8 rs11126666 -0.085 0.061 0.165 -0.009 0.049 0.852 0.052 0.046 0.267 0.044 0.048 0.352 0.011 0.025 0.669 1.000 0.274 0.030 0.027 0.276 1.000 0.623 
9 rs11191560 -0.032 0.068 0.636 0.035 0.051 0.497 0.007 0.046 0.877 0.082 0.052 0.115 0.028 0.026 0.289 1.000 0.557 0.039 0.029 0.178 1.000 0.560 
10 rs11583200 0.009 0.099 0.928 0.005 0.079 0.950 -0.022 0.080 0.779 -0.073 0.091 0.421 -0.020 0.043 0.646 1.000 0.913 -0.026 0.048 0.581 1.000 0.809 
11 rs11688816 -0.067 0.060 0.263 -0.119 0.048 0.012 0.051 0.045 0.252 -0.050 0.049 0.302 -0.041 0.025 0.098 1.000 0.066 -0.035 0.027 0.191 1.000 0.031 
12 rs12286929 -0.139 0.069 0.044 0.032 0.047 0.497 -0.050 0.048 0.302 0.034 0.049 0.490 -0.015 0.026 0.571 1.000 0.125 0.006 0.028 0.841 1.000 0.375 
13 rs12429545 0.032 0.069 0.642 0.020 0.048 0.670 -0.052 0.048 0.279 -0.034 0.057 0.549 -0.013 0.027 0.639 1.000 0.635 -0.021 0.029 0.480 1.000 0.545 
14 rs12566985 -0.013 0.075 0.859 0.028 0.059 0.635 0.057 0.057 0.319 -0.008 0.063 0.898 0.021 0.031 0.511 1.000 0.841 0.028 0.034 0.421 1.000 0.745 
15 rs12940622 0.101 0.064 0.114 -0.017 0.045 0.710 0.058 0.044 0.190 0.008 0.049 0.876 0.030 0.024 0.227 1.000 0.402 0.017 0.027 0.516 1.000 0.482 
16 rs13021737 -0.136 0.120 0.260 -0.026 0.090 0.772 -0.017 0.074 0.819 -0.047 0.085 0.581 -0.043 0.044 0.328 1.000 0.860 -0.029 0.047 0.544 1.000 0.965 
17 rs13201877 0.214 0.178 0.230 -0.192 0.115 0.095 -0.298 0.123 0.015 -0.070 0.116 0.547 -0.132 0.063 0.038 1.000 0.104 -0.182 0.068 0.007 0.518 0.399 
18 rs1441264 0.007 0.061 0.911 -0.001 0.046 0.988 0.036 0.041 0.380 0.059 0.045 0.193 0.028 0.023 0.226 1.000 0.797 0.032 0.025 0.206 1.000 0.647 
19 rs1460676 0.119 0.060 0.049 0.098 0.046 0.034 -0.079 0.043 0.065 0.006 0.045 0.902 0.022 0.024 0.360 1.000 0.012 0.004 0.026 0.880 1.000 0.019 
20 rs1516725 -0.003 0.109 0.977 -0.016 0.085 0.849 -0.137 0.071 0.053 -0.043 0.087 0.624 -0.064 0.042 0.131 1.000 0.624 -0.075 0.046 0.103 1.000 0.500 
21 rs1528435 -0.051 0.061 0.399 0.090 0.046 0.050 0.031 0.047 0.512 0.061 0.048 0.206 0.042 0.025 0.087 1.000 0.299 0.061 0.027 0.024 1.000 0.668 
22 rs1558902 0.033 0.085 0.698 -0.053 0.068 0.436 -0.137 0.068 0.045 -0.102 0.080 0.198 -0.072 0.037 0.052 1.000 0.446 -0.096 0.041 0.019 1.000 0.680 
23 rs16851483 -0.022 0.064 0.730 0.014 0.050 0.782 0.006 0.048 0.904 0.045 0.054 0.411 0.013 0.027 0.636 1.000 0.882 0.020 0.029 0.498 1.000 0.857 
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Table 51 (continued): Interaction between 64 SNPs and fiber intake on BMI 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
24 rs16951275 -0.043 0.059 0.470 0.038 0.041 0.350 0.038 0.041 0.355 -0.079 0.049 0.108 2.93E-04 0.023 0.990 1.000 0.184 0.008 0.025 0.750 1.000 0.121 
25 rs17203016 -0.039 0.082 0.634 0.006 0.061 0.918 -0.003 0.056 0.957 -0.026 0.064 0.684 -0.012 0.032 0.716 1.000 0.965 -0.007 0.035 0.846 1.000 0.932 
26 rs17405819 0.028 0.061 0.649 -0.013 0.044 0.769 -0.030 0.044 0.486 -0.069 0.047 0.143 -0.026 0.024 0.270 1.000 0.635 -0.036 0.026 0.163 1.000 0.679 
27 rs17724992 -0.079 0.058 0.171 0.054 0.044 0.227 -0.020 0.041 0.625 -0.056 0.046 0.229 -0.018 0.023 0.427 1.000 0.222 -0.007 0.025 0.790 1.000 0.215 
28 rs1928295 0.085 0.059 0.146 0.044 0.044 0.320 -0.018 0.042 0.675 0.016 0.047 0.741 0.024 0.023 0.298 1.000 0.511 0.013 0.026 0.617 1.000 0.599 
29 rs2033529 -0.102 0.086 0.233 0.062 0.060 0.304 0.029 0.052 0.586 0.092 0.059 0.115 0.038 0.031 0.215 1.000 0.293 0.058 0.033 0.075 1.000 0.718 
30 rs2033732 -0.037 0.060 0.534 -0.083 0.047 0.078 -0.017 0.042 0.682 0.022 0.046 0.627 -0.027 0.024 0.264 1.000 0.448 -0.025 0.026 0.344 1.000 0.270 
31 rs205262 0.053 0.080 0.503 -0.019 0.064 0.771 0.014 0.063 0.828 -0.086 0.068 0.212 -0.013 0.034 0.710 1.000 0.571 -0.027 0.038 0.467 1.000 0.558 
32 rs2075650 -0.153 0.116 0.186 0.021 0.084 0.806 -0.003 0.079 0.969 -0.273 0.092 0.003 -0.084 0.045 0.062 1.000 0.066 -0.072 0.049 0.142 1.000 0.034 
33 rs2080454 0.044 0.060 0.469 -0.010 0.043 0.814 -0.006 0.041 0.877 -0.010 0.045 0.824 -0.001 0.023 0.962 1.000 0.884 -0.009 0.025 0.725 1.000 0.997 
34 rs2112347 -0.040 0.060 0.505 0.094 0.045 0.035 0.040 0.041 0.335 0.001 0.048 0.982 0.033 0.024 0.158 1.000 0.277 0.047 0.026 0.068 1.000 0.354 
35 rs2176040 -0.089 0.118 0.452 0.036 0.089 0.685 -0.066 0.080 0.408 -0.194 0.090 0.031 -0.076 0.046 0.097 1.000 0.340 -0.074 0.050 0.138 1.000 0.188 
36 rs2207139 -0.017 0.082 0.840 -0.060 0.062 0.335 -0.038 0.067 0.568 -0.005 0.066 0.937 -0.032 0.034 0.344 1.000 0.938 -0.036 0.037 0.343 1.000 0.833 
37 rs2287019 0.116 0.075 0.123 -0.014 0.054 0.789 -0.071 0.054 0.187 -0.040 0.061 0.518 -0.017 0.03 0.561 1.000 0.232 -0.042 0.032 0.195 1.000 0.757 
38 rs2365389 0.020 0.088 0.818 -0.050 0.059 0.400 -0.143 0.065 0.028 -0.009 0.074 0.904 -0.056 0.035 0.104 1.000 0.398 -0.071 0.038 0.062 1.000 0.357 
39 rs2820292 0.059 0.068 0.383 -0.017 0.058 0.764 -0.023 0.051 0.648 0.074 0.057 0.19 0.018 0.029 0.529 1.000 0.496 0.009 0.032 0.773 1.000 0.379 
40 rs2836754 0.049 0.059 0.401 0.043 0.047 0.351 0.057 0.044 0.189 -0.014 0.047 0.771 0.034 0.024 0.160 1.000 0.701 0.031 0.026 0.246 1.000 0.513 
41 rs29941 0.086 0.071 0.231 0.045 0.052 0.386 0.038 0.051 0.463 0.001 0.058 0.980 0.039 0.028 0.172 1.000 0.835 0.030 0.031 0.332 1.000 0.839 
42 rs3101336 0.018 0.099 0.855 -0.094 0.089 0.294 -0.002 0.077 0.978 -0.029 0.088 0.742 -0.027 0.044 0.541 1.000 0.832 -0.037 0.048 0.442 1.000 0.733 
43 rs3817334 -0.023 0.061 0.705 0.059 0.047 0.215 -0.027 0.045 0.546 -0.060 0.050 0.224 -0.011 0.025 0.655 1.000 0.344 -0.009 0.027 0.748 1.000 0.194 
44 rs3849570 -0.130 0.056 0.021 -0.001 0.044 0.983 0.007 0.040 0.857 0.107 0.046 0.021 0.006 0.023 0.776 1.000 0.014 0.034 0.025 0.178 1.000 0.167 
45 rs3888190 0.054 0.097 0.575 0.081 0.077 0.295 -0.036 0.075 0.636 -0.005 0.087 0.958 0.021 0.041 0.606 1.000 0.712 0.014 0.046 0.760 1.000 0.540 
46 rs4256980 0.038 0.060 0.531 0.028 0.043 0.513 0.002 0.041 0.958 0.054 0.048 0.260 0.027 0.023 0.238 1.000 0.872 0.026 0.025 0.310 1.000 0.716 
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Table 51 (continued): Interaction between 64 SNPs and fiber intake on BMI 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
47 rs4740619 -0.022 0.069 0.756 -0.045 0.052 0.391 0.039 0.049 0.431 -0.003 0.057 0.951 -0.005 0.028 0.867 1.000 0.699 -0.001 0.030 0.962 1.000 0.507 
48 rs4787491 -0.075 0.061 0.220 -0.031 0.043 0.475 0.005 0.042 0.910 -0.002 0.047 0.968 -0.019 0.023 0.411 1.000 0.715 -0.010 0.025 0.706 1.000 0.826 
49 rs492400 -0.082 0.081 0.307 -0.029 0.053 0.587 0.046 0.049 0.344 0.127 0.053 0.016 0.033 0.028 0.238 1.000 0.083 0.048 0.030 0.102 1.000 0.114 
50 rs6567160 -0.056 0.084 0.504 0.058 0.058 0.315 0.045 0.058 0.433 0.181 0.064 0.005 0.068 0.032 0.032 1.000 0.137 0.089 0.034 0.009 0.666 0.229 
51 rs6804842 -0.029 0.061 0.634 -0.036 0.048 0.456 -0.024 0.044 0.592 0.038 0.047 0.420 -0.011 0.025 0.651 1.000 0.679 -0.008 0.027 0.775 1.000 0.494 
52 rs7138803 0.012 0.072 0.868 0.011 0.050 0.820 0.031 0.046 0.501 -0.079 0.052 0.130 -0.005 0.026 0.845 1.000 0.425 -0.008 0.028 0.782 1.000 0.256 
53 rs7141420 -0.027 0.060 0.658 -0.042 0.044 0.344 -0.030 0.041 0.464 -0.070 0.046 0.127 -0.043 0.023 0.064 1.000 0.914 -0.046 0.025 0.068 1.000 0.804 
54 rs7164727 -0.034 0.071 0.625 -0.045 0.050 0.359 -0.030 0.049 0.540 0.082 0.051 0.110 -0.005 0.027 0.855 1.000 0.264 7.28E-05 0.029 0.998 1.000 0.151 
55 rs7239883 -0.024 0.060 0.683 -0.015 0.047 0.751 0.015 0.044 0.738 0.074 0.050 0.139 0.014 0.025 0.561 1.000 0.525 0.022 0.027 0.411 1.000 0.422 
56 rs7243357 0.022 0.068 0.742 -0.039 0.053 0.463 0.014 0.058 0.811 -0.082 0.056 0.142 -0.026 0.029 0.365 1.000 0.563 -0.037 0.032 0.247 1.000 0.493 
57 rs7599312 0.442 0.185 0.018 -0.064 0.163 0.693 0.124 0.123 0.312 -0.107 0.178 0.548 0.093 0.078 0.234 1.000 0.122 0.018 0.086 0.834 1.000 0.473 
58 rs7715256 -0.060 0.170 0.723 -0.067 0.128 0.602 -0.001 0.128 0.992 0.039 0.135 0.776 -0.020 0.069 0.776 1.000 0.941 -0.012 0.075 0.878 1.000 0.848 
59 rs7903146 -0.056 0.187 0.765 0.060 0.113 0.593 -0.002 0.157 0.989 0.156 0.155 0.313 0.051 0.073 0.487 1.000 0.823 0.070 0.079 0.378 1.000 0.768 
60 rs9374842 0.026 0.129 0.838 -0.071 0.074 0.338 -0.127 0.075 0.091 0.034 0.082 0.677 -0.051 0.042 0.227 1.000 0.468 -0.060 0.044 0.178 1.000 0.343 
61 rs9400239 -0.108 0.068 0.114 -0.018 0.049 0.708 0.040 0.044 0.362 0.040 0.051 0.440 0.003 0.026 0.904 1.000 0.254 0.021 0.028 0.438 1.000 0.616 
62 rs9641123 -0.122 0.063 0.052 -0.013 0.048 0.791 -0.023 0.043 0.597 -0.026 0.050 0.605 -0.036 0.025 0.142 1.000 0.520 -0.021 0.027 0.448 1.000 0.980 
63 rs977747 -0.110 0.145 0.448 0.140 0.111 0.209 -0.073 0.117 0.535 -0.014 0.104 0.896 -0.002 0.058 0.977 1.000 0.464 0.019 0.064 0.763 1.000 0.388 
64 rs9914578 0.041 0.070 0.555 0.056 0.055 0.313 0.041 0.052 0.436 0.038 0.059 0.525 0.044 0.029 0.128 1.000 0.996 0.045 0.032 0.161 1.000 0.970 




Table 52 shows the interaction results between 64 SNPs and %protein intake on 
Z-BMI.  None of the interaction remained statistically significant after adjusting for 
multiple testing.  Nominal significant negative SNP × %protein interaction on BMI 
was observed for RABEP1 rs1000940 (β=-0.055, SE=0.024, Pinteraction=0.020) and 
NEGR1 rs3101336 (β=-0.095, SE=0.041, Pinteraction= 0.020).  The BMI level 
decreased as the number of reported BMI risk alleles and the intake of %protein 
increased for both SNPs. 
 
6.3.7.6 %Fat 
Table 53 shows the interaction results between 64 SNPs and %fat intake on Z-BMI.  
Nominal significant SNP × %fat interaction on BMI was observed for KCNK3 
rs11126666 (β=-0.057, SE=0.025, Pinteraction=0.023), RPTOR rs12940622 (β=-0.052, 
SE=0.025, Pinteraction=0.038), TDRG1 rs2033529 (β=-0.070, SE=0.031, 
Pinteraction=0.024), INO80E rs4787491 (β=-0.055, SE=0.023, Pinteraction=0.018) and 
NRXN3 rs7141420 (β=-0.047, SE=0.023, Pinteraction=0.039).  For all these SNPs, the 
interaction terms were negatively associated with Z-BMI so that the BMI level 
decreased as the number of reported BMI risk alleles and %fat intake increased. 
 
The interaction effect of C6ofr106 rs205262 with %fat was found to be significant on 
Z-BMI even after adjusting for multiple comparisons (β=0.122, SE=0.033, 
Pinteraction=1.97×10-4, adjusted Pinteraction =0.015).  The positive association between 
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intake of %fat and BMI tended to be stronger among individuals who are 
homozygous for the reported BMI risk allele G of rs205262 as compared to 
individuals who have less copies of the G allele.  Figure 14 showed the association 
between rs205262 and BMI depending on %fat intake using population mean as the 
cut-off (Mean ± SD: 26.87 ± 5.93).  As can be seen, the minor risk allele G would 
decrease the BMI level in the individuals whose %fat intake was lower than the 
population mean while increased BMI level in the individuals whose %fat intake was 
higher than the population mean. 
 




Table 54 shows the interaction results between 64 SNPs and %SFA intake on Z-BMI.  
Nominal significant SNP × %SFA interaction on BMI was observed for TDRG1 
rs2033529 (β=-0.078, SE=0.031, Pinteraction=0.011), C6orf106 rs205262 (β=0.080, 
SE=0.033, Pinteraction=0.016), CCDC171 rs4740619 (β=0.058, SE=0.027, 

























Table 52: Interaction between 64 SNPs and %protein intake on BMI 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
1 rs1000940 -0.155 0.060 0.009 -0.109 0.046 0.019 0.005 0.041 0.901 -0.016 0.046 0.736 -0.055 0.024 0.020 1.000 0.072 -0.036 0.026 0.158 1.000 0.162 
2 rs1016287 0.102 0.065 0.114 -0.027 0.050 0.586 -0.078 0.049 0.115 0.067 0.052 0.199 0.004 0.027 0.872 1.000 0.075 -0.016 0.029 0.593 1.000 0.126 
3 rs10182181 0.080 0.056 0.154 0.032 0.043 0.463 -0.077 0.043 0.073 -0.009 0.046 0.849 -0.002 0.023 0.945 1.000 0.121 -0.018 0.025 0.468 1.000 0.196 
4 rs10733682 -0.057 0.066 0.388 -0.026 0.053 0.631 -0.013 0.047 0.787 0.021 0.054 0.698 -0.015 0.027 0.576 1.000 0.828 -0.007 0.030 0.821 1.000 0.818 
5 rs10938397 0.112 0.069 0.107 -0.021 0.051 0.677 -0.098 0.048 0.044 0.048 0.052 0.358 -0.006 0.027 0.812 1.000 0.054 -0.027 0.029 0.346 1.000 0.121 
6 rs10968576 -0.055 0.075 0.469 -0.006 0.058 0.912 -0.041 0.057 0.468 -0.118 0.058 0.043 -0.055 0.030 0.073 1.000 0.587 -0.055 0.033 0.100 1.000 0.381 
7 rs11030104 0.032 0.059 0.590 -0.006 0.042 0.887 0.087 0.041 0.036 0.005 0.047 0.907 0.031 0.023 0.173 1.000 0.412 0.031 0.025 0.211 1.000 0.238 
8 rs11126666 -0.118 0.061 0.052 0.003 0.049 0.958 -0.029 0.047 0.544 -0.071 0.048 0.144 -0.047 0.025 0.061 1.000 0.425 -0.033 0.028 0.242 1.000 0.566 
9 rs11191560 -0.015 0.063 0.811 -0.021 0.048 0.669 0.048 0.045 0.280 -0.070 0.052 0.183 -0.009 0.025 0.720 1.000 0.384 -0.008 0.028 0.775 1.000 0.219 
10 rs11583200 0.078 0.084 0.353 -0.028 0.073 0.706 0.096 0.076 0.208 0.028 0.096 0.770 0.042 0.041 0.301 1.000 0.656 0.031 0.046 0.505 1.000 0.503 
11 rs11688816 -0.003 0.063 0.958 -0.122 0.045 0.007 0.029 0.045 0.517 0.007 0.050 0.891 -0.026 0.025 0.285 1.000 0.089 -0.031 0.027 0.254 1.000 0.041 
12 rs12286929 0.063 0.067 0.347 0.017 0.050 0.726 0.053 0.047 0.262 -0.031 0.052 0.558 0.023 0.026 0.377 1.000 0.608 0.016 0.029 0.576 1.000 0.494 
13 rs12429545 -0.017 0.069 0.811 0.055 0.048 0.251 -0.008 0.048 0.863 0.023 0.054 0.673 0.017 0.027 0.512 1.000 0.764 0.023 0.029 0.419 1.000 0.646 
14 rs12566985 0.008 0.078 0.917 0.089 0.056 0.111 -0.021 0.052 0.686 -0.022 0.061 0.720 0.014 0.030 0.631 1.000 0.456 0.015 0.032 0.633 1.000 0.272 
15 rs12940622 -0.066 0.060 0.273 -0.006 0.048 0.898 -0.003 0.046 0.944 0.035 0.049 0.480 -0.005 0.025 0.838 1.000 0.641 0.008 0.027 0.782 1.000 0.801 
16 rs13021737 -0.104 0.119 0.384 -0.138 0.086 0.107 -0.027 0.075 0.719 -0.032 0.090 0.726 -0.069 0.044 0.122 1.000 0.749 -0.063 0.048 0.188 1.000 0.573 
17 rs13201877 0.053 0.211 0.802 -0.131 0.093 0.158 0.144 0.105 0.172 -0.105 0.127 0.409 -0.026 0.059 0.653 1.000 0.221 -0.033 0.061 0.589 1.000 0.119 
18 rs1441264 -0.013 0.059 0.829 -0.067 0.047 0.153 0.067 0.041 0.102 -0.013 0.046 0.778 -1.40E-04 0.024 0.995 1.000 0.184 0.002 0.026 0.931 1.000 0.091 
19 rs1460676 -0.017 0.061 0.781 -0.012 0.042 0.783 0.050 0.042 0.235 -0.019 0.046 0.686 0.004 0.023 0.847 1.000 0.639 0.008 0.025 0.747 1.000 0.461 
20 rs1516725 -0.066 0.116 0.572 -0.051 0.087 0.554 0.121 0.070 0.085 -0.040 0.094 0.670 0.016 0.044 0.713 1.000 0.297 0.030 0.047 0.531 1.000 0.211 
21 rs1528435 0.018 0.066 0.788 -0.101 0.045 0.025 0.004 0.044 0.921 0.006 0.049 0.901 -0.025 0.025 0.316 1.000 0.251 -0.032 0.027 0.235 1.000 0.164 
22 rs1558902 0.005 0.082 0.948 0.078 0.062 0.207 0.082 0.067 0.222 -0.141 0.070 0.044 0.013 0.035 0.714 1.000 0.071 0.014 0.038 0.708 1.000 0.030 
23 rs16851483 -0.034 0.067 0.607 -0.035 0.052 0.504 0.052 0.045 0.248 -0.069 0.053 0.196 -0.013 0.026 0.610 1.000 0.326 -0.010 0.029 0.738 1.000 0.188 
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Table 52 (continued): Interaction between 64 SNPs and %protein intake on BMI 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
24 rs16951275 0.003 0.059 0.964 -0.033 0.043 0.444 0.024 0.044 0.591 -2.00E-04 0.047 0.997 -0.003 0.024 0.910 1.000 0.834 -0.004 0.026 0.886 1.000 0.652 
25 rs17203016 0.044 0.089 0.625 -0.031 0.065 0.628 0.005 0.057 0.935 0.057 0.066 0.390 0.014 0.033 0.679 1.000 0.790 0.009 0.036 0.804 1.000 0.632 
26 rs17405819 -0.046 0.063 0.461 -0.041 0.044 0.351 0.007 0.042 0.872 0.030 0.047 0.529 -0.009 0.024 0.712 1.000 0.637 -0.003 0.025 0.921 1.000 0.526 
27 rs17724992 -0.109 0.056 0.052 -0.007 0.044 0.872 0.041 0.042 0.333 0.011 0.047 0.814 -0.006 0.023 0.810 1.000 0.192 0.016 0.026 0.534 1.000 0.728 
28 rs1928295 -0.021 0.058 0.717 0.001 0.043 0.986 0.071 0.041 0.085 -0.035 0.047 0.464 0.011 0.023 0.635 1.000 0.331 0.017 0.025 0.498 1.000 0.217 
29 rs2033529 -0.069 0.081 0.399 -0.091 0.062 0.140 0.054 0.053 0.310 0.006 0.063 0.921 -0.013 0.031 0.675 1.000 0.289 -0.003 0.034 0.918 1.000 0.201 
30 rs2033732 -0.034 0.058 0.552 -0.005 0.045 0.919 -0.001 0.042 0.982 -0.114 0.045 0.011 -0.038 0.023 0.103 1.000 0.240 -0.039 0.025 0.129 1.000 0.122 
31 rs205262 0.018 0.079 0.822 0.203 0.063 0.001 -0.002 0.063 0.971 -0.046 0.070 0.514 0.051 0.034 0.136 1.000 0.036 0.058 0.038 0.122 1.000 0.015 
32 rs2075650 0.098 0.110 0.376 -0.001 0.082 0.986 -0.048 0.075 0.518 -0.035 0.084 0.675 -0.011 0.043 0.804 1.000 0.725 -0.030 0.046 0.523 1.000 0.912 
33 rs2080454 0.088 0.060 0.142 -0.016 0.044 0.714 -0.020 0.042 0.634 0.041 0.045 0.367 0.013 0.023 0.562 1.000 0.391 1.73E-04 0.025 0.995 1.000 0.555 
34 rs2112347 0.039 0.057 0.491 0.011 0.044 0.798 -0.018 0.044 0.687 -0.055 0.047 0.241 -0.009 0.024 0.699 1.000 0.586 -0.019 0.026 0.461 1.000 0.588 
35 rs2176040 -0.117 0.111 0.293 -0.140 0.089 0.117 -0.044 0.087 0.614 0.006 0.087 0.944 -0.068 0.046 0.140 1.000 0.648 -0.058 0.051 0.253 1.000 0.493 
36 rs2207139 -0.008 0.077 0.918 -0.046 0.063 0.464 -0.001 0.064 0.982 0.005 0.066 0.939 -0.014 0.034 0.683 1.000 0.943 -0.015 0.037 0.687 1.000 0.827 
37 rs2287019 0.021 0.076 0.779 0.118 0.057 0.037 -0.059 0.053 0.266 -0.027 0.062 0.661 0.011 0.030 0.710 1.000 0.126 0.009 0.033 0.777 1.000 0.058 
38 rs2365389 0.027 0.082 0.744 -0.037 0.063 0.560 -0.045 0.065 0.489 -0.011 0.071 0.879 -0.022 0.035 0.532 1.000 0.906 -0.032 0.038 0.400 1.000 0.935 
39 rs2820292 0.060 0.066 0.363 -0.092 0.055 0.094 -0.037 0.053 0.492 0.009 0.057 0.875 -0.022 0.029 0.440 1.000 0.315 -0.041 0.032 0.196 1.000 0.440 
40 rs2836754 -0.062 0.059 0.296 -0.024 0.047 0.602 -0.009 0.043 0.835 -0.065 0.048 0.180 -0.036 0.024 0.137 1.000 0.799 -0.031 0.026 0.247 1.000 0.678 
41 rs29941 0.077 0.076 0.316 -0.014 0.053 0.790 -0.058 0.052 0.264 -0.048 0.055 0.387 -0.024 0.029 0.409 1.000 0.495 -0.040 0.031 0.195 1.000 0.824 
42 rs3101336 -0.079 0.113 0.484 -0.190 0.080 0.017 -0.079 0.069 0.251 -0.027 0.082 0.739 -0.095 0.041 0.020 1.000 0.535 -0.098 0.044 0.026 1.000 0.340 
43 rs3817334 0.023 0.060 0.707 -0.032 0.050 0.523 -0.019 0.047 0.681 -0.044 0.051 0.386 -0.021 0.026 0.408 1.000 0.853 -0.031 0.028 0.274 1.000 0.936 
44 rs3849570 -0.019 0.058 0.740 -0.003 0.043 0.936 0.006 0.039 0.880 -0.037 0.049 0.459 -0.010 0.023 0.670 1.000 0.917 -0.008 0.025 0.748 1.000 0.789 
45 rs3888190 -0.094 0.109 0.388 0.040 0.083 0.628 0.091 0.074 0.221 0.043 0.079 0.585 0.037 0.042 0.372 1.000 0.576 0.060 0.045 0.184 1.000 0.873 
46 rs4256980 0.077 0.065 0.239 0.060 0.045 0.181 -0.069 0.041 0.094 -0.073 0.046 0.112 -0.015 0.024 0.518 1.000 0.044 -0.029 0.025 0.248 1.000 0.055 
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Table 52 (continued): Interaction between 64 SNPs and %protein intake on BMI 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
47 rs4740619 0.016 0.064 0.796 0.039 0.052 0.454 0.032 0.048 0.502 0.062 0.055 0.264 0.038 0.027 0.155 1.000 0.958 0.043 0.030 0.148 1.000 0.917 
48 rs4787491 -0.122 0.062 0.049 0.002 0.043 0.966 0.063 0.042 0.131 -0.096 0.047 0.040 -0.021 0.023 0.364 1.000 0.022 -0.004 0.025 0.862 1.000 0.039 
49 rs492400 0.061 0.078 0.436 0.026 0.055 0.643 0.005 0.052 0.930 0.024 0.055 0.655 0.024 0.029 0.413 1.000 0.949 0.018 0.031 0.569 1.000 0.952 
50 rs6567160 0.102 0.079 0.197 0.068 0.059 0.246 0.080 0.056 0.155 -0.015 0.061 0.809 0.056 0.031 0.074 1.000 0.594 0.047 0.034 0.164 1.000 0.474 
51 rs6804842 -0.034 0.062 0.586 0.046 0.047 0.335 0.070 0.046 0.129 -0.048 0.047 0.306 0.014 0.025 0.573 1.000 0.234 0.023 0.027 0.393 1.000 0.169 
52 rs7138803 0.035 0.066 0.595 0.009 0.050 0.850 -0.037 0.049 0.453 0.072 0.054 0.183 0.015 0.027 0.572 1.000 0.505 0.011 0.029 0.704 1.000 0.328 
53 rs7141420 0.061 0.058 0.299 -0.105 0.043 0.015 -0.002 0.043 0.955 0.028 0.043 0.516 -0.013 0.023 0.574 1.000 0.068 -0.026 0.025 0.293 1.000 0.072 
54 rs7164727 -0.012 0.064 0.851 -0.009 0.052 0.861 -0.025 0.051 0.627 0.080 0.051 0.119 0.011 0.027 0.692 1.000 0.462 0.016 0.030 0.601 1.000 0.298 
55 rs7239883 -0.050 0.064 0.434 -0.067 0.045 0.142 0.007 0.042 0.864 -0.088 0.052 0.088 -0.044 0.025 0.071 1.000 0.484 -0.043 0.027 0.103 1.000 0.295 
56 rs7243357 -0.139 0.071 0.050 -1.70E-04 0.052 0.997 -0.011 0.056 0.846 0.005 0.057 0.934 -0.025 0.029 0.389 1.000 0.368 -0.002 0.032 0.946 1.000 0.980 
57 rs7599312 0.257 0.194 0.186 -0.045 0.171 0.794 -0.091 0.136 0.503 -0.053 0.144 0.711 -0.014 0.078 0.863 1.000 0.498 -0.066 0.086 0.440 1.000 0.972 
58 rs7715256 0.208 0.149 0.163 0.070 0.144 0.624 -0.046 0.104 0.656 -0.116 0.127 0.361 0.005 0.063 0.935 1.000 0.359 -0.040 0.070 0.570 1.000 0.621 
59 rs7903146 -0.275 0.226 0.225 0.069 0.150 0.645 0.183 0.182 0.314 0.115 0.145 0.430 0.061 0.084 0.466 1.000 0.425 0.115 0.091 0.204 1.000 0.890 
60 rs9374842 -0.141 0.118 0.233 -0.017 0.079 0.829 -0.037 0.078 0.630 -0.137 0.083 0.098 -0.072 0.043 0.094 1.000 0.651 -0.061 0.046 0.183 1.000 0.537 
61 rs9400239 0.098 0.064 0.126 -0.025 0.048 0.600 0.014 0.045 0.756 -0.009 0.050 0.856 0.010 0.025 0.678 1.000 0.460 -0.006 0.027 0.834 1.000 0.835 
62 rs9641123 -0.038 0.060 0.524 0.052 0.047 0.266 -0.004 0.045 0.934 -0.001 0.050 0.976 0.007 0.025 0.789 1.000 0.664 0.016 0.027 0.562 1.000 0.635 
63 rs977747 -0.030 0.177 0.866 0.276 0.111 0.014 -0.195 0.122 0.111 -0.124 0.104 0.233 -0.012 0.061 0.844 1.000 0.018 -0.010 0.065 0.882 1.000 0.007 
64 rs9914578 0.064 0.073 0.377 0.028 0.054 0.607 0.026 0.053 0.622 -0.074 0.060 0.216 0.009 0.029 0.759 1.000 0.435 -0.002 0.032 0.957 1.000 0.361 





Table 53: Interaction between 64 SNPs and %fat intake on BMI 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
1 rs1000940 -0.106 0.060 0.079 0.011 0.046 0.810 0.030 0.042 0.465 -0.089 0.045 0.050 -0.027 0.023 0.244 1.000 0.103 -0.013 0.025 0.603 1.000 0.124 
2 rs1016287 0.094 0.065 0.147 -0.032 0.051 0.539 -0.024 0.051 0.634 -0.024 0.051 0.641 -0.006 0.027 0.829 1.000 0.410 -0.027 0.030 0.369 1.000 0.993 
3 rs10182181 0.056 0.060 0.352 0.064 0.044 0.146 -0.022 0.044 0.615 -0.071 0.046 0.124 0.002 0.024 0.926 1.000 0.133 -0.008 0.026 0.765 1.000 0.098 
4 rs10733682 -0.010 0.070 0.883 -0.005 0.055 0.925 -0.023 0.047 0.626 0.025 0.055 0.654 -0.005 0.028 0.867 1.000 0.932 -0.004 0.030 0.905 1.000 0.805 
5 rs10938397 0.044 0.065 0.497 0.012 0.050 0.814 0.036 0.047 0.452 0.014 0.052 0.788 0.025 0.026 0.342 1.000 0.969 0.021 0.029 0.460 1.000 0.929 
6 rs10968576 -0.050 0.073 0.493 0.004 0.057 0.951 -0.064 0.054 0.236 -0.135 0.062 0.031 -0.059 0.030 0.050 1.000 0.437 -0.061 0.033 0.066 1.000 0.259 
7 rs11030104 -0.008 0.057 0.896 -0.010 0.042 0.816 0.025 0.040 0.526 -0.084 0.045 0.063 -0.017 0.022 0.457 1.000 0.336 -0.018 0.024 0.452 1.000 0.187 
8 rs11126666 -0.141 0.060 0.018 -0.029 0.048 0.549 -0.017 0.045 0.713 -0.074 0.049 0.129 -0.057 0.025 0.023 1.000 0.356 -0.039 0.027 0.157 1.000 0.669 
9 rs11191560 0.030 0.063 0.639 0.054 0.049 0.270 0.015 0.047 0.741 -0.067 0.054 0.219 0.010 0.026 0.703 1.000 0.405 0.006 0.029 0.838 1.000 0.247 
10 rs11583200 0.122 0.091 0.182 0.010 0.078 0.896 -0.018 0.080 0.826 0.082 0.089 0.357 0.042 0.042 0.314 1.000 0.639 0.021 0.047 0.660 1.000 0.697 
11 rs11688816 0.074 0.062 0.238 -0.116 0.047 0.013 -0.068 0.045 0.131 0.028 0.049 0.570 -0.035 0.025 0.163 1.000 0.042 -0.055 0.027 0.042 1.000 0.099 
12 rs12286929 0.003 0.065 0.959 -0.006 0.048 0.907 -0.037 0.050 0.459 -0.014 0.050 0.777 -0.015 0.026 0.564 1.000 0.957 -0.019 0.029 0.514 1.000 0.897 
13 rs12429545 -0.049 0.067 0.464 0.099 0.048 0.037 -0.008 0.048 0.877 0.114 0.052 0.030 0.049 0.026 0.061 1.000 0.105 0.067 0.028 0.019 1.000 0.163 
14 rs12566985 -0.006 0.073 0.931 0.104 0.056 0.065 -0.034 0.056 0.546 0.024 0.059 0.688 0.025 0.030 0.406 1.000 0.353 0.031 0.033 0.342 1.000 0.219 
15 rs12940622 -0.127 0.061 0.038 -0.068 0.049 0.159 -0.019 0.044 0.667 -0.026 0.050 0.602 -0.052 0.025 0.038 1.000 0.488 -0.037 0.027 0.178 1.000 0.730 
16 rs13021737 -0.158 0.119 0.186 -0.042 0.089 0.633 -0.019 0.080 0.809 -0.097 0.098 0.324 -0.065 0.047 0.167 1.000 0.776 -0.048 0.051 0.348 1.000 0.826 
17 rs13201877 0.333 0.191 0.082 -0.095 0.100 0.341 0.120 0.105 0.254 -0.084 0.110 0.441 0.011 0.058 0.844 1.000 0.122 -0.021 0.060 0.731 1.000 0.261 
18 rs1441264 0.009 0.059 0.876 -0.032 0.046 0.485 0.084 0.042 0.046 0.007 0.047 0.878 0.022 0.024 0.360 1.000 0.297 0.024 0.026 0.352 1.000 0.162 
19 rs1460676 -0.059 0.060 0.325 0.036 0.045 0.419 0.027 0.043 0.533 0.019 0.046 0.679 0.014 0.024 0.554 1.000 0.607 0.027 0.026 0.286 1.000 0.963 
20 rs1516725 -0.117 0.106 0.272 -0.151 0.087 0.082 0.150 0.073 0.039 -0.003 0.090 0.976 -0.004 0.043 0.918 1.000 0.037 0.018 0.047 0.706 1.000 0.028 
21 rs1528435 -0.075 0.062 0.232 -0.089 0.045 0.045 -0.019 0.044 0.655 0.015 0.046 0.744 -0.039 0.024 0.107 1.000 0.365 -0.032 0.026 0.211 1.000 0.249 
22 rs1558902 0.028 0.086 0.742 0.045 0.064 0.479 -3.10E-04 0.066 0.996 -0.039 0.073 0.599 0.010 0.035 0.785 1.000 0.847 0.006 0.039 0.881 1.000 0.685 
23 rs16851483 -0.045 0.065 0.490 0.034 0.052 0.505 0.008 0.046 0.858 -0.102 0.052 0.048 -0.022 0.026 0.397 1.000 0.245 -0.018 0.029 0.536 1.000 0.134 
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Table 53 (continued): Interaction between 64 SNPs and %fat intake on BMI 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
24 rs16951275 0.039 0.060 0.514 -0.014 0.043 0.750 -0.005 0.045 0.917 0.008 0.046 0.858 0.003 0.024 0.908 1.000 0.906 -0.004 0.026 0.878 1.000 0.941 
25 rs17203016 -0.095 0.087 0.276 -0.070 0.064 0.271 0.008 0.059 0.890 0.037 0.069 0.593 -0.023 0.034 0.504 1.000 0.519 -0.010 0.037 0.791 1.000 0.484 
26 rs17405819 -0.083 0.061 0.172 -0.040 0.044 0.362 -0.074 0.042 0.080 0.071 0.047 0.132 -0.029 0.024 0.213 1.000 0.089 -0.020 0.026 0.439 1.000 0.061 
27 rs17724992 -0.092 0.059 0.117 -0.025 0.044 0.574 -0.040 0.041 0.319 0.037 0.047 0.426 -0.025 0.023 0.276 1.000 0.359 -0.013 0.025 0.608 1.000 0.431 
28 rs1928295 -0.013 0.056 0.812 -0.008 0.044 0.855 0.003 0.042 0.943 -0.035 0.046 0.449 -0.012 0.023 0.592 1.000 0.944 -0.012 0.025 0.631 1.000 0.826 
29 rs2033529 -0.166 0.081 0.042 -0.037 0.059 0.528 -0.080 0.053 0.133 -0.036 0.063 0.562 -0.070 0.031 0.024 1.000 0.568 -0.054 0.033 0.108 1.000 0.817 
30 rs2033732 0.009 0.057 0.873 -0.079 0.046 0.091 -0.020 0.042 0.645 -0.015 0.047 0.745 -0.029 0.024 0.223 1.000 0.633 -0.037 0.026 0.158 1.000 0.552 
31 rs205262 -0.026 0.080 0.749 0.139 0.061 0.023 0.169 0.059 0.004 0.143 0.067 0.033 0.122 0.033 1.97E-04 0.015 0.236 0.151 0.036 2.39E-05 0.002 0.928 
32 rs2075650 0.003 0.103 0.979 -0.023 0.083 0.782 -0.097 0.073 0.185 -0.055 0.091 0.545 -0.051 0.043 0.234 1.000 0.853 -0.062 0.047 0.187 1.000 0.795 
33 rs2080454 0.011 0.059 0.852 0.008 0.044 0.856 -0.011 0.042 0.786 0.011 0.046 0.805 0.003 0.023 0.884 1.000 0.980 0.002 0.025 0.938 1.000 0.922 
34 rs2112347 -0.048 0.056 0.387 0.025 0.045 0.581 0.017 0.042 0.681 0.029 0.047 0.540 0.011 0.023 0.651 1.000 0.707 0.023 0.026 0.367 1.000 0.982 
35 rs2176040 -0.167 0.112 0.138 -0.066 0.088 0.453 0.014 0.079 0.856 -0.185 0.089 0.038 -0.086 0.045 0.055 1.000 0.329 -0.071 0.049 0.149 1.000 0.244 
36 rs2207139 -0.028 0.079 0.721 -0.003 0.064 0.960 0.067 0.064 0.298 -0.054 0.068 0.431 -0.001 0.034 0.984 1.000 0.607 0.006 0.038 0.882 1.000 0.430 
37 rs2287019 0.135 0.074 0.067 0.081 0.056 0.152 -0.038 0.052 0.468 -0.063 0.062 0.313 0.018 0.030 0.545 1.000 0.086 -0.005 0.033 0.881 1.000 0.167 
38 rs2365389 -0.007 0.081 0.930 -0.057 0.061 0.343 0.060 0.065 0.352 -0.011 0.069 0.878 -0.005 0.034 0.879 1.000 0.621 -0.005 0.037 0.898 1.000 0.412 
39 rs2820292 0.008 0.068 0.906 0.024 0.057 0.671 -0.006 0.051 0.904 -0.002 0.059 0.969 0.005 0.029 0.858 1.000 0.981 0.005 0.032 0.887 1.000 0.916 
40 rs2836754 -0.008 0.061 0.898 0.002 0.045 0.966 -0.090 0.042 0.031 0.051 0.050 0.309 -0.019 0.024 0.436 1.000 0.165 -0.021 0.026 0.428 1.000 0.080 
41 rs29941 0.137 0.075 0.069 0.081 0.052 0.122 -0.009 0.051 0.856 -0.099 0.055 0.071 0.014 0.028 0.626 1.000 0.032 -0.006 0.030 0.834 1.000 0.059 
42 rs3101336 -0.085 0.106 0.421 -0.175 0.086 0.042 -0.014 0.069 0.843 0.076 0.097 0.432 -0.048 0.043 0.263 1.000 0.240 -0.041 0.047 0.386 1.000 0.132 
43 rs3817334 -0.002 0.062 0.974 -0.065 0.050 0.188 -0.051 0.047 0.286 -0.028 0.049 0.565 -0.040 0.026 0.116 1.000 0.863 -0.048 0.028 0.087 1.000 0.868 
44 rs3849570 -0.011 0.059 0.852 -0.041 0.044 0.348 0.017 0.041 0.672 -0.089 0.047 0.058 -0.030 0.023 0.204 1.000 0.377 -0.033 0.025 0.193 1.000 0.225 
45 rs3888190 -0.058 0.109 0.594 0.048 0.084 0.566 0.120 0.072 0.099 -0.007 0.080 0.926 0.041 0.042 0.324 1.000 0.497 0.058 0.045 0.198 1.000 0.494 
46 rs4256980 0.051 0.063 0.423 0.017 0.045 0.711 0.057 0.043 0.181 -0.023 0.047 0.622 0.024 0.024 0.316 1.000 0.613 0.020 0.026 0.450 1.000 0.449 
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Table 53 (continued): Interaction between 64 SNPs and %fat intake on BMI 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
47 rs4740619 0.076 0.064 0.237 0.057 0.052 0.267 0.010 0.049 0.834 0.022 0.055 0.696 0.038 0.027 0.163 1.000 0.829 0.030 0.030 0.325 1.000 0.794 
48 rs4787491 -0.121 0.060 0.044 -0.028 0.043 0.514 0.005 0.042 0.904 -0.119 0.046 0.010 -0.055 0.023 0.018 1.000 0.133 -0.043 0.025 0.084 1.000 0.124 
49 rs492400 0.033 0.073 0.648 -0.013 0.054 0.807 0.007 0.052 0.899 0.062 0.055 0.263 0.020 0.028 0.488 1.000 0.787 0.017 0.031 0.576 1.000 0.601 
50 rs6567160 0.041 0.076 0.585 0.042 0.060 0.476 -0.085 0.053 0.106 0.039 0.064 0.536 -0.002 0.031 0.956 1.000 0.284 -0.010 0.034 0.763 1.000 0.181 
51 rs6804842 0.002 0.064 0.970 0.043 0.046 0.342 -0.014 0.044 0.751 -0.003 0.048 0.958 0.008 0.024 0.751 1.000 0.824 0.009 0.026 0.743 1.000 0.638 
52 rs7138803 -0.045 0.064 0.478 0.052 0.050 0.295 -0.061 0.045 0.177 -0.002 0.054 0.964 -0.014 0.026 0.591 1.000 0.370 -0.008 0.028 0.785 1.000 0.240 
53 rs7141420 -0.011 0.060 0.856 -0.016 0.043 0.706 -0.076 0.041 0.067 -0.067 0.045 0.134 -0.047 0.023 0.039 1.000 0.670 -0.054 0.025 0.031 1.000 0.573 
54 rs7164727 -0.108 0.070 0.122 -0.025 0.049 0.606 0.035 0.050 0.487 0.021 0.052 0.688 -0.008 0.027 0.767 1.000 0.359 0.009 0.029 0.748 1.000 0.667 
55 rs7239883 0.019 0.061 0.756 -0.032 0.048 0.506 -0.013 0.045 0.777 -0.034 0.051 0.508 -0.018 0.025 0.480 1.000 0.906 -0.025 0.027 0.361 1.000 0.939 
56 rs7243357 -0.157 0.066 0.018 -0.026 0.054 0.628 0.045 0.058 0.441 -0.028 0.056 0.622 -0.034 0.029 0.238 1.000 0.148 -0.005 0.032 0.883 1.000 0.591 
57 rs7599312 0.098 0.195 0.616 -0.103 0.173 0.551 0.001 0.123 0.991 -0.029 0.160 0.856 -0.012 0.078 0.881 1.000 0.892 -0.032 0.085 0.703 1.000 0.885 
58 rs7715256 0.065 0.150 0.667 0.153 0.131 0.240 -0.053 0.109 0.628 -0.049 0.112 0.659 0.013 0.061 0.831 1.000 0.583 0.003 0.067 0.967 1.000 0.405 
59 rs7903146 -0.301 0.254 0.236 -0.087 0.131 0.506 0.348 0.173 0.045 -0.186 0.177 0.295 -0.030 0.085 0.727 1.000 0.077 0.004 0.090 0.960 1.000 0.062 
60 rs9374842 -0.097 0.119 0.413 -0.026 0.079 0.743 0.031 0.073 0.673 -0.045 0.075 0.552 -0.022 0.041 0.590 1.000 0.796 -0.012 0.044 0.786 1.000 0.754 
61 rs9400239 0.028 0.063 0.659 0.003 0.045 0.945 0.032 0.046 0.479 -0.095 0.051 0.061 -0.008 0.025 0.746 1.000 0.250 -0.015 0.027 0.588 1.000 0.156 
62 rs9641123 -0.016 0.061 0.797 0.035 0.046 0.457 -0.001 0.044 0.979 0.044 0.049 0.367 0.018 0.025 0.468 1.000 0.823 0.024 0.027 0.365 1.000 0.760 
63 rs977747 -0.056 0.176 0.753 0.200 0.115 0.083 0.086 0.117 0.461 -0.097 0.103 0.349 0.038 0.060 0.525 1.000 0.247 0.051 0.064 0.429 1.000 0.148 
64 rs9914578 0.063 0.075 0.399 0.035 0.053 0.505 0.016 0.052 0.753 -0.089 0.059 0.131 0.004 0.029 0.902 1.000 0.317 -0.007 0.031 0.824 1.000 0.249 
Q (Cochran’s Q test) was used to measure between-study heterogeneity.  Significant interactions (Padjust < 0 .05) and heterogeneity (Qpvalue < 0.1) findings are in bold.
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NRXN3 rs7141420 (β=-0.049, SE=0.023, Pinteraction=0.033).  In the case of rs205262 
and rs4740619, the interaction term was found to be positively associated with 
Z-BMI.  Thus BMI level increased as the number of reported BMI risk alleles and 
the intake of %SFA increased.  For the rest SNPs, the interaction terms were 
negatively associated with Z-BMI so that the BMI level decreased as the number of 
reported BMI risk alleles and the intake of %SFA increased. 
 
The interaction effect of KCNK3 rs11126666 with %SFA was found to be significant 
on Z-BMI even after adjusting for multiple comparisons (β=-0.086 SE=0.025, 
Pinteraction=5.91×10-4, adjusted Pinteraction =0.044).  The negative association 
between %SFA intake and BMI tended to be stronger among individuals who are 
homozygous for the reported BMI non-risk allele G of rs11126666 as compared to 
individuals who have less copies of the G allele.  Figure 15 showed the association 
between rs11126666 and BMI depending on %SFA intake using population mean as 
the cut-off (Mean ± SD: 9.81 ± 2.76).  As can be seen, the major risk allele A would 
increase the BMI level in the individuals whose %SFA intake was lower than the 
population mean while decreased BMI level in the individuals whose %SFA intake 
was higher than the population mean. 
 
Since an interaction was found between rs11126666 and %SFA on Z-BMI, we further 
investigated whether the interaction was driven by a subtype of SFA (Table 55). None 
of the interaction remained significant after Bonferroni correction (P<0.008=0.05/6). 
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Table 56 shows the interaction results between 64 SNPs and %MFA intake on Z-BMI.  
None of the interaction remained statistically significant after correction for multiple 
comparisons.  Nominal significant SNP × %MFA interaction on BMI was observed 
for C6orf106 rs205262 (β=0.108, SE=0.033, Pinteraction= 0.001) and KCNK3 
rs11126666 (β=-0.056, SE=0.025, Pinteraction=0.027).  In the case of rs11126666, BMI 
level decreased as the number of A allele and the intake of %MFA increased while for 
rs205262, BMI level increased as the number of G allele and %MFA intake increased. 
 
In addition, if meta-analysis was conducted only in SCHS controls and SP2, the 
interaction between rs205262 and %MFA on Z-BMI would still be significant after 























Table 54: Interaction between 64 SNPs and %SFA intake on BMI 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
1 rs1000940 -0.115 0.062 0.062 0.037 0.046 0.416 0.037 0.041 0.368 -0.075 0.046 0.105 -0.014 0.024 0.549 1.000 0.065 0.003 0.025 0.902 1.000 0.129 
2 rs1016287 0.108 0.065 0.096 -0.014 0.052 0.784 -0.078 0.051 0.130 -0.038 0.052 0.464 -0.017 0.027 0.530 1.000 0.152 -0.044 0.030 0.144 1.000 0.677 
3 rs10182181 0.040 0.060 0.501 0.065 0.045 0.146 0.003 0.044 0.943 -0.074 0.046 0.106 0.005 0.024 0.819 1.000 0.161 -0.001 0.026 0.968 1.000 0.093 
4 rs10733682 0.048 0.070 0.490 -0.023 0.055 0.674 0.003 0.048 0.949 -0.040 0.057 0.483 -0.007 0.028 0.806 1.000 0.779 -0.017 0.031 0.569 1.000 0.840 
5 rs10938397 0.118 0.065 0.069 0.032 0.050 0.523 -0.032 0.048 0.503 -0.081 0.054 0.135 -4.33E-04 0.027 0.987 1.000 0.093 -0.025 0.029 0.401 1.000 0.303 
6 rs10968576 -0.070 0.070 0.320 -0.050 0.058 0.387 0.007 0.055 0.901 -0.085 0.061 0.163 -0.045 0.030 0.133 1.000 0.693 -0.040 0.033 0.234 1.000 0.522 
7 rs11030104 0.031 0.057 0.583 0.048 0.043 0.265 0.064 0.041 0.117 -0.037 0.044 0.399 0.028 0.023 0.217 1.000 0.363 0.027 0.025 0.268 1.000 0.203 
8 rs11126666 -0.136 0.060 0.023 -0.045 0.049 0.357 -0.097 0.045 0.032 -0.082 0.050 0.103 -0.086 0.025 5.91E-04 0.044 0.685 -0.076 0.028 0.006 0.444 0.726 
9 rs11191560 -0.003 0.062 0.963 0.062 0.048 0.194 0.031 0.048 0.522 -0.035 0.055 0.528 0.019 0.026 0.459 1.000 0.583 0.024 0.029 0.401 1.000 0.408 
10 rs11583200 0.098 0.093 0.295 0.029 0.078 0.711 0.007 0.080 0.931 0.048 0.088 0.587 0.041 0.042 0.327 1.000 0.901 0.027 0.047 0.571 1.000 0.943 
11 rs11688816 0.074 0.060 0.221 -0.027 0.049 0.584 -0.101 0.046 0.027 0.043 0.049 0.380 -0.014 0.025 0.587 1.000 0.067 -0.032 0.028 0.246 1.000 0.099 
12 rs12286929 -0.016 0.066 0.810 -0.075 0.047 0.107 -0.058 0.050 0.243 -0.026 0.051 0.617 -0.048 0.026 0.063 1.000 0.848 -0.055 0.028 0.055 1.000 0.772 
13 rs12429545 -0.118 0.067 0.078 0.095 0.047 0.042 -0.012 0.048 0.794 0.141 0.054 0.009 0.041 0.026 0.113 1.000 0.008 0.070 0.028 0.014 1.000 0.081 
14 rs12566985 0.001 0.074 0.991 0.086 0.054 0.112 -0.080 0.055 0.143 0.038 0.060 0.535 0.012 0.030 0.698 1.000 0.179 0.014 0.033 0.675 1.000 0.087 
15 rs12940622 -0.139 0.064 0.029 -0.091 0.048 0.058 0.001 0.045 0.985 -0.007 0.049 0.888 -0.048 0.025 0.057 1.000 0.190 -0.031 0.027 0.255 1.000 0.313 
16 rs13021737 -0.021 0.108 0.846 0.022 0.082 0.792 -0.031 0.077 0.687 -0.090 0.100 0.367 -0.025 0.045 0.567 1.000 0.860 -0.026 0.049 0.589 1.000 0.686 
17 rs13201877 0.368 0.178 0.040 -0.008 0.107 0.939 0.149 0.105 0.157 -0.121 0.120 0.314 0.057 0.060 0.340 1.000 0.095 0.018 0.064 0.781 1.000 0.229 
18 rs1441264 -0.008 0.060 0.894 -0.024 0.046 0.606 0.107 0.042 0.011 0.045 0.047 0.341 0.038 0.024 0.110 1.000 0.164 0.046 0.026 0.072 1.000 0.110 
19 rs1460676 -0.098 0.060 0.102 -0.005 0.046 0.913 0.033 0.044 0.457 0.034 0.044 0.444 0.002 0.024 0.919 1.000 0.281 0.021 0.026 0.411 1.000 0.789 
20 rs1516725 -0.180 0.102 0.078 -0.163 0.088 0.064 0.161 0.070 0.021 0.038 0.091 0.671 -0.001 0.042 0.985 1.000 0.007 0.037 0.047 0.430 1.000 0.015 
21 rs1528435 -0.056 0.061 0.358 -0.074 0.045 0.099 -0.004 0.043 0.932 -0.048 0.048 0.315 -0.043 0.024 0.072 1.000 0.716 -0.041 0.026 0.118 1.000 0.521 
22 rs1558902 -0.052 0.082 0.523 0.068 0.063 0.284 0.048 0.067 0.472 -0.026 0.076 0.738 0.020 0.035 0.581 1.000 0.597 0.036 0.039 0.358 1.000 0.626 
23 rs16851483 -0.013 0.066 0.839 0.023 0.052 0.655 -0.017 0.047 0.714 -0.050 0.053 0.348 -0.014 0.027 0.595 1.000 0.807 -0.014 0.029 0.624 1.000 0.614 
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Table 54 (continued): Interaction between 64 SNPs and %SFA intake on BMI 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
24 rs16951275 0.061 0.059 0.304 -0.014 0.043 0.749 -0.002 0.043 0.957 0.041 0.047 0.376 0.015 0.023 0.522 1.000 0.674 0.007 0.025 0.797 1.000 0.662 
25 rs17203016 -0.139 0.089 0.117 -0.077 0.066 0.242 -0.013 0.058 0.825 0.012 0.065 0.857 -0.041 0.033 0.221 1.000 0.489 -0.025 0.036 0.495 1.000 0.610 
26 rs17405819 -0.118 0.060 0.049 -0.039 0.044 0.371 -0.019 0.043 0.654 0.050 0.048 0.291 -0.023 0.024 0.324 1.000 0.168 -0.006 0.026 0.824 1.000 0.355 
27 rs17724992 -0.073 0.060 0.223 -0.051 0.044 0.242 -0.047 0.041 0.250 0.054 0.047 0.248 -0.027 0.023 0.241 1.000 0.246 -0.019 0.025 0.449 1.000 0.178 
28 rs1928295 0.012 0.059 0.837 -0.027 0.045 0.542 -0.003 0.041 0.943 -0.017 0.046 0.712 -0.011 0.023 0.643 1.000 0.952 -0.015 0.025 0.554 1.000 0.921 
29 rs2033529 -0.190 0.082 0.021 -0.071 0.057 0.215 -0.024 0.053 0.657 -0.097 0.063 0.122 -0.078 0.031 0.011 0.814 0.391 -0.060 0.033 0.070 1.000 0.651 
30 rs2033732 0.031 0.058 0.599 -0.098 0.046 0.034 0.002 0.043 0.961 0.032 0.048 0.502 -0.013 0.024 0.601 1.000 0.175 -0.021 0.026 0.418 1.000 0.117 
31 rs205262 -0.035 0.081 0.666 0.068 0.060 0.257 0.110 0.063 0.080 0.139 0.067 0.038 0.080 0.033 0.016 1.000 0.383 0.103 0.036 0.005 0.37 0.729 
32 rs2075650 0.006 0.106 0.955 -0.066 0.081 0.414 -0.105 0.074 0.154 -0.003 0.096 0.975 -0.055 0.043 0.206 1.000 0.776 -0.067 0.047 0.158 1.000 0.701 
33 rs2080454 -0.008 0.058 0.895 0.027 0.044 0.543 -0.043 0.042 0.307 0.038 0.045 0.399 0.003 0.023 0.884 1.000 0.548 0.005 0.025 0.828 1.000 0.354 
34 rs2112347 -0.047 0.057 0.404 -0.039 0.046 0.398 0.033 0.041 0.430 0.033 0.047 0.487 4.12E-04 0.023 0.986 1.000 0.471 0.010 0.026 0.690 1.000 0.435 
35 rs2176040 -0.161 0.109 0.138 0.056 0.085 0.507 0.023 0.078 0.767 -0.062 0.092 0.503 -0.019 0.045 0.678 1.000 0.391 0.010 0.049 0.833 1.000 0.628 
36 rs2207139 -0.001 0.076 0.994 0.040 0.065 0.538 0.007 0.063 0.909 -0.096 0.063 0.128 -0.014 0.033 0.667 1.000 0.471 -0.017 0.037 0.635 1.000 0.289 
37 rs2287019 0.089 0.073 0.221 0.059 0.056 0.287 -0.015 0.051 0.768 -0.041 0.061 0.501 0.016 0.029 0.576 1.000 0.413 0.002 0.032 0.943 1.000 0.434 
38 rs2365389 0.060 0.083 0.468 -0.009 0.063 0.890 0.108 0.065 0.098 -0.021 0.067 0.751 0.032 0.034 0.354 1.000 0.472 0.026 0.038 0.491 1.000 0.304 
39 rs2820292 -0.031 0.069 0.653 0.007 0.056 0.895 -0.004 0.052 0.939 0.035 0.057 0.540 0.004 0.029 0.883 1.000 0.901 0.012 0.032 0.711 1.000 0.877 
40 rs2836754 -0.014 0.061 0.825 -0.029 0.045 0.527 -0.098 0.042 0.019 0.026 0.050 0.599 -0.036 0.024 0.130 1.000 0.271 -0.040 0.026 0.121 1.000 0.153 
41 rs29941 0.107 0.076 0.162 0.089 0.052 0.089 0.023 0.052 0.661 -0.088 0.055 0.113 0.025 0.028 0.384 1.000 0.078 0.012 0.031 0.707 1.000 0.065 
42 rs3101336 0.019 0.097 0.847 0.015 0.086 0.861 0.028 0.071 0.694 0.151 0.089 0.090 0.051 0.042 0.229 1.000 0.649 0.058 0.047 0.214 1.000 0.469 
43 rs3817334 0.002 0.061 0.978 -0.029 0.050 0.553 -0.013 0.049 0.784 -0.011 0.050 0.819 -0.015 0.026 0.575 1.000 0.983 -0.018 0.029 0.527 1.000 0.961 
44 rs3849570 -0.026 0.058 0.657 -0.030 0.045 0.510 0.013 0.041 0.762 -0.027 0.047 0.569 -0.015 0.023 0.527 1.000 0.885 -0.013 0.026 0.620 1.000 0.739 
45 rs3888190 -0.026 0.112 0.815 0.011 0.086 0.894 0.063 0.071 0.374 0.023 0.083 0.778 0.027 0.042 0.515 1.000 0.915 0.036 0.046 0.425 1.000 0.883 
46 rs4256980 0.077 0.063 0.221 -2.60E-04 0.044 0.995 0.055 0.041 0.182 -0.047 0.048 0.320 0.017 0.024 0.468 1.000 0.291 0.007 0.025 0.775 1.000 0.261 
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Table 54 (continued): Interaction between 64 SNPs and %SFA intake on BMI 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
47 rs4740619 0.097 0.064 0.131 0.087 0.052 0.098 0.028 0.049 0.561 0.034 0.057 0.548 0.058 0.027 0.034 1.000 0.748 0.049 0.030 0.102 1.000 0.681 
48 rs4787491 -0.086 0.060 0.148 -0.028 0.043 0.506 -0.010 0.042 0.810 -0.096 0.046 0.037 -0.049 0.023 0.035 1.000 0.469 -0.042 0.025 0.094 1.000 0.355 
49 rs492400 0.009 0.071 0.900 -0.031 0.051 0.547 0.011 0.052 0.828 0.003 0.054 0.961 -0.004 0.028 0.894 1.000 0.938 -0.006 0.030 0.842 1.000 0.830 
50 rs6567160 0.028 0.078 0.717 0.003 0.062 0.962 -0.066 0.055 0.233 0.058 0.062 0.352 -0.001 0.031 0.968 1.000 0.490 -0.007 0.034 0.839 1.000 0.325 
51 rs6804842 0.008 0.062 0.893 0.051 0.046 0.264 -0.033 0.044 0.464 0.080 0.047 0.091 0.027 0.024 0.263 1.000 0.331 0.031 0.026 0.246 1.000 0.191 
52 rs7138803 -0.066 0.063 0.294 0.087 0.051 0.085 -0.024 0.046 0.612 0.020 0.053 0.706 0.009 0.026 0.720 1.000 0.227 0.025 0.029 0.384 1.000 0.271 
53 rs7141420 -0.015 0.060 0.799 -0.015 0.044 0.731 -0.084 0.042 0.047 -0.062 0.043 0.149 -0.049 0.023 0.033 1.000 0.643 -0.055 0.025 0.028 1.000 0.522 
54 rs7164727 -0.191 0.073 0.009 -0.005 0.051 0.923 0.011 0.050 0.825 -0.057 0.051 0.269 -0.041 0.027 0.133 1.000 0.114 -0.016 0.029 0.578 1.000 0.616 
55 rs7239883 0.057 0.063 0.362 -0.029 0.049 0.552 -0.017 0.045 0.713 -0.014 0.051 0.780 -0.007 0.025 0.774 1.000 0.725 -0.020 0.028 0.473 1.000 0.974 
56 rs7243357 -0.136 0.065 0.037 -0.021 0.055 0.706 0.038 0.057 0.504 -0.054 0.057 0.339 -0.037 0.029 0.198 1.000 0.236 -0.013 0.032 0.697 1.000 0.508 
57 rs7599312 0.024 0.220 0.914 -0.361 0.175 0.040 -0.028 0.122 0.816 -0.081 0.182 0.654 -0.104 0.082 0.203 1.000 0.411 -0.124 0.088 0.157 1.000 0.288 
58 rs7715256 0.027 0.149 0.856 0.180 0.133 0.178 -0.119 0.129 0.356 0.007 0.120 0.951 0.020 0.066 0.759 1.000 0.455 0.019 0.073 0.801 1.000 0.271 
59 rs7903146 -0.252 0.268 0.348 -0.207 0.140 0.140 0.267 0.154 0.084 -0.161 0.140 0.252 -0.070 0.080 0.381 1.000 0.086 -0.052 0.083 0.532 1.000 0.047 
60 rs9374842 -0.188 0.126 0.136 -0.040 0.078 0.606 0.050 0.069 0.467 -0.097 0.070 0.169 -0.043 0.040 0.276 1.000 0.291 -0.027 0.042 0.513 1.000 0.322 
61 rs9400239 0.019 0.062 0.753 0.007 0.046 0.878 0.091 0.046 0.049 -0.053 0.052 0.315 0.020 0.025 0.421 1.000 0.226 0.021 0.028 0.459 1.000 0.113 
62 rs9641123 0.017 0.063 0.787 -0.011 0.048 0.814 -0.036 0.043 0.405 0.045 0.050 0.360 -0.001 0.025 0.971 1.000 0.647 -0.004 0.027 0.877 1.000 0.458 
63 rs977747 -0.063 0.187 0.734 0.143 0.111 0.197 0.046 0.114 0.686 -0.041 0.104 0.698 0.035 0.060 0.562 1.000 0.624 0.046 0.063 0.467 1.000 0.484 
64 rs9914578 0.014 0.073 0.847 -0.016 0.054 0.772 -0.009 0.051 0.867 -0.035 0.060 0.564 -0.013 0.029 0.651 1.000 0.964 -0.018 0.032 0.565 1.000 0.945 





Table 55: Interaction between SFA subtypes and rs11126666 on BMI 
 SCHS case SCHS control Meta-analysis 
 Beta SE P Beta SE P Beta SE P Padjust Qp-value 
perSatFA -0.471 0.213 0.028 -0.147 0.171 0.390 -0.273 0.133 0.040 0.240 0.236 
logc150perc -0.056 0.190 0.771 -0.052 0.189 0.785 -0.054 0.134 0.690 1.000 0.988 
logc160perc 0.450 0.587 0.444 -0.204 0.620 0.742 0.141 0.426 0.741 1.000 0.444 
logc170perc -0.447 0.322 0.165 -0.226 0.295 0.443 -0.327 0.217 0.133 1.000 0.613 
logc180perc -0.208 0.321 0.517 -0.124 0.347 0.722 -0.169 0.235 0.473 1.000 0.858 
logc200perc 0.277 0.227 0.223 -0.043 0.251 0.863 0.133 0.168 0.430 1.000 0.344 





Table 56: Interaction between 64 SNPs and %MFA intake on BMI 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
1 rs1000940 -0.093 0.060 0.121 0.011 0.046 0.807 -0.024 0.041 0.553 -0.028 0.046 0.537 -0.026 0.023 0.257 1.000 0.588 -0.015 0.025 0.564 1.000 0.794 
2 rs1016287 0.091 0.063 0.151 -0.043 0.051 0.409 0.026 0.052 0.624 0.016 0.051 0.749 0.016 0.027 0.547 1.000 0.435 -3.23E-04 0.030 0.991 1.000 0.599 
3 rs10182181 0.039 0.060 0.518 0.042 0.043 0.321 -0.019 0.043 0.654 -0.087 0.047 0.062 -0.009 0.023 0.704 1.000 0.176 -0.018 0.026 0.490 1.000 0.123 
4 rs10733682 -0.006 0.070 0.935 -0.062 0.054 0.249 -0.025 0.047 0.600 0.061 0.054 0.264 -0.010 0.027 0.720 1.000 0.434 -0.011 0.030 0.723 1.000 0.255 
5 rs10938397 0.042 0.065 0.514 -0.003 0.051 0.954 0.059 0.048 0.222 0.007 0.051 0.895 0.026 0.026 0.332 1.000 0.802 0.022 0.029 0.440 1.000 0.633 
6 rs10968576 -0.065 0.074 0.383 0.009 0.057 0.868 -0.088 0.055 0.112 -0.074 0.060 0.214 -0.053 0.030 0.078 1.000 0.626 -0.051 0.033 0.123 1.000 0.423 
7 rs11030104 0.012 0.057 0.830 -0.028 0.042 0.511 0.002 0.040 0.951 -0.042 0.047 0.368 -0.015 0.023 0.500 1.000 0.841 -0.020 0.025 0.409 1.000 0.755 
8 rs11126666 -0.119 0.060 0.047 -0.029 0.049 0.554 -0.016 0.046 0.724 -0.085 0.050 0.087 -0.056 0.025 0.027 1.000 0.471 -0.042 0.028 0.132 1.000 0.564 
9 rs11191560 0.052 0.064 0.415 0.061 0.050 0.222 0.015 0.049 0.761 -0.124 0.053 0.020 -3.34E-05 0.027 0.999 1.000 0.054 -0.011 0.029 0.707 1.000 0.033 
10 rs11583200 0.081 0.087 0.357 -0.019 0.079 0.809 -0.005 0.080 0.953 0.009 0.094 0.921 0.014 0.042 0.742 1.000 0.847 -0.006 0.048 0.894 1.000 0.973 
11 rs11688816 0.118 0.063 0.061 -0.113 0.046 0.015 -0.059 0.046 0.203 -0.025 0.050 0.621 -0.038 0.025 0.131 1.000 0.028 -0.067 0.027 0.014 1.000 0.415 
12 rs12286929 0.034 0.067 0.612 0.014 0.048 0.769 -0.038 0.050 0.445 -0.117 0.050 0.020 -0.033 0.026 0.209 1.000 0.188 -0.045 0.028 0.114 1.000 0.165 
13 rs12429545 -0.018 0.068 0.793 0.100 0.049 0.042 -0.056 0.048 0.250 0.089 0.053 0.093 0.032 0.027 0.223 1.000 0.075 0.041 0.029 0.151 1.000 0.044 
14 rs12566985 0.007 0.072 0.919 0.112 0.057 0.051 -0.054 0.057 0.339 0.025 0.058 0.669 0.024 0.030 0.435 1.000 0.231 0.027 0.033 0.416 1.000 0.120 
15 rs12940622 -0.107 0.060 0.077 -0.053 0.049 0.279 0.003 0.045 0.954 -0.052 0.050 0.297 -0.045 0.025 0.075 1.000 0.526 -0.032 0.028 0.250 1.000 0.623 
16 rs13021737 -0.139 0.123 0.257 -0.046 0.087 0.599 0.004 0.074 0.962 -0.037 0.100 0.714 -0.038 0.046 0.403 1.000 0.802 -0.022 0.049 0.655 1.000 0.899 
17 rs13201877 0.282 0.196 0.151 -0.095 0.101 0.347 0.096 0.104 0.354 -0.008 0.105 0.940 0.020 0.057 0.724 1.000 0.296 -0.004 0.059 0.946 1.000 0.418 
18 rs1441264 0.016 0.062 0.797 -0.018 0.046 0.701 0.053 0.042 0.203 0.014 0.046 0.768 0.018 0.024 0.438 1.000 0.724 0.019 0.026 0.463 1.000 0.517 
19 rs1460676 -0.036 0.059 0.541 0.065 0.045 0.147 0.061 0.042 0.142 -0.002 0.046 0.957 0.031 0.023 0.190 1.000 0.403 0.043 0.026 0.090 1.000 0.495 
20 rs1516725 -0.048 0.106 0.650 -0.100 0.086 0.246 0.113 0.071 0.111 -0.036 0.089 0.685 2.97E-04 0.043 0.994 1.000 0.235 0.010 0.047 0.836 1.000 0.135 
21 rs1528435 -0.098 0.063 0.123 -0.093 0.045 0.038 -0.031 0.045 0.487 0.013 0.046 0.778 -0.047 0.024 0.053 1.000 0.317 -0.038 0.026 0.145 1.000 0.250 
22 rs1558902 0.031 0.088 0.720 0.055 0.064 0.385 -0.043 0.066 0.513 -0.072 0.069 0.295 -0.009 0.035 0.797 1.000 0.504 -0.017 0.038 0.662 1.000 0.352 
23 rs16851483 -0.035 0.064 0.589 -0.003 0.052 0.950 0.015 0.046 0.748 -0.039 0.053 0.467 -0.011 0.026 0.666 1.000 0.864 -0.007 0.029 0.819 1.000 0.747 
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Table 56 (continued): Interaction between 64 SNPs and %MFA intake on BMI 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
24 rs16951275 0.067 0.059 0.262 0.002 0.043 0.959 0.032 0.043 0.460 0.038 0.047 0.419 0.030 0.023 0.201 1.000 0.842 0.023 0.026 0.364 1.000 0.828 
25 rs17203016 -0.062 0.088 0.481 -0.089 0.062 0.150 0.015 0.060 0.808 0.008 0.069 0.911 -0.029 0.034 0.388 1.000 0.595 -0.023 0.037 0.521 1.000 0.421 
26 rs17405819 -0.083 0.061 0.171 -0.036 0.045 0.422 -0.024 0.042 0.577 0.023 0.047 0.625 -0.024 0.024 0.307 1.000 0.566 -0.014 0.026 0.598 1.000 0.632 
27 rs17724992 -0.053 0.059 0.371 -0.006 0.044 0.893 -0.044 0.040 0.272 0.010 0.047 0.829 -0.022 0.023 0.346 1.000 0.757 -0.016 0.025 0.519 1.000 0.652 
28 rs1928295 -0.037 0.058 0.525 -0.014 0.045 0.761 0.003 0.041 0.940 -0.047 0.047 0.317 -0.020 0.023 0.388 1.000 0.859 -0.017 0.025 0.507 1.000 0.719 
29 rs2033529 -0.147 0.081 0.069 -0.007 0.061 0.912 -0.087 0.053 0.099 -2.07E-05 0.062 1.000 -0.054 0.031 0.084 1.000 0.380 -0.037 0.034 0.265 1.000 0.473 
30 rs2033732 1.48E-04 0.058 0.998 -0.083 0.046 0.070 0.015 0.042 0.713 0.019 0.047 0.690 -0.012 0.024 0.600 1.000 0.345 -0.015 0.026 0.565 1.000 0.196 
31 rs205262 -0.028 0.078 0.723 0.160 0.060 0.008 0.125 0.062 0.044 0.121 0.065 0.062 0.108 0.033 0.001 0.074 0.277 0.136 0.036 1.47E-04 0.011 0.881 
32 rs2075650 0.064 0.101 0.526 -0.005 0.083 0.956 -0.040 0.075 0.596 -0.042 0.087 0.631 -0.013 0.043 0.767 1.000 0.843 -0.029 0.047 0.534 1.000 0.938 
33 rs2080454 0.015 0.059 0.793 0.010 0.044 0.818 -0.018 0.042 0.676 -0.003 0.045 0.946 -0.001 0.023 0.969 1.000 0.960 -0.004 0.025 0.876 1.000 0.901 
34 rs2112347 -0.029 0.055 0.598 0.044 0.044 0.326 0.030 0.042 0.464 -0.002 0.049 0.964 0.016 0.023 0.494 1.000 0.725 0.026 0.026 0.315 1.000 0.779 
35 rs2176040 -0.152 0.114 0.183 -0.107 0.083 0.198 0.076 0.082 0.358 -0.165 0.09 0.069 -0.073 0.045 0.103 1.000 0.175 -0.059 0.049 0.230 1.000 0.111 
36 rs2207139 0.012 0.079 0.883 0.002 0.064 0.974 0.078 0.062 0.214 0.008 0.068 0.908 0.027 0.034 0.419 1.000 0.818 0.031 0.037 0.410 1.000 0.643 
37 rs2287019 0.169 0.074 0.022 0.070 0.055 0.200 -0.051 0.051 0.316 -0.047 0.063 0.452 0.020 0.029 0.501 1.000 0.046 -0.008 0.032 0.792 1.000 0.208 
38 rs2365389 -0.035 0.081 0.665 -0.060 0.060 0.315 0.085 0.065 0.190 0.024 0.069 0.728 0.004 0.034 0.912 1.000 0.387 0.012 0.037 0.748 1.000 0.253 
39 rs2820292 0.009 0.067 0.895 0.012 0.057 0.832 0.040 0.051 0.437 -0.024 0.057 0.678 0.011 0.029 0.694 1.000 0.877 0.012 0.032 0.710 1.000 0.711 
40 rs2836754 0.035 0.060 0.562 -0.026 0.045 0.569 -0.120 0.042 0.004 0.019 0.049 0.700 -0.036 0.024 0.134 1.000 0.083 -0.049 0.026 0.060 1.000 0.081 
41 rs29941 0.142 0.075 0.059 0.082 0.053 0.122 -0.028 0.051 0.578 -0.073 0.056 0.191 0.016 0.029 0.566 1.000 0.053 -0.005 0.031 0.874 1.000 0.112 
42 rs3101336 -0.049 0.101 0.630 -0.185 0.085 0.030 -0.072 0.069 0.300 0.018 0.092 0.841 -0.076 0.042 0.070 1.000 0.427 -0.082 0.046 0.076 1.000 0.261 
43 rs3817334 0.002 0.062 0.979 -0.059 0.050 0.233 0.012 0.048 0.801 -0.032 0.051 0.528 -0.021 0.026 0.426 1.000 0.741 -0.025 0.029 0.375 1.000 0.578 
44 rs3849570 0.017 0.059 0.772 -0.039 0.044 0.376 0.059 0.041 0.149 -0.048 0.047 0.305 -0.001 0.023 0.963 1.000 0.261 -0.004 0.025 0.862 1.000 0.143 
45 rs3888190 -0.090 0.109 0.412 0.048 0.084 0.571 0.115 0.073 0.117 0.010 0.082 0.905 0.040 0.042 0.349 1.000 0.458 0.062 0.046 0.174 1.000 0.621 
46 rs4256980 0.024 0.063 0.705 0.036 0.044 0.411 0.103 0.043 0.018 0.001 0.047 0.984 0.045 0.024 0.058 1.000 0.418 0.049 0.026 0.058 1.000 0.259 
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Table 56 (continued): Interaction between 64 SNPs and %MFA intake on BMI 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
47 rs4740619 0.058 0.063 0.360 0.076 0.052 0.143 0.007 0.049 0.886 0.044 0.055 0.427 0.044 0.027 0.104 1.000 0.802 0.041 0.030 0.173 1.000 0.625 
48 rs4787491 -0.066 0.059 0.266 -3.62E-04 0.043 0.993 -0.015 0.041 0.724 -0.071 0.046 0.124 -0.032 0.023 0.162 1.000 0.620 -0.026 0.025 0.294 1.000 0.498 
49 rs492400 0.049 0.073 0.502 -0.005 0.054 0.925 -0.026 0.050 0.606 0.092 0.055 0.095 0.022 0.028 0.443 1.000 0.404 0.017 0.030 0.582 1.000 0.252 
50 rs6567160 0.071 0.078 0.367 0.023 0.060 0.700 -0.074 0.055 0.182 0.023 0.062 0.709 -2.29E-04 0.031 0.994 1.000 0.410 -0.014 0.034 0.690 1.000 0.385 
51 rs6804842 -0.024 0.062 0.704 0.048 0.045 0.288 -0.011 0.045 0.803 0.025 0.048 0.603 0.013 0.024 0.581 1.000 0.728 0.020 0.027 0.446 1.000 0.643 
52 rs7138803 -0.065 0.065 0.321 0.043 0.051 0.400 -0.097 0.046 0.036 0.006 0.054 0.918 -0.029 0.026 0.263 1.000 0.181 -0.023 0.029 0.433 1.000 0.104 
53 rs7141420 -0.033 0.060 0.581 -0.004 0.044 0.919 -0.016 0.042 0.704 -0.044 0.045 0.336 -0.023 0.023 0.331 1.000 0.931 -0.021 0.025 0.411 1.000 0.815 
54 rs7164727 -0.138 0.071 0.052 0.001 0.049 0.990 0.051 0.048 0.289 -0.081 0.052 0.121 -0.025 0.027 0.353 1.000 0.091 -0.006 0.029 0.831 1.000 0.174 
55 rs7239883 0.021 0.063 0.740 -0.018 0.048 0.703 0.006 0.045 0.897 -0.066 0.050 0.186 -0.017 0.025 0.508 1.000 0.663 -0.024 0.027 0.385 1.000 0.561 
56 rs7243357 -0.143 0.068 0.037 -0.019 0.053 0.725 0.078 0.058 0.177 -0.085 0.057 0.134 -0.034 0.029 0.239 1.000 0.066 -0.010 0.032 0.754 1.000 0.129 
57 rs7599312 0.026 0.207 0.898 0.024 0.179 0.893 0.108 0.113 0.340 0.030 0.167 0.859 0.065 0.077 0.403 1.000 0.965 0.071 0.083 0.395 1.000 0.889 
58 rs7715256 0.007 0.147 0.963 0.050 0.129 0.701 -0.103 0.106 0.334 -0.085 0.117 0.467 -0.045 0.061 0.463 1.000 0.783 -0.056 0.067 0.407 1.000 0.630 
59 rs7903146 -0.154 0.242 0.525 -0.082 0.126 0.517 0.455 0.198 0.022 0.017 0.166 0.917 0.031 0.084 0.710 1.000 0.114 0.057 0.090 0.528 1.000 0.071 
60 rs9374842 -0.111 0.119 0.352 0.045 0.077 0.562 0.026 0.080 0.745 0.028 0.079 0.724 0.015 0.043 0.727 1.000 0.726 0.033 0.046 0.465 1.000 0.983 
61 rs9400239 0.043 0.064 0.501 0.009 0.046 0.843 -0.005 0.046 0.915 -0.089 0.050 0.078 -0.014 0.025 0.568 1.000 0.348 -0.025 0.027 0.366 1.000 0.309 
62 rs9641123 -0.019 0.062 0.764 0.022 0.047 0.630 0.012 0.045 0.789 -0.032 0.050 0.525 -0.001 0.025 0.973 1.000 0.850 0.003 0.027 0.925 1.000 0.705 
63 rs977747 0.045 0.176 0.798 0.268 0.119 0.025 0.040 0.118 0.735 -0.014 0.095 0.884 0.076 0.059 0.199 1.000 0.306 0.080 0.063 0.203 1.000 0.167 
64 rs9914578 0.006 0.074 0.935 0.055 0.054 0.307 0.009 0.052 0.861 -0.054 0.061 0.370 0.007 0.029 0.800 1.000 0.610 0.008 0.032 0.810 1.000 0.402 




Table 57 shows the interaction results between 64 SNPs and %PFA intake on Z-BMI.  
None of the interaction remained statistically significant after adjusting for multiple 
testing.  Nominal significant SNP × %PFA interaction on BMI was observed for 
BDNF rs11030104 (β=-0.069, SE=0.023, Pinteraction=0.002), C6orf106 rs205262 
(β=0.072, SE=0.033, Pinteraction= 0.029), LOC646736 rs2176040 (β=-0.099, SE=0.045, 
Pinteraction=0.028) and NEGR1 rs3101336 (β=-0.131 SE=0.044, Pinteraction= 0.003).  In 
the case of rs205262, BMI level increased as the number of G allele and the intake 
of %PFA increased while for the rest SNPs, BMI level decreased as the number of 
reported BMI risk alleles and the intake of %PFA increased. 
 
6.3.7.10 %Carbohydrate 
Table 58 shows the interaction results between 64 SNPs and %Carbohydrate intake 
on Z-BMI.  None of the interaction remained statistically significant after correction 
for multiple comparisons.  Nominal significant SNP × %Carbohydrate interaction on 
BMI was observed for LINGO2 rs10968576 (β=0.076, SE=0.030, Pinteraction= 0.013), 
RPTOR rs12940622 (β=0.055, SE=0.025, Pinteraction= 0.026), TDRG1 rs2033529 
(β=0.063, SE=0.031, Pinteraction= 0.042), C6orf106 rs205262 (β=-0.107, SE=0.033, 
Pinteraction= 0.001) and MTCH2 rs3817334 (β=0.054, SE=0.026, Pinteraction=0.041).  In 
the case of rs205262, BMI level decreased as the number of G allele and the intake 
of %Carbohydrate increased while for the rest SNPs, BMI level increased as the 
number of reported BMI risk alleles and the intake of %Carbohydrate increased.
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Table 57: Interaction between 64 SNPs and %PFA intake on BMI 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
1 rs1000940 -0.033 0.059 0.583 -0.022 0.044 0.622 0.043 0.042 0.311 -0.058 0.046 0.212 -0.013 0.023 0.586 1.000 0.418 -0.009 0.025 0.721 1.000 0.259 
2 rs1016287 -0.001 0.064 0.989 -0.033 0.047 0.485 0.043 0.048 0.378 -0.023 0.052 0.658 -0.004 0.026 0.892 1.000 0.695 -0.004 0.028 0.887 1.000 0.486 
3 rs10182181 0.030 0.060 0.620 0.029 0.044 0.507 -0.051 0.044 0.248 0.026 0.045 0.557 0.006 0.024 0.808 1.000 0.511 0.001 0.026 0.958 1.000 0.346 
4 rs10733682 -0.094 0.065 0.146 0.031 0.051 0.547 -0.049 0.051 0.337 0.084 0.056 0.135 -0.002 0.027 0.938 1.000 0.130 0.018 0.030 0.553 1.000 0.204 
5 rs10938397 -0.055 0.068 0.422 0.006 0.048 0.893 0.042 0.047 0.377 0.118 0.052 0.023 0.036 0.026 0.164 1.000 0.198 0.052 0.028 0.066 1.000 0.276 
6 rs10968576 0.043 0.079 0.590 0.049 0.058 0.402 -0.087 0.054 0.105 -0.035 0.060 0.558 -0.017 0.030 0.571 1.000 0.302 -0.028 0.033 0.401 1.000 0.227 
7 rs11030104 -0.080 0.057 0.163 -0.075 0.042 0.074 -0.058 0.041 0.161 -0.069 0.045 0.124 -0.069 0.023 0.002 0.148 0.989 -0.067 0.025 0.006 0.444 0.958 
8 rs11126666 -0.063 0.061 0.301 -0.014 0.046 0.767 0.069 0.047 0.144 -0.051 0.050 0.301 -0.008 0.025 0.745 1.000 0.235 0.003 0.027 0.913 1.000 0.193 
9 rs11191560 -0.008 0.070 0.910 0.031 0.048 0.518 0.010 0.047 0.822 -0.065 0.053 0.221 -0.004 0.026 0.869 1.000 0.582 -0.004 0.028 0.896 1.000 0.377 
10 rs11583200 0.120 0.106 0.260 0.010 0.076 0.894 -0.037 0.078 0.637 0.044 0.091 0.630 0.021 0.043 0.621 1.000 0.682 0.002 0.047 0.964 1.000 0.791 
11 rs11688816 0.010 0.066 0.877 -0.117 0.049 0.018 -0.010 0.045 0.817 0.001 0.048 0.978 -0.032 0.025 0.204 1.000 0.249 -0.039 0.027 0.150 1.000 0.162 
12 rs12286929 0.012 0.066 0.850 0.043 0.051 0.394 0.005 0.048 0.915 0.058 0.050 0.244 0.031 0.026 0.235 1.000 0.869 0.035 0.029 0.226 1.000 0.732 
13 rs12429545 0.021 0.067 0.753 0.041 0.050 0.413 0.014 0.047 0.765 0.026 0.055 0.630 0.026 0.027 0.334 1.000 0.984 0.027 0.029 0.359 1.000 0.927 
14 rs12566985 -0.022 0.076 0.776 0.085 0.057 0.133 0.038 0.056 0.500 -0.036 0.064 0.574 0.025 0.031 0.421 1.000 0.482 0.034 0.034 0.314 1.000 0.365 
15 rs12940622 -0.098 0.061 0.111 0.010 0.047 0.831 -0.034 0.045 0.453 0.007 0.048 0.882 -0.022 0.025 0.386 1.000 0.489 -0.007 0.027 0.808 1.000 0.751 
16 rs13021737 -0.233 0.119 0.051 -0.067 0.088 0.444 -0.002 0.080 0.979 -0.051 0.104 0.622 -0.067 0.047 0.154 1.000 0.452 -0.036 0.051 0.479 1.000 0.849 
17 rs13201877 0.095 0.198 0.632 -0.114 0.109 0.297 -0.078 0.107 0.466 -0.108 0.110 0.327 -0.082 0.060 0.171 1.000 0.816 -0.100 0.063 0.112 1.000 0.970 
18 rs1441264 -0.009 0.058 0.881 -0.017 0.045 0.702 0.010 0.042 0.813 0.008 0.045 0.853 -0.001 0.023 0.975 1.000 0.968 0.001 0.025 0.975 1.000 0.889 
19 rs1460676 0.026 0.059 0.659 0.052 0.047 0.263 -0.014 0.041 0.729 0.021 0.047 0.659 0.018 0.024 0.442 1.000 0.759 0.017 0.026 0.518 1.000 0.562 
20 rs1516725 -0.020 0.119 0.864 -0.070 0.088 0.424 -0.014 0.074 0.848 -0.098 0.090 0.278 -0.050 0.044 0.264 1.000 0.888 -0.054 0.048 0.256 1.000 0.754 
21 rs1528435 -0.028 0.066 0.667 -0.059 0.045 0.191 -0.017 0.044 0.708 0.082 0.049 0.095 -0.006 0.025 0.804 1.000 0.190 -0.003 0.027 0.925 1.000 0.099 
22 rs1558902 0.171 0.083 0.039 0.037 0.065 0.576 -0.049 0.066 0.452 -0.009 0.077 0.903 0.026 0.036 0.465 1.000 0.201 -0.007 0.040 0.859 1.000 0.650 
23 rs16851483 -0.019 0.064 0.772 0.024 0.050 0.624 0.051 0.047 0.269 -0.067 0.051 0.188 0.002 0.026 0.932 1.000 0.351 0.006 0.028 0.825 1.000 0.207 
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Table 57 (continued): Interaction between 64 SNPs and %PFA intake on BMI 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
24 rs16951275 -4.70E-04 0.064 0.994 0.012 0.043 0.780 -0.006 0.044 0.887 -0.059 0.047 0.208 -0.013 0.024 0.570 1.000 0.713 -0.016 0.026 0.543 1.000 0.517 
25 rs17203016 -0.012 0.084 0.888 0.003 0.062 0.967 -0.021 0.062 0.734 0.052 0.065 0.424 0.006 0.033 0.848 1.000 0.864 0.010 0.036 0.787 1.000 0.710 
26 rs17405819 0.005 0.059 0.933 0.008 0.044 0.862 -0.058 0.042 0.165 -0.009 0.046 0.839 -0.017 0.023 0.454 1.000 0.694 -0.021 0.025 0.395 1.000 0.528 
27 rs17724992 -0.096 0.057 0.094 0.019 0.044 0.657 0.001 0.04
 
0.986 0.041 0.045 0.366 0.001 0.023 0.976 1.000 0.280 0.019 0.025 0.442 1.000 0.809 
28 rs1928295 0.001 0.056 0.989 0.059 0.045 0.189 0.045 0.04
 
0.276 2.25E-04 0.046 0.996 0.030 0.023 0.195 1.000 0.743 0.036 0.025 0.158 1.000 0.631 
29 rs2033529 -0.073 0.085 0.395 0.032 0.061 0.602 -0.071 0.05
 
0.173 0.052 0.059 0.382 -0.012 0.031 0.695 1.000 0.326 -0.003 0.033 0.928 1.000 0.236 
30 rs2033732 -0.031 0.056 0.583 0.019 0.045 0.679 -0.025 0.04
 
0.545 -0.068 0.045 0.134 -0.026 0.023 0.265 1.000 0.605 -0.025 0.025 0.329 1.000 0.400 
31 rs205262 -0.004 0.080 0.958 0.152 0.061 0.013 0.084 0.06
 
0.183 0.019 0.066 0.777 0.072 0.033 0.029 1.000 0.342 0.088 0.037 0.015 1.000 0.329 
32 rs2075650 -0.006 0.100 0.949 0.015 0.092 0.868 -0.019 0.07
 
0.813 0.002 0.081 0.984 -0.003 0.043 0.945 1.000 0.994 -0.002 0.048 0.963 1.000 0.960 
33 rs2080454 0.048 0.059 0.417 -0.016 0.045 0.730 0.092 0.04
 
0.025 -0.025 0.046 0.590 0.027 0.023 0.251 1.000 0.186 0.023 0.025 0.368 1.000 0.098 
34 rs2112347 -0.076 0.058 0.186 0.073 0.045 0.100 -0.026 0.04
 
0.541 -0.033 0.046 0.474 -0.009 0.023 0.708 1.000 0.157 0.004 0.025 0.862 1.000 0.168 
35 rs2176040 -0.017 0.113 0.880 -0.196 0.091 0.032 0.004 0.08
 
0.963 -0.165 0.083 0.046 -0.099 0.045 0.028 1.000 0.280 -0.114 0.049 0.020 1.000 0.201 
36 rs2207139 -0.075 0.075 0.317 -0.026 0.061 0.675 0.087 0.06
 
0.164 0.085 0.072 0.242 0.020 0.033 0.541 1.000 0.249 0.044 0.037 0.238 1.000 0.351 
37 rs2287019 0.067 0.073 0.359 0.068 0.057 0.231 -0.036 0.05
 
0.484 -0.091 0.063 0.147 -0.003 0.030 0.928 1.000 0.181 -0.016 0.032 0.611 1.000 0.151 
38 rs2365389 -0.108 0.080 0.178 -0.048 0.060 0.429 -0.006 0.06
 
0.932 0.031 0.070 0.659 -0.029 0.034 0.398 1.000 0.587 -0.011 0.037 0.760 1.000 0.692 
39 rs2820292 0.043 0.066 0.513 0.062 0.059 0.293 -0.044 0.05
 
0.391 -0.028 0.058 0.620 0.002 0.029 0.941 1.000 0.474 -0.008 0.032 0.814 1.000 0.362 
40 rs2836754 -0.023 0.058 0.692 0.021 0.044 0.626 -0.011 0.04
 
0.791 0.017 0.048 0.725 0.003 0.023 0.901 1.000 0.902 0.008 0.026 0.756 1.000 0.846 
41 rs29941 0.070 0.071 0.325 0.042 0.053 0.426 -0.045 0.05
 
0.421 -4.35E-04 0.057 0.994 0.012 0.029 0.674 1.000 0.557 0.001 0.032 0.986 1.000 0.527 
42 rs3101336 -0.143 0.114 0.209 -0.245 0.082 0.003 -0.044 0.07
 
0.567 -0.108 0.089 0.228 -0.131 0.044 0.003 1.000 0.355 -0.129 0.048 0.007 0.518 0.198 
43 rs3817334 -0.012 0.062 0.850 -0.059 0.047 0.212 -0.043 0.04
 
0.373 -0.052 0.049 0.289 -0.045 0.025 0.078 1.000 0.941 -0.051 0.028 0.065 1.000 0.970 
44 rs3849570 -0.005 0.061 0.936 -0.053 0.043 0.219 0.014 0.04
 
0.730 -0.102 0.050 0.042 -0.035 0.024 0.142 1.000 0.302 -0.040 0.026 0.119 1.000 0.186 
45 rs3888190 -0.062 0.104 0.554 0.063 0.080 0.433 0.070 0.07
 
0.353 0.077 0.075 0.305 0.050 0.041 0.219 1.000 0.712 0.070 0.044 0.113 1.000 0.992 
46 rs4256980 0.030 0.063 0.632 0.014 0.044 0.744 -0.006 0.04
 
0.895 0.021 0.045 0.642 0.012 0.023 0.601 1.000 0.961 0.009 0.025 0.710 1.000 0.904 
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Table 57 (continued): Interaction between 64 SNPs and %PFA intake on BMI 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
47 rs4740619 0.051 0.066 0.437 0.011 0.050 0.829 -0.007 0.048 0.884 0.014 0.056 0.801 0.013 0.027 0.637 1.000 0.916 0.005 0.029 0.866 1.000 0.950 
48 rs4787491 -0.142 0.059 0.017 -0.001 0.043 0.982 0.038 0.044 0.380 -0.066 0.046 0.150 -0.029 0.023 0.221 1.000 0.070 -0.008 0.025 0.760 1.000 0.252 
49 rs492400 0.047 0.079 0.547 0.004 0.054 0.936 0.013 0.051 0.800 0.010 0.057 0.864 0.014 0.029 0.621 1.000 0.974 0.009 0.031 0.769 1.000 0.993 
50 rs6567160 0.043 0.077 0.577 0.050 0.055 0.366 -0.036 0.057 0.529 0.047 0.063 0.450 0.023 0.031 0.450 1.000 0.676 0.019 0.033 0.562 1.000 0.484 
51 rs6804842 0.043 0.061 0.480 0.024 0.045 0.592 0.012 0.044 0.794 -0.080 0.048 0.092 -0.004 0.024 0.882 1.000 0.299 -0.012 0.026 0.641 1.000 0.225 
52 rs7138803 -0.038 0.065 0.565 -0.040 0.050 0.419 -0.064 0.047 0.174 -0.026 0.053 0.621 -0.044 0.026 0.096 1.000 0.958 -0.045 0.029 0.117 1.000 0.861 
53 rs7141420 0.001 0.059 0.989 -0.015 0.044 0.731 -0.046 0.042 0.269 -0.051 0.048 0.284 -0.031 0.023 0.185 1.000 0.865 -0.037 0.026 0.147 1.000 0.824 
54 rs7164727 0.079 0.065 0.225 -0.026 0.048 0.588 0.053 0.050 0.293 0.098 0.052 0.057 0.045 0.026 0.086 1.000 0.315 0.039 0.029 0.179 1.000 0.199 
55 rs7239883 -0.003 0.059 0.965 0.022 0.047 0.640 0.015 0.043 0.736 -0.054 0.049 0.277 -0.003 0.024 0.904 1.000 0.681 -0.003 0.027 0.910 1.000 0.471 
56 rs7243357 -0.107 0.068 0.115 -0.030 0.055 0.584 -0.047 0.056 0.403 -0.030 0.055 0.583 -0.049 0.029 0.092 1.000 0.810 -0.036 0.032 0.265 1.000 0.970 
57 rs7599312 0.155 0.196 0.429 0.267 0.181 0.140 -0.124 0.140 0.377 0.100 0.144 0.487 0.069 0.080 0.390 1.000 0.343 0.052 0.088 0.557 1.000 0.212 
58 rs7715256 0.114 0.178 0.519 0.058 0.114 0.613 0.011 0.113 0.920 -0.146 0.135 0.278 0.004 0.064 0.954 1.000 0.602 -0.013 0.069 0.851 1.000 0.494 
59 rs7903146 -0.188 0.204 0.359 0.041 0.150 0.787 0.013 0.147 0.927 -0.082 0.183 0.656 -0.031 0.083 0.709 1.000 0.806 -2.74E-05 0.091 1.000 1.000 0.869 
60 rs9374842 0.029 0.113 0.798 0.004 0.074 0.961 -0.045 0.077 0.560 0.058 0.088 0.512 0.005 0.042 0.905 1.000 0.844 0.001 0.046 0.980 1.000 0.680 
61 rs9400239 0.008 0.064 0.895 -0.021 0.046 0.647 -0.013 0.045 0.772 -0.037 0.050 0.461 -0.018 0.025 0.469 1.000 0.954 -0.023 0.027 0.401 1.000 0.936 
62 rs9641123 -0.058 0.061 0.346 0.106 0.046 0.021 0.019 0.045 0.674 -0.010 0.048 0.843 0.024 0.024 0.320 1.000 0.139 0.040 0.027 0.135 1.000 0.186 
63 rs977747 -0.086 0.160 0.591 0.081 0.126 0.522 0.060 0.116 0.604 -0.152 0.106 0.153 -0.027 0.061 0.654 1.000 0.422 -0.017 0.067 0.794 1.000 0.265 
64 rs9914578 0.124 0.073 0.090 0.049 0.053 0.355 0.025 0.053 0.637 -0.079 0.058 0.173 0.022 0.029 0.448 1.000 0.154 0.003 0.032 0.930 1.000 0.231 





Table 58: Interaction between 64 SNPs and %Carbohydrate intake on BMI 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
1 rs1000940 0.119 0.060 0.048 0.034 0.046 0.462 -0.017 0.042 0.686 0.092 0.046 0.045 0.046 0.024 0.050 1.000 0.185 0.033 0.026 0.199 1.000 0.213 
2 rs1016287 -0.090 0.065 0.171 0.027 0.051 0.593 0.058 0.052 0.260 0.014 0.051 0.779 0.012 0.027 0.651 1.000 0.346 0.033 0.030 0.264 1.000 0.824 
3 rs10182181 -0.046 0.059 0.439 -0.092 0.044 0.036 0.063 0.044 0.151 0.057 0.046 0.221 -0.001 0.024 0.972 1.000 0.036 0.008 0.026 0.766 1.000 0.020 
4 rs10733682 0.047 0.070 0.503 0.053 0.055 0.330 0.040 0.047 0.397 -0.026 0.055 0.639 0.028 0.027 0.311 1.000 0.726 0.024 0.030 0.415 1.000 0.542 
5 rs10938397 -0.053 0.066 0.422 0.060 0.052 0.250 -0.016 0.048 0.745 -0.028 0.052 0.585 -0.005 0.027 0.842 1.000 0.506 0.004 0.029 0.891 1.000 0.425 
6 rs10968576 0.082 0.077 0.285 0.021 0.057 0.714 0.062 0.054 0.254 0.152 0.061 0.013 0.076 0.030 0.013 0.962 0.467 0.075 0.033 0.024 1.000 0.281 
7 rs11030104 0.001 0.058 0.990 0.032 0.042 0.440 -0.047 0.041 0.251 0.056 0.046 0.217 0.009 0.023 0.694 1.000 0.350 0.010 0.025 0.673 1.000 0.196 
8 rs11126666 0.118 0.060 0.049 0.003 0.047 0.956 -0.003 0.046 0.954 0.088 0.048 0.068 0.044 0.025 0.078 1.000 0.245 0.028 0.027 0.300 1.000 0.320 
9 rs11191560 -0.061 0.064 0.342 -0.036 0.049 0.464 -0.060 0.046 0.195 0.089 0.053 0.095 -0.018 0.026 0.496 1.000 0.142 -0.009 0.029 0.748 1.000 0.086 
10 rs11583200 -0.105 0.088 0.233 0.022 0.080 0.780 -0.025 0.078 0.751 -0.056 0.087 0.521 -0.037 0.041 0.372 1.000 0.749 -0.018 0.047 0.708 1.000 0.799 
11 rs11688816 -0.043 0.062 0.485 0.057 0.046 0.212 0.034 0.045 0.455 -0.011 0.049 0.829 0.017 0.025 0.487 1.000 0.537 0.029 0.027 0.288 1.000 0.595 
12 rs12286929 -0.004 0.066 0.946 1.98E-04 0.049 0.997 0.017 0.050 0.727 0.017 0.051 0.732 0.009 0.026 0.735 1.000 0.988 0.011 0.029 0.690 1.000 0.961 
13 rs12429545 0.054 0.068 0.424 -0.089 0.047 0.058 -0.010 0.050 0.841 -0.106 0.052 0.040 -0.050 0.026 0.057 1.000 0.179 -0.068 0.028 0.017 1.000 0.345 
14 rs12566985 0.003 0.075 0.963 -0.114 0.056 0.042 0.054 0.055 0.331 -0.002 0.060 0.979 -0.017 0.030 0.574 1.000 0.188 -0.021 0.033 0.526 1.000 0.095 
15 rs12940622 0.134 0.059 0.023 0.062 0.047 0.192 0.029 0.044 0.511 0.023 0.051 0.650 0.055 0.025 0.026 1.000 0.466 0.038 0.027 0.162 1.000 0.827 
16 rs13021737 0.129 0.126 0.305 0.095 0.087 0.280 0.006 0.079 0.936 0.105 0.097 0.281 0.071 0.047 0.127 1.000 0.785 0.062 0.050 0.218 1.000 0.663 
17 rs13201877 -0.181 0.182 0.321 0.096 0.097 0.321 -0.155 0.103 0.131 0.081 0.111 0.465 -0.011 0.057 0.851 1.000 0.191 0.008 0.060 0.899 1.000 0.151 
18 rs1441264 0.016 0.058 0.785 0.050 0.047 0.290 -0.105 0.042 0.013 0.017 0.047 0.718 -0.014 0.024 0.561 1.000 0.065 -0.020 0.026 0.446 1.000 0.032 
19 rs1460676 0.092 0.062 0.138 0.024 0.045 0.598 -0.051 0.042 0.223 -0.012 0.046 0.787 4.68E-04 0.024 0.984 1.000 0.256 -0.015 0.025 0.555 1.000 0.475 
20 rs1516725 0.110 0.122 0.367 0.162 0.087 0.063 -0.182 0.072 0.012 0.023 0.091 0.806 -0.007 0.044 0.878 1.000 0.014 -0.025 0.048 0.606 1.000 0.008 
21 rs1528435 0.026 0.063 0.679 0.102 0.046 0.028 0.006 0.044 0.894 0.010 0.047 0.828 0.037 0.024 0.133 1.000 0.421 0.038 0.026 0.145 1.000 0.249 
22 rs1558902 -0.022 0.085 0.794 -0.071 0.066 0.280 -0.033 0.066 0.615 0.057 0.073 0.434 -0.021 0.036 0.559 1.000 0.623 -0.021 0.039 0.601 1.000 0.414 
23 rs16851483 0.042 0.065 0.521 0.019 0.052 0.715 -0.027 0.045 0.551 0.108 0.052 0.036 0.030 0.026 0.247 1.000 0.266 0.028 0.029 0.325 1.000 0.141 
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Table 58 (continued): Interaction between 64 SNPs and %Carbohydrate intake on BMI 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalu
 24 rs16951275 -0.016 0.058 0.787 0.044 0.043 0.308 -0.008 0.044 0.850 -0.035 0.046 0.448 -0.001 0.024 0.966 1.000 0.631 0.002 0.026 0.941 1.000 0.439 
25 rs17203016 0.011 0.087 0.902 0.050 0.065 0.439 -0.023 0.059 0.696 -0.025 0.066 0.708 0.001 0.034 0.971 1.000 0.824 -4.30E-04 0.036 0.991 1.000 0.640 
26 rs17405819 0.108 0.062 0.084 0.031 0.045 0.487 0.056 0.042 0.187 -0.053 0.048 0.269 0.029 0.024 0.221 1.000 0.175 0.016 0.026 0.545 1.000 0.214 
27 rs17724992 0.088 0.060 0.146 0.018 0.043 0.668 0.045 0.041 0.265 -0.029 0.046 0.530 0.025 0.023 0.270 1.000 0.435 0.015 0.025 0.554 1.000 0.479 
28 rs1928295 0.046 0.057 0.422 -0.002 0.044 0.958 -0.030 0.042 0.470 0.023 0.046 0.620 0.003 0.023 0.883 1.000 0.706 -0.005 0.025 0.844 1.000 0.693 
29 rs2033529 0.138 0.078 0.079 0.074 0.060 0.216 0.043 0.055 0.440 0.031 0.062 0.618 0.063 0.031 0.042 1.000 0.717 0.049 0.034 0.147 1.000 0.872 
30 rs2033732 0.028 0.057 0.627 0.041 0.046 0.379 0.009 0.042 0.838 0.024 0.046 0.606 0.024 0.024 0.306 1.000 0.965 0.023 0.026 0.366 1.000 0.875 
31 rs205262 0.072 0.078 0.358 -0.163 0.062 0.008 -0.151 0.060 0.012 -0.119 0.068 0.079 -0.107 0.033 0.001 0.074 0.083 -0.146 0.036 5.50E-05 0.004 0.885 
32 rs2075650 -0.027 0.106 0.798 -0.021 0.081 0.796 0.103 0.071 0.151 0.047 0.091 0.607 0.036 0.042 0.394 1.000 0.630 0.048 0.046 0.298 1.000 0.519 
33 rs2080454 -0.027 0.060 0.651 -0.017 0.045 0.711 0.019 0.042 0.652 -0.009 0.046 0.841 -0.005 0.023 0.823 1.000 0.911 -0.001 0.025 0.960 1.000 0.828 
34 rs2112347 0.004 0.057 0.941 0.015 0.045 0.738 -0.002 0.043 0.959 -0.006 0.048 0.906 0.003 0.024 0.904 1.000 0.989 0.003 0.026 0.922 1.000 0.942 
35 rs2176040 0.168 0.111 0.130 0.072 0.093 0.441 -0.031 0.084 0.713 0.130 0.087 0.134 0.074 0.046 0.109 1.000 0.438 0.054 0.051 0.284 1.000 0.399 
36 rs2207139 0.023 0.081 0.776 0.013 0.06 0.829 -0.075 0.064 0.240 0.054 0.069 0.428 3.94E-04 0.034 0.991 1.000 0.544 -0.004 0.037 0.907 1.000 0.360 
37 rs2287019 -0.104 0.075 0.169 -0.130 0.055 0.019 0.020 0.053 0.711 0.023 0.061 0.706 -0.042 0.030 0.157 1.000 0.130 -0.031 0.033 0.344 1.000 0.088 
38 rs2365389 0.021 0.083 0.798 -0.001 0.063 0.981 -0.056 0.065 0.387 -0.014 0.070 0.843 -0.016 0.034 0.641 1.000 0.888 -0.024 0.038 0.529 1.000 0.822 
39 rs2820292 -0.031 0.066 0.637 0.006 0.056 0.908 0.016 0.052 0.764 0.011 0.061 0.852 0.003 0.029 0.913 1.000 0.951 0.011 0.032 0.725 1.000 0.993 
40 rs2836754 -0.028 0.059 0.638 0.019 0.045 0.671 0.077 0.042 0.069 -0.018 0.050 0.715 0.021 0.024 0.374 1.000 0.384 0.031 0.026 0.237 1.000 0.329 
41 rs29941 -0.140 0.075 0.062 -0.034 0.052 0.513 0.026 0.052 0.618 0.113 0.055 0.042 0.007 0.028 0.797 1.000 0.041 0.032 0.031 0.296 1.000 0.153 
42 rs3101336 0.100 0.108 0.355 0.133 0.085 0.115 0.046 0.070 0.507 -0.047 0.092 0.610 0.057 0.043 0.183 1.000 0.518 0.049 0.046 0.293 1.000 0.354 
43 rs3817334 -0.029 0.062 0.644 0.062 0.050 0.212 0.078 0.048 0.108 0.073 0.052 0.158 0.054 0.026 0.041 1.000 0.538 0.071 0.029 0.014 1.000 0.975 
44 rs3849570 -0.021 0.058 0.724 0.057 0.043 0.190 -0.028 0.040 0.488 0.083 0.047 0.078 0.024 0.023 0.305 1.000 0.222 0.032 0.025 0.205 1.000 0.156 
45 rs3888190 0.082 0.111 0.460 0.005 0.084 0.949 -0.137 0.073 0.061 0.005 0.078 0.954 -0.030 0.042 0.467 1.000 0.317 -0.049 0.045 0.278 1.000 0.311 
46 rs4256980 -0.065 0.065 0.318 -0.037 0.044 0.404 -0.027 0.043 0.531 0.051 0.047 0.278 -0.015 0.024 0.539 1.000 0.409 -0.007 0.026 0.789 1.000 0.334 
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Table 58 (continued): Interaction between 64 SNPs and %Carbohydrate intake on BMI 
 SNPs SCHS case SCHS control SP2610 SP21m SCHS + SP2610 + SP21m SCHS control + SP2610 + SP21m 
  Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Padjust Qpvalue Beta SE P Padjust Qpvalue 
47 rs4740619 -0.070 0.064 0.278 -0.065 0.052 0.210 -0.009 0.049 0.863 -0.041 0.054 0.449 -0.043 0.027 0.113 1.000 0.838 -0.037 0.030 0.214 1.000 0.728 
48 rs4787491 0.133 0.060 0.027 0.021 0.043 0.624 -0.032 0.042 0.447 0.101 0.046 0.029 0.042 0.023 0.071 1.000 0.064 0.026 0.025 0.305 1.000 0.101 
49 rs492400 -0.048 0.071 0.504 -0.007 0.052 0.892 -0.013 0.051 0.799 -0.070 0.055 0.206 -0.031 0.028 0.264 1.000 0.829 -0.028 0.031 0.353 1.000 0.663 
50 rs6567160 -0.063 0.076 0.407 -0.009 0.058 0.875 0.052 0.053 0.327 -0.034 0.062 0.591 -0.004 0.030 0.908 1.000 0.582 0.008 0.033 0.814 1.000 0.543 
51 rs6804842 0.034 0.063 0.584 -0.054 0.047 0.246 -0.003 0.044 0.938 0.027 0.048 0.578 -0.004 0.025 0.881 1.000 0.585 -0.011 0.027 0.692 1.000 0.471 
52 rs7138803 0.023 0.067 0.737 -0.054 0.051 0.293 0.080 0.046 0.084 -0.011 0.054 0.838 0.013 0.027 0.627 1.000 0.260 0.011 0.029 0.701 1.000 0.136 
53 rs7141420 -0.035 0.060 0.558 -0.005 0.044 0.911 0.039 0.043 0.358 0.039 0.044 0.377 0.016 0.023 0.495 1.000 0.678 0.025 0.025 0.326 1.000 0.714 
54 rs7164727 0.047 0.070 0.497 0.015 0.050 0.768 -0.018 0.050 0.713 -0.031 0.052 0.545 -0.002 0.027 0.929 1.000 0.791 -0.011 0.029 0.701 1.000 0.802 
55 rs7239883 -0.022 0.061 0.725 0.003 0.047 0.948 0.006 0.044 0.888 0.052 0.051 0.306 0.012 0.025 0.636 1.000 0.807 0.018 0.027 0.500 1.000 0.733 
56 rs7243357 0.210 0.069 0.003 0.008 0.053 0.878 -0.049 0.059 0.406 0.046 0.057 0.422 0.040 0.029 0.175 1.000 0.034 0.003 0.032 0.928 1.000 0.509 
57 rs7599312 -0.005 0.189 0.978 -0.056 0.163 0.731 0.022 0.120 0.856 0.070 0.164 0.669 0.011 0.076 0.888 1.000 0.957 0.014 0.083 0.868 1.000 0.858 
58 rs7715256 -0.138 0.163 0.395 -0.231 0.134 0.085 0.076 0.106 0.476 0.081 0.111 0.464 -0.018 0.062 0.766 1.000 0.199 0.002 0.067 0.978 1.000 0.134 
59 rs7903146 0.335 0.212 0.114 0.022 0.134 0.867 -0.339 0.175 0.053 0.106 0.168 0.530 0.009 0.083 0.911 1.000 0.083 -0.049 0.090 0.582 1.000 0.143 
60 rs9374842 0.044 0.115 0.704 0.046 0.081 0.575 -0.029 0.071 0.680 0.064 0.077 0.406 0.026 0.041 0.534 1.000 0.818 0.023 0.044 0.603 1.000 0.637 
61 rs9400239 -0.070 0.063 0.271 -0.003 0.046 0.947 -0.019 0.046 0.676 0.072 0.050 0.151 4.00E-04 0.025 0.987 1.000 0.326 0.014 0.027 0.622 1.000 0.368 
62 rs9641123 -0.012 0.060 0.840 -0.058 0.046 0.212 0.018 0.044 0.686 -0.036 0.049 0.458 -0.022 0.024 0.374 1.000 0.677 -0.024 0.027 0.377 1.000 0.474 
63 rs977747 0.099 0.185 0.592 -0.259 0.116 0.025 -0.029 0.123 0.810 0.064 0.104 0.539 -0.047 0.062 0.442 1.000 0.162 -0.066 0.065 0.315 1.000 0.109 
64 rs9914578 -0.045 0.074 0.543 -0.059 0.053 0.270 -0.030 0.052 0.563 0.075 0.059 0.203 -0.016 0.029 0.589 1.000 0.354 -0.010 0.031 0.743 1.000 0.216 




In addition, if meta-analysis was conducted only in SCHS controls and SP2, the 
interaction between rs205262 and %Carbohydrate on Z-BMI would still be 




In this study, we investigated the association between diet and BMI, association 
between BMI risk loci and dietary components, and the interaction between dietary 
intake and BMI associated loci on BMI in 3,758 local Singaporean Chinese adults.  
This is the first study that systematically investigated the gene-environment 
interactions for established BMI-susceptibility loci in Asian populations thus far. 
 
Most (84.38%) of the BMI susceptibility loci, although not statistically significant, 
showed directionally consistent association with BMI as reported previously [251].  
Five loci (GNPDA2, KCNK3, NT5C2, QPCTL and MC4R) were significantly 
associated with the outcome and the most strongly associated locus was rs10938397 
on GNPDA2. 
 
Among the ten dietary components tested, total calories, cholesterol, 
starch, %protein, %fat, %MFA and %carbohydrate showed nominal significant 
association with BMI.  After Bonferroni correction, only intake of total calories was 
significantly associated with the outcome.  The increased intake of total calories 
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would increase individual’s BMI level. 
 
When the association between dietary components and 64 established BMI 
susceptibility loci was tested, it was found that the reported BMI risk allele G of 
rs6804842 on RARB would increase intake of total calories.  Rs6804842 is an 
intronic variant on retinoic acid receptor beta (RARB), a member of the 
thyroid-steroid hormone receptor superfamily of nuclear transcriptional regulators.  
However, no studies have been published regarding the relationship between this loci 
and energy intake thus far. 
 
Nominal evidence of interaction was observed between wGRS 
with %fat, %carbohydrate and starch intake on BMI.  However, none of the 
interaction remained statistically significant after adjusting for multiple comparisons.  
When evaluated at single-SNP level, interaction analyses results revealed nominal 
significance for %fat × rs205262, cholesterol × rs4740619 and %SFA × rs11126666 
on BMI.  Rs205262 is an intronic SNP on chromosome 6 open reading frame 106 
(C6orf106).  Little has been known about this region so far.  Previous findings 
showed that this region could promote the malignant progression of breast cancer and 
the specific SNP could interact with cigarette smoking on BMI [255, 268].  We have 
also tested the interaction in our Singaporean Chinese cohort and no significant 
interaction was observed.  To find out the possible mechanism involved, HaploReg, 
a tool for exploring the annotations of the non-coding genome at variants on 
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haplotype blocks was used (http://www.broadinstitute.org/mammals/haploreg) and it 
is found that rs205262 might be able to affect the binding affinity of peroxisome 
proliferator-activated receptors (PPARs), a group of nuclear receptor proteins 
involved in regulation of cellular differentiation, development, and metabolism 
(carbohydrate, lipid, protein).  PPARs are reported to be associated with obesity 
[269-271] and the association between genetic variants on PPARs and BMI could be 
modulated by dietary fat intake [272].  Thus the interaction between %fat and 
rs205262 on BMI might be through affecting the function of PPARs.  Rs4740619 is 
an intronic variant on coiled-coil domain containing 171 (CCDC171), a newly 
identified gene on chromosome 9.  Prediction result using HaploReg showed that 
rs4740619 could also affect the binding affinity of PPARs, as well as forkhead box P1 
(FOXP1), a tumor suppressor.  Rs11126666 is an intronic SNP on potassium two 
pore domain channel subfamily K member 3 (KCNK3).  KCNK3 has been reported 
to be associated with blood pressure and hypertension [273, 274].  Prediction result 
using HaploReg showed that rs11126666 could affect the binding affinity of upstream 
binding protein 1 (LBP-1), MYB proto-oncogene, transcription factor (MYB) and 
myogenic factor (MYF). 
 
FTO, which is located on chromosome 16, has shown strongest association with BMI 
and obesity [110, 111].  Some studies have investigated the modification effect of 
dietary factors on the association between FTO variants and BMI.  However, the 
results were controversial [36, 37, 258, 275-277].  In our Singaporean Chinese 
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cohorts, no such interactions were observed.  One possible explanation for this is the 
modification effect of dietary factors on the association reported elsewhere might be 
population specific. 
 
Some limitations of this study are as follow.  Firstly, since the weight and height 
information in SCHS were self-reported via in-person interviews, a subset of 
individuals (16.92%) did not have measurements for both variables thus were not 
included in current analysis.  This has significantly reduced the sample size.  To 
increase the sample size and statistical power [278, 279], we are currently seeking 
additional cohorts to replicate and further confirm our results.  Secondly, we used 
Hapmap imputation data for those SNPs without genotypes in the cohorts.  Among 
the 97 reported BMI risk loci, only 64 (65.98%) exist in both SCHS and SP2.  More 
SNPs might be captured if 1000 Genomes is used as the imputation panel.  However, 
this is not available at the time of analysis. 
 
In conclusion, the obesity risk SNPs are generally transferable between ethnic groups.  
Higher total calories intake is significantly associated with increased BMI in 
Singaporean Chinese population.  Most known obesity risk loci did not show an 
association with dietary intake or interact with dietary intake to modify BMI levels.  
The association between rs205262 (C6orf106), rs11126666 (KCNK3) and rs4740619 




Chapter 7: Interactions between high-density lipoprotein 
associated risk loci and SNPs across the genome on HDL levels 
and cholesterol ratio in Singaporean Chinese 
7.1 Introduction 
HDL is the smallest and densest lipoprotein particles, the protein to lipids proportion 
of which is highest among the five major lipoprotein groups.  HDL plays a central 
role in reverse cholesterol transport pathway, which delivers excess cholesterol from 
arteries to the liver and then excreted into the bile [280].  Low concentration of HDL 
is strongly associated with accumulation of atherosclerosis within the arteries walls 
and eventually leads to increase risk of stroke, cardiovascular disease and vascular 
disease [40, 41].  Every 1 mg/dl decrease in HDL level will lead to a 6% increase in 
cardiovascular risk [42].  Thus HDL is sometimes referred to as ‘good cholesterol’ 
for its role in preventing atherosclerosis.  Identifying risk factors that could affect 
HDL levels would be important in the diagnosis, treatment and prevention of heart 
disease [45]. 
 
Cholesterol ratio is the ratio between HDL and total cholesterol level in the plasma.  
Some researchers in recent years believe that lipoprotein ratios would be much more 
important in some aspects such as risk prediction for heart disease than the absolute 
lipoprotein levels [43].  Thus interest in cholesterol ratio has become another 




Recently, with the rapid development of large scale GWAS, many SNPs across the 
genome have been identified to be associated with blood HDL levels.  However, the 
SNPs uncovered thus far could only explain a very small fraction of HDL variation 
[281, 282] despite the heritability of HDL was estimated to be up to 70% [283].  The 
large ‘missing heritability’ is believed to be due to variants that could not be captured 
by GWAS, such as rare variants and structure variants as well as due to gene-gene 
interactions and gene-environment interactions. 
 
Gene-gene interaction, also called epistasis, is defined as ‘deviation from additivity’. 
This is the phenomenon that the effect of one gene is dependent on the presence of 
the effect of other genes.  The combined effect of epistatic mutations is usually 
different from the individual gene effect.  Gene-gene interaction is believed to be 
partially responsible for the phenomenon that the same genetic polymorphism 
contributes differently to complex diseases in different environments or different 
genetic backgrounds.  Thus it is suggested that gene-gene interaction is a ubiquitous 
part of the genetic architecture of complex disease [179].  Studying gene-gene 
interactions will help to better understand the etiology of complex diseases, including 
lipid metabolism and cardiovascular disease. 
 
Several studies have explored gene-gene interaction for HDL levels using candidate 
gene approach.  The SNPs studied were usually located on genes involved in HDL 
metabolic pathways.  In addition, those studies were mainly conducted in European 
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ancestry populations [284-286].  Few studies are available in Asian populations that 
systemically investigated gene-gene interactions on HDL levels thus far.  Our study 
attempts to explore the interactions between HDL associated risk loci from GWAS 
catalog [78] and independent SNPs across the genome for HDL levels and cholesterol 
ratio in Singaporean Chinese cohorts. 
 
7.2 Method 
7.2.1 Study Population 
In total, 5,272 adult individuals from three independent Singaporean Chinese cohorts, 
the SCHS (N = 1,284), the SCES (N = 1,889) and the SP2 (N = 2,099) were included 
in the analysis.  Since information for use of anti-hypertensive medication was not 
available in SCHS and the plasma lipid levels were usually abnormal for individuals 
with CHD, only healthy controls from SCHS were included in current study.  All 
study subjects gave written informed consent.  Detailed information regarding 
genotyping, quality control and lipid measurements in these three cohorts was 
described previously in chapter 3. 
 
7.2.2 Candidate SNP selection 
In GWAS catalog [78], 133 SNPs have been reported to be associated with HDL 
levels thus far.  Among these 133 SNPs, 47 of them have been genotyped in all three 
cohorts (Table 59).  These 47 SNPs were acted as the first set of SNPs in the 
analysis.  The second set was SNPs across the whole genome.  These SNPs were 
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Table 59: Single nucleotide polymorphisms includes in Set 1. 
  SNP Region Position Reported Gene(s) Mapped_gene RA/EA RAF/EAF P-value 
1 rs4660293 1p34.3 39562508 MACF1, PABPC4 PABPC4 G 0.24 3.00E-18 
2 rs12145743 1q23.1 156730859 HDGF, PMVK RRNAD1 G 0.34 2.00E-08 
3 rs6754295 2p24.1 20983311 APOB LOC101928271 - APOB C 0.25 4.00E-08 
4 rs13326165 3p21.1 52498102 STAB1 STAB1 A 0.21 9.00E-11 
5 rs2290547 3p21.31 47019693 SETD2 SETD2 A 0.20 4.00E-09 
6 rs2602836 4q23 99093654 ADH5 LOC100507053 A 0.44 5.00E-08 
7 rs2814944 6p21.31 34585020 C6orf106 SPDEF - C6orf106 A 0.16 4.00E-09 
8 rs4917014 7p12.2 50266267 IKZF1 C7orf72 - IKZF1 G 0.32 1.00E-08 
9 rs4731702 7q32.3 130748625 KLF14 LOC105375508 T 0.49 5.00E-17 
10 rs17173637 7q36.1 150832361 TMEM176A AOC1, LOC105375567 C 0.12 2.00E-08 
11 rs12678919 8p21.3 19986711 LPL LPL - LOC105379311 G 0.13 1.00E-149 
12 rs2083637 8p21.3 20007664 LPL LPL - LOC105379311 G 0.26 6.00E-18 
13 rs12686004 9q31.1 104891145 ABCA1 ABCA1 T 0.21 2.00E-18 
14 rs3905000 9q31.1 104894789 ABCA1 ABCA1 G 0.86 9.00E-13 
15 rs4149268 9q31.1 104884939 ABCA1 ABCA1 C 0.64 1.00E-10 
16 rs970548 10q11.21 45517829 MARCH8, ALOX5 39508 C 0.26 2.00E-10 
17 rs11246602 11p11.12 54607190 OR4C46 OR4C46 - OR4A4P C 0.15 2.00E-10 
18 rs7120118 11p11.2 47264739 NR1H3 NR1H3 G 0.42 4.00E-08 
19 rs7395662 11p11.2 48497341 FOLH1, MADD OR4A47 - OR4A45P G 0.61 6.00E-11 
20 rs2923084 11p15.4 10367235 AMPD3, ADM CAND1.11 G 0.18 5.00E-08 
21 rs174546 11q12.2 61802358 FADS1, FADS2, FADS3 FADS1 T 0.36 8.00E-28 
22 rs12801636 11q13.1 65623846 KAT5 PCNXL3 A 0.23 3.00E-08 
23 rs964184 11q23.3 116778201 APOA1, APOC3, APOA4, APOA5 LOC105369514 - ZPR1 C 0.84 6.00E-48 
24 rs7941030 11q24.1 122651667 UBASH3B GLULP3 - UBASH3B C 0.39 1.00E-14 
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Table 59 (continued): Single nucleotide polymorphisms includes in Set 1. 
  SNP Region Position Reported Gene(s) Mapped_gene RA/EA RAF/EAF P-value 
25 rs7134375 12p12.2 20320824 PDE3A LOC105369688 A 0.43 1.00E-08 
26 rs7134594 12q24.11 109562388 MVK, MMAB MMAB C 0.48 2.00E-13 
27 rs4983559 14q32.33 104810872 ZBTB42, AKT1 ZBTB42 - LINC00638 G 0.40 1.00E-08 
28 rs10468017 15q21.3 58386313 LIPC LOC102724766 T 0.30 8.00E-23 
29 rs1532085 15q21.3 58391167 LIPC LOC102724766 A 0.40 1.00E-188 
30 rs12708980 16q13 56978467 CETP CETP C 0.10 2.00E-28 
31 rs1532624 16q13 56971567 CETP CETP C 0.57 9.00E-94 
32 rs1800775 16q13 56961324 CETP HERPUD1 - CETP A 0.49 4.00E-93 
33 rs1864163 16q13 56963321 CETP CETP G 0.80 7.00E-39 
34 rs3764261 16q13 56959412 CETP HERPUD1 - CETP A 0.32 1E-769 
35 rs9989419 16q13 56951227 CETP HERPUD1 - CETP G 0.60 1.00E-32 
36 rs2271293 16q22.1 67868167 CTCF, PRMT8 NUTF2 A 0.11 9.00E-13 
37 rs255049 16q22.1 67979568 LCAT DPEP3 G 0.22 3.00E-08 
38 rs2925979 16q23.2 81501185 CMIP CMIP T 0.31 1.00E-19 
39 rs4148008 17q24.2 68879153 ABCA8 ABCA8 G 0.33 1.00E-12 
40 rs4129767 17q25.3 78407903 PGS1 PGS1 G 0.48 2.00E-11 
41 rs4939883 18q21.1 49640844 LIPG LOC105372112 G 0.83 2.00E-11 
42 rs2278426 19p13.2 11239812 TSPAN16, SPC24, RAB3D, KANK2, DOCK6, LOC55908 DOCK6, C19orf80 ? 0.30 3.00E-09 
43 rs2967605 19p13.2 8404854 ANGPTL4 RAB11B - MARCH2 T 0.16 1.00E-08 
44 rs737337 19p13.2 11236817 DOCK6, LOC55908 DOCK6 C 0.11 5.00E-17 
45 rs17695224 19q13.41 51820963 HAS1 FPR3, LOC105369197 A 0.26 2.00E-13 
46 rs1800961 20q13.12 44413724 HNF4A HNF4A T 0.05 2.00E-34 
47 rs7679 20q13.12 45947863 PLTP PCIF1 C 0.19 4.00E-09 
RA: risk allele; EA: effect allele; RAF: risk allele frequency; EFA: effect allele frequency
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pruned in (r2 < 0.10) by PLINK version 1.07 independently in three cohorts.  The 
number of overlapping SNPs is 74,409.  Thus the threshold for significance in 
current study was 1.43×10-8 (P = 0.05/ (47×74,409)) after Bonferroni correction. 
 
7.2.3 Statistical analysis 
Quantitative variables were presented as mean ± SD while categorical variables were 
presented as number of individuals (percentage %).  Age and HDL levels were not 
normally distributed thus differences between means of these two variables were 
evaluated by Kruskal-Wallis rank test.  Plasma cholesterol level was normally 
distributed thus the difference of mean across cohorts were compared by one way 
analysis of variance (ANOVA).  Differences in frequencies of categorical variables 
were evaluated by the chi square test.  Cholesterol ratio was calculated as plasma 
HDL level divided by cholesterol level.  HDL and cholesterol ratio were Z-score 
transformed before the analysis.  Interaction analyses were first performed between 
47 SNPs and 74,409 independent genome-wide SNPs in an additive model in PLINK 
version 1.07.  Linear regression model was used by introducing the interaction term 
(SNP1 x SNP2) with the specific SNPs (SNP1 and SNP2) included as covariates.  
Analysis was carried out in each cohort individually and subsequently meta-analyzed 
using the inverse-variance weighted method in STATA (version 12.1, Statacorp, 
College Station, TX, USA).  Those top hits were further analyzed by including 
additional covariates age, gender and anti-hyperlipidemia medication usage in the 
model in STATA.  P value of 1.43×10-8 (2 tailed) was considered statistically 
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significant after adjusting for multiple comparison based on 3,497,223 tests 
(47×74,409).  The power to detect the interactions was estimated by QUANTO 
(Version 1.2.4, Table 60). 
 
Table 60: Power estimation of gene-gene interaction for HDL level/cholesterol ratio 
Minor allele 
frequency of SNP1 
Minor allele 




































The study was conducted to investigate the gene-gene interaction between HDL 
associated loci and independent SNPs across the whole genome for HDL levels and 
cholesterol ratio in Singaporean Chinese population. 
 
7.3.1 Demographic and clinical characteristics of study populations 
The main demographic and clinical characteristics of the study subjects are presented 
in Table 61.  In total, 5,272 individuals (1,284 from SCHS controls, 1,889 from  
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Table 61: Baseline characteristics in different cohorts 
 SCES SCHS SP2610 SP21m P 
 N = 1889 N = 1284 N = 1146 N = 953  
rs7134375      
CC 1107(58.60%) 767(59.74%) 656(57.24%) 534(56.03%) 
0.194 CA 676(35.79%) 437(34.03%) 410(35.78%) 370(38.82%) 
AA 106(5.61%) 80(6.23%) 80(6.98%) 49(5.14%) 
rs266667      
AA 1594(84.38%) 1078(84.09%) 979(85.43%) 769(80.69%) 
0.026 AG 280(14.82%) 196(15.29%) 158(13.79%) 181(18.99%) 
GG 15(0.79%) 8(0.62%) 9(0.79%) 3(0.31%) 
rs3764261      
CC 1359(72.13%) 917(71.42%) 811(70.77%) 680(71.35%) 
0.980 CA 477(25.32%) 337(26.25%) 303(26.44%) 248(26.02%) 
AA 48(2.55%) 30(2.34%) 32(2.80%) 25(2.62%) 
rs9366874      
AA 872(46.19%) 590(45.95%) 517(45.11%) 436(45.75%) 
0.881 AG 833(44.12%) 584(45.48%) 523(45.64%) 421(44.18%) 
GG 183(9.69%) 110(8.57%) 106(9.25%) 96(10.07%) 
Age (year) 58.46±9.54 66.30±7.82 48.67±11.37 46.94±10.34 <0.001 
HDL (mmol/L) 1.30±0.40 1.35±0.33 1.45±0.35 1.34±0.36 <0.001 
Cholesterol (mmol/L) 5.43±1.04 5.18±0.90 5.21±0.94 5.15±0.87 <0.001 
Male 961(51.34%) 816(63.55%) 268(23.39%) 608(63.87%) <0.001 
Hyperlipidemia medication 443(23.45%) - 105(9.16%) 65(6.83%) <0.001 
 
SCES, 2,099 from SP2 (SP2610: N = 1146; SP21m: N = 953)) had data available for 
analysis.  As can be seen, HDL levels were similar in SCHS controls and SP21m 
and it was significantly higher in SP2610 and lower in SCES (P < 0.001).  Level of 
cholesterol was just the opposite that it was significantly higher in SCES than in the 
rest cohorts (P < 0.001).  The genotype distributions of rs7134375, rs3764261 and 
rs9366874 were not significantly different across the cohorts (rs7134375: P = 0.194; 
rs3764261: P = 0.980; rs9366874: P = 0.881) while there was significant difference 
regarding the genotype distribution of rs266667 (P = 0.026).  For age, participants 
were significantly older in SCHS and significantly younger in both SP2610 and 
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SP21m (P < 0.001).  The percentage of males was quite different across cohorts, 
with SP2610 had significant lower percent (P < 0.001).  Table 62 shows the 
comparison of HDL levels among individuals with and without use of 
anti-hyperlipidemia medication in different cohorts.  Individuals who were not on 
anti-hyperlipidemia medication treatment had significantly higher HDL levels than 
those who were on the treatment in all cohorts (SCES: P < 0.001; SP2610: P = 0.016; 
SP21m: P = 0.021).  Thus age, gender and anti-hyperlipidemia medication usage 
were included in the model as covariates in subsequent analysis. 
 
Table 62: Comparison of HDL levels between individuals with or without 
anti-cholesterol medication 
HDL (mmol/L) Without Medication With medication P value 
SCES 1.32 ± 0.40 1.22 ± 0.38 <0.001 
SP2610 1.46 ± 0.36 1.37 ± 0.32 0.016 
SP21m 1.35 ± 0.37 1.23 ± 0.28 0.021 
 
7.3.2 Main effect and epistasis of SNPs on HDL levels / cholesterol ratio 
To investigate whether the association between HDL associated risk loci and HDL 
level or cholesterol ratio could be modified by gene-gene interaction, epistasis 
analysis was first performed individually in three independent Chinese cohorts.  
Pair-wise SNP × SNP interactions between HDL risk loci (N = 47) and independent 
genome-wide SNPs (N = 74,409) were tested for HDL level and cholesterol ratio. 
 
We observed one gene-gene interaction between rs7134375 and rs266667 for HDL 
levels (β = 0.286; SE = 0.053; Pinteraction = 7.37×10-8) and one gene-gene interaction 
between rs3764261 and rs9366874 (β = -0.216; SE = 0.039; Pinteraction = 2.68×10-8) for 
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cholesterol ratio that reached significance level of 10-8.  Although both of them did 
not reach the significant threshold of 1.43×10-8 for multiple comparisons, the 
interaction results were quite consistent across different cohorts and the interaction 
p-values were very close to the threshold. 
 
Table 63 shows the association between rs7134375 / rs266667 and HDL levels.  As 
can be seen, the minor allele A of rs7134375 would increase HDL levels in most 
cohorts except in SCHS controls.  Although the A allele was reported to 
significantly increase HDL levels in GWAS catalog [287, 288], the association was 
not significant in our Singaporean Chinese.  The minor allele G of rs266667 was 
negatively associated with HDL levels in SCES, SCHS controls and SP2610.  After 
meta-analysis, it also could not significantly change the level of HDL in local cohorts. 
 
The result of interaction between rs7134375 and rs266667 on HDL level is presented 
in Table 64 and Figure 16.  As can be seen, a positive interaction was observed 
between rs7134375 and rs266667 on HDL levels.  The results were consistent and 
there was no heterogeneity among different cohorts.  Significant association was 
found between rs7134375 and HDL level in the heterozygous and minor allele 
homozygous group of rs266667.  The minor allele A of rs7134375 would increase 
HDL level in these two groups.  In addition, the association was stronger in the 
heterozygous group (P = 0.001) than the minor allele homozygous group (P = 0.005).
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Table 63: Main effect between rs7134375/rs266667 and HDL levels 
 SCES SCHS SP2610 SP21m Meta-analysis   Heterogeneity 
 β SE P β SE P β SE P β SE P β SE P Q P_Q 
rs7134375 0.017 0.035 0.622 -0.017 0.044 0.696 0.053 0.044 0.234 0.017 0.051 0.734 0.017 0.021 0.409 1.266 0.737 
rs266667 -0.059 0.054 0.274 -0.108 0.069 0.117 -0.047 0.073 0.513 0.018 0.075 0.806 -0.053 0.033 0.109 1.550 0.671 
 
Table 64: Interaction between rs7134375 and rs266667 for HDL levels 
 SCES SCHS SP2610 SP21m Meta-analysis Heterogeneity 
 β SE P β SE P β SE P β SE P β SE P Q P_Q 
rs7134375 -0.034 0.038 0.367 -0.061 0.047 0.197 0.010 0.048 0.834 -0.041 0.057 0.473 -0.032 0.023 0.171 1.174 0.759 
rs266667 -0.224 0.071 0.002 -0.217 0.084 0.010 -0.204 0.097 0.035 -0.126 0.097 0.196 -0.200 0.043 2.73×10-6 0.739 0.864 
Interaction 0.318 0.088 3.16×10-4 0.247 0.110 0.025 0.270 0.112 0.017 0.291 0.126 0.021 0.286 0.053 7.37×10-8 0.280 0.964 
 
Table 65: Main effect between rs3764261/rs9366874 and cholesterol ratio 
 SCES SCHS SP2610 SP21m Meta-analysis   Heterogeneity 
 β SE P β SE P β SE P β SE P β SE P Q P_Q 
rs3764261 0.275 0.043 2.01×10-10 0.216 0.053 4.18×10-5 0.138 0.053 0.009 0.236 0.058 5.69×10-5 0.223 0.025 <1×10-8 4.101 0.251 
rs9366874 0.011 0.034 0.745 0.039 0.042 0.356 0.012 0.043 0.783 0.017 0.046 0.708 0.019 0.020 0.351 0.310 0.958 
 
Table 66: Interaction between rs3764261 and rs9366874 for cholesterol ratio 
 SCES SCHS SP2610 SP21m Meta-analysis   Heterogeneity 
 β SE P β SE P β SE P β SE P β SE P Q P_Q 
rs3764261 0.376 0.058 1.33×10-10 0.420 0.071 5.06×10-9 0.254 0.076 0.001 0.379 0.085 3.39×10-6 0.361 0.035 <1×10-8 2.784 0.426 
rs9366874 0.067 0.039 0.089 0.152 0.050 0.002 0.066 0.051 0.192 0.071 0.054 0.188 0.087 0.024 2.54×10-4 2.210 0.530 
Interaction -0.167 0.065 0.010 -0.349 0.083 2.92×10-5 -0.175 0.082 0.033 -0.204 0.087 0.019 -0.216 0.039 2.68×10-8 3.405 0.333 
227 
 
Figure 16: HDL levels depending on the genotypes of rs7134375 and rs266667 
 
 
Table 65 shows the association between rs3764261 / rs9366874 and cholesterol ratio 
in Singaporean Chinese.  As shown in Table 65, the minor allele A of rs3764261 
would significantly increase cholesterol ratio in all cohorts.  After meta-analysis, the 
association between rs3764261 and cholesterol ratio reached genome-wide 
significance level (β = 0.223; SE = 0.025; P < 1×10-8).  The same allele was 
previously reported in GWAS catalog to significantly increase HDL cholesterol levels 
[288-290].  The minor allele G of rs9366874 was positively associated with 
cholesterol ratio, but the association was not significant after meta-analysis. 
 
The result of interaction between rs3764261 and rs9366874 on cholesterol ratio is 
presented in Table 66 and Figure 17.  As can be seen, a negative interaction was 
observed between rs3764261 and rs9366874 on cholesterol ratio.  The minor allele 
A of rs3764261 was significantly associated with cholesterol ratio only in the 



























association was much stronger in the major allele homozygous group (P < 0.001) than 
the heterozygous group (P = 0.001).  And the trend of association was much obvious 
in the homozygous group. 
 




Our study attempted to systematically investigate the interactions between HDL 
associated risk loci from GWAS catalog and independent SNPs across the genome for 
HDL levels and cholesterol ratio in Singaporean Chinese cohorts.  The analysis was 
conducted in three independent cohorts individually first and then meta-analyzed with 
the inverse-variance weighted method.  Although none of the interactions remained 
statistically significant after adjusting for multiple comparisons, the interaction 
between rs7134375 and rs266667 for HDL levels and the interaction between 
rs3764261 and rs9366874 for cholesterol ratio reached significance level of 10-8.  
The interaction results were consistent across different cohorts and the p-values were 



























and rs266667 on HDL levels.  It was found that the minor allele A of rs7134375 
would significantly increase HDL level in the heterozygous and minor allele 
homozygous group of rs266667.  A negative interaction was observed between 
rs3764261 and rs9366874 on cholesterol ratio.  The minor allele of rs3764261 was 
significantly associated with cholesterol ratio only in the heterozygous and major 
allele homozygous group of rs9366874.  Meanwhile, the association was much 
stronger in the major allele homozygous group. 
 
Rs7134375 is a non-coding transcript variant located within LOC105369688 gene on 
chromosome 12.  The minor allele A of rs7134375 was reported to significantly 
increase HDL levels [287, 288], but the association could not be replicated in the 
Singaporean Chinese.  To find out the possible mechanism involved, HaploReg 
(http://www.broadinstitute.org/mammals/haploreg) was used to predict the possible 
function of rs7134375.  The result showed that the allele change of rs7134375, 
which is located on eleven predicted motif sequences, will likely affect the binding 
affinity of eleven proteins, such as Jun proto-oncogene, AP-1transcription factor 
subunit (AP-1), Activating transcription factor 3 (ATF3), CCCTC-binding factor 
(CTCF), ETS proto-oncogene 1, transcription factor (ETS1), Myogenic 
differentiation 1 (MYOD1), RAD21 cohesin complex component (RAD21), SIX 
homeobox 5 (SIX5), Structural maintenance of chromosomes 3 (SMC3), T-box 5 
(TBX5), TGFB induced factor homeobox 1 (TGIF1) and E1A binding protein p300 
(EP300).  However, most of the genes coding for these proteins were reported to 
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associate with different types of cancer.  One gene, TBX5, was reported to play a 
role in heart development and specification of limb identity [291, 292].  Rs266667 is 
an intergenic variant that is also located on chromosome 12.  Prediction result from 
HaploReg suggested that rs266667 might be able to affect the binding affinity of 
histone deacetylase 2 (HDAC2), a protein playing an important role in transcriptional 
regulation, cell cycle progression and developmental events.  Moreover, histone 
deacetylases (HDACs) was reported to be involved in cardiovascular development 
and pathology [293].  Since rs7134375 was reported to be significantly associated 
with HDL level and rs266667 was predicted to affect the binding of the heart disease 
related HDAC2, it is probable that these two SNPs or their might indeed have a 
biological interaction with each other to affect HDL. 
 
Rs3764261 is an intergenic SNP on chromosome 16.  The minor allele A of 
rs3764261 was reported to significantly increase HDL levels previously [288-290].  
In our study, the same allele was also significantly associated with elevated 
cholesterol ratio.  HaploReg prediction result showed that the allele change of 
rs3764261, which is located on four predicted motif sequences, will likely affect the 
binding affinity of four proteins, such as GATA binding protein 3 (GATA3), 
GLI family zinc finger 1 (GLI1), Heart and neural crest derivatives expressed 
1 (HAND1) and Zic family member 1 (Zic1).  Among the genes coding for these 
four proteins, HAND1 plays a role in cardiac morphogenesis and is the mediator for 
congenital heart disease [294].  Rs9366874 is an intronic SNP within LOC340184 
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gene on chromosome 6.  Prediction result from HaploReg showed that this SNP 
might be able to affect the binding affinity of RAD21 and sterol O-acyltransferase 1 
(SOAT1).  RAD21 is involved in the repair of DNA double-strand breaks but no 
studies have been published regarding the effect of RAD21 on lipid levels thus far.  
SOAT1 catalyzes the formation of fatty acid-cholesterol esters and the mutation on 
SOAT1 was reported to be associated with variations in plasma cholesterol and 
triglyceride levels [295].  Since the minor allele of rs3764261 was reported to 
significantly increase HDL level and rs9366874 was predicted to affect the binding 
affinity of SOAT1, the mutation of which was reported to be associated with 
variations in plasma cholesterol and triglyceride levels, these two SNPs might interact 
with each other to affect cholesterol ratio. 
 
Although an increasing number of novel polymorphisms associated with lipid traits 
have been identified through large-scale GWAS, the number of gene-gene interaction 
studies for plasma lipids is limited.  Most of the previous findings were derived from 
studies involving variants from genes that are involved in lipid metabolism.  For 
example, in 2010, an interaction was found between a novel intergenic polymorphism 
rs1774572 and TaqIB polymorphism in the CETP for HDL cholesterol concentrations 
[284].  CETP plays a central role in the reverse cholesterol transport pathways.  
The association between TaqIB polymorphism and HDL levels has been firmly 
existed in several populations.  We also included some genetic variants from CETP 
in our study, but no significant interactions were observed.  In the same year, 
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interaction between the upstream stimulatory factor (USF1) and APOA5 on lipid 
levels and atherosclerosis was reported in another study [296].  USF1 regulates the 
expression of multiple genes involved in lipid metabolism [297] and APOA5 is 
involved in TG metabolism [298, 299].  Genetic variants on APOA5 were also 
included in set one.  However, no significant interactions were observed in current 
study.  Investigating gene-gene interactions by choosing SNPs within genes that are 
involved in lipid metabolic pathways may be more likely to detect the interactions 
and explain the possible mechanisms involved.  However, selecting SNPs by the 
candidate gene approach will also mean missing out yet to be identified genetic 
variants that associated with plasma lipid levels.  Our study has systematically 
investigated the interactions between HDL associated risk loci from GWAS catalog 
and independent SNPs across the genome for HDL levels and cholesterol ratio in 
Singaporean Chinese cohorts.  Although none of the interactions remained 
statistically significant after adjusting for multiple comparison, we found two 
interactions that are consistent across different cohorts and the p-values were very 
close to the threshold.  Additional Chinese cohorts are needed to further confirm our 
findings. 
 
In summary, we observed the interaction between rs7134375 and rs266667 for HDL 
levels and the interaction between rs3764261 and rs9366874 for cholesterol ratio that 
reached significance level of 10-8 in Singaporean Chinese, which are very close but 
has not reached the significance level after adjustment for multiple comparisons.  
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Our study sheds light on the possible gene-gene interactions for lipid traits, which 
could partially make up for the ‘missing heritability’ for complex diseases.  
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Chapter 8: Conclusion 
8.1 Main findings 
This dissertation is focused on the genetic epidemiological investigations of CAD and 
its related traits. 
 
The rapid development and the reduction in the cost currently made GWAS a 
powerful tool to provide a valuable first insight into genetic architecture or candidate 
loci of CAD and its related traits for subsequent validation and biological analysis 
[23]. 
 
In 2011, an intronic SNP rs6903956 on chromosome 6p24.1 within the C6orf105 
region was found to be associated with CAD risk in a GWAS conducted in a Han 
Chinese population.  It is found that the mRNA expression of C6orf105 was 
significantly lower in the minor allele homozygous (AA) and heterozygous (AG) 
groups compared to the major allele homozygous (GG) group [46].  Later in the 
same year, C6orf105 region was found to code for a novel transmembrane protein.  
This novel transmembrane protein could regulate mRNA expression, cellular 
distribution and anticoagulant activity of TFPI gene, both under native condition and 
in response to androgen.  As such, it has been named androgen-dependent TFPI 
regulating protein (ADTRP).  The association between rs6903956 and CAD risk has 
been replicated in several independent Chinese cohorts [47, 107] as well as in the 
Japanese but differing in the risk allele [48].  Notably, the association has not been 
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found in the European populations [89].  Our group had reported previously that the 
minor A allele of rs6903956 significantly increased CAD risk in the Singaporean 
Chinese and that association was not explained by plasma lipid levels [47].  Besides 
lipid levels, coagulative factors also played a central role in advancing atherosclerosis 
as well as leading to CAD [49-51].  High levels of FVII and fibrinogen have been 
found to be significantly associated with increased risk of coronary events [52].  We 
conducted analysis both in Chinese adults and neonates to investigate whether there is 
any association between rs6903956 and coagulation factors.  No significant 
association was observed in both adult and neonatal cohorts and thus the genetic 
variant was not associated with either FVII or fibrinogen level in the Singaporean 
Chinese (Study I). 
 
To date, GWAS have identified many SNPs that are associated with CHD and its 
related risk factor traits.  The identification of these SNPs made it possible to utilize 
genetic information to predict individual risk of getting CHD.  Numerous phenotype 
based equations for predicting risk of ‘hard’ CHD are currently available, such as the 
Framingham Risk Equation, SCORE and QRISK [152, 155, 157, 229, 230].  The 
most popular model ATPIII [231] performed well in multiple cohorts with or without 
model recalibration [160, 164, 165, 233].  However, there were still a proportion of 
individuals with few risk factors and predicted to be at low risk of developing disease 
were actually CHD patients [234, 235].  Therefore, we believed that including 
genetic information into phenotype based equations could provide additional 
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accuracy.  We constructed and tested four GRS that contains multiple SNPs 
selecting by two different criteria.  All the GRS was significantly associated with 
incident ‘hard’ CHD after adjustment for traditional risk factors (age, TC, SBP, HDL, 
cigarette smoking and anti-hypertension medication usage) and recent ones such as 
hsCRP and creatinine.  The inclusion of the GRS into the phenotypic risk models led 
to the improvement in discrimination and risk classification in most situations.  The 
performance of the GRS containing larger number of SNPs (reported to be associated 
with CHD or its related traits) was better than the GRS including only a small set of 
SNPs (reported to be associated with CHD or MI) in terms of their effect sizes, model 
discrimination and risk classifications.  It is also found that the performance of the 
GRS containing SNPs filtered by the Cox proportional hazards models with 
adjustments for age and gender was much better than the GRS containing SNPs 
robustly associated with CHD and its risk factors.  Although the extent of 
improvement of c-statistics was smaller in women than those in men when compared 
to the same base model using the same GRS, the addition of GRS to all models 
resulted in better c-statistics in women, especially the 51-SNPs GRS, which attained 
c-statistics all above 0.80 (Study II). 
 
As with all complex disease traits, it is known that gene-gene and gene-environment 
interactions also play a role in determining the outcome of CAD and its related risk 
factors in addition to the direct effect of genetic and lifestyle factors.  The last 
component of the dissertation included gene-diet interaction study for BMI and 
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gene-gene interaction study for plasma lipid, HDL and cholesterol ratio. 
 
Being overweight or obese will lead to adverse metabolic effects on blood pressure 
and lipid levels.  Individuals who are overweight or obese will have higher risk 
for various diseases, including CHD [8, 30].  Recent GWAS have identified 97 BMI 
associated SNPs.  These obesity risk SNPs are generally transferable between ethnic 
groups.  However, differences exist in dietary patterns between ethnic groups and 
whether dietary intake of various nutrients can modify obesity associations at these 
recently identified risk loci is not well known.  We first tested the association 
between various dietary components (total calories, cholesterol, %protein, starch, 
fiber, %fat, %SFA, %MFA, %PFA and %carbohydrate) and BMI.  Only total 
calories intake was significantly associated with increased BMI after adjusting for 
multiple comparisons.  We also replicated the association between these reported 
BMI risk loci and BMI levels in our Singaporean Chinese population.  It is found 
that most of the BMI susceptibility loci, although not statistically significant, showed 
directionally consistent association with BMI as reported previously [251].  We then 
investigated whether these BMI associated risk loci could affect various dietary 
intake and found the reported BMI risk allele G of rs6804842 on RARB gene would 
increase intake of total calories.  Finally, we checked whether dietary intake can 
modify obesity associations at these recently identified risk loci.  Interaction 
analyses results revealed nominal significance for %fat × rs205262 (C6orf106), 





Besides BMI, HDL is also a risk factor for CAD risk.  Low concentration of HDL is 
strongly associated with increased risk of cardiovascular disease [40, 41] and every 1 
mg/dl decrease in HDL level will lead to a 6% increase in cardiovascular risk [42].  
GWAS has identified hundreds of SNPs associated with plasma lipid levels thus far 
[78].  We thus explored the interactions between HDL associated risk loci from 
GWAS catalog [78] and independent SNPs across the genome for HDL levels and 
cholesterol ratio in Singaporean Chinese cohorts.  Although none of the interaction 
results remained statistically significant after Bonferroni correction, interaction 
between rs7134375 and rs266667 for HDL levels and the interaction between 
rs3764261 and rs9366874 for cholesterol ratio reached significance level of 10-8.  In 
addition, the interaction results were quite consistent across different cohorts and the 
p-values were very close to the threshold (Study IV). 
 
8.2 Limitation and future work 
Our previous study reported that the association between rs6903956 and CAD risk 
was not explained by plasma lipid levels [47].  In Study I, we further investigated 
and found that the genetic variant was not associated with FVII and fibrinogen.  The 
effect of the rs6903956 on CAD risk might therefore be mediated through other 
coagulation factors, such as TF or TFPI.  The influence might be more upstream in 
the coagulation cascade since ADTRP is known to regulate the levels of TFPI.  
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Additional investigation is needed to uncover the actual mechanisms involved. 
 
In genetic epidemiological study, one tries to identify the association of risk factors 
with diseases and quantitative traits.  In addition, one also tries to unravel the causal 
relationship between genes and the outcomes.  For Mendelian traits, the genetic 
variant is usually a sufficient cause for the outcome.  In other words, the individuals 
will have the disease as long as the mutation exists.  While for complex diseases the 
genetic variant is a probabilistic cause which can increase the likelihood of the 
outcome as well as in altering the level of quantitative traits, [300].  The 
probabilistic cause is neither necessary nor sufficient.  Thus it is much more 
complicated to prove causal relationship in complex diseases and quantitative traits 
than Mendelian traits [301].  GWAS is a popular and powerful tool to identify 
susceptibility loci for various diseases and quantitative traits.  However, the 
relationship identified by GWAS between SNPs and various outcomes can only be 
established as association and not causation.  GWAS is unable to identify the 
causative or susceptibility genes involved in complex diseases and quantitative traits.  
When an association between polymorphism and a disease or quantitative trait is 
identified by GWAS, it could be due to one of the following reasons: (1) true 
causation; (2) false positive findings; (3) the identified polymorphism is in LD with 
the true causative allele; (4) systematic bias.  To prove an association as the 
causation, other evidence is needed.  In 1965, a list of guidelines for epidemiological 
causation in environmental and occupational medicine were raised by Sir Austin 
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Bradford Hill [302].  Replication is one of the best ways to prove the validity of the 
result thus to infer the possible causation (consistency and unbiasedness of 
association).  In Study III, although we observed nominal significance for %fat × 
rs205262 (C6orf106), cholesterol × rs4740619 (CCDC171) and %SFA × rs11126666 
(KCNK3) on BMI, additional cohorts are necessary to replicate and further confirm 
the results.  In addition, we could check whether the association we observe is 
biological plausibility.  In Study III and Study IV, we used HaploReg, a tool for 
exploring the annotations of the non-coding genome at variants on haplotype blocks 
to find out the possible biological plausibility.  However, the results provided by 
HaploReg are just a prediction for the gene function.  Experimental evidence is still 
needed to consolidate the causal relationship. 
 
Sample size is an extremely important element in GWAS and population studies.  In 
Study II, we did not split our dataset into a separate training and validation dataset 
due to relatively small sample size.  We are mindful that there could be over-fitting 
with our results and hence have attempted to minimize this by performing internal 
cross-validation when reporting the results.  External replication in independent 
cohorts is ultimately needed to further validate the predictiveness of the GRS.  
Multiple testing is another issue in GWAS [129].  In Study IV, we used the 
candidate gene approach to select the first set of SNPs and only included SNPs that 
have been genotyped so as to reduce the number of multiple comparisons.  Although 
interaction between rs7134375 and rs266667 for HDL levels and the interaction 
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between rs3764261 and rs9366874 for cholesterol ratio reached significance level of 
10-8, which is very close to the threshold, both of the interaction results could not 
attain statistical significance after correction for multiple testing.  Additional 
Chinese cohorts are therefore needed to further confirm our findings. 
 
Since the genotyping arrays used for GWAS are based on tagging SNPs, it does not 
directly genotype all genetic variants in the genome.  For SNPs without genotype 
information, imputation of the genotypes based on a reference panel can be used to 
boost the coverage of genomic variation.  In both Study II and Study III, genotype 
calls were based on International HapMap Project [123] East-Asian samples that were 
derived from Han Chinese from Beijing (CHB) and the Japanese in Tokyo (JPT).  
To further increase the number of SNPs that can be included in the study, the 1000 
Genome Project [124] could be used as a imputation reference panel.  This was not 
available at the time of our analysis but can be included in the future. 
 
With the identification and validation of the gene-gene and gene-environment 
interaction for CAD and its related traits in addition to BMI and HDL, the 
incorporation of interaction terms into the risk prediction models is expected to 
further improve prediction accuracy.  Additionally, although GWAS is a powerful 
tool to identify susceptibility loci, individually the SNPs uncovered by GWAS only 
explain a small proportion of the variance / heritability of CHD and its related traits.  
Additional studies to identify more common variants and other variants not 
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effectively captured by GWAS using other methods, such as rare variants and 
structural variants, and include them in future models may further improve risk 
prediction accuracy. 
 
Traditional case-control studies usually identify disease-causing genes by comparing 
a group of diseased individuals with a group of healthy individuals.  In recent 
decades, there is an argument stating that sequencing the genomes of very healthy old 
people (super controls) to identify the protective rare gene variants can offer better 
insights into mechanisms [303].  In contrast, we could also sequence the genomes of 




In conclusion, this dissertation has demonstrated that the genetic variant rs6903956 
within the ADTRP gene is not associated with the plasma coagulation factors, FVII 
and fibrinogen.  It is also found that the inclusion of genetic information into 
phenotype based risk prediction equations could further improve prediction accuracy 
and model performances.  The identification of the gene-diet interaction for BMI 
and gene-gene interaction for HDL could deepen the understanding of complex 
etiology of CAD and its related traits.  It also provides a possible way to further 
improve risk prediction model for CAD.  Replication and further experimental 
studies will be necessary to uncover the mechanisms involved.  
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